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Corticosteroids are very effective in the treatment of acute relapse of 
multiple sclerosis (MS), an inflammatory demyelinating disease of the central 
nervous system (CNS). Furthermore, steroids also have the ability to suppress an 
animal model of this condition, experimental allergic encephalomyelitis (EAE). It 
has been proposed that the anti-inflammatory effects of corticosteroids may be 
mediated, in part, via the induction of effector proteins termed lipocortins. This 
thesis has investigated whether the potential exists for lipocortins to play a role in 
the mechanism of action of steroids in MS and EAE.
Using Western blotting immunoreactive lipocortins I, II, IV and V were 
detected in normal human CNS tissues and lipocortins I, II and V in rat CNS 
samples. Increased levels of all lipocortins were found in diseased CNS tissues 
from MS patients and elevated amounts of lipocortin I in the CNS of rats with 
EAE.
Immunolocalisation of lipocortin I revealed that in normal CNS tissue the 
protein was present in the walls of blood vessels. Increased lipocortin I 
immunoreactivity in MS was found to be due to expression of the protein by 
activated astrocytes, and in EAE to result from widespread immunostaining of 
infiltrating lymphocytes and macrophages. Measurement of corticosterone in the 
sera of EAE-inoculated rats showed that changes in lipocortin I immunoreactivity 
in the CNS closely paralleled fluctuations in endogenous corticosteroid.
To determine whether the levels of lipocortins I, II and V in the CNS might 
be influenced by exogenous or endogenous corticosteroids, the effect of 
manipulating the circulatory steroid concentration during EAE was investigated. 
Dosing EAE-diseased rats with corticosterone or dexamethasone appeared to have 
no influence on the amount of lipocortin in the cervical spinal cord. Moreover,
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administration of the glucocorticoid antagonist RU 38486 or adrenalectomy prior 
to inoculation did not prevent the disease-associated increase in lipocortin I 
immunoreactivity. These findings suggest that steroids do not modulate the 
absolute amount of lipocortin in the CNS.
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Multiple sclerosis (MS) was first identified and characterised by Charcot as 
long ago as 1868. The name of the disease is descriptive and was derived from the 
characteristic multiple grey sclerotic lesions (or plaques) which were found at post­
mortem in the brain and spinal cord of patients dying with MS.
Today MS is considered to be the leading cause of serious neurological 
disease in young and middle-aged adults in Western Europe and the United States 
(Johnson et al. 1979). In the United Kingdom between 50,000 and 100,000 people 
are affected by the disease. Although much has been learned about the disease 
since Charcot's time: in the last 15 years alone more than 10,000 articles about MS 
have been published (Poser 1992), at present the aetiology of MS is still unknown, 
the pathogenesis of the disease remains debatable and there is no definitive 
treatment.
1.1.1 Clinical Aspects
The first symptoms of MS can occur anytime between the ages of 15 and 
50 but the maximum incidence is at 20-30 years of age. Although both men and 
women are susceptible, the disease it is more prevalent in females (Cuzner & 
Davison 1979).
One aspect of MS which hampers research on the disease is that the clinical 
course is extremely variable and unpredictable (McFarlin & McFarland 1982a).
The majority of patients (approximately two thirds) are affected by a relapsing and 
remitting type of MS which is characterised by acute exacerbations of neurologic 
dysfunction followed by periods of remission. The average time to recovery is 
between 6 and 12 weeks and in the early stages remission may be complete with 
neurological function returning to normal. In the later stages there is less
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improvement with each remission and the disease gradually enters a chronic phase 
of progressive neurological impairment.
Other less common disease types include progressive MS which is 
characterised by a continuous but gradual decline in neurologic function, and the 
rare acute form where deterioration is rapid and can be terminal within a few 
months. A benign type of MS also exists where one or a few mild exacerbations 
are followed by complete recovery. In addition, there is evidence that MS occurs 
subclinically, because MS-type lesions are occasionally found at postmortem in 
asymptomatic patients.
The symptoms of MS are also highly variable but tend to reflect the 
involvement of the white matter. The most common presenting symptoms are 
sensory and visual disturbances, and weakness or incoordination of the limbs 
(Swanson 1989). As the disease progresses patients may develop persistent 
problems with fatigue, spasticity, pain, tremor, bowel, bladder and sexual 
dysfunction, paroxysmal phenomena, depression and cognitive impairment 
(Noseworthy 1991). For most patients however, diagnosis of MS carries a 
reasonable prognosis: the majority are still ambulatory 25 years after onset (Percy 
et al. 1971) and the disease is rarely lethal.
1.1.2 Histology and Pathology
Lesions in the central nervous system (CNS) of patients with MS vary in 
size and may be up to several centimetres in diameter. The majority are found 
scattered throughout the white matter but there are distinct regions of predilection, 
the most commonly affected areas being the optic nerves, brain stem, spinal cord 
and the periventricular white matter of the cerebral hemispheres (Lumsden 1970). 
Although the symptoms of MS tend to reflect the involvement of particular areas 
of the CNS, the correlation between the number and distribution of plaques and
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clinical symptoms is often quite poor (Thompson et al 1990). Recent serial 
magnetic resonance imaging (MRI) studies have shown that despite the relapsing- 
remitting nature of the symptoms, the disease process is continually active: patients 
frequently exhibit many more new lesions than relapses and the lesions are 
continually changing in size, with some fading whilst others are simultaneously 
growing and becoming confluent (Koopmans et al 1989).
Histologically lesions are generally classified as acute or chronic (see: 
Adams 1976, Weller 1985). Acute plaques are soft and oedematous and 
characterised by evidence of active myelin breakdown and widespread 
inflammation (Adams et al 1989). Throughout the plaque, destruction of the 
myelin sheath is accompanied by some loss of oligodendrocytes although neurones 
are relatively well preserved. Demyelinated areas are hypercellular due to 
infiltration by inflammatory cells and proliferation of astrocytes. Monocytes and 
lymphocytes accumulate in the perivascular compartment between the walls of 
blood vessels and the glial basement membrane forming thick perivascular cuffs. 
Many of these cells migrate into the parenchyma and large numbers of 
lymphocytes, macrophages and plasma cells are found throughout the lesion. At 
the plaque margins, foamy macrophages containing myelin breakdown products are 
found closely associated with demyelinating axons. Glial hyperplasia occurs at the 
periphery with the accumulation of numerous reactive astrocytes and microglia in 
this area. There is also some increase in oligodendrocyte numbers and evidence of 
scanty remyelination at the plaque edge.
Chronic plaques are much more common and can be subdivided as either 
active or inactive. Chronic active plaques are persistently oedematous (McDonald 
& Barnes 1989) and exhibit evidence of continued demyelination and inflammation 
at the periphery. The core is demyelinated, hypocellular and gliotic, few 
oligodendrocytes remain and there is some degeneration of axons. Active myelin
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breakdown is confined to the rim of the plaque which is hypercellular and contains 
many perivascular cuffs of lymphocytes and plasma cells together with large 
numbers of microglia, foamy macrophages and reactive astrocytes (Prineas & 
Wright 1978). As in acute plaques a slight increase in oligodendrocytes and a 
small amount of remyelination are found at the plaque edge.
Chronic inactive plaques lack the hypercellular rim of active plaques, show 
no evidence of further demyelination and appear to be "burnt out". They are of a 
rubbery consistency, hypocellular and densely gliotic. In the demyelinated area 
oligodendrocytes are no longer present and axonal loss may be substantial. The 
plaque is repaired by astrocyte fibres and processes from these cells are often 
observed surrounding preserved axons. Blood vessels frequently have thick 
collagenous walls which probably reflects the presence originally of perivascular 
cuffs. Oligodendrocytes are normal in number at the periphery and there is no 
further remyelination.
A pictorial summary of the different types of plaque is shown in Figure 1. 
Both active and inactive plaques may be found within the same brain; these 
histological variations appear to represent different ages of plaque and it seems 
probable that lesions initially develop as acute plaques, progress through a chronic 
active stage and then eventually become inactive (Adams 1976, Weller 1985).
What triggers the formation of the initial or subsequent lesions is not 
known. Plaques tend to develop around small cerebral blood vessels, usually veins. 
Recent MRI and histological studies have shown that breakdown of the blood- 
brain barrier (BBB) is a very early event which precedes cellular infiltration 
(McDonald & Barnes 1989, Kermode et al 1990, Newcombe et al 1991) and it 
has been proposed that these foci of BBB leakage may represent the primary lesion 
in MS (Miller et al 1988).
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As
a. Normal white matter: three axons are myelinated by 
oligodendrocytes (Ol). Fine processes of astrocytes (As) 
extend towards blood vessel (BV) —  an artery or a vein.
b. Edge of an active plaque. The three axons are 
demyelinated as they enter the plaque below. Axon 1 shows 
some thin, short segments of remyelination. Perivascular 
lymphocytes and monocytes are seen between the blood 
vessel wall and the perivascular glial basement membrane. 
Microglia (m), foamy macrophages (M). lymphocytes (L) and 
plasma cells (PC) are seen at the edge of the plaque. The 
astrocytes have become reactive (RAs) and hypertrophied.
c. Edge of a chronic inactive plaque. It lacks the cellularity of 
the active plaque. Axon 1 has degenerated and axons 2 and 3 
are demyelinated as they enter the plaque; axon 3 shows 
some remyelination with short segments o f myelin. There is 
no perivascular inflammation and the blood vessel wall has 
become thickened and fibrotic. Astrocytes (As) have many 
long thin processes orientated parallel to the surviving axons. 
Oligodendrocytes (01) are not present in the demyelinated 
plaque region and only occasional microglia (m) are seen.
Figure 1. A diagrammatic summary of the histological features of multiple 
sclerosis
Reproduced with permission from: McAlpine's Multiple Sclerosis, 2nd Edition, W. 
B. Mathews et al. , Churchill Livingstone (Edinburgh) 1990.
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The cause of the influx of cells from the blood into the CNS has not been 
identified although it has been suggested that expression of Class II major 
histocompatibility complex (MHC) antigens by endothelial cells may promote 
passage of activated T lymphocytes across the BBB (Traugott et al 1985). Early 
inflammatory events appear to be T cell orchestrated (Raine & Scheinberg 1988) 
with acute/peripheral cuffs being comprised predominantly of lymphocytes (Cuzner 
& Davison 1979). Subsequent mediator release probably then causes recruitment 
of other inflammatory cells, and chronic-type cuffs within plaques, are composed 
mainly of plasma cells and monocytes (Jellinger 1977).
Ongoing demyelination appears to be dependent upon the presence of 
macrophages (Traugott et al 1983), in early lesions these appear to be 
haematogenous in origin but in more established plaques, resident microglia also 
appear to become involved (Adams et al 1989). Within areas of myelin loss foamy 
macrophages containing myelin debris are found in close contact with 
demyelinating sheaths (Prineas et al 1984, Weller 1985) and in addition to the role 
played by these cells as lipid scavengers there is evidence that they may actively 
strip myelin from intact axons by phagocytosis (Prineas & Connell 1978). Soluble 
mediators involved in demyelination have not been identified but it has been 
proposed that macrophage lysosomal enzymes may be responsible for the initial 
attack on myelin (Einstein et al 1972, Adams 1977). Selective loss of myelin basic 
protein (MBP) and increased proteolytic activity have been detected in MS plaques 
(Einstein et al 1972, Bowen & Davison 1974). In addition, there is a marked loss 
of phospholipid in demyelinated tissues (Cuzner 1980) and the lipolytic enzyme 
phospholipase A2  (PLA2 ) has also been implicated in demyelination (Woelk et al 
1974,1976).
Established plaques are persistently oedematous and appear to enlarge 
through cycles of renewed peripheral activity (McDonald & Barnes 1989). With
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time the centre of the plaque becomes inactive and eventually the whole lesion may 
become a gliotic, chronic inactive plaque. It has been suggested that the extensive 
gliosis which is a feature of inactive areas is probably a reaction to tissue damage 
rather than part of the mechanism of demyelination (Weller 1985).
A major discrepancy between the pathology of MS and the clinical course 
of the disease is the question of what forms the basis of remissions. Remyelination 
does not appear to be the cause, because although there is a limited amount of 
remyelination at the edge of many plaques, in most the majority of axons remain 
demyelinated (Prineas & Connell 1979). One proposal is that recovery is caused 
by restoration of conduction in demyelinated nerves, and it has been postulated that 
this may be due to proliferation of sodium channels along the axonal membrane, 
thus allowing conduction in the absence of myelin (Bostock & McDonald 1982), 
however there is little evidence for this mechanism. Another possibility which has 
received support from CNS imaging studies (Sears et al. 1978), is that the 
extensive oedema which pervades and surrounds the lesions may be responsible for 
temporarily inhibiting conduction in many neurones, either by increasing local 
pressure, causing delamination of myelin, or altering the ionic environment 
(Waksman & Reynolds 1984). Thus restoration of conduction and the rapid 
reversal of functional loss may simply be due to regression of oedema.
1.1.3 Aetiology
Familial studies suggest that susceptibility to MS is inherited: the incidence 
of MS being 15-20 times higher in first degree relatives than in the general 
population (McDonald & Halliday 1977). Concordance for MS in identical twins 
however, is relatively low (26%) (Ebers et al 1986) indicating that although there 
is a genetic component in susceptibility, the pattern of inheritance is not simple.
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In genetic studies MS has been found to be associated with particular MHC 
antigens. In Caucasians the Class I human leukocyte antigens A3 and B7 occur 
more commonly in patients with MS (Batchelor et al 1978) and the disease is also 
linked to some Class II specificites such as DR2 which is present 3 to 4 times more 
frequently in MS patients than in the general population (Oger & Amason 1980). 
MHC antigens appear to be involved in the control of immune regulation but the 
significance of these associations is not yet known.
Epidemiological research has shown that MS is not uniformly distributed 
throughout the world. There is a marked variation according to latitude, the 
prevalence being much greater in temperate (30-80 cases per 100,000 population) 
than in tropical or sub-tropical regions (<5 per 100,000) (Kurtzke 1980).
Migration studies on people moving from high risk to low risk areas (and vice 
versa) indicate that migrants who relocate during childhood acquire the prevalence 
of their host area, but those migrating as young adults retain the prevalence of their 
place of origin (Alter et al 1978), suggesting that susceptible individuals acquire 
the disease from an environmental factor during adolescence.
Mainly as a result of studies on the epidemiology and pathology of the 
disease, two opposing theories have developed as to the cause of MS: one that MS 
is due to an infectious agent and the other that it is an autoimmune disease.
The idea that MS is the result of a slow infection by a virus or some other 
organism originates primarily from epidemiological studies. The main points of 
evidence for this hypothesis are: the similarity between the lesions of MS and those 
observed in viral diseases such as progressive multifocal leukoencephalopathy and 
subacute sclerosing panencephalitis caused by measles virus (Graves 1984); the 
presence of increased immunoglobulin G (IgG) and oligoclonal bands in the 
cerebrospinal fluid (CSF) of MS patients (Walsh et al 1983) which is a feature of 
many other infectious diseases where the antibody is directed against the aetiologic
25
agent; the detection of antibody to measles (Adams & Imagawa 1962) and other 
viruses (Norrby et al. 1974) in the CSF and serum of patients with MS; and 
evidence from animal models that viral infection can cause demyelinating lesions 
similar to those of MS (Rodriguez 1989). Although many candidates have been 
proposed as the causative agent of MS including spirochetes, mycoplasma, 
protozoa and several viruses (see: McFarlin & McFarland 1982b), the strongest 
argument against this theory is that no infectious organism has been consistently 
isolated from the brain or other tissues of patients with MS. Furthermore, it has 
not been possible to transmit the disease to primates by inoculation with infected 
CNS tissue (Sibley et al. 1980).
It was first suggested that MS might be immunologically mediated due to 
the presence of inflammation and tissue damage occurring in the absence of a 
known infectious agent and the observation of similarities in the pathology of MS, 
other human autoimmune diseases and encephalomyelitis induced in animals by 
administration of CNS tissue (Waksman & Reynolds 1984). There is considerable 
evidence of an active immune response in the CNS of MS patients. Intrathecal 
production of immunoglobulins occurs in 90% of patients and antibodies to MBP 
and other CNS components have been detected in the CSF (Walsh et al. 1983), 
findings which suggest involvement of the humoral immune system. The presence 
of large numbers of T lymphocytes and macrophages in MS lesions (Prineas & 
Wright 1978) indicates that cell-mediated immunity may be important in disease 
pathogenesis. In addition, various immune abnormalities in the peripheral blood of 
patients with MS point to immune regulatory changes in the disease. Furthermore, 
the observation that some immunosuppressive therapies have beneficial effects also 
suggests that immune mechanisms are important in MS (Waksman & Reynolds 
1984).
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Many workers in the field now support the theory that both infection and 
autoimmunity play a role in the pathology of MS. Several hypotheses have been 
put forward (see: McKhann 1982, McFarlin & McFarland 1982b, Rodriguez 1989) 
suggesting that infection of either the immune system, oligodendroglia or other 
CNS cells, triggers directly or indirectly, an autoimmune reaction to components of 
the CNS which results in demyelination. At present none of these hypotheses has 
been proven or disproven and whether the process begins in the CNS or at the 
peripheral level is not clear.
1.1.4 Treatment of MS
The cause and pathogenesis of MS are unknown and at present no 
preventative measures or definitive therapies exist. Treatments used in MS can be 
divided into three groups: 1) those used to control individual symptoms (which are 
not discussed here), 2) experimental therapies aimed at altering the course of the 
disease and 3) adrenocorticotrophic hormone (ACTH) and corticosteroids which 
are used clinically to treat acute relapses. Unfortunately the unpredictability of the 
disease, the occurrence of spontaneous remissions, a marked placebo influence and 
the absence of any reliable indicators of disease activity make it very difficult to 
effectively evaluate potential therapies for MS.
As the pathology of MS appears to have an immunologic component there 
is a rationale for treatment with immunosuppressive therapy. Since the early 
1960's numerous immunosuppressive and immunomodulatory agents have been 
tried in MS, the most extensively studied being the cytostatic global 
immunosuppressives, cyclophosphamide and azathioprine.
Cyclophosphamide is an alkylating agent which acts mainly by cross-linking 
DNA. It has been used in Europe for more than 20 years and several early 
uncontrolled studies concluded that cyclophosphamide reduced relapse rate and
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slowed disease progression (Kappos 1988). These conclusions were confirmed by 
two controlled clinical trials (Hauser et al 1983, Goodkin et al 1987) but because 
of side effects such as nausea, vomiting, alopecia, bladder toxicity and possible 
induction of malignancies, the drug was recommended only for patients with 
rapidly progressive disease. Recently lower doses of cyclophosphamide have been 
reported to be effective in both progressive (Mauch et al 1989) and relapsing- 
remitting MS (Killian et al 1988) with only minor side effects, however other 
workers have been unable to find a beneficial effect (Likosky 1988) and the drug is 
not recommended as a routine treatment.
Azathioprine, a phase-specific anti-metabolite, has been more extensively 
used in MS than any other immunosuppressive agent, partly due to its relatively 
low toxicity. In early uncontrolled studies (Kappos 1988) azathioprine was found 
to be without effect in chronic progressive MS but was reported to reduce relapse 
rate and disease progression in the majority of patients with relapsing-remitting 
disease. However in a large multi-centred, double-blinded placebo-controlled 
study by the British and Dutch Multiple Sclerosis Azathioprine Trial Group (1988) 
the drug was found to be no better than placebo in the first two years, to have only 
marginal effects on disease progression in the third year and it was concluded that 
the benefits obtained were too small to justify the use of azathioprine in relapsing 
and remitting MS.
Cyclosporin A is a newer immunomodulatory agent which has a specific 
and reversible effect on T lymphocyte function and is believed to act primarily by 
preventing the production of interleukin-2 (IL-2). In a clinical trial comparing low 
dose cyclosporin A with azathioprine it was found that although there was no 
significant difference with respect to clinical effect, there was a much higher 
incidence of side effects such as nephrotoxicity and elevated blood pressure in 
cyclosporin treated patients (Kappos etal 1988). Furthermore, following a recent
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double-blind trial of two doses of cyclosporin A versus placebo, the authors 
concluded that the side effects were of such severity as to preclude the use of 
cyclosporin in a high enough dose to alter the course of the disease (Rudge et al
1989).
The anti-viral and immunomodulatory properties of the interferons (IFNs) 
have lead to clinical trials of IFNs a, (3 and y in MS. Several uncontrolled studies 
on the use of IFN-a showed a slight therapeutic benefit, but in a large placebo 
controlled trial IFN-a did not significantly alter disease progression and was 
associated with a substantial number of adverse drug reactions (AUSTIMS 1989). 
Intrathecally administered IFN-P has been found to be effective in reducing 
exacerbations in one controlled trial, however there was no significant effect on 
disease progression and the route of administration is potentially hazardous (Jacobs 
et al. 1987). In one pilot study of IFN-y given to 18 patients with relapsing- 
remitting MS, 7 out of 18 developed an acute exacerbation within the first month 
(Panitch et al. 1987). IFN-y is an immune enhancer and other immune activating 
drugs such as levamisole (Dau et al. 1976) and isoprinosine (Confavreux et al
1986) have also been shown to increase relapse rate and accelerate disease 
progression.
Physical non-pharmacological methods of immunosuppression such as 
plasma exchange (Tindall 1988) and total lymphoid irradiation (Cook et al 1987) 
have also been tried in MS, however conflicting reports exist and the efficacy of 
these procedures has not been proven.
In general the beneficial effects of global immunosuppression in MS appear 
to be relatively small, transient and associated with significant toxicity. Recently 
more disease-specific approaches have been assessed as potential therapies for MS. 
Desensitisation with MBP proved ineffective (Campbell et al 1973) however a 
synthetic peptide, Copolymer 1 (COP 1) originally designed as an MBP analogue
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appeared to cause some reduction in relapse frequency and disease progression in 
patients with early exacerbating and remitting MS, unaccompanied by serious side 
effects (Bomstein et al. 1987). COP 1 is non-toxic and further trials are underway; 
its mechanism of action in MS is not known.
Many different therapies have been tried in MS (see: Amason et al. 1982) 
including other immunosuppressive/immunomodulatory compounds and 
procedures such as d-penicillamine, cytosine arabinoside, selective histamine and 
serotonin antagonists, transfer factor, thymic hormones, immunoglobulins, anti­
lymphocyte serum, lymphocytapheresis, thoracic duct drainage, thymectomy and 
combined treatments; anti-inflammatory agents such as chloroquine and the non­
steroidal anti-inflammatory drugs (NSAIDs); dietary supplements, particularly 
those rich in polyunsaturated fatty acids; and other miscellaneous treatments for 
example protease inhibitors, superoxide dismutase, calcium chelating agents, 
calcium channel blockers, potassium channel blockers and hyperbaric oxygen.
Some have been shown to be ineffective, others are still under investigation, many 
are toxic, and in common with the treatments described earlier none is 
recommended for routine clinical use.
1.1.5 Corticosteroid Therapy in MS
Corticotrophin and corticosteroids were first investigated as possible 
treatments for MS because of their ability to suppress allergic and inflammatory 
reactions, their successful use in the therapy of various autoimmune disorders, and 
because they were effective in suppressing animal models of the disease. Early 
clinical trials of ACTH and steroids in MS produced conflicting results (Merritt et 
al. 1954, Miller etal. 196lab, Tourtellotte & Haerer 1965). However in 1970 the 
National Co-operative ACTH Study Group (Rose et al. 1970) published the results 
of a large multi-centred double-blind study comparing corticotrophin therapy with
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placebo in 197 patients in acute exacerbation, which demonstrated that ACTH 
hastened the improvement of signs and symptoms and that the treatment was 
associated with no major complications or side effects.
In the 20 years since this report was published the use of ACTH and 
corticosteroids for the treatment of acute exacerbations of relapsing-remitting MS 
has become common in neurologic practice (Troiano et al 1987). There is no 
consensus as to whether ACTH or corticosteroids are superior in the treatment of 
MS (Davis & Stefoski 1988, Trioano et al 1989, Poser 1989). Both compounds 
accelerate recovery from relapse thus reducing the duration of disabling symptoms, 
however there is no evidence that they enhance the degree of recovery or modify 
the course of the disease. Side effects associated with short courses of treatment 
are mild and relatively infrequent, the most common reported by Rose et al (1970) 
being: acne (31%), moon face (7%), hirsutism (7%), impaired glucose tolerance 
(5%) and weight gain (5%).
Recently much attention has been focused on the use of pulsed, high-dose, 
intravenous steroids which in early uncontrolled studies showed a very rapid onset 
of improvement, occurring in some cases overnight, or even during perfusion 
(Buckley et al 1982, Goas et al 1983). Subsequent controlled trials confirmed 
that high dose intravenous methylprednisolone was significantly better than placebo 
in both chronic progressive and relapsing-remitting MS (Durelli et al 1986, 
Milligan et al 1987) although in comparative studies this form of treatment 
appeared to be, at best, only marginally more effective than ACTH (Abbruzzese et 
al 1983, Barnes et al 1985, Thompson et al 1989). Nevertheless, high dose 
intravenous steroids are becoming more widely used. The main advantages are 
that they are more easily administered, have a more rapid onset of action (typically 
3-6 days) and are free of serious side effects due to the short duration of use 
(Lyons et al 1988).
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Many early studies demonstrated that chronic treatment of MS with 
conventional doses of steroids had no long term benefit on disease progression in 
either relapsing-remitting or chronic progressive MS (Merritt et al 1954, Miller et 
al. 1961a, Fog 1965, Tourtellotte & Haerer 1965, Miller et al. 1967). Recently it 
has been suggested that long-term high dose corticosteroids (Troiano et al 1987) 
or repeated pulses given at regular intervals (Polman et al 1991) might be effective 
in preventing disease progression. Unfortunately, with this type of regimen, there 
is a risk that patients may develop serious complications such as osteoporosis, 
muscle wasting, recurrent infections, cataracts and psychosis.
The mechanism by which ACTH and corticosteroids hasten recovery from 
acute relapse of MS is not known. It is probable that ACTH acts indirectly by 
stimulating release of endogenous glucocorticoids from the adrenal cortex, 
although it has been postulated that corticotrophin may have direct effects upon the 
immune system and neural tissue independent of corticosteroid release (Davis & 
Stefoski 1988, Poser 1989). Three main theories exist as to the mode of action of 
steroids in MS: 1) a direct effect on nerve conduction, 2 ) an immunologically 
mediated mechanism and 3) resolution of oedema.
Although there is some experimental evidence that steroids may directly 
influence conduction along demyelinated axons (Arnason & Chelmicka-Schorr 
1974) which, it has been suggested, may be due to changes in brain electrolyte 
concentrations (Troiano et al 1987), there is little evidence for this mechanism in 
MS.
Steroids have numerous effects on the immune system and many studies 
have reported normalising effects of steroid treatment on immunologic 
abnormalities present in MS. Elevated intrathecal IgG synthesis and oligoclonal 
band intensity are substantially decreased following treatment with ACTH and 
corticosteroids (Tourtellotte etal 1980, Durelli et al. 1986). Furthermore,
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abnormally high CSF leukocyte numbers (Naess & Nyland 1981), free MBP and 
antibody to MBP (Warren et al. 1986) plus immune complexes and antibody to 
myelin associated glycoprotein (Wajgt et al. 1983) have all been shown to be 
reduced by steroid therapy. Peripherally, steroid treatment has been found to 
return elevated levels of serum soluble IL-2 receptor to normal (Bansil et al. 1991) 
and to reduce the number of circulating T lymphocytes (Kaschka & Hilgers 1980). 
It should be noted however that other groups have found no significant effects of 
steroid treatment on immunologic abnormalities in MS (Compston et al 1987). 
Moreover the importance of these parameters in the pathology of exacerbations is 
not known.
Recently evidence has accumulated from studies using gadolinium enhanced 
MRI and computed tomographic scanning which suggests that blockade of nerve 
conduction in MS is caused by local tissue inflammation and oedema, and that the 
main mechanism of steroid action may be to reverse these processes. Several 
studies have shown that high dose intravenous methylprednisolone substantially 
decreases both the signal intensity and the apparent number of active lesions, 
indicating a reduction in vascular permeability and resolution of oedema (Sears et 
al. 1978, Trioano etal. 1984,1987, Barkhofef al. 1991, Burnham et al. 1991). As 
with clinical improvement, the onset of this effect is very rapid often occurring 
within 8 hours of treatment (Troiano et al. 1984). Presumably restoration of BBB 
integrity also restricts the passage of serum factors and immunocompetent cells 
from the blood into the CNS (Troiano et al. 1984) which may explain the reduction 
in inflammatory infiltrates observed in the brains of steroid treated MS patients at 
postmortem (Guseo & Jellinger 1975).
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1.2 EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS
1.2.1 Induction and Symptoms
Experimental allergic encephalomyelitis (EAE) is a paralytic autoimmune 
disease which is readily inducible in laboratory animals and is widely used as a 
model for MS. EAE was discovered early in the 20th century as a result of 
attempts to explain the occurrence of "paralytic accidents" in some patients 
receiving the Pasteur rabies vaccine. This vaccine consisted of fixed rabies virus 
prepared in rabbit CNS tissue and it was hypothesised by Remlinger (1905) that the 
"paralytic accidents" were caused by the nervous tissue rather than the viral 
component of the vaccine. Subsequently it was shown that rabbits (Stuart & 
Krikorian 1928) and monkeys (Rivers & Schwentker 1935) injected repeatedly 
with CNS tissue developed an acute disseminated encephalomyelitis which shared 
many of the clinical and histological features of post-rabies vaccine encephalitis, 
including the presence of mononuclear perivascular infiltrates and focal areas of 
demyelination in the CNS. These studies represented the first work on what is 
now known as EAE.
In 1947 a further advance was made when Freund and co-workers (Freund 
et al. 1947) discovered that inclusion of an adjuvant comprising killed bacteria, 
paraffin oil and an emulsifying agent with the CNS tissue inoculum, resulted in an 
accelerated form of the disease which was very reproducible and could be induced 
in several species, within 2-3 weeks, following only a single injection of CNS- 
adjuvant emulsion. Gradually it was realised that EAE had many histological and 
pathological similarities to MS and today EAE in its various forms is widely used 
as an experimental model for this disease.
The most extensively studied type of EAE is the acute form caused by 
active sensitisation to CNS antigen. This can be induced in a large number of
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mammalian species including monkeys, rabbits, guinea pigs, rats and mice and also 
in some birds. Susceptibility varies considerably between strains: whereas Lewis 
rats are highly susceptible to EAE, many others such as the Brown Norway are 
strongly resistant to the disease (Levine & Wenk 1963). Active EAE is usually 
induced by subcutaneous depot injection in the flanks, nuchal region or foot pads, 
with an emulsion comprising brain or spinal cord homogenised 1:1 in saline or 
water plus an equal volume of complete Freund's adjuvant (CFA), a mineral oil 
containing an emulsifier and killed mycobacterium (Raine 1984). In the early 
1960's the encephalitogenic, EAE inducing, activity of CNS tissue was found to be 
mainly due to MBP, the major protein constituent of myelin (Kies 1965). Indeed 
purified MBP is now frequently substituted for CNS tissue for the induction of 
EAE.
Following inoculation most animals develop an acute monophasic paralytic 
disease which is invariably fatal in the case of monkeys, rabbits, guinea pigs and 
mice although in the rat EAE is self-limiting and most animals recover. Rats 
sensitised for acute EAE usually develop the disease within 11-14 days of 
immunisation. Initially a sudden and dramatic weight loss is observed, followed 
over a period of about 48 hours by the development of an ascending flaccid 
paralysis starting with limpness of the tail, progressing through ataxic gait caused 
by weakness of the hind legs, to paresis or paralysis of both hind limbs, often 
accompanied by urinary incontinence. Although the symptoms may be very severe, 
the majority of rats recover completely within 4-5 days (Paterson 1976).
A chronic relapsing form of EAE (CREAE) can be induced in some 
animals. Juvenile strain 13 guinea pigs sensitised with spinal cord-CFA develop a 
milder chronic type of EAE, that relapses and remits throughout the life of the 
animal (Snyder et al. 1975). A similar disease is inducible in Lewis rats by
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treatment with low doses of cyclosporin A (Polman et al 1988) or 
cyclophosphamide (Minagawa et al 1987).
In addition to active induction of the disease it is also possible to passively 
transfer EAE by injection of lymphoid cells taken from animals previously 
sensitised to CNS tissue (Paterson 1960). Following inoculation with donor 
lymphoid cells the recipients develop, about 2 -6  days later, a clinical syndrome with 
CNS lesions which appear to be identical to those found in actively induced EAE. 
Stimulation of the cells in vitro with MBP greatly increases the efficiency of 
adoptive transfer (Driscoll et al 1979).
1.2.2 Histology. Pathology and Comparison with MS
Animals inoculated for EAE develop lesions in the CNS consisting of focal 
areas of perivascular inflammation accompanied by varying degrees of myelin 
damage, which share many similarities with those found in the brains of patients 
with MS. In EAE as in MS, the white matter is more affected than the grey and 
lesions are most often found near the ventricular system, in the subcortical white 
matter and in the brain stem and spinal cord (Paterson 1978).
Lesions generally form around small veins or venules. The earliest 
abnormal findings observed in the CNS of EAE-inoculated animals are: increased 
permeability of the BBB (Oldstone & Dixon 1968); expression of la antigens by 
CNS vascular endothelium (Hickey et al 1985); and a low grade diffuse infiltration 
of the CNS by T lymphocytes (Traugott et al 1982). These changes occur within 
the first few days of inoculation, well before the appearance of neurological signs 
(Juhler 1988, Traugott 1989).
Just preceding the onset of symptoms, extensive vasogenic oedema 
develops in the CNS (Leibowitz & Kennedy 1972, Oldendorf & Towner 1974) and 
there is a massive invasion of the target tissue by large numbers of inflammatory
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cells (Paterson 1976, Raine 1984). Mononuclear cells cross the blood vessel walls 
and accumulate in the perivascular space forming thick concentric layers. These 
perivascular infiltrates are composed predominantly of monocytes/macrophages 
plus some B lymphocytes and a few plasma cells; T lymphocytes are found 
scattered throughout the white matter parenchyma (Traugott et al. 1982). Myelin 
breakdown occurs shortly after the arrival of mononuclear cells (Raine 1984). In 
acute EAE demyelination is slight, but in chronic-relapsing models myelin loss may 
be extensive (Shaw & Alvord 1984) and some remyelination occurs at the edge of 
lesions (Raine 1984). At the same time as the appearance of the first inflammatory 
infiltrates astrocytes proliferate and become hypertrophied (Smith & Eng 1988), 
and microglia accumulate particularly in the vicinity of the lesions (Matsumoto et 
al. 1986). In chronic EAE as the disease progresses, fibrous astrocytes move into 
demyelinated areas and form dense gliotic scars similar to those observed in MS 
(Raine 1984, Smith & Eng 1988).
In early studies it was observed that the lesions of EAE resembled those of 
delayed-type hypersensitivity reactions (see: Paterson 1976). Since that time, 
compelling evidence has accumulated that EAE is primarily a T cell-mediated 
disease, although B cell-mediated humoural mechanisms probably also play a role 
in the pathology (Waksman & Reynolds 1984, Juhler 1988). A strong indication 
that the disease had an immunological basis was provided by the observation that 
removal of lymph nodes draining the site of inoculation prevented the development 
of EAE (Condie & Good 1959) and this was substantiated by the demonstration 
that EAE could be passively transferred with sensitised lymphoid cells (Paterson 
1960). The importance of thymic function was established by studies which 
showed that thymectomized rats were resistant to EAE (Amason et al. 1962), but 
in the chicken, removal of the bursa of fabricius (the B cell organ in birds) did not 
significantly inhibit disease induction (Blaw et al. 1967). Later, complex
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experiments in Lewis rats involving depletion of immune cells and reconstitution of 
the bone marrow with various lymphocyte subsets confirmed that T cells are a 
prerequisite for the induction of EAE (Gonatas & Howard 1974).
T lymphocytes are the first cells to appear in the CNS following 
inoculation. How these cells gain entry into what is normally an immunologically 
privileged site is not known, but it has been proposed that expression of la antigens 
by vascular endothelial cells may promote adherence and subsequent penetration of 
activated lymphocytes (Wisniewski et al. 1982), and increased BBB permeability 
may also aid entry of immune reactive agents normally excluded (Juhler 1988). 
Primary invasion of the CNS by a small number of specific T cells is then followed 
by recruitment of large numbers of activated non-specific monocytes/macrophages 
and smaller numbers of specific and non-specific T and B lymphocytes (Waksman 
& Reynolds 1984).
Demyelination is almost certainly attributable to macrophages. Electron 
microscopical studies indicate that there appear to be two different mechanisms by 
which these cells damage the myelin sheath: de-lamination via extension of cell 
processes between the myelin lamellae, and lysis caused by release of soluble 
factors (Lampert & Carpenter 1965, Wisniewski 1977). Myelinolysis is probably 
enzymatic and may be mediated by proteases (Cammer et al. 1978) and/or lipolytic 
enzymes (Vogel 1950) such as PLA2 ? which is abundant in macrophages and has 
been found to digest myelin in vitro (Trotter & Smith 1984).
Although some workers have postulated that the clinical signs of EAE are 
due to demyelination and their disappearance a consequence of remyelination 
(Pender 1989), it has been argued that the transience of symptoms and the speed 
with which animals recover is not compatible with this mechanism (Simmons et al.
1981). Paterson (1982) found no relationship between neurological signs and the 
presence of inflammatory demyelinating lesions but did observe a close correlation
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between signs and intra-CNS fibrin deposition, a phenomenon associated with 
accumulation of fluid in the extracellular space. Other studies have also 
demonstrated the occurrence of a dramatic increase in CNS vascular permeability 
concomitant with the onset of clinical symptoms (Leibowitz & Kennedy 1972, 
Oldendorf & Towner 1974, Simmons etal 1982), and it has been speculated that 
build up of fluid within the physically limited space of the CNS compartment may 
cause increased pressure on nerve fibres, resulting in nerve dysfunction and the 
characteristic neurological signs of EAE (Paterson 1982, Simmons etal 1982).
From the foregoing description of the clinical signs, histology and 
pathology of EAE, it is clear that although there are some important differences, 
the disease has many similarities with the human condition MS (see Table I for 
summary). It has been suggested that the course of disease and pathological 
changes in acute EAE are more analogous to early neuropathological events in 
MS, whereas the chronic relapsing model is more representative of the situation in 
chronic MS (Raine 1984) and moreover, where the human and animal diseases do 
diverge this is probably due to a difference in time scale rather than the nature of 
the disease process (Liebowitz 1983).
1.2.3 Modulation bv Drugs and Immunotherapy
In the search for new drugs which might be of use in the treatment of MS, 
many compounds have been studied for their ability to influence the course of 
EAE. Most investigations have concentrated on inhibition/prevention (drug 
administered prior to sensitisation) or suppression (drug administered after 
sensitisation but before the onset of neurological signs). Fewer, because of the 
practical difficulties involved, have explored treatment of the disease, where the 
drug is administered therapeutically after signs have developed, although this is 
clearly most relevant to the clinical situation in MS. Despite the very large number
39
Table I
Summary of the main similarities and differences between MS and EAE
EAE MS
Relapsing and chronic paralysis + +
Predilection of lesions for white matter + +
Perivascular inflammatory infiltrates: + +
CD4+ T-cells + +
Macrophages + +
CNS demyelination + +
Axonal survival + +
Meningitis + +
Elevated CSF IgG + +
Antibodies to CNS antigens in CSF + +
IgG deposition in areas of injury + +
Circulating glial cell and myelinotoxic + +
antibodies
Cutaneous DTH reaction to CNS antigens + 0
Autoantigens MBP, PLP ?
Linkage to MHC Class II + +
T-cell mediated pathogenesis + ?
Known aetiology +
Sources: Paterson 1978, Zamvil & Steinman 1990 
DTH, delayed-type hypersensitivity; PLP, proteolipid protein
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of drugs tested, the majority of active compounds fall into one of two categories: 
immunosuppressive/immunomodulatory agents and anti-inflammatory drugs.
Many of the early cytotoxic immunosuppressives were found to be effective 
in modulating EAE. In 1952 Kolb and co-workers reported that nitrogen mustard 
caused a significant decrease in paralysis and mortality of EAE-inoculated guinea 
pigs. Subsequently, other alkylating agents were shown to be active. 
Cyclophosphamide was found to completely prevent both the development of 
disease symptoms and the appearance of inflammatory lesions in the CNS of Lewis 
rats (Rosenthale etal 1969). Furthermore, the drug reversed disease progression 
in rats with advanced paralytic signs (Paterson & Drobish 1969). Purine and 
pyrimidine analogues such as 6 -mercaptopurine, thioguanine and azathioprine were 
also observed to be potent in preventing and suppressing the disease (Rosenthale et 
al 1969, Komarek & Dietrich 1971), as was the folic acid antagonist methotrexate 
(Rosenthale et al 1969).
Many of the newer immunosuppressive and immunomodulatory agents also 
exhibit disease modifying activity in EAE. Cyclosporin A, a fungal peptide with 
powerful immunosuppressive properties, inhibits both humoural and cell-mediated 
allergic reactions, probably by preventing the action and production of IL-2 (Borel 
et al 1976). Prophylactic administration of cyclosporin A has been shown to 
prevent the appearance of clinical and pathological signs of EAE in rats, guinea 
pigs and primates (Bolton etal 1982b). Furthermore in each species, treatment of 
established disease was found to reduce both the frequency and severity of 
symptoms and the number of CNS lesions. Cyclosporin A also inhibits adoptively 
transferred EAE if spleen cells are cultured with the drug prior to transfer, and the 
incidence of disease is reduced when recipient animals are pretreated with this 
agent (Bolton etal 1982a). Unfortunately as discussed earlier, cyclosporin A 
appears to be too toxic for use in MS (Rudge et al 1989).
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FK506 is a relatively new immunomodulatory agent isolated from the 
fermentation broth of Streptomyces tsukubaensis. This compound probably has a 
similar mode of action to cyclosporin A although it appears to be more potent 
(Kino et al 1987ab). FK506 has been shown to prevent the development of 
neurological signs of EAE in Lewis rats dosed during the induction phase of the 
disease. Also the cutaneous delayed-type hypersensitivity reaction to MBP and 
serum anti-MBP antibodies were completely suppressed in these animals (Inamura 
et al 1988). Recently FK506 has been demonstrated to inhibit adoptive transfer of 
EAE (Bolton 1992). At present FK506 is undergoing clinical trials for use in the 
management of organ transplantation and has yet to be examined in MS.
Another immunosuppressive drug that appears to be active in EAE is 15- 
Deoxyspergualin, which has recently been shown to suppress acute EAE and to 
prevent relapses of CREAE in the Lewis rat (Schorlemmer & Seiler 1991). Again 
this compound has been used in organ transplantation, but has not yet been tested 
in MS.
It should be noted that not all immunomodulatory compounds found to be 
effective in EAE are of benefit in the treatment of MS. A case in point is IFN-y, 
which has been shown to completely suppress clinical signs of EAE in the Lewis 
rat (Voorthuis et al 1990) but cause an increase in the exacerbation rate when 
administered to patients with MS (Panitch et al 1987).
The other main group of compounds containing many members effective in 
modulating EAE are the anti-inflammatory agents, which tend to act by inhibiting 
the generation of phospholipid derived pro-inflammatory mediators. Anti­
inflammatory steroids which inhibit the production of both eicosanoids and platelet 
activating factor (PAF) are very effective in modulating EAE and will be discussed 
in detail in the next section. In contrast NSAIDs such as aspirin, indomethacin and 
phenylbutazone which prevent production of prostaglandins (PGs) by inhibiting
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cyclo-oxygenase are ineffective (Rosenthale et al 1969) and may even exacerbate 
the disease (Bolton & Cuzner 1980, Ovadia & Paterson 1982), although it is not 
known whether this is caused by specific immunological enhancement related to 
inhibition of PG synthesis or due to increased toxicity resulting from disease related 
metabolic disturbances (Levine & Sowinski 1980). Interestingly, the dual cyclo- 
oxygenase/lipoxygenase inhibitor BW755C which blocks generation of both PGs 
and leukotrienes (LTs) has recently been shown by Prosiegel et al (1989a) to 
suppress EAE in guinea pigs but unfortunately this compound is too toxic for use 
in humans. The same group have demonstrated that sulphasalazine, which has a 
selective inhibitory effect on LTs, is also effective and they have suggested that the 
drug, which is frequently used clinically in the treatment of inflammatory bowel 
disease, be investigated for activity in MS (Proseigel et al 1989b). However, it 
should be noted that other workers have reported sulphasalazine to have no 
beneficial effects in EAE (Uitdehaag et al 1991, Correale et al 1991). Other 
mechanistically related compounds that have recently been tested in EAE are the 
LTB4  receptor antagonist SC-14930 which was found to cause some inhibition of 
EAE in the guinea pig (Fretland et al 1991) and the PAF antagonists PC A 4248 
and WEB 2170 which do not appear to protect against the development of EAE in 
the Lewis rat (Vela et al 1991).
Another approach to the treatment of MS has been to investigate ways of 
specifically manipulating the immune system. It has long been known that EAE 
can be prevented, suppressed and treated by administration of whole white matter, 
purified MBP, MBP fragments and random copolymers such as COP 1 (see: 
Paterson 1976,1978). This early work has led to more sophisticated approaches 
and one strategy which is currently being pursued is prevention of T cell activation 
by inhibition of the interaction between antigen, MHC and the T cell receptor 
(TCR) using either MBP peptides (Sakai et al 1989), anti-class II MHC antibodies
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(Steinman et al. 1981) or anti-TCR antibodies (Owhashi & Heber-Katz 1988). 
Another approach which is being investigated is vaccination against autoreactive T 
cells by immunisation with attenuated T lymphocytes (Ben-Nun et al. 1981) or 
synthetic T cell receptor peptides (Vandenbark et al. 1989, Howell et al. 1989). 
With the exception of MBP, which was found to be ineffective (Campbell et al. 
1973), and COP 1, which appeared to be of only limited benefit (Bornstein et al.
1987), specific immunotherapy has yet to be tried in MS.
1.2.4 Exogenous and Endogenous Steroids in EAE
A large number of studies have shown that prophylactic dosing with 
corticosteroids or corticotrophin beginning at or just after sensitisation, is very 
effective in suppressing both the neurological signs and CNS lesions of EAE in a 
variety of species including rats (Rosenthale et al. 1969, Komarek & Dietrich 
1971, Bolton & Flower 1989), guinea pigs (Moyer et al. 1950, Field & Miller 
1962) and monkeys (Kabat et al. 1952). In a comparative study in the rat, 19 out 
of 21 different steroid compounds were observed to be active in preventing EAE 
and fluorinated steroids were found to be considerably more potent than either 
alkylating agents or anti-metabolites (Komarek & Dietrich 1971). Corticosteroids 
are also effective therapeutically. In rodents administration of steroids after the 
onset of neurological signs reduces the severity of symptoms and shortens disease 
duration, indicating that steroids have the ability to reverse established disease 
(Greig et al. 1970, Levine & Sowinski 1980, Steiner et al. 1991). Furthermore, it 
has been demonstrated that passive transfer of EAE may be inhibited either by 
dosing the recipient animals with dexamethasone (Levine & Strebel 1969), or by 
incubation of sensitised cells with physiological concentrations of corticosterone 
prior to transfer (Leonard et al. 1990).
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Recently a great deal of evidence has accumulated that endogenous 
corticosteroids may influence disease activity in EAE. Environmental stress such 
as that caused by enforced physical restraint or electric shock, applied after 
immunisation, has been shown to suppress the development of clinical and 
histological signs of both actively induced (Levine et al 1962a, Bukilica et al
1991) and adoptively transferred EAE (Levine & Strebel 1969), an effect which is 
probably mediated by stress-induced release of corticosteroids from the adrenal 
cortex. Moreover, it appears that endogenous adrenal steroids are responsible for 
the spontaneous recovery from EAE which is observed in some species. Several 
studies in the rat have demonstrated that plasma corticosterone levels rise 
dramatically with the onset of neurological symptoms, peak just before the 
initiation of recovery and then return to basal levels following remission (Levine et 
al 1980, MacPhee etal 1989, Mackenzie etal 1989, Leonard etal 1990). If 
this glucocorticoid surge is prevented by removal of the adrenals prior to 
inoculation (Levine et al 1962b, MacPhee et al 1989) or antagonised by treatment 
during induction with the anti-glucocorticoid RU 38486 (Bolton & Flower 1989) 
disease severity is markedly increased and recovery usually abolished. The effect 
of adrenalectomy (Adx) on disease progression can be completely reversed by 
corticosteroid replacement therapy at levels which mimic those normally produced 
during EAE (MacPhee et al 1989). Interestingly Adx (Levine et al 1980) or anti­
glucocorticoid treatment (Bolton & Flower 1989) of convalescent rats can 
precipitate a relapse of symptoms indicating that endogenous steroids may be 
important not only for the induction, but also the maintenance of clinical remission.
The mechanism of action of exogenous and endogenous steroids in 
recovery from EAE has not been explored in detail. Glucocorticoids have 
powerful anti-inflammatory effects which appear to be due to their inhibitory action 
on inflammatory mediator production (Flower 1988), but they also suppress the
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immune response in a number of ways (Fauci 1979) and influence the permeability 
of the blood-brain barrier (Long & Holaday 1985). Presumably any or all of these 
effects may be relevant to their mode of action in EAE.
1.3 LIPOCORTINS AND THE MECHANISM OF STEROID ACTION
The unexpected discovery in 1949 that cortisone dramatically reduced the 
symptoms of rheumatoid arthritis (Hench et al 1949), heralded a new era in the 
treatment of inflammatory disease. Since that time steroids have become widely 
used in the therapy of many inflammatory conditions including MS, rheumatoid 
arthritis, asthma and psoriasis.
The anti-inflammatory steroids are all analogues of hydrocortisone, a 
naturally occurring steroid hormone released by the adrenal cortex and involved in 
glucose homeostasis. Extensive studies have shown that these compounds 
influence virtually every phase and component of the inflammatory and immune 
responses (see: Fauci 1979). One of the main actions of steroids is to prevent the 
accumulation of leukocytes at sites of inflammation and immune reactivity.
Another important effect is their ability to inhibit the synthesis of, and cellular 
responsiveness to, many immune and inflammatory mediators such as IFNs, ILs, 
PGs, LTs, PAF, bradykinin, histamine and neutral proteases. In addition, steroids 
appear to influence many aspects of leukocyte function for example: cellular 
activation, proliferation, differentiation, phagocytosis and antigen processing, 
although many of these effects have been observed in vitro and it is not clear if they 
occur at physiologically/pharmacologically relevant concentrations in vivo.
As well as their ability to regulate immune and inflammatory responses, 
glucocorticoids also play an important physiological role in the homeostasis of
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substrates for energy production. They have profound effects on carbohydrate, 
protein and fat metabolism which unfortunately are responsible for most of the side 
effects associated with steroid therapy. Acute dosage is generally well tolerated, 
but chronic treatment can result in the development of buffalo hump, moon face, a 
tendency to bruise easily, hypertension, osteoporosis, muscle wasting, skin thinning 
and glaucoma due to metabolic disturbances, and decreased resistance to infection 
caused by immunosuppression. Thus the use of these potent and very powerful 
drugs in chronic disease is often limited by the side effects which frequently arise 
from prolonged treatment (Flower & Dale 1989).
1.3.1 Early Studies on the Mechanism of Steroid Action (1971 - 1984)
Over the last two decades a great deal of work has been done to elucidate 
the mechanism by which steroids exert their anti-inflammatory actions. In 1971 it 
was discovered that the anti-inflammatory effects of aspirin and other NSAIDS 
were due to inhibition of cyclo-oxygenase, the enzyme responsible for synthesis of 
PGs from arachidonic acid (Vane 1971). Steroids were found to be inactive 
against cyclo-oxygenase (Flower et al. 1972), however several studies then 
demonstrated that glucocorticoids were able to block PG release (Herbaczynska- 
Cedro & Staszewska-Barczak 1974, Lewis & Piper 1975) but not the conversion 
of exogenous arachidonic acid (Gryglewski et al 1975, Nijkamp et al. 1976). 
Subsequently, experiments utilising radio-labelled phospholipids determined that 
glucocorticoids were preventing eicosanoid production by inhibiting the release of 
arachidonic acid (Hong & Levine 1976, Blackwell et al. 1978). Since the rate 
limiting step in eicosanoid generation was thought to be the PLA2  catalysed 
hydrolysis of arachidonic acid from membrane phospholipids, these studies 
suggested that steroids may be having a specific inhibitory effect on this enzyme.
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At about this time it was realised that most, if not all, steroid actions are 
mediated indirectly via what is now known as the "classical pathway of steroid 
action" where binding of the steroid to a specific cytoplasmic receptor is followed 
by translocation of the activated steroid-receptor complex to the nucleus. Here it 
binds to specific sites on the DNA, initiating transcription of mRNA and the 
synthesis of new protein (Buller & O'Malley 1976, Baxter 1976, Munck & Leung 
1977). These proteins are the effectors through which steroid actions are brought 
about, with different effects being mediated by different proteins. Discovery of the 
classical pathway prompted several workers to investigate whether glucocorticoids 
were inducing a protein inhibitor of PLA2 .
Subsequently it was demonstrated by a number of groups, using various in 
vitro systems, that inhibition of eicosanoid synthesis by steroids, correlated with 
and was dependent upon glucocorticoid receptor occupancy, and could be 
abolished by inhibitors of RNA and protein synthesis (Danon & Assouline 1978, 
Flower & Blackwell 1979, Di Rosa & Persico 1979, Russo-Marie et al 1979, 
Hirata et al. 1980, Russo-Marie & Duval 1982). Each group then set about 
isolating and identifying the proteins that might be responsible for the PLA2  
inhibitory actions of the anti-inflammatory steroids.
Using the isolated guinea pig perfused lung, Flower, Blackwell and 
colleagues at the Wellcome Laboratories in Kent, demonstrated that steroids 
caused release of an anti-phospholipase factor which could be destroyed by boiling 
or proteolytic enzymes (Flower & Blackwell 1979). At the same time Di Rosa and 
co-workers at the University of Naples observed that glucocorticoid inhibition of 
PG production by rat peritoneal lavage cells was also mediated by release of a 
phospholipase inhibitory protein (Camuccio et al. 1980). Collaborative studies by 
the Wellcome and Naples groups showed that the two factors were probably the 
same substance, a polypeptide with a molecular mass of about 15 kDa which was
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named macrocortin (Blackwell et ah 1980). Partial purification of macrocortin 
from the peritoneal lavage fluid of steroid treated rats revealed several different 
peptides with anti-phospholipase activity, the most prominent species having 
molecular masses of 40 and 15 kDa (Blackwell et ah 1982). Further purification 
using a PLA2  affinity column yielded a highly purified 41 kDa protein (Parente & 
Flower 1985a).
Another group working at the National Institute of Health in Bethesda, 
observed that prevention of neutrophil chemotaxis by steroids involved inhibition 
of PLA2  and concluded that this was due to the induction of a protein inhibitor of 
the enzyme which appeared to have a molecular mass of approximately 40 kDa 
(Hirata et ah 1980) and was named lipomodulin (Hirata et ah 1981). Lipomodulin 
was purified to near homogeneity from conditioned media from primary cultures of 
rabbit neutrophils stimulated with glucocorticoids and the molecular mass of the 
predominant species was 40 kDa although others of 15 and 25-30 were also found 
(Hirata 1983).
Yet another group, headed by Russo-Marie at the Necker Hospital in Paris, 
were investigating the inhibitory effect of corticosteroids on PG release from 
cultured rat renomedullary cells. They found that abolition of eicosanoid 
production was due to inhibition of phospholipase and that this was caused by 
generation of a heat-labile, non-dialysable factor which they termed renocortin 
(Cloix et ah 1983). Partial purification of renocortin from the culture supernatants 
of dexamethasone treated cells revealed two species of 15 and 30 kDa and another 
of 45 kDa in the absence of serum (Rothhut et ah 1983).
Collaborative work by the three groups lead them to conclude that 
macrocortin, lipomodulin and renocortin were functionally identical and that the 
disparity in molecular weights was probably due to proteolysis. In 1984 the 
composite name lipocortin was agreed (Di Rosa et ah 1984).
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1.3.2 The Lipocortins fl980 - 1987)
The lipocortins were defined by their discoverers as steroid-modulated anti- 
phospholipase proteins which might be responsible, in part, for the anti­
inflammatory effects of the glucocorticoids (Di Rosa et al 1984).
1.3.2.1 Inhibition of PLA2
In most of the original experiments evidence for the inhibition of PLA2  by 
lipocortins was only circumstantial. In 1981, Hirata was the first to demonstrate 
inhibition of the enzyme by purified lipocortin in a cell-free assay system. Using 
micellular phosphatidylcholine as a substrate, lipocortin was shown to inhibit 
porcine pancreatic, snake venom and bee venom PLA2  enzymes in a concentration 
dependent manner (Hirata 1981). A further study (Hirata 1983) suggested that a 
stoichiometric complex was formed between enzyme and inhibitor, and that 
lipocortin altered the Vmax of the reaction but not the Km of the enzyme. 
Inhibition of the pancreatic enzyme by purified lipocortin was confirmed by other 
workers using pure phospholipid vesicles (Blackwell et al 1982) or [^Hjoleate 
labelled E. coli (Rothhut et al 1983).
The most likely target however, for down regulation of eicosanoid release 
by anti-phospholipase proteins is the calcium-dependent membrane-bound enzyme. 
Studies showing that lipocortins could prevent arachidonic acid release from rabbit 
neutrophil (Hirata et al 1980) and rat renomedullary cell (Russo-Marie & Duval
1982) membranes, strongly suggested an inhibitory effect on endogenous PLA2 , 
and subsequently lipocortin inhibition of macrophage membrane PLA2  was 
demonstrated directly (Blackwell 1983, Ghiara et al. 1984).
It was also observed that lipocortins could be phosphorylated by a cAMP- 
dependent protein kinase and that phosphorylation caused a decrease in anti-
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phospholipase activity (Hirata 1981) which was reversible by treatment with 
alkaline phosphatase (Hirata et al 1982). Phosphorylation/dephosphorylation of 
lipocortins was suggested to be a mechanism by which the anti-phospholipase 
activity of these proteins might be regulated in vivo.
1.3.2.2 Modulation by Steroids
Lipocortin-like activity was first detected in vitro in culture supernatants 
from steroid-treated neutrophils, peritoneal leukocytes and renomedullary cells and 
in the perfusion effluent of steroid-treated lungs (Hirata et al. 1980, Blackwell et 
al. 1980, Cloix et al. 1983). Detailed studies on the time course of steroid-induced 
release of anti-phospholipase proteins using rat peritoneal lavage cells, suggested a 
biphasic response to steroid treatment occurred in these cells, with an initial rapid 
release of existing pools after about 30 minutes, followed by a slower phase of 
resynthesis and further release after approximately 4-5 hours (Blackwell et al.
1980, Camuccio et al. 1981). Furthermore, it was demonstrated that lipocortin 
secretion from peritoneal leukocytes was specific for glucocorticoids and did not 
occur in response to other steroids or non-steroid macrophage activation 
(Blackwell 1983). Human tissues were also found to synthesise and release 
lipocortins following in vitro treatment of embroyonic skin fibroblasts (Errasfa et 
al. 1985) and endometrium fragments (Gurpide et al. 1986) with dexamethasone.
In addition to these in vitro studies, steroid induction of anti-phospholipase 
proteins was also observed in vivo. Blackwell et al. (1982) showed that lipocortin- 
like activity in the peritoneal lavage fluid of rats was increased by injection of 
dexamethasone or hydrocortisone, but not if the animals were first treated with 
inhibitors of RNA/protein synthesis. Furthermore, the presence of much lower 
levels of anti-phospholipase proteins in the lavage fluid of Adx rats, coupled with 
the observation that treatment with ACTH induced release of the proteins in
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normal but not Adx animals, suggested that lipocortin levels were normally 
regulated by endogenous glucocorticoids. In another study utilising immunoassay 
techniques, lipocortin-immunoreactivity was detected in all tissues of the rat and 
guinea pig and following treatment with dexamethasone, immunoreactivity was 
found to be increased in almost all organs except some gastrointestinal tissues 
(Flower 1984).
J.3.2.3 Anti-inflammatory Effects
Evidence that lipocortins were steroid modulated and possessed the ability 
to inhibit PLA2  was followed by experiments showing that the purified proteins 
were able to mimic many of the anti-inflammatory effects of the glucocorticoids.
In vitro studies demonstrated that, like the glucocorticoids, lipocortins 
suppressed production of both cyclo-oxygenase and lipoxygenase derived 
mediators. In initial experiments crude extracts of anti-phospholipase proteins 
were found to inhibit thromboxane release from the guinea pig perfused lung 
(Blackwell et al 1980), PGE2  production by rat leukocytes (Di Rosa & Persico 
1979, Blackwell etal. 1980, Camuccio etal. 1980,1981) and renomedullary cells 
(Russo-Marie & Duval 1982), and the release of arachidonic acid from cultured 
fibroblasts (Hirata et al 1981). Subsequently it was shown that partially purified 
lipocortin inhibited production of PGE2  and LTB4  by phagocytosing rat peritoneal 
leukocytes (Parente et al 1984), and that the PLA2 -affinity purified protein 
blocked zymosan-induced release of lyso-PAF from these cells (Parente & Flower 
1985a), effects which were reversed by a specific anti-lipocortin monoclonal, 
RM23. Moreover, studies demonstrating that the inhibitory effects of steroids on 
PG release from macrophages (Flower 1984) and human fibroblasts (Errasfa et al
1985) could be prevented by lipocortin antibodies, suggested that lipocortin release 
occurred physiologically.
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Consistent with their proposed function as second messengers of the anti­
inflammatory effects of the glucocorticoids, lipocortins were demonstrated to be 
active in vivo, suppressing animal models of inflammation. Blackwell et al (1982) 
observed that crude extracts of peritoneal lavage fluid from dexamethasone treated 
rats, inhibited fluid exudation and leukocyte accumulation associated with 
carrageenan-induced pleurisy, when injected into the pleural cavity. Partially 
purified lipocortins were shown to exhibit local anti-inflammatory properties in the 
rat carrageenan paw oedema model (Parente et al 1984, Calignano et al 1985).
Work by Hirata's group suggested that lipocortins might be implicated in 
some of the immunosuppressive actions of corticosteroids. Hirata and Iwata 
(1983) demonstrated that lipocortin was released by T lymphocytes and that the 
purified protein inhibited the proliferative response of thymocytes to mitogens such 
as phytohaemagglutinin and concanavalin A. Furthermore, they showed that 
whereas lipocortin antibody caused a selective loss of suppressor function, culture 
of thymocytes with lipocortin, inhibited proliferation of T helper cells and 
promoted the maturation of T suppressors suggesting that lipocortins had the 
ability to modulate T cell subset ratios. In other studies purified lipocortins were 
found to suppress the IgE response (Uede et al 1983), inhibit natural killer activity 
and antibody-dependent cellular cytotoxicity (Hattori et al 1983 a), and block IL-2 
production by T helper cells (Hirata 1984).
In addition, purified lipocortin was also shown to mimic other effects of 
steroids such as induction of differentiation (Hattori et al 1983b), their protective 
action in reperfusion injury (Koltai et al 1984) and teratogenic effects (Gupta et 
al 1984).
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1.3.2.4 Sequencing, Cloning and Relationships to Other Proteins
In 1986 workers at Biogen, Massachusetts, purified and partially sequenced 
a 37 kDa protein which was the major PLA2  inhibitor present in rat peritoneal 
lavage fluid (Pepinsky et al. 1986). Using amino acid sequence information from 
the rat protein, the human gene was located in a U937 cDNA library, cloned and 
expressed in E. coli, resulting in the availability, for the first time, of large amounts 
of highly purified recombinant protein (Wallner et al 1986). In a further study on 
anti-phospholipase proteins in human placental extracts, two different species of 
lipocortin were observed. One was identical to the recombinant protein and was 
named lipocortin I. The other which was of a similar molecular mass and shared 
approximately 50% sequence homology was labelled lipocortin II (Huang et al.
1986).
A suprise finding which emerged following the sequencing of lipocortins I 
and II (Pepinsky & Sinclair 1986, Huang et al 1986) was that lipocortin I was 
identical with a protein termed p35, which was first isolated as an endogenous 
substrate for the epidermal growth factor receptor/kinase from A431 cells (Fava & 
Cohen 1984). Furthermore, lipocortin II was found to be the human analogue of 
p36 from bovine intestinal brush borders, a major substrate for the viral oncogene 
kinase pp60v"src (Gerke & Weber 1984). Moreover, it soon became apparent that 
calpactin II a protein with calcium, phospholipid and actin binding properties, 
thought to be involved in cytoskeletal biochemistry or vesicle secretion, was also 
identical to lipocortin I (Glenney et al 1987).
Further studies by the Biogen group extended the known number of 
lipocortins to six (Pepinsky et al 1988). Gradually it was realised that the 
lipocortins were structurally related to many other proteins which had been 
independently isolated from a variety of tissues and named according to their 
source and properties, such as the placental anti-coagulant proteins (Funakoshi et
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al. 1987b), calelectrins (Geisow & Walker 1986), chromobindins (Creutz et al.
1987), endonexins (Geisow & Walker 1986), calcimedins (Smith & Dedman 1986) 
and synexin (Bums et al. 1989). The independent discovery, by several different 
groups, of proteins with apparently diverse biological functions, has resulted in a 
confused literature with many different names describing the same protein.
Recently it has been proposed (Crumpton & Dedman 1990) that the name annexin 
(Geisow 1986) followed by the numbering system of the lipocortins (Pepinsky et 
al. 1988) be adopted.
1.3.3 The Annexin Family of Proteins (1987 - To Date)
The annexins are an exceptionally homologous group of proteins, with 
different proteins sharing approximately 50% sequence identity, and interspecies 
identities for the same protein ranging from 85-98% (Pepinsky et al 1988). To 
date twelve different members of the annexin family have been identified (Table II). 
The common structural feature present in all these proteins is a core region 
comprised of multiple copies of a 70 amino acid residue sequence. Within each of 
these repeats there is a very highly conserved 17 amino acid consensus sequence 
which was the first structural feature to be recognised as a common theme in these 
proteins (Kretsinger & Creutz 1986, Geisow et al. 1986). Most annexins have a 
molecular mass in the range 30-40 kDa and contain four copies of this motif (Saris 
et al. 1986, Pepinsky et al. 1988). Annexin VI which has a molecular mass of 
approximately 6 8  kDa has eight (Moss et al. 1988).
The core domain of each protein is preceded by an amino terminal sequence 
which although variable in length, is generally shorter and is unique to each protein. 
In many annexins the N-terminal region carries sites for phosphorylation by 
tyrosine (Glenney & Tack 1985, Pepinsky & Sinclair 1986) and serine-threonine 
kinases (Schlaepfer & Haigler 1988) and this region of annexins I and II has been
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Table H
The annexin family of proteins
Annexin Mr Schematic Structure
N-terminal Core
I 38  1 H H H I
II 38  1----H— H— H I
ro III 35  CZHHICZ1CZ]
IV 3 5  H H M H I




Lipocortin 1, p35, Calpactin II, Chromobindin 9, 
GIF
Lipocortin II, p36, Calpactin I, Chromobindin 8 ,
Protein I, PAP-IV
/
Lipocortin III, PAP III, 35-a Calcimedin
Lipocortin IV, Endonexin I, Protein II, 32.5k 
Calelectrin, Chromobindin 4, PAP II, PP4-X, 35-P 
Calcimedin
Lipocortin V, IBC, PAP I, 35k Calelectrin, 
Endonexin II, PP4, VAC-a, 35-y Calcimedin, 
Anchorin CD, Calphobindin I, Chromobindin 5
Lipocortin VI, p6 8 , p70, p73, 67k Calelectrin, 
Protein III, Chromobindin 20, 67k Calcimedin, 
Calphobindin II
VII 47  lb HZZHZIKZ3 Synexin
VIII 37  1-----H— H--- H— I VAC-P
p35, p36 - kinase substrates
p35 was originally isolated as the major substrate for the epidermal growth factor receptor/kinase from the A431 human carcinoma cell 
line (Fava & Cohen 1984). p36 was isolated from bovine intestinal brush borders as a substrate for the viral oncogene kinase pp60v“src 
(Gerke & Weber 1984). As kinase substrates these proteins are thought to be involved in the mitogenic signal transduction pathway and 
thus the regulation of cell growth and replication.
Calpactins
The calpactins were so named because of their calcium-dependent interaction with phospholipids and actin. Calpactin I is a heterotetramer 
composed of two 36 kDa heavy chains of annexin II and two 11 kDa light chains belonging to the SI 00 protein family (Glenney & Tack 
1985). Calpactin I has been shown to promote fusion of adrenal chromaffin granules (Drust & Creutz 1988), to be of importance in 
exocytosis in permeabilised chromaffin cells (Ali et al 1989) and to cause bundling of actin filaments (Ikebuchi & Waisman 1990). It has 
been suggested that these proteins play a role in membrane trafficking and may be involved in the control of secretion and cell motility.
Chromobindins
Chromobindins were identified in bovine adrenal medulla (Creutz et al 1978) as a group of proteins associating with chromaffin granules 
in the presence of calcium and are thought to play a role in exocytosis (Creutz et al 1987).
Calelectrins
The 35 kDa calelectrin was a calcium-binding protein originally purified from the electric organ of Torpedo marmorata (Walker 1982). 
Subsequently a family of Ca^+-dependent membrane binding proteins was characterised by Sudhof etal 1988.
Calcimedins
The calcimedins are five related Ca^+-binding proteins which were isolated from smooth muscle homogenates by Moore and Dedman 
(1982). Recently the 67 kDa calcimedin has been shown to modify gating behaviour of the calcium release channel in skeletal muscle 
sarcoplasmic reticulum and thus has been proposed to be important in excitation-contraction coupling (Diaz-Munoz et al. 1990).
Proteins I, II and III
These proteins were originally identified in intestinal epithelium as constituents of the brush border cytoskeleton (Shadle et al. 1985). 
Endonexins
Endonexins were first isolated from liver and adrenal medulla (Geisow et al 1984). Endonexin II has been shown to have anticoagulant 
properties in vitro (Kaplan et al 1988).
PAP
Placental anticoagulant proteins (PAPs) were isolated from human placenta and found to inhibit blood coagulation in vitro (Funakoshi et 
al 1987a, Tait et al 1988). They appear to do so by binding to anionic phospholipids thereby preventing binding of clotting factors 
important in blood coagulation. PAPs have been suggested to function as circulating components of the coagulation system.
IBC
Inhibitor of blood coagulation (IBC) has been shown to block blood coagulation in vitro and it has been proposed, may regulate the 
clotting cascade in vivo (Iwasaki et al 1987).
VAC
Vascular anticoagulant (VAC) proteins isolated from human umbilical cord arteries (Maurer-Fogy et al 1988).
PP4 and PP4-X
Placental proteins (PP) first isolated from human placenta (Bohn et al 1985), also shown to have anticoagulant properties (Romisch et al
1990).
Synexin
Synexin was originally isolated from bovine adrenal medulla as the result of a search for proteins regulating the fusion of granule 
membranes during exocytosis (Creutz et al 1978). Recently it has been demonstrated that the protein can act as a voltage-sensitive 
calcium channel (Rojas & Pollard 1987, Pollard et al 1990).
Anchor in Cl I
Isolated from chondrocyte membranes (Mollenhauer & von der Mark 1983), appears to mediate binding of collagen to the cell surface 
(Pfaffl ze ta l  1988).
GIF
Glycosylation inhibitory factor (GIF): a protein released from T cells thought to be involved in suppression of the IgE response (Uede et 
al 1983).
p68
A Ca^+-binding protein first identified as a component of lymphocyte plasma membranes (Davies et al 1984, Crompton et al 1988). 
Annexin III
Annexin III has recently been found to be identical with inositol 1,2,-cyclic phosphate 2-phosphohydrolase, an enzyme of the 
phosphatidylinositol signalling pathway (Ross etal 1990).
Annexins IX-X1I
Annexins IX-XII are novel proteins which have recently been discovered in Drosophila melanogaster (XI and X; Johnston et al 1990), 
bovine tissues (XI; Towle & Treadwell 1992) and Hydra vulgaris (XII; Schlaepfer et al 1992).
shown to be particularly susceptible to proteolysis (Huang et al. 1987, Glenney & 
Tack 1985). In addition, loci for the dimerization of annexin I (Pepinsky et al
1989) and the association of annexin II with the pi 1 protein to form calpactin I 
(Glenney 1986) are also located in this area.
A common property of all annexins is their ability to bind calcium and 
anionic phospholipids. They differ however from other calcium binding proteins 
such as the calmodulin family, in that they lack the classical "EF-hand" calcium 
binding motif (Kretsinger & Creutz 1986). Binding sites for calcium and 
phospholipids are located in the core region, but appear to be modulated by the N- 
terminal domain since both phosphorylation (Schlaepfer & Haigler 1987, Powell & 
Glenney 1987) and cleavage of the amino terminus (Ando et al. 1989) have been 
shown to influence binding affinities.
In addition to their proposed role as humoral mediators of the anti­
inflammatory actions of the glucocorticoids, many other functions have been 
postulated for various members of the annexin family including 
regulation/mediation of: membrane trafficking, exocytosis and secretion; cell 
growth, replication and differentiation; the inositol phosphate signalling pathway; 
excitation-contraction coupling; cell surface collagen binding and phagocytosis. 
They have also been suggested to act as: structural proteins; circulating 
anticoagulants and voltage dependent calcium channels (for details and references 
see Table II). None of these proposed functions is universally accepted and few 
clues have arisen from studies on the distribution of these proteins. Annexins have 
been found in all eukaryotic organisms investigated so far including mammals, fruit 
flies (Johnston et al 1990), sponges (Robitzki et al 1990), hydra (Schlaepfer et al
1992) and plants (Smallwood et al 1990). However studies on their cellular 
localisation in vertebrates have shown that the various proteins are differentially 
distributed, with some, such as annexins II (Gould et al 1984) and IV (Silva et al
60
1986) confined to a few distinct cell populations, but others for example annexin 
VI (Silva et al 1986) appearing to be ubiquitously distributed, indicating that the 
individual genes may be independently regulated (Pepinsky et al. 1988). It has 
been suggested that the core region of the annexins may carry a common function 
whereas the N-terminal might confer different biological properties to each protein. 
At present the precise function of any member of this protein family has yet to be 
established.
The recent availability of highly purified recombinant annexins and specific 
monoclonal and polyclonal antibodies to these proteins, has resulted in a great deal 
of new work on the potential role of annexins as second messengers of the anti­
inflammatory actions of the glucocorticoids. The remainder of this chapter will 
review recent developments in this area. Since the name annexin was proposed 
after the initiation of this project and has not been unequivocally agreed upon, the 
term lipocortin will be retained throughout the rest of this thesis.
1.3.3.1 The Mechanism of PLA2 Inhibition
Following the cloning of lipocortin I several studies demonstrated that the 
recombinant protein was able to inhibit PLA2  in vitro (Wallner et al 1986, Huang 
et al 1986, Pepinsky et al 1986, Peers et al 1987) thus confirming the results of 
earlier work using partially purified preparations. In addition, Pepinsky et al 
(1988) isolated and purified six different lipocortins (lipocortins I-VI) which were 
all shown to possess PLA2  inhibitory activity. Since that time however the 
mechanism of PLA2  inhibition by lipocortins has become highly controversial. In 
1987, Davidson and colleagues investigating the inhibition of PLA2  by calpactin I 
(lipocortin II) found that calpactin was unable to bind PLA2  but did bind to the 
phospholipid substrate, and that whereas pre-incubation of calpactin with the 
enzyme had no effect, pre-incubation with excess substrate prevented inhibition.
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Furthermore they demonstrated that enzyme inhibition was dependent upon the 
concentration of phospholipid and could be completely abolished by high substrate 
concentrations (Davidson et al. 1987). These workers concluded that inhibition of 
PLA2  by calpactins/lipocortins was not due to a direct interaction of inhibitor and 
enzyme but was caused instead by the protein binding to phospholipids, thus 
depleting the substrate and blocking enzyme access. Two other groups working on 
the inhibition of PLA2  by lipocortin I (Haigler et al. 1987) and a human monocyte 
lipocortin (Aarsman et al. 1987) reported similar findings and reached the same 
conclusion.
Although some workers claim to have observed inhibition of PLA2  by 
lipocortins in the presence of excess substrate (Pepinsky et al. 1988) or using the 
phospholipid substrate phosphatidylcholine, for which the protein has a low affinity 
(Ahn et al. 1988, Moss et al. 1988), at present the balance of evidence suggests 
that in cell-free assay systems, lipocortins inhibit PLA2  by binding to substrate 
phospholipids (Flower 1988, Davidson & Dennis 1989). Whether, and by what 
mechanism, lipocortins inhibit the phospholipase enzymes involved in regulation of 
eicosanoid release in vivo has not been established.
1. 3. 3.2 Steroid Induction and Secretion
Controversy has also recently arisen as to whether lipocortins are steroid 
modulated and whether they are secreted from cells - apparent pre-requisites for 
proteins proposed to be humoral mediators of glucocorticoid effects.
Most investigations on steroid inducibility have concentrated on lipocortin 
I. The promoter regions of the rat and human lipocortin I genes have been shown 
to contain a number of potential glucocorticoid recognition elements (Pepinsky et 
al. 1988, Kovacic et al. 1991) and a large number of studies have demonstrated 
increases in lipocortin I mRNA and/or protein following treatment of cells, tissues
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or whole animals with glucocorticoids. Steroid induction of lipocortin I mRNA 
has been observed in several mouse cell lines (Wong et al. 1990), and induction of 
the protein in a rat epithelial cell line (Piltch et al. 1989) and differentiated U937 
cells (Solito et al. 1991). Furthermore, increased levels of lipocortin I mRNA or 
protein have been detected in primary cultures of human peripheral blood 
monocytes (Wallner et al. 1986, Browning et al. 1990), human amnion cells 
(Mitchell et al. 1988), rat alveolar epithelial cells (Ambrose & Hunninghake 
1990b), rat peritoneal macrophages (Browning et al. 1990) and cat trachea 
(Lundgren et al. 1988), in response to in vitro treatment with corticosteroids.
Induction of lipocortin I has also been observed in vivo. Several studies 
have shown that administration of glucocorticoids to rats induces lipocortin I in 
resident peritoneal leukocytes (Wallner et al. 1986, Smillie et al. 1989b, Solito et 
al. 1990, Peers et al. 1993). In humans, increased amounts of the protein have 
been found in peripheral blood mononuclear cells (Goulding et al. 1990) and 
bronchoalveolar lavage fluid (Smith et al 1989a, Ambrose & Hunninghake 1990a) 
following anti-inflammatory steroid treatment. Moreover, studies on cells and 
tissues taken from Adx rats or animals treated with the glucocorticoid antagonist 
RU 38486 suggest that lipocortin I levels are normally modulated by endogenous 
corticosteroids (Vishwanath et al 1992, Peers et al. 1993). There is also some 
evidence that lipocortins II and V may be steroid-regulated. Glucocorticoid 
induction of lipocortin II was detected in vitro in differentiated U937 cells (Solito 
et al. 1991) and in vivo, induction of both lipocortins II and V has been observed 
in rat peritoneal macrophages (Smillie et al. 1989b, Solito et al. 1990, Peers et al.
1993).
There have however been a substantial number of reports where the authors 
have found no change in lipocortin levels following steroid treatment despite, in 
some cases, observing steroid-mediated effects. Several studies have demonstrated
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inhibition of eicosanoid release by glucocorticoids in vitro, independent of 
lipocortin induction (Hullin et al 1989, Bienkowski et al. 1989, Piltch et al. 1989, 
Gebicke-Haerter et al. 1991). Furthermore, in a number of studies the authors 
were unable to detect steroid induction of lipocortin I protein or mRNA in various 
cell lines (Bienkowski et al. 1989, Isacke et al. 1989, Beyaert et al. 1990, Violette 
et al. 1990) and in primary cultures of fibroblasts, lymphocytes and macrophages 
(Bronnegard etal. 1988, Northup etal. 1988, Wong etal. 1991), endothelial cells 
(Hullin et al. 1989) and astrocytes (Gebicke-Haerter et al. 1991). In addition, no 
change was observed in lipocortin I levels in mouse peritoneal macrophages (Wong 
et al. 1991) and rat brain (Strijbos et al. 1991) following in vivo treatment with 
corticosteroids. Other studies have reported no induction by steroids of lipocortin 
II in cultured cell lines (Isacke et al. 1989, Beyaert et al. 1990) and lipocortin VI in 
endothelial cells (Hullin et al. 1989).
The reasons for these discrepancies are not clear. Recently it has been 
proposed that the presence of additional factors (Philipps et al. 1989, Browning et 
al. 1990) or a critical differentiation state (Browning et al. 1990, Solito et al.
1991) may be required for steroid induction. It has also been suggested that 
steroids may alter the subcellular localisation of lipocortins, causing translocation 
of protein from the cytoplasm to the cell surface (Smillie et al. 1989b, Browning et 
al 1990, Goulding etal. 1990, Peers etal. 1993).
Debate over whether lipocortins are secreted has arisen partly due to early 
immunological studies which indicated that annexins were intracellular proteins 
(Geisow etal. 1984, Glenney etal. 1987, Zokas & Glenney 1987) and partly 
because all annexin genes sequenced so far appear to lack the hydrophobic signal 
sequence which is essential for entry into the classical secretory pathway. Some 
workers have been unable to detect secretion of lipocortins in vitro (Northup etal. 
1988, Isacke et al. 1989, Frey et al. 1991). However other studies have
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demonstrated release of lipocortins into the media of cultured cells both 
spontaneously (Pfaffle et al. 1988, Jacquot et al 1990, Violette et al 1990) and in 
response to steroids (Solito etal 1991). Furthermore, there is evidence that 
lipocortins I and V are selectively secreted into human prostate fluid (Christmas et 
al 1991). Recently it has been suggested that lipocortins may belong to a new 
class of proteins which exit the cell via a mechanism alternative to the classical 
pathway (Muesch et al 1990).
1.3.3.3 Biological Activity
Early studies on partially purified lipocortins showed that they had anti­
inflammatory actions consistent with their proposed role as second messengers of 
the glucocorticoids. Despite controversy over steroid-inducibility and the 
mechanism of PLA2  inhibition, many recent studies have demonstrated that highly 
purified and recombinant lipocortins possess similar properties and are able to 
mimic many of the anti-inflammatory effects of both the early protein preparations 
and the steroids themselves.
Most work has been done on lipocortin I. Several studies have reported 
that recombinant human (rh) lipocortin I and other highly purified preparations 
have the ability to inhibit release of eicosanoid pro-inflammatory mediators in vitro. 
Prostacyclin production by human umbilical artery fragments (Cirino & Flower 
1987a) and rat peritoneal leukocytes (Cirino & Flower 1987b), plus thromboxane 
generation by the guinea pig perfused lung (Cirino et al. 1987), were all found to 
be blocked by the recombinant protein, although Northup et al. (1988) found that 
lipocortin I purified from human placenta was unable to inhibit zymosan-induced 
arachidonic acid release from mouse peritoneal macrophages. As well as their 
effects on eicosanoid synthesis, naturally occurring and recombinant lipocortin I 
have been shown to suppress the generation of active oxygen metabolites by
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human neutrophils (Stevens et al 1988) and guinea pig alveolar macrophages 
(Maridonneau-Parini et al 1989) and to mimic steroid-induced differentiation in 
human carcinoma cells (Violette et al 1990).
Recombinant human lipocortin I has also been demonstrated to have anti­
inflammatory activity in vivo. Several studies have shown that local administration 
of rh lipocortin I inhibits rat paw oedema induced by carrageenan (Miele et al 
1988, Cirino et al 1989, Browning et al 1990), or PLA2  (Cirino et al 1989), 
although other workers have observed no effect of placental lipocortin I on 
carrageenan paw oedema (Northup et al 1988). In addition the recombinant 
protein has been demonstrated to block IL-1 elicited neutrophil accumulation in the 
mouse air pouch model (Perretti & Flower 1993) and to suppress migration of 
leukocytes into inflammatory lesions in the rat when given intravenously (Errasfa & 
Russo-Marie 1989). Interestingly, a nonapeptide fragment of lipocortin I 
corresponding to residues 246-254, termed antiflammin, has also been shown to 
exhibit PLA2  inhibitory activity and in vivo anti-inflammatoiy actions (Miele et al 
1988, Ialenti et al 1990, Perretti et al 1991) but conflicting reports do exist (van 
Binsbergen et al 1989, Marki et al 1991).
Fewer recent studies have been performed on the immunological properties 
of lipocortin I, although Goulding and Guyre (1988) have shown that rh lipocortin 
I impairs erythrocyte-antibody rosette formation by human leukocytes and 
recombinant mouse lipocortin I has been found to suppress the mitogenic response 
of murine splenic mononuclear cells (Sakata et al 1990).
Little information is available on the biological activity of other members of 
the lipocortin family, however human lipocortin II has recently been cloned and has 
been demonstrated in one study to have similar inhibitory effects to lipocortin I on 
PGE2  release by macrophages and on carrageenan paw oedema (Parente et al
1990). In addition, Russo-Marie's group have purified, but not fully characterised,
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several lipocortins possessing anti-inflammatory properties both in vitro (Fradin et 
al 1988, Errasfa et al 1988, Errasfa & Russo-Marie 1989, Comera et al 1990) 
and in vivo (Errasfa & Russo-Marie 1989), the most extensively studied of which is 
a 32 kDa protein that appears to be lipocortin V (Browning et al 1990).
Further evidence for the role of lipocortins in corticosteroid action has 
come from studies demonstrating that neutralising antibodies to lipocortin I are 
able to block glucocorticoid effects in several systems. In vitro, specific 
monoclonal antibodies raised against lipocortin proteins have been shown to 
prevent glucocorticoid inhibition of eicosanoid release from neutrophils (Fradin et 
al 1988), respiratory glycoconjugate secretion by cat trachea (Lundgren et al 
1988) and PLA2  activation by IL-1 in human fibroblasts (Solito & Parente 1989). 
In vivo administration of anti-lipocortin I antibodies reverses dexamethasone 
inhibition of IL-1 -elicited neutrophil accumulation in the mouse air pouch (Perretti 
et al 1992) and the anti-inflammatory effect of dexamethasone in the rat 
carrageenan paw oedema model (Duncan et al 1993), findings which suggest that 
lipocortins may play a physiological role in mediating the anti-inflammatory actions 
of steroids.
The use of steroids for the treatment of chronic inflammatory diseases is 
frequently limited by their side effects. As potential mediators of the anti­
inflammatory actions of corticosteroids, lipocortins have been the subject of intense 
interest, as they represent a possible mechanism through which the beneficial 
effects of steroids might be selectively brought about and thus may open up 
opportunities for the development of new therapies free of the major side effects 
associated with steroid treatment. At present however, it is not clear if any, some 
or all members of the annexin family of proteins are the steroid-regulated, 
phospholipase-inhibitory, second messengers of anti-inflammatory steroid action,
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th a t th e  lip o c o r t in s  w e r e  in itia lly  p r o p o se d  to  b e.
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1.4 AIMS
Corticosteroids are frequently used in the treatment of MS and are also 
effective in suppressing the animal counterpart, EAE. It is conceivable that the 
beneficial effects of steroids in these diseases may be mediated, in part, via the 
induction of lipocortins. Thus the aims of this project were to:
1) Determine whether the potential exists for lipocortins to be involved 
in these diseases by investigating the occurrence of lipocortins in the 
CNS of MS patients and EAE-diseased rats.
2) Shed light on the function of lipocortins in the CNS by studying their 
cellular distribution in MS and EAE.
3) Investigate the involvement of lipocortins in the mechanism of steroid 
action by studying the influence of exogenous and endogenous steroids 
on lipocortin levels in the CNS during EAE.
It is hoped that such a study will provide insight into the role of lipocortins 





2.1 HUMAN CNS SAMPLES
2.1.1 CSF
CSF samples from patients with a variety of diseases were obtained from 
Mr D. Marshall, Pathology Laboratory, Royal United Hospital, Bath. Samples had 
been collected within the previous week and were stored at 4°C. CSF protein 
concentrations plus erythrocyte and leukocyte counts were also supplied and for 
most patients a final diagnosis was provided from hospital records by Dr J. Lever.
2.1.2 CSF Supernatants
Cell-free CSF supernatants from patients with MS and other neurological 
diseases were supplied by Professor A.N. Davison, Institute of Neurology, London 
and were stored at -20°C.
2.1.3 CNS Tissue
Samples of post-mortem human brain and spinal cord were provided by Dr 
J. Newcombe, The Multiple Sclerosis Society Tissue Bank, Institute of Neurology, 
London. Tissues were supplied in coded form, from six control cases without 
neurological disease and seven patients diagnosed clinically as having MS. The 
clinical diagnosis of MS was subsequently confirmed by routine histological 
staining of CNS tissue with haematoxylin & eosin (H & E) and Oil-Red-O, which 
revealed the presence of inflammatory infiltrates and demyelinated plaques with 
axon sparing which are characteristic of the disease. The average age of the 
subjects, duration of clinical disease and time elapsed between death and freezing 
of the CNS tissue are shown in Table III. Medical records indicated that none of 
the patients with MS had received steroid therapy within two years of death. No 
information was available for control cases.
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Table ITT
Age, disease duration and death to freezing interval for MS and control cases 
from which post-mortem CNS tissue was obtained.
MS Control
Number of cases 7 6
Age (years) 50 (33-74) 38 (20-50)
Duration of clinical 18 (0.75-49) N\A
disease (years)
Death to freezing 41 (27-82) 20 (9-33)
interval (hours)*
Figures for age, duration of disease and death to freezing interval are means, range 
is given in parenthesis. * Time elapsed between death of subjects and freezing of 
CNS tissue sample.
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Small areas of CNS tissue were dissected, prepared and classified by Dr 
Newcombe as described below. MS cases were dissected to provide samples of 
plaque tissue, macroscopically normal appearing white matter adjacent to a plaque, 
apparently uninvolved white matter remote from plaque areas and grey matter. 
Following histological staining, four of the plaques exhibited perivenular 
inflammation, hypercellularity and macrophages containing Oil-Red-O-positive 
degenerating myelin and these were thus considered to be actively demyelinating 
lesions. Two hypocellular Oil-Red-O-negative demyelinated plaques were 
classified as chronic plaques. No positive Oil-Red-O staining or myelin loss was 
detected microscopically in MS white matter samples. Control samples of white 
and grey matter were obtained by dissection from corresponding areas of the brain 
and spinal cord of normal controls.
Each tissue block was cut into two pieces of approximately 1 cm^, one 
piece was placed in OCT compound (Gurr, BDH) on a cork disc then snap-frozen 
in isopentane cooled on liquid nitrogen for immunohistochemistry, the other was 
frozen at -70°C prior to Western blotting.
2.2 RAT CNS SAMPLES
2.2.1 Animals
Inbred male Lewis rats were used in all experiments and either obtained 
from the University Animal House breeding colony or purchased from Bantin and 
Kingman (Hull). The rats were housed 5-6 per cage, in temperature controlled 
rooms (2 2  ± 2°C) on a 12 hour light /dark cycle (light period: 6 am-6 pm) with free 
access to Labsure CRM rat diet and tap water. Cages containing severely 
paralysed animals had food pellets soaked in water placed inside the cage to
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prevent death due to starvation and dehydration. Both in-house and externally 
purchased animals were randomly grouped and placed in the experimental room at 
least one week prior to the beginning of an experiment.
2.2.2 EAE
2.2.2.1 Induction of EAE
EAE was induced using an inoculum comprising guinea pig spinal cord, 
Freund's incomplete adjuvant (Difco) and sterile 0.01 M phosphate buffered saline 
(PBS) pH 7.2, in the ratio 1:1:1 plus 10 mg/ml killed Mycobacterium tuberculosis 
H37 RA (Difco). For preparation of the inoculum PBS was added to the guinea 
pig spinal cord which was then chopped with scissors and briefly homogenised by 
repeated passage through a 1 ml syringe. Following the addition of M. 
tuberculosis and Freund's incomplete adjuvant, the mixture was shaken vigorously 
and then emulsified by repeated passage between two 2 0  ml syringes connected by 
a short length of tubing. This was continued until the inoculum reached a thicker 
consistency and did not disperse when a drop was floated in a beaker of water. For 
the induction of EAE, rats weighing 200-250 g received 0.1 ml of this inoculum in 
each hind foot pad.
In some experiments control animals were injected with an inoculum in 
which the guinea pig spinal cord was substituted with sterile saline. Thus the 
inoculum consisted of an emulsion of Freund's incomplete adjuvant and sterile 
saline 1:2 plus 10 mg/ml M. tuberculosis. These were termed CFA controls.
2.2.2.2 Assessment of EAE
Following inoculation animals were weighed and examined daily for signs 
of EAE. The severity of disease was assessed and graded by assigning a numerical
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score from 0-4 using the following system. Rats with no signs of disease were 
scored zero. If from day 7 post-inoculation (PI) onward but before the appearance 
of physical symptoms, the rats showed a small weight loss (1-2  g) for two 
consecutive days or a larger weight loss (> 2  g) for one day they were classified as 
exhibiting disease-related weight loss. These were also scored zero. Animals were 
considered to have a flaccid tail and assigned a score of 1 if the tail was immobile 
and drooping when they were raised briefly by the base of the tail. Hind limb 
weakness was indicated by an ataxic gait and scored 2. Rats with only one leg 
completely paralysed, or both legs moving but neither functional were categorised 
as having partial hind limb paralysis and scored 3. A score of 4 was assigned to 
cases of complete hind limb paralysis.
Mean numerical scores were used to assess disease severity before and after 
experimental treatments. The significance of differences between treatment and 
control groups was assessed using the Mann-Whitney U test, with the Bonferroni 
Correction for multiple comparisons.
2.2.3 Administration of Drugs and Surgery
All surgery and administration of drugs were performed by the University 
Animal House staff.
2.2.3.1 Corticosterone
Corticosterone (Sigma) was suspended in approximately 0 .2  ml arachis oil 
and administered subcutaneously (sub. cut.) to rats inoculated for EAE at a dose of 
10 or 50 mg/kg body weight. EAE-inoculated vehicle controls received arachis oil 
only. Dosing was commenced either on the first day of total paralysis or on the 
first day of complete recovery from symptoms. In some experiments the rats were 
dosed twice (morning and afternoon) and killed the following morning, in other
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experiments they were dosed 3 times (morning, afternoon and the following 
morning) and CNS and blood samples collected two hours after the last dose.
2.2.3.2 Dexamethasone
EAE-inoculated animals were dosed sub. cut. with 0.5 or 1 mg/kg 
dexamethasone sodium phosphate (Oradexon-Organon) diluted in approximately 
0.2 ml sterile PBS. EAE-inoculated controls received vehicle only. The rats were 
dosed three times, twice on the first day of paralysis (morning and afternoon) and 
again the following morning. CNS and blood samples were collected two hours 
later.
2.2.3.3 RU 38486
The glucocorticoid antagonist RU 38486 (mifepristone; supplied by Dr R. 
Deraedt, Roussel UCLAF, France) was suspended in an aqueous solution 
containing 1% Q /^v) carboxymethyl cellulose, sodium salt, (Sigma) and 0.05% 
(y/y) Tween 80 (Sigma). EAE-inoculated rats were dosed orally twice daily on 
days 10-14 PI inclusive with 20 mg/kg RU 38486 in approximately 0.2 ml vehicle. 
Controls which had also been inoculated for EAE received vehicle only. In 
addition, normal animals were dosed with either RU 38486 or vehicle for five days 
according to the same schedule. CNS tissue and blood samples were collected the 
day after the last dose, day 15 PI for EAE-inoculated rats.
2.2.3.4 Adrenalectomy
Rats weighing 180-200 g were anaesthetised by intraperitoneal injection 
with 3.3 ml/kg of an aqueous solution containing 1.25 mg/ml midazolam (Roche) 
plus 0.79 mg/ml fentanyl citrate and 2.5 mg/ml fluanisone (Hypnorm, Janssen) 
(Flecknell 1987). Under aseptic conditions a small midline incision was made in
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the dorsum, through which both adrenal glands were removed. The incision was 
then sealed with Michel clips. Sham-operated controls were subjected to the same 
procedure except that the adrenals were not removed. Adx rats were maintained 
on 0.9% (w/y) saline. Both sham-operated and Adx animals were allowed 8-12 
days to recover before inoculation for EAE.
2.2.4 Sera
Anaesthesia and the collection of blood samples were carried out by the 
University Animal House technicians. To limit fluctuations in corticosterone due 
to circadian variation, samples were always collected in the morning when plasma 
corticosterone levels are at their lowest (DAgostino et al 1982). If the 
experiment was to be continued following blood sampling, the animals were 
anaesthetised with halothane, 1 ml of blood was collected by cardiac puncture and 
the rats were then allowed to recover. If CNS samples were also to be taken the 
animals were rendered unconscious by carbon dioxide (CO2 ) inhalation, 2  ml of 
blood was collected by cardiac puncture and the animals were then asphyxiated.
Blood samples were allowed to clot at 4°C and then centrifuged at 370 g 
for 10 min at 4°C and the serum collected. The sera were then clarified by a 
further centrifugation step and the supernatants stored at -20°C.
2.2.5 CSF
Rats were asphyxiated with CO2 , exsanguinated and an incision made at 
the base of the skull to expose the meninges covering the cistema magna. A CSF 
needle (Figure 2) attached to a length of translucent vinyl tubing was then inserted 
through the membrane into the cavity. Spinal fluid was drawn off by gentle suction 
















Figure 2. CSF needle
Brass needle adapters were made by Mr G. Venn, Science Schools Workshop. At 
one end o f the adapter a 1 cm length o f a 23 gauge needle (diameter 0.6 mm, 
Sherwood) with the bevel filed to approximately half length was fixed with Araldite 
adhesive. Translucent vinyl tubing (internal diameter 1.0 mm, external diameter 
2.0 mm, Portex) was attached to the other end.
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2.2.5.1 Enumeration of cells in CSF
CSF leukocyte and erythrocyte numbers were determined using a Fuchs- 
Rosenthal chamber with a ruled area consisting of 25 one millimetre squares with a 
depth of 0.2 ml. The number of cells in 25 squares was counted and the cell count 
per ml of CSF calculated using the formula:
In initial experiments cell counts were performed on unstained CSF and red 
and white cells were differentiated on the basis of morphology and size. In later 
experiments a total cell count was performed on undiluted CSF and a leukocyte 
count by diluting 1:1 with white cell counting fluid. The number of erythrocytes 
was then calculated by subtracting the white cell count from the total. Samples 
containing > 1  x 1 0^ erythrocytes per ml were discarded.
2 .2 .6  CNS Tissue
Rats were asphyxiated with CO2  and exsanguinated. For removal of the 
cervical spinal cord a midline incision was made from the head down the back, the 
skin eased apart and some of the muscle tissue cut away. After piercing the 
membrane covering the cistema magna the dorsal cervical vertebrae were removed 
using bone cutters and the first 3 cm of spinal cord (which in a 200-250 g rat 
corresponds approximately to the cervical section) were dissected out, washed in 
PBS and blotted dry. In most experiments the cord was then bisected down the 
midline, one half was immediately frozen at -20°C prior to Western blotting, the 
other was placed cut side down on histology card and transferred to fixative
Number of cells 
per ml
Number of cells X 200 
in 25 squares
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solution. In one set of experiments the cerebellum was also removed and prepared 
as described above.
2.3 SODIUM DODECYL SULPHATE-POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE) AND IMMUNOBLOTTING
The techniques of SDS-PAGE and immunoblotting were performed using 
a method already established in our laboratory.
2.3.1 Preparation of Samples and Standards
To ensure solubility of lipocortins, ethylene diamine tetraacetic acid, 
disodium salt, dihydrate (EDTA, Sigma) was added to all samples. EDTA chelates 
calcium ions and has been shown to prevent calcium-dependent binding of 
lipocortins to phospholipids thus releasing the protein from cell membranes (Cirino 
& Flower 1987b, Klee 1988).
2.3.1.1 Human and Rat CSF
To each 60 pi aliquot of CSF, 6  pi of 100 mM EDTA was added to give a 
final concentration of 11 mM EDTA. Samples were then frozen and thawed five 
times to lyse cells, centrifuged at 11,000 g for 5 min to remove cell debris and the 
supernatants collected.
2.3.1.2 Human CSF Supernatants
Human CSF supernatants which had been stored at -20°C were thawed and 
6  pi of 100 mM EDTA was added to each 60 pi sample to give a final 
concentration of 11 mM EDTA.
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2.3.1.3 Rat CSF Supernatants
Freshly collected rat CSF samples were spun at 11,000 g for 5 mins to 
pellet the cells and the supernatants were collected.
2.3.1.4 Human and Rat CNS Tissue
CNS tissue samples which had previously been stored at -20°C were 
thawed and weighed. Chilled homogenisation medium comprising 10 mM N-(2- 
hydroxyethyl) piperazine-N'-2-ethanesulphonic acid, sodium salt (HEPES, Sigma), 
5 mM EDTA, 100 mM sodium chloride (Sigma) and 200 pM 
phenylmethylsulphonyl fluoride (PMSF, Sigma) pH 7.6 (Rothhut etal. 1987), was 
added to each sample at a rate of 0.5 ml per 100 mg of tissue. The samples were 
then chopped using scissors and homogenised on ice by repeated passage firstly 
through a syringe alone and then through 19 and 21 gauge needles. The 
homogenates were frozen and thawed twice, centrifuged at 19,000 g for 30 mins at 
4°C and the supernatants collected.
Supernatants were assayed for total protein using the method of Bradford 
(1976). Sample aliquots of 10 or 20 pi were diluted to 100  pi with distilled water. 
Protein standards were prepared by dissolving bovine serum albumin (Sigma) at 1 
mg/ml in distilled water and then diluting to provide 100  pi of standards ranging 
from 0.2-1.0 mg/ml. Protein reagent was prepared in advance by dissolving 100 
mg of Coomassie Brilliant Blue G-250 (Sigma) in 50 ml of ethanol (Fisons), 100 
ml of 85% orthophosphoric acid (Fisons) was then added and the solution diluted 
to one litre with distilled water and shaken thoroughly. Five millilitres of protein 
reagent were added to 100  pi of duplicate samples and standards, and mixed 
thoroughly by vortexing. After two min the absorbence at 595 nm was measured 
in a Pye Unicam PU8610 spectrophotometer against a zero protein blank prepared 
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Figure 3. A typical standard curve obtained for the Coomassie G-250 protein 
assay
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of CNS supernatants was calculated from a standard curve obtained by plotting 
protein concentration of standards against absorbence. A typical standard curve is 
shown in Figure 3. Each supernatant was then diluted to 2 mg/ml with 
homogenisation medium.
2.3.1.5 Lipocortin I  Standard
Recombinant human lipocortin I (Wallner et al. 1986) was supplied by Dr 
J. Browning, Biogen Research Corporation, USA. For use as a standard in SDS- 
PAGE, rh lipocortin I was diluted to an appropriate concentration in 
homogenisation medium. Unfortunately standards for lipocortins II, IV and V 
were not available.
In each case following the treatment described above the samples or 
standards were then mixed in the ratio 1:1 with a sample buffer comprising 0.1 M 
Tris(hydroxymethyl)aminomethane (TRIS, Sigma), 0.1 MN,N-bis(2- 
hydroxyethyl)glycine (BICINE, Sigma), 2% (w/y) sodium dodecyl sulphate (SDS, 
BDH), 5% (v/v) 2-mercaptoethanol (Fisons), 10% (w/y) sucrose (BDH) and 
0.05% (w/y) bromophenol blue (BDH), heated in a boiling water bath for 5 min 
and stored at -20°C prior to SDS-PAGE.
2.3.1.6 Molecular Mass Markers
Pre-stained high molecular mass markers for immunoblotting were obtained 
from Sigma (code: SDS-7B, range: 180,000-26,600 lcDa). Following the addition 
of 0 .8  ml of sample buffer (without bromophenol blue) per vial, the markers were 
boiled for 5 min and then stored in aliquots at -20°C. Unstained low molecular 
mass markers for use on protein stained gels were prepared in the same way (code: 
SDS-7, range: 66,000-14,200 kDa, Sigma).
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2.3.2 SDS-PAGE
SDS-PAGE was performed essentially as described by Laemmli (1970) 
using a "Mighty Small II" vertical slab gel system (Hoefer Scientific Instruments) 
according to the manufacturers instructions.
Ten percent acrylamide resolving gels (82 x 60 x 1.5 mm) were prepared 
from stock solutions of 30% (w/y) acrylamide/0.8% (w/y) NN'- 
methylenebisacrylamide (electrophoresis grade, BDH) and 1 M TRIS/BICINE and 
polymerised chemically by the addition of NNNTST- tetramethylethylenediamine 
(TEMED, Sigma) and freshly prepared 10% (w/y) ammonium persulphate (BDH) 
solution. Final concentrations in the gel were: 10% O^/y) acrylamide, 0.27% (^/y) 
NN’-methylenebisacrylamide, 0.1 M TRIS, 0.1 MBICINE, 0.1% (w/y) SDS, 
0.09% (w/y) ammonium persulphate and 0.1% (v/y) TEMED. Immediately after 
pouring, 0.3 ml of 50% (v/y) ethanol was gently layered onto the surface of each 
gel. When set, the gels were rinsed with distilled water, wrapped in polythene and 
stored at 4°C for up to one week.
The electrode buffer was also made from stock solutions and comprised 0.1  
M TRIS/BICINE and 0.1% (w/y) SDS. Stacking gels containing 7.5% acrylamide 
were prepared immediately before use by mixing acrylamide/NN- 
methylenebisacrylamide stock solution, distilled water and electrode buffer in the 
ratio 1:1:2 and were also polymerised with TEMED and ammonium persulphate. 
The final concentrations in the stacking gel were: 7.5% (w/y) acrylamide, 0.2% 
(w/y) NN'-methylenebisacrylamide, 0.05 M TRIS, 0.05 M BICINE, 0.05% (w/y) 
SDS, 0.07% O^y) ammonium persulphate and 0.7% (v/y) TEMED. Sample wells 
were formed in the stacking gel by means of a comb device suspended above the 
resolving gel. Stacking gel was poured beneath the comb and when set the comb 
was removed and the chamber filled with electrophoresis buffer. Wells were 
loaded with 5-20 pi of prepared samples or standards using a Hamilton syringe.
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The gels were run at a constant current of 15 mA/gel until the samples had 
passed through the stacking gel (approximately 7 min) and then at 35 mA/gel until 
the bromophenol blue dye front reached the bottom of the gel (approximately 1 
hr).
2.3.3 Staining Gels for Protein
Gels were stained for total protein using PAGE Blue 83. Following 
overnight incubation with an aqueous solution containing 0.2% (™/v) PAGE Blue 
83 (BDH), 50% (v/y) methanol (Fisons) and 10% (v/y) acetic acid (Fisons), the 
proteins were visualised by destaining the background with several changes of a 
solution comprising 2 0 % (y/v) methanol and 10% (v/y) acetic acid in distilled 
water.
2.3.4 Immunoblotting
Electrophoretic transfer of proteins from unstained gels to nitrocellulose 
membranes was performed essentially by the method of Towbin et al (1979), using 
a Transphor electrophoresis tank (Hoefer Scientific Instruments) according to the 
manufacturers instructions. The electrode buffer was prepared from a stock 
solution of 0.25 M TRIS and 1.92 M glycine (Sigma) and the final solution 
comprised 25 mM TRIS, 192 mM glycine and 20% (v/y) methanol. Proteins were 
transferred to 0.45 pm nitrocellulose membranes (Schleicher & Schuell) at a 
constant voltage of 80 volts for 1 hr. Blots were often stored frozen at this point.
For the detection of lipocortins after protein transfer, membranes were 
subjected to the following procedure:
1) Incubated with 3% (w/y) milk powder for 1 hr to block remaining 
protein binding sites
2) Probed overnight with primary anti-lipocortin antibody. See Table IV
85
Table IV
Primary antibodies used for immunoblotting
Code Type Raised against Species
specificity
Known cross reactivities 
within the lipocortin family
Dilution




















mAb IB Mouse monoclonal Recombinant 
human lipocortin I
Human - 1:500
Ab-1 Rabbit polyclonal Recombinant Human _ 1 :1 0 0 0
human lipocortin II
All antibodies except Ab-1 were generously supplied by Dr J. L. Browning, Biogen Research Corporation, USA. Crossreactivity data for 
these antibodies have been reported by Pepinsky et al (1988). Ab-1 was kindly supplied by Dr L. Parente, Sclavo Research Centre, Siena, 
Italy.
3) Washed 2x15  min
4) Incubated for 1 hr with a 1 :1 0 0 0  dilution of goat anti-rabbit IgG- 
horseradish peroxidase conjugate (Sigma) if the primary antibody 
was a rabbit polyclonal, or sheep anti-mouse IgG-horseradish 
peroxidase conjugate if the primary antibody was a mouse 
monoclonal
5) Washed 1x15 min
6 ) Washed 1x15 min in PBS
7) Incubated with 0.05% (w/y) filtered 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Aldrich) plus 0.02% (™/v) hydrogen 
peroxide (H2 O2 , BDH) in PBS for approximately 10 min until the 
colour was fully developed
8) Washed 2 x 5  min in distilled water
All incubations were carried out at room temperature in PBS containing 
0.1% (v/y) Tween 20 (Sigma) (PBS-Tween) unless otherwise stated. The 
incubation volume was always 50 ml except for steps using antibodies where it was 
reduced to 25 ml to conserve reagents.
2.3.5 Comparison of Immunoblotting Detection Methods
Due to the very low levels of lipocortin detected in initial studies, an 
experiment was performed to compare the sensitivity of various putative methods 
of signal enhancement (Stott, 1989). Several gels loaded with a range of 
concentrations of rh lipocortin I standard (0.05-100 ng/lane) were prepared under 
identical conditions. Immunoblotting was initially performed as described above 
but following incubation with lipocortin I antisera, the primary antibody was 
detected using one or a combination of the following methods: peroxidase
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conjugate, streptavidin-biotin complex, peroxidase-anti-peroxidase, and nickel and 
cobalt enhancement.
Antibody reagents for each technique were used at the manufacturers 
recommended working dilution and incubations were always performed at room 
temperature in PBS-Tween unless otherwise stated. All blots were blocked, 
probed with lipocortin antisera (842) and washed twice for 15 min in PBS-Tween 
as described previously. Detection was then completed using one of the protocols 
listed below.
2.3.5.1 Streptavidin-biotin Complex (Coggi et al. 1986).
1) Incubated 1 hr with biotinylated donkey anti-rabbit IgG (Amersham) 
diluted 1:400
2) Washed 2x15  min
3) Incubated 30 min with streptavidin-biotinylated horseradish 
peroxidase complex (Amersham) diluted 1:3000
4) Washed 1x15 min
5) Washed 1x15 min in PBS
6 ) Incubated with 0.05% (w/y) filtered DAB plus 0.02% (w/y) H2 O2  in 
PBS until colour developed
7) Washed 2 x 5  min in distilled water
2.3.5.2 Peroxidase-anti-peroxidase Complex (Frazer and Wisdom 1985).
1) Incubated 1 hr with goat anti-rabbit IgG (Sigma) diluted 1 :2 0 0
2) Washed 2x15  min
3) Incubated 1 hr with rabbit peroxidase-anti-peroxidase complex (PAP, 
Sigma) diluted 1 :200
4) Washed 1 x 15 min
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5) Washed 1x15 min in PBS
6 ) Incubated with 0.05% (w/y) filtered DAB plus 0.02% C^/y) H2 O2  in 
PBS until colour developed
7) Rinsed 2 x 5  min in distilled water
2.3.5.3 Nickel and Cobalt Enhancement (De Bias and Cherwinski 1983)
Blots were probed using one of the techniques described above but after 
incubation with the final peroxidase conjugated reagent and rinsing in PBS-Tween 
and PBS, immunoreactive bands were visualised by the following method:
1) A 0.05% (w/y) solution of DAB in PBS was prepared and filtered
2) An aqueous solution of 1% (w/y) cobalt chloride (C0 CI2 .6H2 O,
Sigma) and 1% (^/y) ammonium nickel sulphate 
([NH4 j2 SO4 .NiSO4 .6H2 O, BDH) was prepared (Ni/Co)
3) Ni/Co solution was added dropwise to stirring DAB solution,
3 ml per 100 ml DAB
4) Membranes incubated in 50 ml Ni/Co/DAB solution for 10 min
5) Blots then transferred to an identical solution containing 0.02% (w/y) 
H2 O2  for approximately 2  min until colour fully developed
6 ) Washed 2 x 5  min distilled water
The combination of PAP complex with Ni/Co enhancement was found to 
give maximum sensitivity (approximately 0.5-1 ng lipocortin/lane) with acceptable 
background staining and was approximately 10 times more sensitive than the 
original peroxidase conjugate technique (Figure 4). For titration of reagents used 
in the PAP method, two blots containing 50 ng of rh lipocortin I in each lane were 
prepared. After probing with the primary antibody one blot was divided into strips 





Figure 4. Comparison of immunoblotting detection methods
Six identical blots loaded with a range o f concentrations o f rh lipocortin I standard 




Nickel and Cobalt salt enhancement (Ni/Co)
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Figure 5. Titration of antibody reagents for the PAP immunoblotting 
detection method
a) Goat anti-rabbit IgG, optimum dilution: 1:500
b) PAP, optimum dilution: 1:10,000
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(goat anti-rabbit IgG) and then developed in the normal way. The second blot was 
used to titrate the tertiary reagent (PAP complex) in the same manner. Optimum 
dilutions of goat anti-rabbit IgG and PAP were 1:500 and 1:10,000 respectively 
(Figure 5).
To check the specificity of staining, control blots containing representative 
CNS samples were subjected to the same immunoblotting procedure except that 
the primary antibody was omitted and replaced with PBS.
2.3.6 Estimation of Molecular Mass
To estimate the molecular mass of unknown bands on gels and blots, Rf 
values were calculated for standards and unknowns using the formula :
The Rf values of standards were plotted against log molecular mass and the 
calibration curve obtained used to calculate the molecular mass of unknowns. 
Typical standard curves for low and high molecular mass markers are shown in 
Figures 6  and 7 respectively.
2.3.7 Densitometry of Immunoblots
In order to provide a semi-quantitative assessment of lipocortin levels, the intensity 
o f immunoreactive bands was measured using a Joyce-Loebl Chromoscan 3 
densitometer. Blots were scanned in reflectance mode (range: 0-1) using a KG3 
(white light) filter, an aperture setting of 0.1 x 3 mm and a scan length of 60 mm. 
For background correction the valley-to-valley method was used with the pre-set 
ramp rate (10) and height, width and noise thresholds of 5, 4 and 3 respectively. 
Results were expressed as integral values.
Rf
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Figure 7. A representative standard curve obtained using pre-stained high 
molecular mass markers for SDS-PAGE and immunoblotting.
The electrophoretic mobility o f protein standards is slightly altered by conjugation 
with the marker dye such that molecular masses calculated using pre-stained 
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Figure 8 . Densitometry of Western blots: relationship between protein 
concentration and integral value.
a) Blot loaded with a range o f concentrations o f lipocortin I
b) Plot o f  integral value against protein concentration
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Linearity of the relationship between concentration and integral value was 
assessed by scanning a blot loaded with a range of concentrations of lipocortin I.
A plot of concentration against integral value (Figure 8) showed that the 
relationship was reasonably linear over the range 1-40 ng. At higher 
concentrations integral values decreased from maximum. For this reason blots 
were always loaded with the minimum amount of protein sufficient to give a clear 
band falling within the linear range. In experiments on human CNS tissue, blot to 
blot variability was evaluated on blots probed for lipocortin I by calculating a 
coefficient of variation using integral values obtained by scanning the constant 
amount of lipocortin I standard (6.5 ng) which was run on all blots.
Statistical analysis of densitometry data from blots of human CNS tissue 
was performed by Dr P. Christie of Bath University Computer Services. To assess 
the significance of differences in the lipocortin content of various types of human 
CNS tissue, the integral values were first log transformed to stabilise the variance 
and then data for each protein was analysed by one way Analysis of Variance 
(ANOVA). For comparison of white matter subtypes three orthogonal contrasts 
were fitted: control versus all MS white matter subtypes, remote MS white matter 
versus plaque plus adjacent white matter, and adjacent white matter versus plaque. 
To determine whether differences between the groups might be explained by 
differing rates of breakdown of lipocortin I, a two way ANOVA was performed 
including putative breakdown products as a second factor.
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2.4 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR 
LIPOCORTIN I
2.4.1 Preparation of Samples
2.4.1.1 Human CSF
EDTA was added to each CSF sample such that the final concentration was 
1 mM. Samples were then freeze/thawed five times, clarified by centrifugation at
11,000 g for 5 min and the supernatants collected for assay.
2.4.1.2 Human CSF Supernatants
EDTA (1 mM) was also added to cell-free CSF supernatants.
2.4.1.3 Human CNS Tissue
Frozen supernatants from human CNS tissue homogenates that had 
previously been prepared for SDS-PAGE but which had not had sample buffer 
added, were thawed and adjusted to 1 mg/ml protein with homogenisation buffer.
To test for possible sources of interference, a range of dilutions of 
homogenisation medium and two representative CNS tissue samples (one rich in 
lipocortin, the other containing low levels of the protein) were spiked with a 
known amount of rh lipocortin I standard (1 0  or 2 0  ng). Controls were spiked 
with an equivalent volume of buffer.
2.4.1.4 Rat CNS Tissue
In one experiment rat CNS tissues were homogenised as described 
previously in homogenisation medium, with or without 5 mM 
[ethylenebis(oxyethylenenitrilo)]tetraacetic acid (EGTA, Sigma). After
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freeze/thawing three times, samples were divided and one half centrifuged at
19,000 g for 30 min and the other at 100,000 g for 1 hr. Supernatants were 
collected, divided again, and one half of each was extracted three times with 
chloroform as follows: a double volume of chloroform was added, vortex mixed 
twice for 1 min, centrifuged at 2 2 0  g for 10 min to separate phases and the 
aqueous phase retained. Aliquots from each treatment were assayed spiked with a 
known amount of rh lipocortin I (20 ng) or with an equal volume of buffer.
2.4.2 ELISA
Following preparation as described above, CSF and CNS samples were 
assayed for lipocortin I using a "sandwich-type" ELISA (Smith et al. 1990). In this 
assay the wells of a microtitre plate are coated with monoclonal antibody to 
lipocortin I, remaining protein binding sites are blocked with foetal calf serum and 
samples and standards are then added. Lipocortin I binds specifically to the 
monoclonal antibody and polyclonal antisera to lipocortin I is then added which 
also binds to the lipocortin, thus forming an antibody-antigen-antibody "sandwich". 
The polyclonal antibody is then bound by a third enzyme conjugated antibody. 
Enzyme substrate is added to produce a colour reaction, the intensity of which is 
proportional to the amount of lipocortin present.
ELISA was performed in Nunc Maxisorp 96 well microtitre plates (Gibco). 
The reaction volume was always 100 pi and all incubations were for 1 hr at 37°C 
unless otherwise stated. For details of antibodies to lipocortin I see Table IV. The 
assay protocol is listed below:
1) All wells incubated overnight at 4°C with 2 pg/well purified mouse 
monoclonal antibody to lipocortin I (mAb IB) in 0.05 M 
carbonate/bicarbonate buffer, pH 9.6
2) Washed x 3 in carbonate/bicarbonate buffer
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3) Incubated 1% (y/w) foetal calf serum (Gibco) in PBS, pH 7.4 (Oxoid) 
(PBS-FCS)
4) Standards and samples were prepared and incubated as follows: 
Lipocortin I standard which had previously been diluted to 0.8 
mg/ml in PBS-FCS was used to prepare doubling dilutions in PBS 
containing 1% Tween 20 (Sigma)(PBS-Tween), ranging from 4 
pg-0.03 ng/well. Samples and standards were also diluted in PBS- 
Tween. Blanks contained PBS-Tween only.
5) Washed x 5 in 0.15 M sodium chloride solution containing 0.05% 
(y/w) Tween 20 (Saline-Tween)
6 ) Incubated with rabbit polyclonal antisera to lipocortin I (code: 842) 
diluted 1:1000 in PBS-Tween
7) Washed x 5 in Saline-Tween
8 ) Incubated with goat anti-rabbit alkaline phosphatase conjugate 
(Sigma) diluted 1:1000 in PBS-Tween
9) Washed x 5 in Saline-Tween
10) Enzyme substrate: 0.1% (w/y) disodium-p-nitrophenyl phosphate 
(Sigma) in carbonate/bicarbonate buffer added, plate covered in foil 
and incubated approximately 40 min at room temperature until colour 
developed
11) Optical density measured using a Titertek Multiscan MCC/340 at 405 
nm with a 620 nm reference filter
A standard curve of optical density against log lipocortin I concentration was 
constructed and used to calculate the lipocortin content of unknown samples. A 
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Figure 9. A typical standard curve obtained for the lipocortin I ELISA.
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2.5 HISTOLOGY
2.5.1 Human CNS Tissue
Histology and immunohistochemistry were performed on human CNS 
tissue by Dr J. Newcombe, Institute of Neurology, London.
2.5.1.J Histology
Sections 10 pm thick were cut from snap-frozen blocks of human CNS 
tissue using a cryostat and mounted onto glass slides. To assess cellular infiltration 
and the extent of demyelination, sections from each block were stained with H & E 
and Oil-Red-O using standard methods.
2.5.1.2 Immunohistochemistry for Lipocortin I
Immunohistochemistry was performed essentially as described by 
Newcombe and Cuzner (1988). Cryostat cut sections were mounted onto gelatin- 
coated slides and fixed in acetone for 10 min at 4°C. After incubation with the 
appropriate blocking sera, adjacent sections from each sample were probed either 
with rabbit antisera to lipocortin I (code: 842) or with a mouse monoclonal 
antibody directed against the astrocyte protein, glial fibrillary acidic protein 
(GFAP, Newcombe et al. 1986) or the pan macrophage marker EBM/11 (Dako). 
Sections were immunoperoxidase stained with a mouse or rabbit avidin-biotin 
complex kit (Vector Laboratories) using 0.05% DAB (Sigma), 0.013% 
(w/y) H2 O2  and 0.04% (w/y) nickel (II) chloride hexahydrate. Slides were then 
dehydrated, cleared in ethanol-xylene and mounted in DPX (BDH).
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2 .5 .2  R a t  C N S  T is su e
2.5.2.1 Histology
In most experiments cervical spinal cords were fixed in Camoy's fluid (Fava 
et al. 1989) comprising absolute alcohol, chloroform and acetic acid in the ratio 
6:3:1 and then dehydrated and cleared as follows:
1) Camoy's fluid 90 min
2) Absolute alcohol 1 hr, 3 changes
3) Cedar wood oil (Fisons) 1 hr, 2 changes 
The cords were then stored in cedar wood oil prior to further processing.
Sectioning of the tissues and H & E staining were kindly performed by staff 
at the Department of Cellular Pathology, Royal United Hospital, Bath. Briefly, 
cedar wood oil was removed by overnight incubation with chloroform and the 
tissues were embedded in paraffin wax. Longitudinal horizontal sections, 6  pm 
thick, were cut at one standard depth which was defined as the widest point when 
starting from the uncut surface. Two sections from each block were mounted onto 
glass slides and stained with H & E. Sections for immunohistochemistry were 
mounted onto 3-aminopropyltriethoxysilane (Sigma) coated slides.
In one set of experiments in order to estimate CNS tissue lesion load, 
cervical spinal cords and cerebella were fixed in 10% formol saline, H & E stained 
sections were then prepared as described above. The number of perivascular 
infiltrates per section was determined by light microscopy.
2.5.2.2 Immunohistochemistry for Lipocortin I
Sections were de-paraffinized and brought through graded alcohols to 
water using the following protocol:
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1) Xylene 2  min, 2 changes
2) 50% xylene in alcohol 30 sec
3) Absolute alcohol 30 sec
4) 95% alcohol 30 sec
5) 70% alcohol 30 sec
6 ) 40% alcohol 30 sec
7) Distilled water 30 sec
For the detection of immunoreactive lipocortin I a PAP method based on that used 
for Western blotting was employed. Slides were processed according to the 
following procedure and all incubations and washing steps were performed in PBS 
at room temperature unless otherwise stated:
1) Blocked with 0.5 ml (y/w) 10% goat serum (Gibco) for 30 min
2) Incubated with 20 pi antisera raised against rh lipocortin I (code:
842) under a glass coverslip in a humidified chamber, overnight at 
4°C
3) Rinsed 3 x 5  min
4) Incubated 30 min with 0.5 ml goat anti-rabbit IgG (Sigma)
5) Rinsed 3 x 5  min
6 ) Incubated 30 min with 0.5 ml rabbit PAP (Sigma)
7) Rinsed 3 x 5  min
8) 0.05% (w/y) filtered DAB plus 0.03% (w/y) H2 O2  until colour fully 
developed
9) Rinsed 3 x 5  min in distilled water
Antibody reagents 842, anti-rabbit IgG and PAP were titrated on serial sections 
taken from a typical EAE-diseased animal, optimum dilutions were found to be 
1:250, 1:50 and 1:1,000 respectively (Figure 10).
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Figure 10. T itra tio n  o f reagents for immunohistochemistry.
Antibody reagents for the peroxidase-anti-peroxidase (PAP) technique were titrated on serial sections o f  cervical 
spinal cord taken from a typical EAE-diseased animal. A  representative area o f  each slide is shown at x40 
magnification and the figures below each indicate the dilution o f  the reagent under test. Primary, secondary and 
tertiary reagents were titrated one at a time, in order, and the optimum dilutions o f  lipocortin I antisera (842), goat 
anti-rabbit IgG and PAP complex were found to be 1:250, 1:50 and 1:1000 respectively.
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Control experiments were performed on sections taken from normal rats 
and from EAE-inoculated animals at the height of disease. To test for the presence 
of endogenous peroxidase activity and the effectiveness of a standard quenching 
technique (Polak and Van Noorden, 1986), slides were pre-incubated respectively 
with either PBS or 0.3% (w/y) H2 O2  in PBS for 30 min at room temperature. The 
sections were then subjected to a sham immunohistochemistry procedure where all 
antibody reagents were replaced with PBS and then finally incubated with the 
DAB/H2 O2  substrate. However no staining was detected on either quenched or 
non-quenched sections from normal or EAE-diseased animals (Figure 11) 
indicating that no endogenous peroxidase activity was present in the prepared 
sections.
Specificity of staining was determined by incubating slides with either PBS 
or non-immune rabbit serum (Sigma) instead of lipocortin antisera. In some 
experiments to further assess specificity of immunostaining, 842 was diluted 1:250 
in PBS and aliquots incubated with a range of concentrations of rh 
lipocortin I (0.1-100 pg/ml), firstly for 1 hr at 37°C and then overnight at 4°C.
This pre-adsorbed antisera was then used in place of 842 after which the slides 
were processed in the normal way.
Following immunohistochemistry, all sections were lightly counterstained 
with toluidine blue:
1) 1% (w/y) aqueous toluidine blue 1-4 hr
2) Rinsed distilled water 2  sec
3) Differentiated in 95% alcohol 2 sec
4) Dehydrated in absolute alcohol 30 sec, 3 changes
5) 50% xylene in alcohol 30 sec
6) Cleared in xylene 30 sec, 2 changes
7) Blotted dry with filter paper and mounted in DPX (BDH)
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+V E Control Quenched Non-quenched
Quenched+VE Control Non-quenched
Figure 11. Control sections: test for endogenous peroxidase
Cervical spinal cord sections from normal and EAE-diseased rats were incubated with 0.3% H2 O2  to quench 
endogenous peroxidase (Quenched). Control sections were incubated with PBS (Non-quenched). Sections were then 
subjected to a sham immunohistochemistry procedure, where all antibody reagents were replaced with PBS and 
finally, incubated with D A B /H 2 O2  substrate to test for endogenous peroxidase. +VE controls were developed in the 
normal way. Magnification x40.
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Slides were observed and photographed using a Nikon Optiphot-2 microscope and 
Kodak Vericolor in professional film.
2.6 RADIOIMMUNOASSAY FOR CORTICOSTERONE
Corticosterone in rat serum was measured using an ICN RSL 125j_ 
corticosterone radioimmunoassay (RIA) kit obtained from IDS. The basis of this 
assay is that the corticosterone present in an unknown serum sample competes with 
a known quantity of l^I-labelled corticosterone to bind a limited amount of 
specific antibody. Thus the more corticosterone present in the sample, the less 
radiolabelled corticosterone is able to bind to the antibody. The antigen-antibody 
complexes formed are separated from unbound corticosterone by precipitation and 
centrifugation and the amount of radiolabelled corticosterone complexed with 
antibody is estimated by gamma-counting the pellet. The radioactive counts are 
used to calculate the percentage of 1 ^ ^I-corticosterone bound, which is inversely 
proportional to the amount of corticosterone in the sample.
The RIA has a range of 25-1,000 ng/ml and was performed according to 
the manufacturer's instructions, except that serum samples which were below the 
limit of detection were assayed at 1:50 dilution instead of the recommended 1:200. 
To reduce the influence of assay to assay variation, whenever possible serum 
samples from the same experiment were run in the same RIA.
2.6.1 Assay Protocol
The assay was performed in duplicate in 12 x 75 mm borosilicate disposable 
glass tubes (Kemble).
1) Rat serum thawed and diluted 1:200 (or 1:50) with steroid diluent
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2) 0.3 ml steroid diluent added to non-specific binding (NSB) tubes and 
0 .1  ml to zero calibrator tubes
3) 0.1 ml of corticosterone standards, rat serum controls or diluted rat 
serum samples added to appropriate tubes
4) 0.2 ml 125i_corticosterone added to all tubes
5) 0.2 ml anti-corticosterone added to all tubes except NSB
6 ) Tubes vortexed and incubated for 2 hr at room temperature
7) 0.5 ml precipitant solution added to all tubes and vortexed thoroughly
8 ) All tubes centrifuged at 1 ,000  g for 15 min and then the supernatant 
decanted and the rim of the tube blotted dry on absorbent paper
9) Precipitate counted in a LKB 1277 Gammamaster automatic gamma 
counter for 2 min
2 .6 .2  Calculations and Statistics
Results were expressed in counts per minute (CPM) and the percentage 
I-corticosterone bound was calculated for both standards and samples using the 
formula:
% b /B o =  X CPM (sample) - x CPM fNSBI x 100 
x CPM (0 ng/ml) - x CPM (NSB)
Where: % B/Bo
x CPM (sample) 
x CPM (NSB) 
x CPM (0 ng/ml)
= percentage 1 ^ I-corticosterone bound
= mean CPM of standard or sample 
= mean CPM of non-specific binding 
= mean CPM of standard containing 0 
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Figure 12. A representative standard curve obtained using the ICN 1 2 51- 
corticosterone radioimmunoassay kit
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A standard curve of percentage bound against log concentration was constructed
and the corticosterone concentration of unknown samples read directly from the
curve. A typical standard curve is shown in Figure 12. Values obtained for
samples which had been diluted 1:50 were corrected by dividing by four.
Simple statistical comparisons between two different groups were
performed using the Mann-Whitney U test, with the Bonferroni Correction when
three groups were compared. The Wilcoxon Signed-Rank test was used to analyse
the significance of differences between samples collected from the same group
before and after treatment. For experiments requiring multiple comparisons
between several groups, results were assessed using one way ANOVA and the
significance of differences between group means determined using the Newman-
Keuls procedure (Snedecor and Cochran, 1967).
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RESULTS




Cell-free CSF supernatants from patients with MS and control cases of 
systemic lupus erythematosus, chronic meningitis and idiopathic back pain were 
assessed for the presence of lipocortins I, II, IV and V by SDS-PAGE and Western 
blotting using the peroxidase conjugate technique. A gel stained for total protein 
with PAGE Blue 83, confirmed that adequate separation of CSF proteins could be 
achieved using this method and showed that the samples contained small but 
variable amounts of protein (Figure 13 a). However, when Western blots of these 
samples were probed for lipocortins I, II, IV and V, no immunoreactive bands of 
appropriate molecular mass were detected in either MS or control CSFs, although 
very faint bands between 50 and 70 kDa were observed in all lanes of each blot 
(Figure 13 b-e).
3.1.2 Whole CSF
Since lipocortins were undetectable in any of the cell-free supernatants 
studied, the same technique was used to investigate the lipocortin content of whole 
CSF which was prepared by repeated freezing and thawing in order to lyse the cells 
and thus allow measurement of both intracellular and extracellular protein.
Samples were obtained from patients with a variety of diseases although only one 
of these was diagnosed as having MS. A protein-stained gel and Western blots 
from one representative experiment are shown in Figure 14. A summary of all the 
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Figure 13. Im m unoblots for lipocortins in cell-free C S F from M S  patients and controls
(a) Protein-stained gel and (b-e) Western blots o f  cell-free CSF supernatants from MS patients and controls probed 
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2 AW Multiple myeloma
3 YC -
4 CT Malignant lymphoma
5 DT Astrocytoma
6 EN Dementia
7 PH Viral infection
8 DM Migraine
9 EP Tuberculous meningit
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Figure 14. Lipocortins in whole human CSF
(a) Protein-stained gel and (b-e) Western blots o f  whole human CSF lysate from patients with a variety o f  diseases 












I II IV V
AW Multiple myeloma 0.87 <1 570 . _ , ‘
YC - 0.28 <1 3 - - - -
CT Malignant lymphoma <0.3 <1 115 - - - -
DT Astrocytoma 2.9 90 10 + - - +
EN Dementia - - - - - - -
PH Viral Infection <0.3 <1 <1 - - - -
DM Migraine - - - - - - -
EP Tuberc. meningitis 1.14 162 10 ? - - -
EP Tuberc. meningitis - - - ? - - -
KD Vit A  deficiency 1.45 1 10 - - - -
LS Convulsions - - - - - - -
DT Astrocytoma 2.7 50 5800 + - - -
SR Viral infection <0.3 <1 <1 - - - -
EA Mononeuritis 0.84 <1 2 - - - -
BJ — 0.34 2 505 - - - -
KN Deform of ankle & foot 0.50 <1 4 - - - -
HC Pylonephritis <0.3 1 6 - - - -
GW Urinary tract infection <0.3 <1 <1 - - - -
LN Multiple sclerosis 0.68 3 <1 - - - -
TC Pyrexia <0.3 <1 <1 - - - -
SW Backache 0.39 <1 <1 - - - -
NW - 0.7 <1 175 - - - -
JB Backache 0.76 <1 1120 — - - -
LS Slipped disc 1.38 <1 <1 - - - -
RJ Upper resp tract infect <0.3 <1 <1 - - - -
SM Peripheral neuropathy <0.3 <1 <1 - - - -
KG - 3.72 3320 280 + - - +
CB Migraine <0.3 <1 15 - - - -
LT - 1.3 <1 <1 - - - -
MP - <0.3 <1 <1 - - - -
MB Stroke 1.0 6 3 — — — —
IG Headache <0.3 <1 4 — — - —
AR Chest infection <0.3 <1 <1 — — — —
MH Backache <0.3 <1 205 — — - —
DC Breast cancer 0.5 <1 13 - - - —
ET Polyneuritis 0.56 <1 <1 - - - -
CM - - - - - — - -
CS Ear infection <0.3 <1 325 — — - -
JB Meningococcal meningitis 4.68 1240 150. +
Lipocortins were detected by Western blotting using the following polyclonal 
antibodies: lipocortin I, 842; lipocortin II, 774; lipocortin IV, 179; lipocortin V, 
890. +, lipocortin present; -, lipocortin not detected; ? indicates presence of 
lipocortin immunoreactive protein of lower molecular mass (31 kDa).
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protein concentration, erythrocyte and leukocyte counts plus the final diagnosis, 
where available.
On blots probed for lipocortin I low levels of an approximately 36 kDa 
immunoreactive protein were detected in four out of the 39 samples tested. The 
molecular mass of this band is very similar to that reported for human lipocortin I 
(37 kDa) by Wallner et al (1986). Of the four samples containing lipocortin I-like 
protein, two were diagnosed as astrocytomas, one as meningitis and one was of 
unknown pathology. In addition, a lipocortin I-immunoreactive protein of a 
slightly lower molecular mass (approximately 31 kDa) was observed in two 
samples from another patient with meningitis. It is likely that this band is a 
breakdown product of lipocortin I (Pepinsky et al 1986). In each case the 
presence of lipocortin I immunoreactivity was associated with substantially 
elevated CSF protein levels and a very high leukocyte count.
Two of the samples in which lipocortin I-like protein was detected, also 
exhibited very low levels of a 30 kDa band on blots probed for lipocortin V. The 
molecular mass of this band is close to that reported by Comera et al (1989) (32 
kDa) for lipocortin V isolated from human peripheral blood mononuclear cells. 
Lipocortins II and IV did not appear to be present in any of the samples tested. 
Several very faint higher molecular mass bands between 50 and 70 kDa were 
observed on all blots.
3.1.3 ELISA for Lipocortin I in CSF
Selected CSF samples were assayed for lipocortin I using the more 
sensitive ELISA technique, which was performed by Dr N. Goulding. This 
confirmed the presence of nanogram amounts of the protein in two samples of 
whole CSF which had previously been shown to contain low levels of the protein 
by Western blotting. Furthermore, ELISA of cell-free CSF supernatants which had
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Table VI
Quantitation of lipocortin I in human CSF by ELISA
Patient Diagnosis CSF Type





471 MS-Chronic progressive II
299 Chronic meningitis II
253 Systemic lupus erythematosus II
259 Low back pain II
279 Backache II
DT Astrocytoma Lysate









Detection limit of ELISA is approximately 0.8 ng/ml. (-) indicates lipocortin I 
concentration was below limit of detection.
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appeared negative for lipocortin I using Western blotting, revealed the presence of 
extremely low levels of the protein in several samples including two from patients 
with progressive MS (Table VI).
3.2 CNS TISSUE
3.2.1 Detection of Lipocortins bv SDS-PAGE and Immunoblotting
As only limited amounts of lipocortin were detected in CSF and that which 
was present appeared to be cell-associated, attention was turned to CNS tissue. 
Using SDS-PAGE and the PAP method lipocortins I, II, IV and V were assessed in 
samples of white and grey matter from normal controls, and in plaque tissue, white 
matter adjacent to a plaque, white matter remote from a plaque and grey matter 
from patients with MS. The relative amounts of lipocortin in each sample-type 
were then semi-quantitatively estimated by densitometry. The results of this work 
have been published in the Journal of Neuroimmunology (Elderfield et al 1992).
In a preliminary experiment to determine the optimum loading of the gels 
for good visualisation, adequate separation of bands and accurate densitometry, 14 
samples were run at several different protein concentrations namely: 20, 10 and 5 
pg total protein per lane. In each case the same qualitative differences were 
observed; 5 pg per lane was found to be optimum for lipocortins I and V and 10 
pg and 20 pg for lipocortins IV and II respectively. Results obtained in one typical 
experiment are shown in Figure 15. Figure 15a shows a gel stained for total 
protein and indicates that adequate separation of proteins occurred and that 
following adjustment of protein concentration all samples contained equivalent 
amounts of protein. Figure 15b-e shows Western blots probed for lipocortins I, II, 
IV and V respectively.
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a) Protein b) Lipocortin I (842)
I
kDa
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
c)  Lipocortin II (774) d) Lipocortin IV (179)
kDa - kDa
1 2 3 4 5 6 7 8 9
e) Lipocortin V (890)
kDa
Lane Sample
1 Molecular mass markers
2 Control white matter
3 M S white matter-near plaque
4 M S white matter-plaque
5 M S white matter-plaque
6 M S white matter-remote from plaque
7 Control white matter
8 Control grey matter
9 rh lipocortin I standard (6.5-25 ng)
1  2 3 4  5 6 7 8 9
Figure 15. Lipocortins in C NS tissues from  M S patients and controls
(a) Protein stained-gel and (b-e) Western blots o f  CNS tissues from MS patients and controls probed for lipocortins I, 
II, IV and V. Code numbers o f  antibodies are shown in parenthesis.
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On blots probed for lipocortin I using antibody 842, three distinct 
immunoreactive bands of approximately 37, 35 and 33 kDa were consistently 
detected in almost all samples. The 37 kDa band co-migrated with rh lipocortin I 
standard and the molecular mass of this band is concordant with that reported for 
human lipocortin I by Wallner et al (1986). The two lower molecular mass 
species may represent breakdown products of lipocortin I, particularly the 33 kDa 
band which migrated to the same position as a small amount of contaminant 
protein observed in the lipocortin I standard which was originally a highly purified 
recombinant protein preparation (Wallner et al 1986). Similar lower molecular 
mass species have been observed in human tissues by other workers and appear to 
be due to enzymatic degradation of lipocortin I (Huang et al 1987, Smith et al 
1990b, Ambrose & Hunninghake 1990a). In order to assess possible differences 
between the groups in the degree of lipocortin I degradation, following 
densitometry a preliminary Two Way Analysis of Variance was performed 
including the three bands as a second factor, this showed no difference between 
any of the groups in the proportion of protein in each band. An alternative 
explanation for the presence of the 35 kDa band is the possibility that this may be 
lipocortin IH, as it is of the appropriate molecular mass and the 842 antibody is 
known to exhibit strong cross-reactivity with this protein (Pepinsky et al 1988). 
Many bands between 40 and 80 kDa were observed on these blots including one at 
68 kDa, however they were very faint compared to the main bands.
On blots probed for lipocortin II with antibody 774, several bands between 
30 and 40 kDa were observed, although the major band was approximately 35 kDa 
which corresponds to the reported molecular mass of lipocortin II (Huang et al 
1986, Pepinsky et al 1988). In addition, two higher molecular mass bands were 
observed at approximately 61 and 54 kDa and the antibody was also found to 
cross-react with lipocortin I standard. To check the identity of the major band
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some samples were re-assayed using a different antibody raised against rh 
lipocortin II (Ab 1). This antibody, which did not cross-react with lipocortin I, 
gave only two bands in the 30-40 kDa region, the main band having a molecular 
mass of approximately 34 kDa. Quantitative changes in lipocortin II-like protein 
appeared to be identical with both antibodies (Figure 16).
Several bands were present on blots probed for lipocortin IV (antibody 
179), the predominant species having a molecular mass of approximately 40 kDa. 
Blots probed for lipocortin V (antibody 890) exhibited two main bands one at 
approximately 30 kDa, which is close to the molecular mass reported by Comera et 
al. (1989) for lipocortin V (32 kDa), and another at approximately 67 kDa.
Neither antiserum appeared to cross-react with lipocortin I.
Figure 17 shows a control blot comprising eight typical samples, where the 
primary antibody was omitted to determine non-specific staining. Only one very 
faint non-specific band was observed at approximately 50 kDa in each sample 
indicating that all other bands are due to binding of lipocortin antisera.
In total 35 CNS tissue samples were assayed with 5-7 samples per group. 
For purposes of comparison, three representative samples from each group are 
shown in Figure 18. On all blots the molecular mass of the major band was close 
to that reported for the appropriate lipocortin in the literature. The intensity of the 
main band in each sample was therefore measured using densitometry in order to 
provide a semi-quantitative assessment of the amount of each lipocortin-like 
protein. Densitometry data for all samples are summarised in Table VII. To 
reduce the influence of blot-to-blot variations in staining intensity, samples in the 
same group were randomised between different blots. Using the densitometer 
values obtained by scanning the constant amount (6.5 ng) of rh lipocortin I run on 
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kDa
1 2 3 4 5 6
Ab 1
Lane Sample
1 High molecular mass markers
2 MS white matter-plaque
3 MS white matter-near plaque
4 MS grey matter
5 MS white matter-remote from plaque
6 Control grey matter
8 rh lipocortin I (25 ng)
Figure 16. Comparison oflipocortin II antisera
Western blots containing identical CNS tissue samples from MS patients and 
controls probed with two different lipocortin II antisera, 774 and Ab 1.
1 2 2
Lane Sample
1 High molecular mass markers
2 Control white matter
3 Control grey matter
4 MS white matter-remote from plaque
5 MS grey matter
6 Control white matter
7 MS white matter-remote from plaque
8 MS grey matter
9 Control white matter
10 rh lipocortin I (25 ng)
Figure 17. Control blot omitting primary antiserum
Western blot of human CNS tissues from MS patients and controls immunoblotted 
using the PAP method but incubated with PBS in place of specific lipocortin 
antiserum.
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Figure 18. Comparison of lipocortins in normal CNS tissues with lesioned 
and apparently normal CNS tissues from patients with MS
Western blots of grey and white matter from normal controls and plaque tissue, 
apparently unaffected white matter adjacent to a plaque, white matter remote from 
a plaque and grey matter from MS patients were probed for lipocortins I, II, IV 
and V. In total 35 CNS samples were assayed with 5-7 samples per group, for 
clarity three representative samples from each group are shown, rh lipocortin I 
standard was applied at 25 ng per lane. MWM, high molecular mass markers.
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Table VH
Densitometer values for western blots of MS and control CNS tissues probed for lipocortins I, II, IV and V.
Tissue n I
White matter -  Control 7 865±247
MS -  remote from plaque 6 2551±1387
MS -  adjacent plaque 5 2585±1111
MS -  plaque 6 2842±1308





1 8 2 2 ± l l i r 468±399 > 1243±184>
2771±740c „ * * * 486±168c
a
► ** 1356±428
3086±438 , 689±548 > 1530±703,
435±318 78±23 662±318
612±378 132±44b 707±188
The density of the major band on each immunoblot was assessed using a Joyce-Loebl Chromoscan 3. Results are expressed as mean 
integral + standard deviation. For statistical analysis the data were log transformed to stabilise the variance and analysed by One Way 
Analysis of Variance. Three orthogonal contrasts were fitted for comparison of white matter sub-types.
*P<0.05; **P<0.01; ***P<0.001 for all MS white matter sub-types versus control. 
aP<0.02 MS white matter remote from plaque versus plaque and adjacent white matter. 
bP<0.05 MS grey matter versus control grey matter, 
n = number of samples per group (except c, where n = 4).
As can be seen in Figure 18 and Table VII, immunoreactive lipocortins I,
II, IV and V were detected in both grey and the white matter samples from normal 
control subjects and in all other sample types studied. CNS tissues from MS 
patients appeared to contain markedly increased amounts of all four lipocortins.
An overall comparison of all MS white matter subtypes with control white matter 
showed that immunoreactive lipocortins I, II, IV and V were significantly increased 
in MS tissue (P<0.001, P<0.001, PO.Ol, P<0.05 respectively). Moreover, as well 
as the elevated amount observed in apparently normal MS white matter, levels of 
each lipocortin were further raised in plaque tissue and in adjacent white matter. 
Thus within the CNS of individuals with MS there appeared to be a graduation in 
the tissue content of each lipocortin, with plaque > white matter adjacent to a 
plaque > white matter remote from a plaque. This pattern was observed for all 
four lipocortins but reached statistical significance only for lipocortin II. 
Comparison of control and MS grey matter showed a slight increase in all 
lipocortins compared to controls, but was only significant at P<0.05 for lipocortin 
IV.
3.2.2 ELISA for Lipocortin I
Since densitometry is only a semi-quantitative technique, an attempt was 
made to measure the amount of lipocortin I in human CNS samples more 
accurately using the lipocortin I ELISA. In a preliminary experiment to determine 
the correct dilution at which to assay the samples, fourteen samples were assessed 
at four different dilutions corresponding to total protein concentrations of 0.4, 0.2, 
0.1 and 0.05 mg/ml. Values obtained for the lowest dilution (0.4 mg/ml) fitted best 
on the linear portion of the standard curve but at all dilutions the majority of 
samples were within the detection range of the assay. The results for each dilution 
were normalised by conversion to ng lipocortin I / mg protein and are shown in
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Table VIII
Lipocortin I ELISA of CNS tissue: comparison of different sample dilutions
Total protein concentration 




CNS sample type 0.4 0.2 0.1 0.05
Control white matter
Lipocortin I ng/mg protein 
48 75 125 114
2 MS white matter - adjacent plaque 326 601 731 774
3 MS white matter - plaque 716 1082 1661 2000
4 MS white matter - plaque 310 452 496 530
5 MS white matter - remote from plaque 32 49 37 ♦
6 Control white matter ♦ ♦ * *
7 Control grey matter 12 * ♦ *
8 MS white matter - remote from plaque 213 252 419 468
9 MS white matter - plaque 407 652 968 838
10 MS white matter - adjacent plaque 324 537 682 826
11 MS grey matter 25 19 * *
12 MS white matter - adjacent plaque 62 93 143 178
13 MS white matter - plaque 170 238 303 390
14 Control white matter 13 * * *
CNS tissue samples from MS patients and controls were homogenised in buffer 
containing 5 mM EDTA and the supernatants assayed for lipocortin I by ELISA. 
Each sample was assayed at four different dilutions and the total protein 
concentration at each dilution is shown at the top of each column. Results are 
expressed as ng lipocortin I / mg of protein. Values marked with an asterisk were 
below the detection limit of the assay, 0.5 ng/ml.
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Table VIII. As can be seen by comparison of the results in Table VIII with those 
in Figure 18 and Table VII, at each dilution the overall pattern in the lipocortin I 
content of the different sample types was very similar to that observed using 
Western blotting, with the highest amounts found in plaque tissue and the lowest 
levels in control grey and white matter. However, for any given sample different 
values were obtained at each dilution: in each case the more concentrated the 
sample at assay, the lower the apparent lipocortin content.
To investigate whether the presence of CNS tissue homogenate was 
preventing accurate measurement of lipocortin, four representative samples were 
assayed at 0.4 mg/ml protein, spiked with either a known amount of rh lipocortin I 
standard (10 ng) or an equal volume of assay buffer. Table IX shows that values 
obtained for spiked samples were much lower than expected, with only a fraction 
of the added lipocortin being detected, suggesting that a component of the sample 
or homogenisation buffer was interfering with the assay.
To determine the source of this interference a similar spiking experiment 
was performed to assess the influence of CNS tissue homogenate or 
homogenisation medium alone on the measurement of lipocortin I. The effect of 
the amount of lipocortin I originally present in the sample was also investigated. In 
addition, the influence of media/sample concentration was studied, with both 
homogenisation medium and CNS samples being assayed at several different 
dilutions in the presence or absence of 10 ng lipocortin I spike. To account for the 
possibility that the position of the sample on the plate might influence the results, 
samples to be tested were sandwiched between two columns of controls 
comprising 10 ng lipocortin I standard diluted in assay buffer only. Wells were 
filled one column at a time from left to right. A plan of the plate layout used in this 
experiment is shown in Figure 19.
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Table IX
Lipocortin I ELISA of CNS tissue: effect of samples on measurement of 
lipocortin
Sample CNS Sample Type Lipocortin I Difference
No. ng/well
- + (+K-)
1 Control white matter 3.8 4.3 0.5
4 MS white matter-plaque 25.9 17.8 -8.1
7 Control grey matter 0.8 3.7 2.9
11 MS grey matter 1.2 3.8 2.6
CNS tissue supernatants were diluted to 0.4 mg/ml total protein and spiked with 
either 10 ng rh lipocortin I (+) or an equal volume (10 pi) of assay buffer (-). 
Unspiked samples were assayed in quadruplicate, spiked samples in duplicate. 
Results are mean values expressed in ng lipocortin I/well.
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1 2 3 4 5 6 7 H 9 10 11 12
HM 4 11 HM 4 11
A B 4 16 0.06 40 40 40 40 40 40 C
B B 2 8 0.03 40 40 40 40 40 40 c
+ + + + + +
C B 1 4 c 20 20 20 20 20 20 c
D B 0.5 2 c 20 20 20 20 20 20 c
+ + + + + +
E B 0.25 1 c 10 10 10 10 10 10 c
F B 0.13 0.5 c 10 10 10 10 10 10 c
+ + + + + +
G B 0.06 0.25 c 5 5 5 5 5 5 c
H B 0.03 0.13 c 5 5 5 5 5 5 c
+ + + + + +
Figure 19. Lipocortin 1 ELISA of CNS tissue: plate plan
Plan of the microtitre plate used to determine the influence of homogenisation 
medium, CNS tissue homogenate and the lipocortin content of CNS homogenates 
on the measurement of a known amount of lipocortin I.
Column 1 Blanks (assay buffer only)
Column 2-4B Standard curve: figures show lipocortin/well in pg (column 
2) and ng (columns 3 & 4)
Column 4C-H Controls: 10 ng rh lipocortin I per well 
Column 5-10 Samples and homogenisation medium: figures represent 
volume (pi) of sample or medium added to well which for 
CNS samples corresponded to the following protein 
concentrations:
40 pi = 0.4 mg/ml 
20 pi = 0.2 mg/ml 
10 pi = 0.1 mg/ml 
5 pi = 0.05 mg/ml 
Columns 5 + 8 homogenisation medium 
Columns 6 + 9 CNS sample 4, MS plaque rich in 
lipocortin I
Columns 7+10  CNS sample 11, MS grey matter 
containing little lipocortin I 
+, indicated presence of 10 ng/well lipocortin I spike 
-, indicates absence
Each well was made up to 100 pi with assay buffer 
Column 11 - -Controls: 10 ng/well rh lipocortin I standard/well.
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Table X
Lipocortin I ELISA of CNS tissue: effect of homogenisation medium, CNS 
tissue homogenate and the lipocortin content of CNS samples on the 
measurement of lipocortin I
Sample Protein Spike Lipocortin Appare
(plate position) concentration/ (10 ng) I value c
volume ng/well spike (n
(+M-
Lipocortin I standard n=6 - + 8.0 8.0
(column 4)
Homogenisation medium 40 - 0
(columns 5 & 8) 40 + 14.2 14.2
20 - 0
20 + 10.1 10.1
10 - 0
10 + 7.9 7.9
5 - 0
5 + 6.6 6.6
Sample 4 0.4 _ 13.4
MS plaque-lipocortin rich 0.4 + 15.3 1.9
(columns 6 & 9) 0.2 - 8.9
0.2 + 11.1 2.2
0.1 - 5.1
0.1 + 8.0 2.9
0.05 - 2.7
0.05 + 5.6 2.9
Sample 11 0.4 _ 0.9
MS grey matter- 0.4 + 2.8 1.9
lipocortin poor 0.2 - 0.6
(columns 7 & 9) 0.2 + 2.9 2.3
0.1 - 0.4
0.1 + 3.1 2.7
0.05 - 0.4
0.05 + 2.6 2.2




Homogenisation medium and two CNS tissue samples, one rich in lipocortin I and 
the other containing very little of the protein, were assayed at various dilutions 
spiked with either 10 ng rh lipocortin I (+), or an equal volume of assay buffer (-). 
Results are mean values of duplicates (except lipocortin I standard) expressed in ng 
lipocortin I/well. The second column shows the protein concentration of the 
sample in mg/ml or the volume of homogenisation medium in p i The right hand 
column indicates the apparent value of the 10 ng lipocortin I spike in the presence 
of medium or CNS samples, which was calculated by subtracting the value 
obtained for the non-spiked sample from that of the spiked sample.
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The results of this experiment are shown in Table X. Values obtained for 
lipocortin controls were 8.0 + 1.0 ng (mean ± SD) for column 4 and 5.2 ± 0.5 ng 
for column 11. Thus even when lipocortin I was diluted in assay buffer only (PBS- 
Tween) and measured in the absence of media or samples, the observed values 
were lower than expected, particularly on the right hand side of the plate.
However, since the samples were sandwiched between these two columns of 
controls, the calculated values obtained for the spike would be expected to lie 
between 8.0 and 5.2 ng if no interference occurred.
Homogenisation medium alone did not appear to inhibit measurement of 
lipocortin I although the results were quite variable. In the presence of CNS tissue 
homogenate however, a marked reduction in the detection of lipocortin I was 
observed, even at relatively dilute protein concentrations. There appeared to be no 
difference between the effect of a lipocortin rich sample and one containing very 
little of the protein, thus the amount of lipocortin already present in the sample did 
not appear to influence recovery.
These results suggested that a factor present in the CNS tissue was 
interfering with the assay. To determine whether this substance might be a protein, 
two identical Western blots containing seven typical CNS samples were prepared 
and each was probed with one of the antibodies used in the ELISA. Figure 20 
shows that although there was some very faint staining of higher molecular mass 
bands, both antibodies (mAbl and 842) appeared to bind only to lipocortin I and 
its putative breakdown products to any extent, suggesting that interference was not 
due to non-specific binding of the antibodies to other proteins in the samples.
CNS tissue has a very high lipid content which could potentially interfere 
with this assay, either by binding to lipocortin or preventing binding of lipocortin to 
the monoclonal antibody. To investigate whether this might be the case and 
examine possible means of prevention, another spiking experiment was performed
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1 2 3 4 5 6 7 8 9  
b) Polyclonal (842)
Lane Sample
1 High molecular mass markers
2 Control white matter
3 MS white matter-adjacent plaque
4 MS white matter-plaque
5 MS white matter-plaque
6 MS white matter-remote from plaque
7 Control white matter
8 Control grey matter
9 rh lipocortin I (10 ng)
Figure 20. Specificity of antibodies used in the lipocortin I ELISA
Two identical blots containing representative CNS tissue samples were probed 
with the antibodies used in the lipocortin I ELISA, (a) monoclonal antibody to 
lipocortin I (mAb IB) was used at a dilution o f 1:500. (b) polyclonal lipocortin I 




Lipocortin I ELISA of CNS tissue: effect of pre-treatment of samples with 5 
raM EGTA and/or high speed centrifugation on the measurement of 
lipocortin I
Sample/Treatment Spike Lipocortin I Apparent
(20 ng/well value of spike
ng) (+H-)
Lipocortin I standard n=5 (column 4) + 34 34
CNS tissue-Normal preparation 0
+ 11 11
CNS tissue-5 mM EGTA _ 0
+ 2 2
CNS tissue-100,000 g 0
+ 11 11
CNS tissue-5 mM EGTA & 100,000g 0
+ 0 0
Lipocortin I standard n=8 (column 7) + 45 45
Rat CNS tissue was homogenised in homogenisation medium in the presence or 
absence of 5 mM EGTA and aliquots were then centrifuged at either 19,000 or 
100,000 g. The supernatants were adjusted to 0.4 mg/ml total protein, spiked with 
either 20 ng rh lipocortin I (+) or an equal volume (10 pi) of assay buffer (-) and 
then assayed by ELISA for lipocortin I. Lipocortin I standard was run in columns 
4 and 7 and samples in columns 5 and 6. Calculated apparent values for the spike 
are shown in the column on the right. Values obtained for the lipocortin I standard 
were higher than expected because the standard curve was not very accurate in this 
assay run, however this data has been included because the results obtained for the 
test groups were very clear cut.
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using rat CNS tissue. Several methods for pre-treating the samples were 
employed: chloroform extraction of lipids; centrifugation at 100,0000 g for 1 hour 
to remove liposomes; and inclusion of 5 mM EGTA in the homogenisation medium 
to chelate calcium and prevent calcium-dependent binding of lipocortin to 
phospholipids. Each procedure was tested both alone and in combination with the 
others. Results are shown in Table XI except for the chloroform treatment, these 
samples could not be assayed because extraction resulted in the removal of all 
protein from the samples. As previously observed, measurement of lipocortin I 
was inhibited in the presence of CNS tissue. High speed centrifugation of samples 
had no effect on this inhibition, inclusion of 5 mM EGTA resulted in a further 
reduction in the measurement of lipocortin I.
Due to the problems encountered in attempting to use the ELISA technique 
to measure lipocortin I in human CNS tissue supernatants, these experiments were 
not continued.
3.2.3 Localisation of Lipocortin I Immunoreactivitv
The cellular localisation of lipocortin I immunoreactivity in normal human 
CNS tissue and in tissues from patients with MS was investigated using rabbit 
polyclonal antiserum to rh lipocortin I (code no. 842) and an avidin-biotin complex 
immunoperoxidase kit which resulted in brown staining of immunoreactive 
lipocortin I. These experiments were performed by Dr J. Newcombe and a 
manuscript is in preparation for publication.
3.2.3.1 Normal
In normal control white matter lipocortin I immunoreactivity was located 
primarily in the walls of blood vessels (Figure 21). In addition, very weak staining 
of the perikarya of some unidentified cells, which appeared to be scattered
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Figure 21. Immunolocalisation of lipocortin I in normal human CNS white 
matter
Cryostat sections o f  normal adult human spinal cord white matter, 
immunoperoxidase stained for lipocortin I. (a) low power field (xl87) 
demonstrating several lipocortin I positive blood vessels, plus very weak staining o f 
the perikarya o f unidentified cells, (b) Higher power view o f the same section 
(x750) showing lipocortin I immunostaining o f blood vessel walls.
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throughout the parenchyma, was also observed. No staining was present on 
control sections where the primary antibody was omitted or replaced with non- 
immune rabbit serum.
3.2.3.2 MS
In actively demyelinating MS plaque tissue lipocortin I immunoreactivity 
was dramatically increased compared to normal control white matter (Figure 22a). 
This increase was due to widespread staining of small cells which had very strongly 
stained perikarya, extensive immunostained processes, and were morphologically 
typical of reactive astrocytes (Figure 22b). In addition, the nuclei, perikarya and 
processes of small numbers of swollen hypertrophic astrocytes also stained positive 
for lipocortin I.
For comparative purposes Figure 23 shows adjacent sections from an active 
plaque immunostained for lipocortin I, the astrocyte marker glial fibrillary acidic 
protein, and the pan macrophage marker EBM 11. Both anti-lipocortin I and anti- 
GFAP stained a dense network of cell processes and the similarity in staining 
patterns strongly suggests that the lipocortin I positive cells in active plaques are 
astrocytes. In contrast a quite different staining pattern was observed on sections 
probed with the pan macrophage marker EBM 11. This antibody visualised a large 
number of reactive macrophages and microglia in actively demyelinating plaques. 
However on adjacent sections these cells did not appear to be positive for 
lipocortin I, although immunoreactivity was occasionally observed in 
monocytes/macrophages in the walls of blood vessels.
In macroscopically normal white matter remote from a plaque, lipocortin I 
immunoreactivity was slightly increased compared to normal control tissue due to 
the presence of scattered lipocortin I positive astrocytes. Staining of blood vessels 




Figure 22. Immunolocalisation of lipocortin I in M S plaque tissue
Cryostat sections o f  an actively demyelinating plaque in spinal cord white matter, 
immunoperoxidase stained for lipocortin I. (a) Low power view (x l87) showing 
extensive lipocortin I immunostaining (cf. normal white matter Figure 21a). (b) 
Higher power view (x750) demonstrating strong staining o f astrocyte cell bodies 
and processes.
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Figure 23. Adjacent sections from an actively demyelinating M S  plaque immunostained for lipocortin I ,  the 
astrocyte protein G F A P , and the pan macrophage m arker E B M  11
(a) Astrocyte perikarya and processes immunostained with lipocortin I antisera, (b) A similar pattern o f  
immunostained cell processes was observed with a monoclonal antibody to the astrocyte marker glial fibrillary acidic 
protein (GFAP). (c) Activated macrophages and microglia immunostained for the pan macrophage marker EBM 11, 
these cells did not appear to be positive for lipocortin I. All at magnification x750.
matter. Control sections of MS plaque tissue were negative when the primary 
antibody was omitted or replaced with non-immune rabbit serum.
PART B: LIPOCORTINS IN THE RAT CNS DURING EAE
3.3 CEREBROSPINAL FLUID
3.3.1 Cell-free Supernatants
Western blotting was used to investigate the lipocortin content of cell-free 
CSF supernatants taken from normal rats and EAE-inoculated animals at the height 
of disease and immediately following recovery. Samples were run individually and 
a gel stained for total protein showed that all the samples contained minimal 
amounts of protein, although slightly increased levels were observed in CSF from 
EAE-inoculated animals (Figure 24). However, when samples were 
immunoblotted for lipocortin I using the polyclonal antiserum code no. 842 and the 
peroxidase conjugate technique, lipocortin I was undetectable. Very faint bands at 
64 and 56 kDa were present in each sample but appeared to be similar in all 
animals regardless of treatment.
3.3.2 Whole CSF
The same technique was also used to investigate lipocortin I in lysate of 
whole CSF. Samples were collected from normal and CFA-inoculated controls 
and EAE-inoculated animals during the induction, diseased and recovery phases.
In a preliminary experiment samples were run individually to assess variation within 
groups, and results of this experiment are shown in Figure 25. Lipocortin I was 
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Figure 24. Immunoblot for lipocortin I in cell-free CSF from normal and 
EAE-inoculated Lewis rats
(a) Protein-stained gel and (b) Western blot o f cell-free CSF supernatants from 
normal, EAE-diseased and EAE-recovered rats, probed for lipocortin I using 
antibody code number 842
b) Lipocortin I (842)
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Figure 25. L ipocortin  I  in the C S F  o f individual Lewis rats during various stages o f E A E
Western blots o f  whole CSF lysate taken from normal, CFA-inoculated and EAE-inoculated animals were probed with 
lipocortin I  antiserum code no. 842. Days post-inoculation (pi) on which the animals were sampled are shown in 
parenthesis. The first lane o f  each blot contains high molecular mass markers, subsequent lanes, CSF from individual 
animals, and the final lane o f  each blot was loaded with 50 ng rh lipocortin I. The figures below each lane show the 
CSF leukocyte count (L) and erythrocyte count (E) in cells/ml (xlO^). Mean counts for each group are shown on the 
right.
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taken from EAE-inoculated animals during the induction phase. However, small 
amounts of an approximately 38 kDa lipocortin I-like immunoreactive protein were 
present in the spinal fluid of four out of six animals with neurological symptoms of 
EAE and two out of six animals which had recently recovered from the disease. In 
addition, two very faint bands at approximately 83 and 68 kDa were observed in all 
samples but these did not appear to change significantly throughout the course of 
the disease.
The groups in which the lipocortin I-like protein was detected had higher 
CSF leukocyte counts than groups where the protein was absent, although for 
individual samples within these groups there appeared to be no relationship 
between cell number and the presence or absence of the protein. There was no 
correspondence between the occurrence of lipocortin and erythrocyte number.
Since this initial experiment revealed only minimal variation in the lipocortin 
content of samples within the same group, pooled spinal fluid samples were used in 
subsequent experiments. This allowed all groups to be run on the same blot, thus 
eliminating errors which may arise from comparison of samples processed on 
different blots.
Two separate experiments were performed to assess lipocortins in pooled 
samples of CSF lysate. Due to the low levels previously found in CSF, the more 
sensitive PAP-Ni/Co method of immunoblotting was developed and used for the 
detection of lipocortins in these samples. The results of one such experiment are 
shown in Figure 26. In the first experiment lipocortins appeared to be below the 
limit of detection in spinal fluid from normal, CFA controls and EAE-inoculated 
animals during the induction phase. However, in the second experiment extremely 
low levels of a 37 kDa lipocortin I-like protein were detected in these groups. In 
each case increased levels of the protein were found in CSF taken from EAE- 
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Figure 26. Lipocortins in pooled C SF taken from  Lewis rats during various stages o f E A E
(a) protein-stained gel and (b-d) Western blots o f  whole CSF lysate pooled from groups o f  normal (N ), CFA- 
inoculated (CFA), and EAE-inoculated rats during the induction (Ind), disease (Dis), and recovery (Rec) phases, 
probed for lipocortins I, II and V. Antibody code numbers are given in parenthesis. Figures below each lane show the 
mean number o f  leukocytes and erythrocytes per ml (xlO4) and the number o f  samples per group (n). The final track 
o f  blot b contains 10 ng rh lipocortin I standard (LCI).
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addition, very low levels of a 31 kDa lipocortin I immunoreactive protein were also 
detected in these samples. Again the increased amount of immunoreactive 
lipocortin I in the disease and recovery groups appeared to coincide with an 
elevation in the CSF leukocyte count and there seemed to be no concordance with 
CSF erythrocyte number.
In contrast immunoreactive proteins corresponding to the molecular weight 
of lipocortins II and V were not detected in CSF from either normal or EAE- 
inoculated animals. Interestingly a band of approximately 51 kDa was observed on 
the blot probed for lipocortin II which was markedly increased in EAE-diseased 
animals. Several very faint bands between 50 and 80 kDa were present on all blots, 
some of which also appeared to increase during EAE.
Although the method used to collect rat CSF was adequate for obtaining 
samples from control animals, it proved very difficult to consistently obtain 
sufficient volumes of CSF from rats with EAE. In each experiment 6-8 animals 
were inoculated for EAE per group, but often far fewer samples were collected. 
Due to the difficulty in obtaining sufficient volumes of spinal fluid from rats with 
EAE, and the very low levels of lipocortin found in CSF samples these experiments 
were not continued.
3.4 CNS TISSUE
3.4.1 Detection of Lipocortins I. II and V
These experiments were performed in conjunction with Dr C. Bolton and 
have been published in the Journal of Neuroimmunology (Bolton et al 1990). To 
investigate the presence of lipocortins in the CNS of Lewis rats during the course 
of EAE, cervical spinal cords and cerebella were collected from normal, CFA-
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inoculated controls and EAE-sensitised rats during the induction, diseased and 
recovery phases. CNS tissues were bisected down the midline and one half was 
sectioned and stained with H & E in order to estimate tissue lesion load while the 
other portion was probed for lipocortins I, II and V using Western blotting and the 
peroxidase conjugate technique. In a preliminary immunoblotting experiment 
samples were run individually, since this revealed little variation in lipocortin 
content within the groups (not shown), samples were subsequently pooled to 
enable all groups to be run on one blot. Two separate identical experiments were 
performed with six animals per group and essentially the same results were 
observed in each. Results for the second experiment are shown in Figure 27.
Immunoreactive bands corresponding to the molecular masses of 
lipocortins I, II and V were detected in both the cervical spinal cord and 
cerebellum of normal Lewis rats. On blots probed for lipocortin I the major band 
was approximately 38 kDa and co-migrated with rh lipocortin I standard. A lower 
molecular weight band of approximately 33 kDa was also observed which appeared 
to be proportional to the main band. The principle bands on blots probed for 
lipocortins II and V were approximately 37 and 35 kDa respectively which is 
similar to the molecular mass reported for these proteins by Pepinsky et al. (1988).
As can be seen in Figure 27, levels of lipocortin I-like protein were slightly 
increased in the cervical spinal cord of CFA-inoculated animals compared to 
normal controls, and a similar elevation was observed in cords taken from EAE- 
inoculated rats during the induction phase. Onset of symptoms was accompanied 
by a further marked increase in immunoreactive lipocortin I in the spinal cords of 
physically sick animals, with a slight decrease in convalescent rats. In the 
cerebellum a similar pattern was observed, with raised levels of the protein present 
in CFA-inoculated controls and in EAE-inoculated pre-diseased and diseased 
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Figure 27. Lipocortins in the cervical spinal cord and cerebellum of Lewis rats throughout the course o f E A E
Protein-stained gel and Western blots o f  pooled rat CNS tissue supernatants probed for lipocortins I, II and V. Spinal 
cords and cerebella were taken from normal and CFA-inoculated controls and from EAE-inoculated rats during the 
induction, diseased and recovery phases (n=6). Antibody code numbers are shown in parenthesis.
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Table XH
Perivascular infiltrates in CNS tissues during the course of EAE
Mean number of lesions per section 
CtSD)
Treatment Spinal Cord Cerebellum
Normal ND ND
CFA 0 0
EAE - Induction 0 0
EAE - Diseased 54+13 2+2
EAE-Recovery 29+10 4+3
Sections were cut at one standard depth, stained with H & E and the total number 
of lesions per section was determined using light microscopy. Values are means of 
six animals ± SD. ND, not done.
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spinal cord and there appeared to be a further slight increase in lipocortin I 
immunoreactivity in this region following recovery.
In contrast to the results obtained for lipocortin I, the levels of lipocortins 
II and V did not appear to change in either CFA or EAE-inoculated animals. On 
ail blots fainter bands between 62 and 70 lcDa were observed although the pattern 
of distribution remained unchanged throughout the course of EAE.
Increases in the lipocortin I content of the cervical spinal cord and 
cerebellum of EAE-inoculated rats coincided with the appearance of inflammatory 
lesions in these tissues (Table XII). In both CNS areas, lesions were absent during 
the induction period. In the cervical spinal cord, large numbers of perivascular 
infiltrates were present during the disease phase with a reduced amount following 
recovery, whereas in the cerebellum low numbers of lesions were found in diseased 
animals, which appeared to be slightly increased in rats which had recently 
recovered.
3.4.2 Distribution of Lipocortin I
To investigate the cellular localisation of lipocortin I immunoreactivity in 
the CNS throughout the course of EAE, polyclonal antiserum raised against rh 
lipocortin I (842) and PAP immunohistochemistry were used. The presence of 
immunoreactive-lipocortin I was revealed by brown staining and to aid 
identification of cells, sections were lightly counterstained with toluidine blue. In 
two separate experiments the distribution of lipocortin I immunoreactivity was 
studied in cervical spinal cord sections from normal and CFA-inoculated controls, 
and from animals inoculated for EAE. EAE-sensitised rats were sampled during 
the pre-clinical phase on days 4 and 7 PI, during the disease stage on the first day 
of exhibiting either weight loss, flaccid tail, hind limb weakness or paralysis and 
during the recovery phase on the first day of complete absence of neurological
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signs. Serum samples were also collected from these animals for measurement of 
corticosterone. The results of this work have been published in the Journal of the 
Neurological Sciences (Elderfield etal. 1993).
3.4.2.1 Normal
In cervical spinal cord sections from normal animals, lipocortin I 
immunoreactivity was localised predominantly in the walls of larger blood vessels 
(Figure 28a,b). However staining was patchy and many blood vessels appeared 
unstained or only weakly positive. Some capillaries were also very faintly stained 
(Figure 28c), although most were at or below the visual limit of detection. 
Occasionally very heavily stained cells were seen within the lumen of blood vessels 
and capillaries, three such cells are shown in Figure 28d. The nuclei of many 
neurones also appeared to be faintly stained (Figure 28a) but this proved to be non­
specific (see below). No staining of oligodendrocytes or astrocytes was observed.
Control sections from normal animals are shown in Figure 29. When 
lipocortin I antiserum was omitted or replaced with non-immune rabbit serum, 
sections were completely negative (Figure 29b,c). However when sections were 
incubated with antiserum which had been pre-adsorbed with 100 pg/ml rh 
lipocortin I, staining of vascular structures and intravascular cells was inhibited, but 
staining of neuronal nuclei was still present indicating that this was non-specific 
(Figure 29d,e).
3.4.2.2 EAE
Typical sections taken from EAE-inoculated animals at various stages of 
disease and immunostained for lipocortin I, are shown under low magnification in 
Figure 30. In the cervical spinal cord of EAE-inoculated rats, prior to the onset of 
neurological symptoms, the distribution and intensity of lipocortin I
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Figure 28. Im munolocalisation o f lipocortin I  in the cervical spinal cord of normal Lewis rats
(a) Low power view (xlOO) showing localisation o f  lipocortin I immunoreactivity in the walls o f  blood vessels plus 
very faint non-specific staining o f  neuronal nuclei. (b,c) Higher power fields (x400) o f  lipocortin I positive blood 
vessels and capillaries respectively, (d) Three typical examples o f  the very heavily stained cells which were 
occasionally observed within the lumen o f  blood vessels (x600).
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BFigure 29. C ontrol sections: norm al CNS tissue
Cervical spinal cord sections from normal Lewis rats incubated with: (a) lipocortin I  antisera, positive control showing 
immunostained blood vessels (xlOO); (b) PBS only, no primary antibody, negative control (xlOO); (c) non-immune 
rabbit serum (xlOO); (d) lipocortin antiserum pre-adsorbed with 100 pg/ml rh lipocortin I. (e) Higher power view o f  d 
demonstrating an unstained blood vessel and non-specific staining o f  neuronal nuclei (x400).
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immunoreactivity was the same as that found in normal animals. However the 
onset of symptoms and the appearance of inflammatory lesions coincided with a 
marked increase in lipocortin I immunostaining. As the disease progressed the 
extent of staining increased, and appeared to be proportional to the number of 
lesions and the severity of symptoms. Cords from rats exhibiting weight loss or 
flaccid tail had only a few small lipocortin-stained lesions, whereas progression of 
symptoms to hind limb weakness and paralysis was characterised by widespread 
staining of numerous inflammatory infiltrates. Generally, fewer lipocortin-stained 
lesions were present in sections taken from animals which had recently recovered 
from paralysis. Sections from CFA-inoculated controls showed the same 
distribution and degree of staining as normal and pre-diseased animals.
Staining of CNS lesions was quite variable: whilst a few were totally 
unstained, in many more all infiltrating cells appeared to be positive for lipocortin I. 
In general however, lipocortin I immunoreactivity was present in the vast majority 
of cells constituting the inflammatory infiltrates. Several typical lipocortin-stained 
lesions in sections taken from animals displaying complete paralysis are shown in 
Figure 31 and two representative perivascular infiltrates are shown under higher 
magnification in Figure 32. Most of the cells were moderately stained and 
possessed the morphological characteristics of lymphocytes (small and round with 
a round nucleus surrounded by a thin rim of cytoplasm) and macrophages (larger, 
irregularly shaped, with an irregular nucleus and a higher cytoplasmic to nuclear 
ratio). In addition, some very heavily stained cells, which were large and 
heterogenously shaped, were observed in association with the cellular infiltrates 
and often some distance into the surrounding parenchyma (Figures 31 & 32).
These cells appeared to be similar to some of those occasionally seen within the 
blood vessels of normal animals (Figure 28d). Their size and morphology suggests 





Figure 30. Lipocortin I  im m unoreactivity in cervical spinal cords taken from Lewis rats at various stages of 
E A E
Low  power views (x40) o f  representative sections taken from EAE-inoculated animals during the pre-diseased phase 
on days 4 (a) and 7 (b) post-inoculation, during the diseased stage from animals displaying signs o f  flaccid tail (c) and 
complete paralysis (d) and immediately after recovery from EAE (e). (f) section from CFA-inoculated rat taken on 
day 15 post-inoculation.
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Figure 31. L ipocortin I  im munostaining of inflam m atory lesions in the cervical spinal cord o f EAE-diseased 
rats
All sections are from rats displaying symptoms o f  complete paralysis. (a,b) Low  power views (xlOO) showing 
extensive immunostaining o f  several inflammatory lesions. (c,d) Higher power fields (x400) o f  typical perivascular 




Figure 32. Immunolocalisation of lipocortin I in CNS lesions of EAE-diseased 
rats
Higher power views (x600) o f two perivascular lesions illustrating lipocortin I 
immunostaining o f  macrophages (M), lymphocytes (L) and some very densely 
stained macrophage-like cells (*).
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Figure 33. Control sections: EAE-diseased animals
Cervical spinal cord sections from EAE-diseased rats, (a) Positive control, immunostained for lipocortin I (xlOO). (b) 
Non-immune rabbit serum (x400). (c) Lipocortin I antiserum pre-incubated with 100 pg/ml rh lipocortin I (xlOO).
(d) Serial sections through a single lesion demonstrating the effect o f  pre-adsorption o f  lipocortin I antiserum with 
various concentrations o f  rh lipocortin I. Figures below panels show concentration o f  lipocortin I in pg/ml. -VE, 
negative control, lipocortin antiserum omitted. +VE, positive control, lipocortin antiserum pre-incubated with PBS.
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because much of the cell structure was masked by the intensity of staining, even on 
lightly stained sections.
Throughout the course of EAE there appeared to be no difference in the 
type or proportion of cells positive for lipocortin I, nor in the staining intensity of 
each cell-type. Furthermore, staining of blood vessels did not change during the 
disease and no specific staining of neurones, oligodendroglia or astrocytes was 
observed.
Control sections from EAE-diseased animals are shown in Figure 33. No 
staining was observed on sections where the lipocortin antisera was omitted or 
substituted with non-immune rabbit serum (Figure 33b). Figure 33c,d 
demonstrates the effect of pre-adsorption of the lipocortin antisera with various 
concentrations of rh lipocortin I. Pre-incubation of the antisera with 0.1 pg/ml 
lipocortin I did not appear to be sufficient to prevent staining, partial inhibition was 
observed with 1 and 10 pg/ml, but pre-incubation with 100 pg/ml was found to 
completely abolish staining of the lesions.
3.4.2.3 Serum Corticosterone
Corticosterone levels in the sera of rats used in the previous 
immunohistochemistry experiments are shown in Figure 34. Baseline serum 
corticosterone in normal animals was 39 + 51 ng/ml (mean + SD, n=9). In pre­
diseased EAE-inoculated animals, corticosterone appeared slightly elevated at day 
4 PI but had returned to baseline by day 7. However, clinically sick rats had serum 
corticosterone levels which were significantly higher than in normal controls and 
which progressively increased with the severity of symptoms, peaking at the 
paralysis stage at 276 + 186 ng/ml (n=7, P<0.01). Following recovery, levels were 
reduced and although slightly elevated in comparison, they were not significantly 
different to normal animals. The serum corticosterone concentration of CFA-
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Figure 34. Corticosterone levels in the serum of normal and CFA-inoculated 
controls, and EAE-inoculated rats at various stages of the disease
Normal rats (Norm). CFA controls (CFA) were sampled 15 days post-inoculation. 
EAE-inoculated rats were sampled on day 4 or 7 post-inoculation or on the first 
day o f exhibiting weight loss (WL), hind limb weakness (HLW), paralysis (Para) or 
recovery (Rec). Results are expressed as mean + SD and are pooled from two 
separate experiments, the number o f animals in each group is shown in parenthesis. 
Results were analysed using ANOVA and the significance o f differences between 
group means determined using the Newman-Keuls procedure: * P<0.01 when 
compared to normal controls.
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inoculated rats was 138 + 36 ng/ml (n=4) and although this appeared to be higher 
than that of normal controls and somewhat lower than the value obtained for 
corresponding EAE-inoculated rats, neither difference reached statistical 
significance.
3.5 EFFECT OF MANIPULATING CIRCULATING STEROIDS ON 
LIPOCORTIN LEVELS IN THE CNS DURING EAE
Several methods were used to manipulate circulating corticosteroid levels 
in EAE-inoculated rats. In some experiments the plasma steroid concentration was 
raised by dosing animals with either the natural hormone corticosterone or with the 
synthetic steroid dexamethasone. In other experiments endogenous steroids were 
antagonised with the anti-glucocorticoid RU 38486 or abolished by removal of the 
source of natural steroids, the adrenals. To assess the effect of each treatment on 
CNS lipocortin levels, cervical spinal cords were removed and pooled samples 
Western blotted for lipocortins I, II and V using the polyclonal antisera 842, 774 
and 890 respectively and the PAP Ni/Co detection method. On all blots the 
molecular mass of the major band was close to that reported for the appropriate 
lipocortin in the literature and the intensity of this band was measured using 
densitometry in order to provide a semi-quantitative estimate of the amount of 
immunoreactive lipocortin in each group. In addition, serum samples were 
collected for measurement of circulating corticosterone to determine the 
effectiveness of each treatment in influencing plasma steroid levels.
Previous experiments (see section 3.4.1) established that levels of 
immunoreactive lipocortin I in the CNS of EAE-inoculated rats changed during the 
course of the disease. Thus in experiments designed to compare lipocortins in the
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CNS of drug treated and vehicle treated EAE-inoculated animals it was important 
to ensure that the two groups were well matched for stage of disease. 
Consequently, rats were usually dosed at the height of disease and were only used 
if they exhibited signs of complete or partial paralysis. Those displaying the same 
symptoms and course of disease were paired, with one receiving drug and the other 
vehicle. Unfortunately this degree of selectivity resulted in low sample numbers in 
some experiments because, although in each experiment 18-30 animals were 
inoculated for EAE, those which showed no symptoms, developed only a mild 
form of EAE, or died of the disease could not be included.
3.5.1 Corticosterone
Three separate experiments were performed to assess the effect of 
corticosterone administration on lipocortin levels in the CNS.
In the first experiment EAE-inoculated rats at the height of disease were 
dosed twice with 10 mg/kg corticosterone. Following treatment, clinical scores of 
corticosterone dosed animals seemed to be slightly decreased and there appeared 
to be some elevation in the serum corticosterone concentration in this group. 
However Western blotting and densitometry of cervical spinal cord samples 
revealed no difference between steroid and vehicle treated animals in the levels of 
immunoreactive lipocortins I, II and V (Figure 35).
In the second study animals were dosed in the same manner as in the 
previous experiment but on the first day of complete recovery from paralytic 
symptoms. In this experiment treatment with corticosterone did not appear to 
cause an appreciable increase in circulating corticosterone levels and no difference 
in lipocortins I, II or V was detected (Figure 36).
In the third experiment corticosterone was again administered to rats at the 
height of disease but the dose was raised to 50 mg/kg and the number of doses
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n Clinical Score Serum Corticosterone
ng/ml
Before After 
Vehicle 3 3.3 ± 0 .6  3.3 ± 0 .6  137 ± 6 9
Corticosterone 3 3.3 + 0.6 1.7 + 0.6 278 +  219
Figure 35. Effect o f corticosterone (10 mg/kg) on lipocortins in the CNS of EAE-diseased rats
EAE-inoculated rats were dosed at the height o f  disease sub. cut. with 10 mg/kg corticosterone in 0.2 ml arachis oil 
twice, morning and afternoon, and then sampled the following morning. Vehicle controls received arachis oil only. 
Cervical spinal cord samples from vehicle (V) and corticosterone (C) treated animals were immunoblotted for 
lipocortins I, I I  and V: MWM, molecular mass markers; LC I, 10 ng rh lipocortin I  standard. Histograms show  
densitometer values for the major band on each blot. Clinical scores (mean ±  SD) were assessed before and after 
treatment. Serum corticosterone (mean + SD) was measured at the end o f  the experiment.
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Figure 36. Effect o f corticosterone (10 mg/kg) on lipocortins in the CNS of rats im mediately after recovery 
from  E A E
EAE-inoculated rats which had previously exhibited symptoms o f  complete or partial paralysis were dosed on the first 
day o f  complete recovery sub. cut. with 10 mg/kg corticosterone in 0.2 ml arachis oil twice, morning and afternoon 
and then sampled the following morning. Vehicle treated controls received arachis oil only. Cervical spinal cord 
samples from vehicle (V ) and corticosterone (C) treated animals were immunoblotted for lipocortins I, II and V: 
MWM, molecular mass markers; LCI, 10 ng rh lipocortin I standard. Histograms show densitometer values for the 
major band on each blot. Serum corticosterone (mean ±  SD) was measured at the end o f  the experiment.
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Figure 37. Effect o f corticosterone (50 m g/kg) on lipocortins in the CN S o f EAE-diseased rats
EAE-inoculated rats were dosed at the height o f  disease sub. cut. with 50 mg/kg corticosterone in 0.2 ml arachis oil 
three times, morning afternoon and the following morning, and were sampled tw o hours after the last dose. Vehicle 
treated controls received arachis oil only. Cervical spinal cord samples from vehicle (V ) and corticosterone (C) 
treated animals were immunoblotted for lipocortins I, II and V: MWM, molecular mass markers; LCI, 10 ng rh 
lipocortin I standard. Histograms show densitometer values for the major band on each blot. Clinical scores (mean ±  
SD) were not significantly different before treatment (P= 0.445), and the change in score was not significantly 
different after treatment (P=0.665), Mann-Whitney U  test. Serum corticosterone (mean ±  SD) was significantly 
higher in the drug treated group, P<0.05, Mann-Whitney U  test.
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increased to three. This dosing regimen did not appear to influence the symptoms 
of EAE, since clinical scores were not significantly different before treatment and 
the change in scores was not significantly different after treatment. However, 
serum corticosterone was significantly elevated in the steroid treated group. 
Despite this, no difference in CNS lipocortin levels was observed (Figure 37).
3.5.2 Dexamethasone
The effect of dexamethasone sodium phosphate on lipocortins in the CNS 
during EAE was investigated in two separate experiments. Western blotting and 
densitometry are most sensitive at lower sample protein concentrations (see 
Materials and Methods, Figure 8), and to avoid small differences in lipocortin 
levels between vehicle and drug treated groups being masked by overloading, 
pooled CNS tissue samples were run at several different protein concentrations.
Results for the first experiment are shown in Figure 38. Animals were 
dosed three times at the height of disease with 0.5 mg/kg dexamethasone sodium 
phosphate. Treatment with dexamethasone did not reduce the clinical score. 
However mean serum corticosterone in the vehicle treated group was 125 ± 58 
ng/ml, whereas in the dexamethasone treated group levels were below the limit of 
detection in three out of four animals. The fourth animal had a very high 
circulating corticosterone concentration, however this rat was very sick when 
sampled and appeared to be moribund. No difference was observed in the levels of 
lipocortins I, II or V in cervical spinal cords from vehicle and dexamethasone 
treated rats.
In a repeat experiment (Figure 39) the dose of dexamethasone was 
increased to 1 mg/kg. Again, dexamethasone treatment appeared to have no effect 
on neurological symptoms, but serum corticosterone was suppressed below the
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Vehicle 3 4.0 +  0.0 3 .0  ± 1 .0  125 + 58
Dexamethasone 4 4 .0 +  0.0 4 .0 +  0.0 <*
Figure 38. Effect o f dexamethasone (0.5 m g/kg) on lipocortins in the CNS of EAE-diseased rats
EAE-inoculated rats were dosed at the height o f  disease sub. cut. with 0.5 mg/kg dexamethasone sodium phosphate in 
PBS three times, morning, afternoon and the following morning and were sampled two hours after the last dose. 
Vehicle controls received PBS only. Blots show cervical spinal cord samples from vehicle (V ) and dexamethasone 
(D ) treated animals probed for lipocortins I, II and V: MWM, molecular mass markers; LCI, 10 ng rh lipocortin I 
standard; figures below each track indicate total protein loaded in pg. Histograms show densitometer values for the 
major band on each blot. Clinical scores were assessed before and after treatment. Serum corticosterone (mean +
SD ) w as below the limit o f  detection (25 ng/ml) in three out o f  four dexamethasone treated animals in the fourth it 
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Figure 39. Effect of dexamethasone (1 mg/kg) on lipocortins in the C NS of EAE-diseased rats
EAE-inoculated rats were dosed at the height o f  disease sub. cut. with 1 mg/kg dexamethasone sodium phosphate 
three times, morning, afternoon and the following morning and sampled tw o hours after the last dose. Blots show  
cervical spinal cord samples from vehicle (V ) and dexamethasone (D ) treated animals probed for lipocortins I, II and 
V: MWM, molecular mass markers; LCI, 10 ng rh lipocortin I standard; values below each track indicate total protein 
loaded in ng. Histograms show densitometer values for the major band on each blot. Clinical scores were not 
significantly different before treatment (P=1.0) and the change in score was not significantly different after treatment 
(P=0,89), Mann-Whitney U test. Serum corticosterone (mean ±  SD) w as measured at inoculation and at the time o f  
sampling and was below the limit o f  detection (25 ng/ml) in all dexamethasone treated animals (<). There was no 
significant difference in serum corticosterone between the two groups before treatment (P=0.710), but at the end o f  
the experiment corticosterone levels were significantly reduced in the dexamethasone treated group, P<0.01 when 
compared to vehicle treated group at the time o f  sampling, Mann-Whitney U test; P<0.02 when compared to 












limit of detection in all dexamethasone dosed rats. No effect on CNS lipocortins 
was detected.
3.5.3 RU 38486
To assess the influence of endogenous corticosteroids on lipocortins in the 
CNS of EAE-diseased rats, animals were inoculated for EAE and dosed with the 
glucocorticoid antagonist RU 38486 on days 10-14 PI inclusive, starting prior to 
the onset of symptoms and the disease-related rise in serum corticosterone (see 
section 3.4.2.3 and Mackenzie et al 1989, MacPhee et al. 1989). Control animals 
were inoculated for EAE but dosed with vehicle only. In addition the effect of RU 
38486 on lipocortins in the CNS of normal animals was investigated.
Results are shown in Figure 40. The difference in clinical scores between 
drug and vehicle dosed EAE-inoculated animals was not statistically significant 
(P=0.07, Mann-Whitney U test). However at the time of sampling, rats in the RU 
38486 treated group appeared to be moribund whereas those which had received 
vehicle seemed to be following a typical disease course. Corticosterone levels 
were not significantly different between drug and vehicle treated groups for either 
normal or EAE-inoculated animals, although there appeared to be a trend towards 
higher levels in the RU 38486 treated groups. Again, immunoreactive lipocortin I 
was found to be increased in cervical spinal cords from EAE-diseased animals 
compared to normal controls. However, treatment with RU 38486 did not appear 
to influence the levels of lipocortins I, II or V in CNS tissues from either normal or 
EAE-diseased rats.
3.5.4 Adrenalectomy
The influence of endogenous steroids on lipocortins in the CNS of EAE- 
diseased rats was also investigated by comparing lipocortin levels in cervical spinal
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Figure 40. E lec t o f the glucocorticoid antagonist R U  38486 on lipocortins in the C NS of normal and E A E - 
inoculated rars
EAE-inoculattd rats were dosed orally, tw ice daily on days 10-14 post-inoculation inclusive with 20 mg/kg RU 38486 
in 1% carboxynethyl cellulose and 0.05% Tween 80. EAE-inoculated vehicle controls received vehicle only. Normal 
animals were tosed with RU 38486 or vehicle in the same manner for the same length o f  time. Cervical spinal cord 
samples were ;ollected from RU 38486 (RU) or vehicle (V ) treated animals the day after the last dose (day 15 post­
inoculation foi EAE-inoculated animals) and immunoblotted for lipocortins I, II and V: MWM, molecular mass 
markers; LCI, 10 ng rh lipocortin I standard. Histograms show the densitometer values for the major band on each 
blot. Clinical icores o f  EAE-inoculated animals were assessed at the time o f  sampling (day 15) and were not 
statistically different (P=0.07), Mann-Whitney U  test. There was no significant difference in serum corticosterone 
between vehice and RU 38486 treated groups for either normal (P=0 312), or EAE-inoculated (P=0.248) animals, 
Mann-Whitne' U  test.








cord samples taken from Adx, sham-operated and non-operated rats inoculated for
EAE.
In a preliminary experiment six Adx and three sham-operated animals were 
immunised for EAE 7/12 days after surgery. Of the Adx rats, one was found dead 
on day 2 PI and one on day 15. The remaining animals succumbed to EAE very 
early (day 10 or 11) and developed an extremely severe form of the disease which 
progressed rapidly from no symptoms to complete paralysis over a period of about 
8 hours. Of the sham-operated group, one animal showed no signs of disease and 
the other two developed very mild symptoms (flaccid tail on days 11-13 and 12-14) 
and then recovered, although one of these rats subsequently relapsed, exhibiting 
partial paralysis on day 23. Thus, whereas Adx rats were particularly susceptible 
to EAE, sham-operated animals appeared to be relatively resistant, and seemed to 
develop a delayed, milder form of the disease than that normally observed in the 
Lewis rat. Since previous studies had shown that lipocortin levels in the CNS may 
be influenced by stage of disease, it was originally intended to collect samples from 
sham-operated controls exhibiting the same symptoms as Adx animals. However 
the results of this initial experiment suggested that sham-operated rats were not the 
ideal control group for this type of study. In two subsequent experiments the 
following three groups were studied:
Adx - Rats were Adx and 11/12 days later inoculated for EAE. CNS 
samples were collected at the height of disease, approximately 10/11 days 
PI.
Sham-operated - Rats were sham operated and 11 days later inoculated for 
EAE. CNS samples were taken on day 10/11 PI providing time matched 
controls, although most of the animals showed no symptoms.
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Non-operated - N o r m a l, n o n -o p e r a te d  rats w e r e  in o c u la te d  fo r  E A E .
These animals were sampled at the height of disease, usually day 14, and 
were thus matched to the Adx group for stage of disease.
Serum samples for measurement of corticosterone were taken at inoculation and 
again when CNS samples were collected.
Two identical experiments were performed and similar results were 
observed in each. The majority of Adx rats developed a very severe form of EAE, 
characterised by an early onset and very rapid progression of symptoms. However 
several Adx rats which appeared healthy on day 9 or 10 were found dead the next 
morning and therefore could not be used. In addition, a few Adx animals did not 
develop signs of EAE until about day 14 and then exhibited a normal course of 
disease. CNS tissues from these animals were not used since it was assumed that 
resistance to EAE was due to the presence of residual adrenal tissue, subsequently 
these rats were found to have detectable levels of circulating corticosterone.
Results for the second experiment are shown in Figure 41. All Adx rats 
sampled, developed severe symptoms on day 10 PI whereas sham-operated 
controls killed on the same day showed no signs of disease. Non-operated rats 
were sampled at the height of disease and thus clinical scores were not significantly 
different to the Adx group. Serum corticosterone was below the limit of detection 
in all Adx rats used, both at the time of inoculation and at the end of the 
experiment and was thus significantly lower than in the other two groups at both 
time points. Differences between sham-operated and non-operated animals were 
not significant either at inoculation or at the time of sampling. Corticosterone 
levels in sham-operated animals appeared to decrease slightly during the 
experiment but the change was not statistically significant. Furthermore, 
circulating corticosterone in non-operated rats appeared to be increased at the 
height of disease but sample numbers were too low for valid statistical analysis.
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Group n Day pi Clinical Score Serum Corticosterone 
ng/ml
Inoculation Sampling
Non-operated 4 11/14 3.8 ± 0 .5 177 ± 6 4 257 ±  92
Adrenalectomised 7 10 3.7 ± 0 .5 < <
Sham-operated 6 10 0.0 ± 0 .0 195 ± 5 0 135 ± 5 9
Figure 41. Lipocortins in the CN S o f adrenalectomised, sham-operated and non-operated rats inoculated for 
E A E : experim ent EL
Adrenalectomised, sham-operated and non-operated rats were inoculated for EAE and sampled on days 10, 10 and 
11/14 post-inoculation respectively. Blots show  cervical spinal cord samples from non-operated (N), 
adrenalectomised (A) and sham-operated (S ) animals probed for lipocortins I, II and V: MWM, molecular mass 
markers; LCI, 10 ng rh lipocortin I standard. Histograms show densitometer values for the major band on each blot. 
Clinical scores (mean ±  SD) were assessed at the time o f  sampling and the mean score o f  the sham-operated group 
was significantly lower than that o f  adrenalectomised (P<0.005) and non-operated (P<0.05) animals, but there was no 
significant difference between the latter tw o groups (P=0.913), Mann-Whitney U test with the Bonferroni correction. 
Serum corticosterone (mean ±  SD) was measured at inoculation and at the time o f  sampling, and was below  the limit 
o f  detection (25 ng/ml) in all adrenalectomised animals at both time points (<). Corticosterone levels did not change 
significantly during the experiment in either sham-operated (P=0.173) or adrenalectomised rats, W ilcoxon signed-rank 
test. At inoculation there was no significant difference in serum corticosterone between sham-operated and non- 
operated animals (P=0.522) but levels in adrenalectomised animals were significantly lower than non-operated 
(P<0.01) and sham-operated (P<0.005) rats. At the time o f  sampling levels were still significantly lower in 
adrenalectomised rats than in non-operated (P<0.01) or sham-operated animals (P<0.005) and the difference between 
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Figure 42. Lipocortins in the C N S o f adrenalectomised, sham-operated and non-operated rats inoculated for 
EAE: experiment HI.
Adrenalectomised, sham-operated and non-operated rats were inoculated for EAE and sampled on days 10/11, 10/11 
and 14 post-inoculation respectively. Blots show cervical spinal cord samples from non-operated (N), 
adrenalectomised (A) and sham-operated (S) animals probed for lipocortins I, II and V: MWM, molecular mass 
markers; LCI, 10 ng rh lipocortin I standard. Histograms show densitometer values for the major band on each blot. 
Clinical scores (mean ±  SD) were assessed at the time o f  sampling and the mean score o f  the sham-operated group 
was significantly lower than that o f  either adrenalectomised (P<0.02) or non-operated (P<0.005) animals, but there 
was no significant difference between the latter tw o groups (P=0.718), Mann-Whitney U  test with the Bonferroni 
correction. Serum corticosterone (mean ±  SD) was measured at inoculation and at the time o f  sampling, and was 
below the limit o f  detection (25 ng/ml) in all adrenalectomised rats at inoculation (<), although tw o animals had very 
low  levels at the end o f  the experiment, approximately 10 and 23 ng/ml (<*). Within group comparisons showed a 
significant decrease in circulating corticosterone in sham-operated animals (P<0.05) and a significant elevation in non- 
operated rats (P<0.02) during the experiment, W ilcoxon signed-rank test. At inoculation there was no significant 
difference in serum corticosterone between sham-operated and non-operated animals (P=0.253), but levels were 
significantly lower in the adrenalectomised group than in either sham-operated (P<0.02) or non-operated rats 
(P<0.02). At the end o f  the experiment corticosterone levels in adrenalectomised animals were still significantly lower 
than in sham-operated (P<0.05) or non-operated (P<0.02) animals and levels in non-operated rats were significantly 
higher than in the sham-operated group (P<0.05), Mann-Whitney U  test with the Bonferroni correction.
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Lipocortin I immunoreactivity in the cervical spinal cord of Adx animals appeared 
to be elevated in comparison to sham-operated and non-operated controls. 
Immunoreactive lipocortins II and V seemed to be the same in all groups.
In the third experiment (Figure 42), Adx and non-operated animals were 
again sampled at the height of disease and statistical analysis of scores confirmed 
there was no significant difference between these groups. Two sham-operated 
controls showed mild signs of EAE at sampling (flaccid tail), but the mean score of 
this group was still significantly lower than that of the other two treatments.
Serum corticosterone was below the limit of detection in all Adx animals at 
inoculation, although at the time of sampling two animals had very low circulating 
levels suggesting the existence of some residual adrenal tissue in these animals. 
However steroid levels did not appear to be sufficient to alter the course of the 
disease and at both time points the difference between adrenalectomised and other 
groups was statistically significant. At inoculation there was no significant 
difference in serum corticosterone between sham-operated and non-operated 
controls but by the end of the experiment levels in non-operated rats were 
significantly higher than in the sham-operated group. Moreover, during the course 
of the experiment there was a significant decrease in circulating corticosterone in 
sham-operated animals and a significant increase was observed in non-operated 
rats. As in the previous study, levels of immunoreactive lipocortin I in cervical 
spinal cord samples from Adx rats appeared to be higher than those of sham- 
operated and non-operated control animals. Furthermore, in this experiment levels 
in sham-operated rats appeared to be lower than those of non-operated animals. 
Again no difference in immunoreactive lipocortins II and V was detected.
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DISCUSSION
4.1 LIPOCORTINS IN CSF
Studies on lipocortins in the CNS in MS and EAE were begun by 
investigating the lipocortin content of CSF. Cerebrospinal fluid is formed in the 
choroid plexus from plasma. It covers both the inner and outer surfaces of the 
brain and spinal cord and is continuous with the extracellular space of the tissue. 
There is free passage of solutes between the extracellular fluid and CSF across the 
ependymal lining of the ventricles and it is believed that the CSF acts as a sink into 
which the extracellular fluid and tissue metabolites drain. CSF is therefore 
considered to be useful for studying biochemical processes occurring within the 
CNS tissue (Walsh etal 1983, Weller 1985). In inflammatory CNS diseases such 
as MS and EAE breakdown of the BBB results in the passage of blood-derived 
cells and plasma proteins into the CNS tissue, some of which may then pass into 
the CSF. Thus the protein content of the CSF in such conditions reflects not only 
production of proteins by endogenous and infiltrating cells within the brain, but 
also the entry of serum proteins into the CSF from blood vessels in the tissue 
(Walsh etal. 1983, Tourtellotteetal. 1988).
Initial studies were performed on cell-free CSF supernatants. When cell- 
free CSF samples from MS patients and controls were probed for lipocortins I, II, 
IV and V using Western blotting, all lipocortins were undetectable. Using the 
more sensitive ELISA technique extremely low levels of lipocortin I were observed 
in some of these samples, although the concentration was too close to the detection 
limit of the assay to be measured accurately. Likewise, investigation of the 
lipocortin content of cell-free CSF supernatants taken from normal and EAE- 
diseased rats also revealed that lipocortin I was below the limit of detection by 
Western blotting. This was despite observation of an increase in total protein in 
the CSF of animals with EAE.
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Since lipocortins were virtually undetectable in cell-free CSF supernatants 
and some immunocytochemical and cell fractionation studies have suggested that 
lipocortins may be cytoplasmic or membrane associated proteins (Greenberg & 
Edelman 1983, Geisow etal 1984, Glenney etal. 1987) the lipocortin content of 
whole CSF was investigated. Samples were lysed and treated with EDTA to allow 
measurement of total intracellular, extracellular and calcium-dependent membrane- 
bound protein.
Assessment of lipocortins in 39 samples of whole human CSF from patients 
with a variety of diseases revealed the presence of low levels of a 36 kDa lipocortin 
I-like protein in four samples by immunoblotting, which was confirmed in two of 
these using the lipocortin I ELISA. Two of the samples also contained low levels 
of a 31 kDa lipocortin I immunoreactive protein which is probably a degradation 
product of lipocortin I (Pepinsky et al. 1986, also see section 4.2 for fuller 
discussion of lower molecular mass bands). Small amounts of a lipocortin V-like 
protein were also detected in two samples. The CSF samples in which lipocortin- 
like proteins were detected were of diverse pathology. However two features 
common to all were the occurrence of very high protein levels and leukocyte 
counts. In fact, the four samples in which immunoreactive lipocortin I was 
detected had the highest number of leukocytes in the group. This observation 
together with the virtual absence of lipocortins in cell-free CSF (despite elevations 
in protein concentration) suggests that lipocortins in CSF are leukocyte associated.
The human CSF samples used in the present study were a random cross 
section of those obtained by Bath Royal United Hospital Pathology Laboratory. 
Unfortunately, only one of the samples was taken from a patient with MS. No 
lipocortins were detected in this CSF, but it cannot be ruled out that this sample 
was atypical of the situation in MS. However, it should be noted that all samples 
in which lipocortin-like proteins were detected contained at least 50 leukocytes per
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n W  CSF. This is much higher than is generally found in MS where the total CSF 
leukocyte count is normal (< 5 per mm^) in 66% of patients, <15 per mm^ in 95% 
and only rarely exceeds 50 per mm^ (Walsh et al. 1983, Tourtellotte et al 1988). 
Samples of whole CSF from patients with MS were not readily available, but since 
the amount of lipocortin in spinal fluid appears to be related to the leukocyte count, 
then in view of the range in leukocyte number normally found in the CSF in MS, it 
is unlikely that using the techniques in this study, significant quantities of 
lipocortins would have been detectable.
In studies on whole rat CSF, using the peroxidase conjugate 
immunoblotting technique, lipocortin I was undetectable in CSF from normal and 
CFA-inoculated rats and in EAE-inoculated animals during the induction phase, 
but low levels of a lipocortin I-like protein were seen in samples from diseased and 
convalescent animals. Experiments utilising the more sensitive PAP Ni/Co 
detection method revealed very low levels of immunoreactive lipocortin I in the 
spinal fluid of normal and CFA controls, and again a similar increase in this protein 
was observed in CSF from EAE-diseased animals, with a slight reduction following 
recovery. Proteins corresponding to the molecular mass of lipocortins II and V 
were undetectable in all rat spinal fluid samples but a band of approximately 51 
kDa which was markedly increased in CSF from EAE-diseased animals was 
observed on blots probed for lipocortin n , the identity of this protein is not known 
(see section 4.2 for fuller discussion of higher molecular mass bands). Detection of 
lipocortins in CSF from animals in the disease and recovery phases of EAE 
coincided with an elevation in the CSF leukocyte count. As in human CSF, the 
highest levels were found in samples which had the greatest white blood cell 
counts, again suggesting that the lipocortin is associated with leukocytes.
To my knowledge there have been no previous studies on lipocortins in 
either human or animal CSF. The virtual absence of lipocortins from cell-free CSF
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supernatants suggests that large amounts of lipocortin are not released from cells in 
the CNS either in normal or diseased states. Furthermore, since CSF is derived 
from plasma this result is consistent with the work of Goulding et al (1990) who 
were unable to detect free lipocortin I in human plasma using the ELISA 
technique, although low levels of annexins I and V have been found in human 
plasma by other workers (Christmas et al. 1991).
In both the human and animal studies the lack of lipocortins in cell-free 
CSF supernatants and the presence of lipocortin-like proteins in lysate of whole 
CSF, but only in significant quantities when the leukocyte count is very high, all 
suggest that lipocortin in CSF is associated with infiltrating leukocytes. Moreover, 
the absence of a concordance between lipocortin levels and erythrocyte number 
indicates that the presence of lipocortin is not simply due to blood contamination.
The pleocytosis which was observed in CSF taken from animals with EAE 
is a characteristic feature of the disease. In Lewis rats inoculated for EAE the 
majority of cells in the CSF are lymphocytes and macrophages which are thought 
to be derived from inflammatory lesions, especially those in the meninges (Paterson
1978). Although cell types present in the human CSF samples were not 
determined, they are likely to be a mixture of lymphocytes, macrophages and 
polymorphonuclear leukocytes which have migrated from the blood into the CNS 
in varying proportions depending upon the nature of the disease. Although there 
have been no previous studies on lipocortins in CSF, the occurrence of lipocortin I 
in all these cell types (Pepinsky et al. 1986, Goulding et al 1990) and the presence 
of lipocortin V in lymphocytes and monocytes (Pepinsky et al. 1988, Comera et al
1989) is well documented.
In summary, results of studies on lipocortins in CSF revealed that very little 
lipocortin is present in rat or human CSF either under normal circumstances or in 
inflammatory CNS disease states. Furthermore, that which was present appeared
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to be associated with leukocytes. Whole CSF from patients with MS was not 
available, but it is unlikely that significant amounts of lipocortin would have been 
detected due to the relatively low CSF leukocyte count found in the disease. In 
studies on EAE, although no problems were encountered in obtaining samples 
from normal and CFA-inoculated rats or EAE-inoculated animals during the 
induction phase, it proved very difficult to collect sufficient volumes of CSF from 
EAE-diseased rats. This appeared to be due to swelling of the brain tissue, 
resulting in occlusion of the cistema magna and displacement of CSF. Levine et al 
(1966) have observed this swelling and suggest it is caused by oedema. Due to the 
problems encountered in obtaining CSF and the very low levels of lipocortin 
detected in spinal fluid, studies on CSF were not continued. The apparent 
association of lipocortin I with cells in the CSF suggested that investigation of 
lipocortins in CNS tissue might prove more fruitful.
4.2 DETECTION OF LIPOCORTINS IN CNS TISSUE
Investigation of lipocortins I, n, IV and V in human CNS tissues by 
Western blotting revealed the presence of lipocortin immunoreactive material in 
both the grey and white matter of normal human CNS tissue. Similar proteins 
were detected in the spinal cord and cerebellum of normal Lewis rats. Generally, 
for both human and rodent tissue, the molecular mass of the principle band in each 
sample was close to that reported in the literature for the appropriate lipocortin, 
although in many cases they did not correspond exactly either with each other or 
with all literature reports.
It should be noted that the pre-stained molecular mass markers used in the 
present study to estimate the molecular mass of immunoreactive proteins only
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appeared to be accurate to within + 2 kDa. Furthermore, molecular masses 
reported for lipocortins in the literature tend to be very variable, with different 
values frequently reported for the same protein. This appears to be due, in part, to 
the tendency of lipocortins to give spurious size estimates on SDS-PAGE. For 
example Huang et al (1987) have observed that in their hands the apparent size of 
lipocortin I by SDS-PAGE is approximately 35 kDa, which is nearly 4 kDa smaller 
than the 38.5 kDa its sequence indicates. In another interesting study Learmonth 
et al. (1992) identified two different forms of annexin V with apparent molecular 
masses of 33 and 37 kDa by SDS-PAGE, however complete sequence analysis of 
the two proteins revealed only two amino acid substitutions corresponding to a 
mass difference of 15 Da. Pepinsky and Sinclair (1986) have suggested that errors 
in estimation of the molecular mass of lipocortins may be due to the unusually 
charged amino acid composition of these proteins, since charged amino acids are 
known to affect electophoretic mobility in SDS-gels (Tung & Knight 1972).
When human CNS tissues were probed for lipocortin I using antibody 842, 
three main bands were detected with apparent molecular masses of approximately 
37, 35 and 33 kDa. Studies on rat CNS tissues revealed a major band at 
approximately 38 kDa and a minor one at about 33 kDa. In each species the 
molecular mass of the largest peptide was identical to that reported in the literature 
for lipocortin I (Wallner et al 1986, Pepinsky et al 1988). Further evidence that 
these proteins may be lipocortin I was provided by their co-migration with rh 
lipocortin I standard. The detection of lipocortin I-like proteins in normal human 
and rat CNS tissues confirms the results of several other recent studies 
demonstrating the presence of immunoreactive lipocortin I in normal human 
(Johnson ef al 1989b) and rat (Smillie etal 1989a, Smith etal 1989b, Strijbose/ 
al 1991) CNS tissues.
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The 35 and 33 kDa immunoreactive proteins detected in human CNS 
samples and the 33 kDa species found in rat tissues are very probably degradation 
products of lipocortin I. In early studies on lipocortin in rat peritoneal exudates, a 
significant proportion of the protein was found in a degraded form (Pepinsky et al 
1986). Subsequently lower molecular mass forms have been detected in human 
tissues: in BALF four separate proteins at 37, 36, 34 and 33 kDa were observed by 
Ambrose and Hunninghake (1990a) and a 34 kDa form by Smith et al (1990b), a 
35 kDa species has also been detected in placenta (Valentine-Braun et al 1987) 
and in seminal plasma, a 32 kDa form lacking the first 29 amino acids has been 
found (Christmas et al 1991). Furthermore in two recent studies on CNS tissue, 
32 and 34 kDa forms of lipocortin I have been detected in rat brain homogenates 
(Gebicke-Haerter et al 1991) and pig spinal cord and cortex (Regnouf et al 1991) 
respectively.
In vitro studies have shown that the N-terminal domain of lipocortin I is 
highly susceptible to proteolysis and forms lacking different portions of this 
sequence can be generated through the action of exogenous proteases. Incubation 
with plasmin results in generation of 32 and 3 kDa cleavage products (Huang et al 
1987, Varticovski et al 1988) whereas elastase yields several fragments of 33, 30, 
27, 20, 18, 16 and 15 kDa (Huang et al 1987). Calpain has been shown to cleave 
lipocortin I at Lys-26 to give a 34 kDa species, and cathepsin D at Try-12 to 
generate a 35.5 kDa form (Ando et al 1989). In addition it has been observed that 
lipocortin I may be proteolysed by an endogenous A431 membrane protease 
(Chuah & Pallen 1989) and by conditioned media from BALF cells (Smith et al 
1990b).
Thus it is probable that the lower molecular mass species observed in the 
present study are breakdown products of lipocortin I, produced by enzymatic 
degradation of the protein. Although the medium used for homogenisation of CNS
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samples contained the protease inhibitor PMSF, it is not known if these 
degradation products occur in significant amounts naturally or are an artefact 
generated during preparation of the tissue. Interestingly, a greater proportion of 
lipocortin I appeared to be in a degraded form in human CNS samples than in rat 
tissues. This might possibly be explained by the much longer death to freezing 
interval for human (mean 41 hrs) in comparison to rodent tissues (<15 min).
An alternative explanation for the 35 kDa band observed in human tissue, is 
the possibility that this protein may be lipocortin III. Pepinsky et al. (1988) have 
reported that the lipocortin I antiserum 842, exhibits strong cross-reactivity with 
this protein, and the molecular mass of the band detected in this study is 
concordant with that reported for lipocortin III in the literature (Pepinsky et al
1988). It should be noted however that this band was also detected by the anti- 
lipocortin I monoclonal antibody mAb IB (Figure 20), which is not known to 
cross-react with other members of the lipocortin family (Pepinsky et al. 1990).
In both human and rat CNS tissues a number of weakly stained bands 
between 40 and 80 kDa were also observed. These were generally much fainter 
than the major bands, although in many samples fairly heavy staining of a 68 kDa 
immunoreactive protein was frequently detected. It is possible that this may arise 
from cross-reactivity of the antiserum with an unrelated protein, with a related 
protein such as the 68 kDa lipocortin VI, or with an as yet uncharacterised member 
of the annexin family. Alternatively, this protein could be a dimer of lipocortin I.
A 68 kDa dimeric form of lipocortin I has been characterised in human placenta 
(Pepinsky et al. 1989) and a 74 kDa dimer in human epidermoid carcinoma cells 
(Ando et al. 1991). Cross-linkage appears to occur at Glu-18 in the amino 
terminal and can be induced following incubation of purified lipocortin with 
transglutaminase (Pepinsky etal. 1989, Ando etal. 1991). Recently, a dimeric
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form of lipocortin I has been reported to be present in rat cerebral cortex (Pradel & 
Rendon 1993).
Investigation of lipocortin n  in CNS tissues revealed only one band at 
approximately 37 kDa when rat tissues were probed using the polyclonal antiserum 
774. However when human tissues were immunoblotted with the same antibody 
several bands were observed in the 30-40 kDa region, with the principle band at 
approximately 35 kDa. Using a different polyclonal antibody (Ab-1) which was 
raised against rh lipocortin n, only two immunoreactive species were detected in 
human tissue. A major one was found at 34 kDa and a minor one at 33 kDa, 
suggesting that the 35/34 kDa protein is probably lipocortin II, although 
unfortunately lipocortin II standard was not available for confirmation. The 
molecular masses of the main bands observed in human and rat CNS tissues are 
similar to those which have been reported for human lipocortin n , 38 kDa 
(Pepinsky et al. 1988), and human placental lipocortin n , 35 kDa (Huang et al. 
1986). Several other studies have previously demonstrated the presence of 
immunoreactive lipocortin II in rat brain (Pepinsky et al. 1988, Smillie et al.
1989a) and cerebellum (Burgoyne et al. 1989). Although in contrast to the present 
study Reeves et al. (1992) were unable to detect expression of lipocortin II in 
normal adult human brain using immunohistochemistry.
Some of the lower molecular mass bands seen when human CNS tissues 
were probed for lipocortin II may well be degradation products of the protein. In 
studies on human placenta Huang etal. (1986) observed three species of lipocortin 
n  with molecular masses of 34.5, 34 and 33 kDa and concluded that the smaller 
forms were generated by proteolysis. Lower molecular mass forms of lipocortin II 
have also been detected in CNS tissue: in rat cerebellum by Burgoyne et al. (1989) 
and in pig cortex and spinal cord by Regnouf et al. (1991). It should be noted 
however, that the polyclonal antiserum 774 also has quite a high titre of antibodies
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that cross-react with lipocortin I (Pepinsky et al 1988) and it is therefore possible 
that some of these proteins may be lipocortin I or its breakdown products.
In addition, a number of strongly stained higher molecular mass species 
were also seen, the main bands having molecular masses of approximately 61 and 
54 kDa. Pepinsky et al (1988) have also observed binding of the 774 antibody to 
higher molecular mass proteins in various tissues. The identity of these bands is 
not clear because, although lipocortin II is frequently found in association with the 
pi 1 protein, forming the heterotetramer calpactin I, at 90 kDa (Glenney & Tack 
1985) the molecular mass of calpactin I is considerably higher than that of the 
proteins detected in the present study. Interestingly, Regnouf et al. (1991) have 
recently detected a 90 kDa annexin II immunoreactive protein which may be the 
heterotetramer in porcine spinal cord, although the protein appeared to be absent 
from brain cortex.
The antiserum raised against lipocortin IV (179) could not be used on rat 
CNS tissue because this antibody is known not to cross-react with the rat protein 
(J. L. Browning, personal communication). Investigation of lipocortin IV in human 
CNS tissues with this antibody revealed several immunoreactive bands, although 
there was only one in the 30-40 kDa region. At 40 kDa, the molecular mass of this 
band is slightly higher than that generally reported for lipocortin IV. Pepinsky et 
al (1988) suggested a molecular mass of 35 kDa, but in most other studies on the 
protein, the molecular mass of lipocortin IV is quoted as 32.5 kDa (Klee 1988, 
Boustead ef a/. 1991, Massey et al 1991). Due to the discrepancy in molecular 
mass it is not clear if the protein detected in human CNS tissue is lipocortin IV.
The antiserum used for detection is thought to be specific for lipocortin IV and 
exhibits no cross-reactivity with known members of the lipocortin family (Pepinsky 
et al 1988). However without access to lipocortin IV standard it was not possible 
to verify the identity of this protein.
186
There have been very few studies on lipocortin IV in CNS tissue. To my 
knowledge there have been no studies in the rat or in man, although lipocortin IV- 
like proteins have been detected in porcine and bovine brain (Woolgar et al. 1990, 
Regnoufe/a/. 1991).
When CNS tissues were probed for lipocortin V, only two principle bands 
were detected. In human tissue these were at 30 and 67 kDa, in rat samples the 
main band was at 35 kDa and a similar higher molecular mass band was also 
observed. Molecular masses reported for lipocortin V in the literature vary 
considerably. Pepinsky et al. (1988) described the molecular mass of rat and 
human lipocortin V as 35 kDa, but observed 32 and 33 kDa forms of the protein in 
bovine intestinal mucosa. Whereas a 32 kDa lipocortin V-like protein was 
detected in human peripheral blood mononuclear cells by Comera et al. (1989). 
Possible reasons for these discrepancies have been outlined earlier but they may 
also be due to tissue or species differences.
Several studies have previously reported the presence of lipocortin V-like 
protein in rat CNS tissue (Smillie et al. 1989a, Smith et al. 1989b, Donato et al. 
1990, Pula et al. 1990, Giambanco et al. 1991) and the protein has also been 
detected in porcine (Woolgar et al. 1990) and bovine brain (Pula et al. 1990, 
Bianchi et al. 1992). In bovine brain Learmonth et al. (1992) found two isoforms 
of annexin V (CaBP33 & CaBP37) with apparent molecular masses of 33 and 37 
kDa, although they reported that only the 33 kDa form was present in rat tissue 
which is concordant with the observation of a single band in the 30-40 kDa range 
in the present study. To my knowledge there have been no previous studies on 
lipocortin V in human CNS tissues.
Comparison of the levels of lipocortin-like proteins in normal human CNS 
tissues with samples from patients with MS revealed that immunoreactive 
lipocortins I, II, IV and V were significantly increased in white matter from MS
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patients. Moreover, a further elevation in lipocortin immunoreactivity was 
observed in plaque tissue and immediately adjacent white matter such that, within 
the CNS of MS patients there appeared to be a gradient in the amount of each 
lipocortin, with the lowest levels in apparently unaffected white matter, an 
intermediate amount in tissue adjacent to a plaque, and the highest concentrations 
within plaque tissue.
An attempt was made to quantitate lipocortin I in human CNS tissue 
samples using the lipocortin I ELISA. This assay is a sandwich-type ELISA which 
was developed by Smith, Goulding and colleagues (Smith et al 1990a) and utilises 
a monoclonal antibody (mAb IB or 105) characterised by Pepinsky et al (1990) 
and the polyclonal antiserum 842 (Pepinsky et al 1988). It has a working range of 
1-2000 ng/ml and has been used previously to measure lipocortin I in human BALF 
(Smith et al 1990a) and human peripheral blood leukocytes (Goulding et al
1990).
In a preliminary experiment samples were assayed at several different 
dilutions and it was noticed that when results were converted to ng lipocortin I /mg 
total protein, the amount of lipocortin I in any individual sample appeared to be 
different at each dilution, with the apparent lipocortin concentration increasing as 
the samples were diluted. This suggested that the CNS homogenates might be 
interfering with the assay.
To investigate whether this was the case, several representative samples 
were assayed, spiked with a known amount of rh lipocortin I. Ten nanograms of 
standard was added because this would approximately double the lipocortin 
concentration in normal CNS tissues, but both spiked and unspiked samples should 
still fall within the linear portion of the standard curve. Results showed that only a 
fraction of the standard added was measurable in the presence of CNS 
homogenates suggesting that either a constituent of the CNS tissue or a component
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of the homogenisation medium, was preventing accurate measurement of 
lipocortin.
A further experiment was performed to find out if interference was caused 
by the homogenisation medium, the CNS tissue homogenate, or was influenced by 
the amount of lipocortin already present in the sample. Homogenisation medium 
alone appeared to have little effect on the measurement of lipocortin I. The 
presence of CNS tissue however, caused a marked reduction in the detection of 
lipocortin, even at relatively dilute protein concentrations, although the amount of 
lipocortin originally present in the sample did not appear to influence recovery.
The results of this study indicated that interference was due to a constituent 
of the CNS tissue rather than the homogenisation medium. To determine if this 
interfering substance might be a protein which was cross-reacting with one or both 
of the antibodies used in this assay, in the next experiment two identical blots 
containing representative CNS tissue samples were probed with each antibody. 
Both antibodies were found to bind only to lipocortin I and its putative breakdown 
products to any extent. This suggested that interference was not due to non­
specific binding of the antibodies to other proteins present in the samples, and also 
demonstrates the specificity of the lipocortin I ELISA, when used on CNS tissue, 
for lipocortin I and cleavage products of the protein, since only proteins bound by 
both antibodies will be detected in the assay. Interestingly, Smith et al (1990a) 
have suggested that this ELISA only detects the intact molecule and probably 
would not detect degradation products of lipocortin I. However, Pepinsky and co­
workers who originally characterised the antibodies on which the assay is based 
have noted that the polyclonal antiserum 842 does react with lower molecular mass 
forms of lipocortin I (Pepinsky et al 1988), furthermore, they report that the 
monoclonal antibody mAb IB recognises a site between amino acids 30 and 55 in 
the lipocortin sequence and therefore recognises the commonly encountered N-
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terminal clipped des-30 adduct (Pepinsky et al 1990). Observations which are 
concordant with findings in the present study.
CNS tissue contains a high proportion of lipid which could potentially 
interfere with the assay by binding either to the lipocortin or to the monoclonal 
antibody. Thus a further study was performed to determine whether this might be 
the source of the problem and to investigate methods which might overcome this. 
An attempt to extract the lipid with chloroform resulted in removal of all the 
protein from the samples, although in it may have been possible to selectively 
extract lipid without affecting the protein using a less powerful chloroform/organic 
solvent mixture. High speed centrifugation was tried in an effort to remove 
liposomes from the samples, but this had no effect on measurement of lipocortin I. 
The addition of EGTA in order to chelate calcium and thus prevent calcium- 
dependent binding of lipocortin to phospholipids further reduced lipocortin 
detection.
From these results it is not clear if interference in the measurement of 
lipocortin in CNS samples is due to lipids or not. However, since no method was 
found which improved detection, attempts at the quantitation of lipocortin I in 
human CNS tissue by ELISA were abandoned.
For investigation of lipocortin levels in the rat CNS during EAE, the 
cervical spinal cord and cerebellum were studied because the former represents an 
area which is particularly susceptible to the development of lesions, and the latter a 
region which is less severely affected (Paterson 1978, Juhler 1988). Levels of 
lipocortin I-like protein were found to be elevated in cervical spinal cords taken 
from EAE-inoculated rats compared to normal controls. In pre-diseased animals a 
slight increase in lipocortin immunoreactivity was observed, but a much greater 
increase was found in cords from clinically sick rats which also corresponded with 
maximum cellular infiltration, levels then appeared to reduce following recovery
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and regression of lesions. In the cerebellum a similar pattern was observed 
although changes in lipocortin I immunoreactivity were smaller in this region, 
which appeared to be a reflection of the lower number of lesions. Again greatest 
amounts were detected at the time when the lesion number was maximal, which in 
this area was during the recovery phase. In contrast levels of immunoreactive 
lipocortins n  and V did not appear to alter in either area throughout the course of 
the disease.
Changes observed in lipocortin I-like protein during EAE are consistent 
with those found in the CNS of patients with MS. In EAE, lipocortin I 
immunoreactivity was increased in diseased tissue, and appeared to be proportional 
to the extent of lesioning. In MS, levels were also increased compared to normal 
controls, and the highest amounts were found within plaques. However 
immunoreactive lipocortins II and V were also found to be elevated in MS CNS 
tissue, but in EAE these proteins did not appear to change. This discrepancy could 
arise from inherent differences between the human disease and animal model, or 
possibly may reflect CNS regional differences since not exactly the same areas of 
the CNS were studied in each disease. An alternative explanation is that since 
differences in immunoreactive lipocortins II and V in MS CNS tissue were not of 
the same magnitude as those observed for lipocortin I, it may be that smaller 
changes in these proteins did occur during EAE but were not detected for the 
following reasons. 1) In studies on human CNS tissue lipocortins were detected 
using the PAP Ni/Co system, but when rat tissue was investigated this method had 
not yet been developed and the less sensitive peroxidase conjugate method was 
used. It should be noted however, that when the PAP Ni/Co technique was utilised 
in a later experiment investigating the effect of RU 38486 (section: 3.5.3) there 
appeared to be little difference in the levels of immunoreactive lipocortins II and V 
between normal and EAE-inoculated vehicle treated animals. 2) It is possible to
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obtain large areas of relatively pure plaque tissue from patients with MS, whereas 
the tissue samples studied in EAE would have contained a large proportion of 
unaffected tissue. This would have the effect of diluting out any changes occurring 
principally within the lesions.
There have been no previous studies on lipocortins in the CNS in MS and 
EAE, although increased expression of lipocortins has been observed in other CNS 
diseases. Johnson et al (1989ab) have found increased lipocortin I 
immunoreactivity in human brains exhibiting gliosis due to trauma, infarction or 
neurodegeneration and in many CNS glial tumours. Furthermore, expression of 
high levels of annexin II has been detected in human brains with high grade gliomas 
(Reeves et al 1992). In another relevant study Relton et al (1991) noted that 
following induction of cerebral ischaema in the rat, immunostaining for lipocortin I 
was markedly increased in infarcted brain regions. Moving away from the CNS, it 
is interesting to note that elevated levels of lipocortin I have also been found in 
diseased tissues in other inflammatory, steroid-responsive conditions such as 
lesional skin tissue in psoriasis (Bastian et al 1991, Kitajima et al 1991) and in 
BALF from patients with inflammatory lung diseases (Ambrose & Hunninghake 
1990a, Smith etal 1990ab).
Lipocortins have been proposed to act as "second messengers" of the anti­
inflammatory effects of steroids. In the present study no corticosteroids were 
administered to animals with EAE and none of the patients with MS had received 
steroid therapy within the two years prior to post-mortem. However endogenous 
corticosteroids would of course be present circulating in the blood. It has been 
hypothesised by Munck and co-workers (1984) that one of the main physiological 
functions of circulatory glucocorticoids is to regulate inflammatory and immune 
mechanisms. Induction of an inflammatory/immune response causes stimulation of 
the hypothalamic-pituitary-adrenal (HPA) axis probably via the central action of
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cytokines, and subsequently release of corticosteroids. Yet corticosteroids are 
known to possess profound immunosuppressive and anti-inflammatory properties. 
Munck suggests that normal basal steroid levels exert a constant modulatory effect 
on inflammatory and immune systems and that when stress due to infection or 
tissue damage causes steroid levels to rise they serve to switch off these systems in 
order to prevent overshoot and damage to the organism. Thus endogenous 
corticosteroids appear to mediate negative feedback on these processes, and 
presumably steroid therapy augments this natural mechanism. Since lipocortins 
have been proposed to be steroid-inducible molecules possessing anti-inflammatory 
(Flower 1988) and immunomodulatory (Hirata 1989) actions, it is conceivable that 
regulation of the immune system and inflammatory response by endogenous 
glucocorticoids might be mediated via the lipocortins. Thus it may be that 
lipocortins present in normal CNS tissue constitute the basal level required for 
normal immune and inflammatory regulation.
There is evidence that endogenous steroids play a role in both MS and 
EAE. In EAE, corticosteroid levels have been found to rise dramatically 
immediately prior to the onset of remission (Levine et al. 1980, Mackenzie et al 
1989, MacPhee et al 1989). This surge in glucocorticoids appears to be 
responsible for self cure since if it is abolished by adrenalectomy animals do not 
recover (Levine et al 1962), although this effect can be reversed by corticosteroid 
replacement (MacPhee et al 1989). The increase in lipocortin I immunoreactivity 
detected in the CNS of animals with EAE happened at the same time as changes 
known to occur in serum corticosterone. Bringing together both Munck's work 
and the lipocortin theory it may be hypothesised that following induction of EAE, 
the release of cytokines and stress associated with the disease cause steroid levels 
to rise, this results in increased expression of lipocortin in the CNS which then 
mediates self cure.
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Interestingly, a slightly elevated amount of immunoreactive lipocortin I was 
also found in CNS tissues from CFA-inoculated animals and small but significant 
rise in serum corticosterone has been observed in CFA-immunised rats on day 15 
post-inoculation by Mackenzie et al. (1989). This may reflect non-specific 
stimulation of the immune system by the adjuvant and possibly the induction of 
sub-clinical adjuvant arthritis since injection of CFA into Lewis and other strains of 
rat is known to cause an experimental form of arthritis (Pearson 1956).
There is some evidence that dysfunction of the HPA axis occurs in patients 
with MS and that this may influence the course of the disease. However, the 
relationship between endogenous corticosteroids and disease activity is not nearly 
as well defined as in EAE. Some studies have shown that stress may affect onset 
of exacerbations in MS, but the nature of this influence is not clear as some 
workers have observed that stress appears to precipitate a relapse (Warren et al. 
1982, Franklin et al. 1988, Grant et al. 1989), whereas others have found that 
stressful events seem to have a protective effect against disease exacerbation 
(Sibley et al. 1991, Nisipeanu & Korczyn 1993). Basal corticosteroid levels do not 
appear to be abnormal in MS. Although in one report elevated concentrations of 
plasma ACTH were detected (Allen et al. 1980) and in another basal cortisol 
values were observed to be increased in acutely relapsed patients (Millac et al. 
1969), in many other studies unstimulated levels of urinary steroid metabolites and 
plasma cortisol have been found to be within the normal range (Garcia-Reyes et al. 
1952, Teasdale etal. 1967, Brambilla etal. 1974, Maida & Summer 1979, Reder 
et al. 1987, Klapps et al. 1992). However, much evidence has accumulated which 
suggests that the post-stimulatory adrenocortical response may be defective in MS. 
Cortisol secretion following administration of ACTH has been observed to be 
markedly reduced in MS patients (Ketelaer & Delmotte 1972, Maida & Summer
1979) and the rise in cortisol and ACTH invoked by hypoglycaemia or other HPA
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stimulants also appears to be impaired (Teasdale et al. 1967, Rinne 1968, Millac et 
al. 1969, Ketelaer & Delmotte 1972, Brambilla etal. 1974). In addition, a reduced 
response to the dexamethasone suppression test has been found in some patients 
(Reder et al. 1987). These studies suggest that adrenocortical secretory function 
may be inadequate in MS, although whether the deficiency occurs at the level of 
the adrenals, pituitary or hypothalamus in not clear. It has been postulated by 
Alexander et al. (1971) that such a defect may be inherent in MS patients and may 
contribute to the development of the disease.
The circulatory steroid levels of the MS patients from which CNS tissue 
samples were taken in the present study are not known. However in the light of 
the reports discussed above it may be postulated that the increased levels of 
lipocortins detected in the CNS of patients with MS may be due to induction of the 
proteins by endogenous corticosteroids and might represent an (unsuccessful?) 
attempt to overcome the chronic inflammation which is present in this disease. 
Moreover it is possible that lipocortin levels may be insufficient to suppress 
inflammatory and immune processes due to reduced efficiency of the HPA axis.
The efficacy of steroid treatment may result from a further induction of lipocortins 
to a level which is sufficient to be effective in suppressing these mechanisms and 
thus alleviating symptoms of the disease.
One possible reason for failure to control the inflammatory process in MS 
may be that the lipocortin is inactivated. In studies on BALF, Smith and co- 
workers (1990b) observed that in healthy volunteers a high percentage of 
lipocortin I was in the native form, whereas a greater proportion was in a degraded 
N-terminal clipped form in BALF from patients with inflammatory lung disease. 
Since the N-terminal region appears to play an important role in regulating the 
function of lipocortins, they have suggested that enzymatic degradation may cause 
inactivation of the protein leading to uncontrolled inflammation. With respect to
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the present study, it should be noted that statistical analysis of densitometer values 
obtained for the three bands detected in human CNS tissues from normal 
individuals and patients with MS, revealed no difference between any of the groups 
in the proportion of protein in each band, suggesting no difference in the degree of 
degradation.
In summary, elevated levels of immunoreactive lipocortins have been 
detected in CNS tissues from MS patients and the greatest amounts found within 
plaque tissue. In EAE, lipocortin I immunoreactivity was found to increase in CNS 
tissues during the course of the disease and this coincided with the appearance of 
inflammatory infiltrates in the CNS and with changes in serum corticosterone 
reported by other workers. Diseased CNS tissue in MS and EAE contains a great 
many lymphocytes and macrophages which are known to be a rich source of 
lipocortins. Thus the increased amount of lipocortins found in lesioned areas may 
be due to an influx of lipocortin containing cells and/or induction of the proteins in 
either endogenous or infiltrating cell types. However increases observed in normal 
appearing white matter in MS are more likely derived from indigenous cells 
because generally few infiltrating cells are found in white matter remote from 
plaque areas (Weller 1985). In the next stage of this study the distribution of 
lipocortins in CNS tissues from MS patients and EAE-diseased rats was 
investigated to determine the source of the increases in lipocortins observed in 
these diseases and in the case of EAE to clarify the relationship between lipocortin 
levels in the CNS and serum corticosterone.
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4.3 DISTRIBUTION OF LIPOCORTIN I IN CNS TISSUES
The polyclonal antiserum 842 was used to investigate the distribution of 
lipocortin I in CNS tissues from MS patients and controls and in cervical spinal 
cord samples taken from normal and EAE-inoculated rats at various stages of the 
disease. The specificity of this antiserum was determined in previous Western 
blotting studies which showed that when used to probe human and rat CNS tissues 
this antibody reacts only with lipocortin I-like protein and putative breakdown 
products to any extent. It was not possible to study the distribution of lipocortins 
II, IV and V because the respective antibodies 774, 179 and 890 were all found to 
stain higher molecular mass bands with an intensity equal to that proposed to be 
the lipocortin protein and in the absence of lipocortin standards it would not be 
possible to determine the specificity of staining on CNS tissue sections by pre­
adsorption experiments.
In normal human white matter lipocortin I immunoreactivity was found to 
be located primarily in blood vessel walls. A very similar distribution was observed 
in rat spinal cord where specific immunostaining for lipocortin I was seen in the 
walls of blood vessels and capillaries. A previous investigation of lipocortin I 
immunoreactivity in human CNS tissue by Johnson et al (1989b) revealed very 
little immunostaining in the bulk of the white matter, although immunoreactive 
lipocortin I was detected in ependymal cells and a sub-population of astrocytes 
beneath the ependymal layer and surrounding the central canal of the spinal cord; 
areas which were not specifically investigated in the present study. However in a 
study on rat CNS tissue Strijbos et al. (1991) observed similar weak and somewhat 
patchy staining for lipocortin I in blood vessels throughout the brain. In addition, 
these workers found brain tanycytes, ependymal cells and certain varicose nerve 
fibres and neuronal cell bodies were also positive for lipocortin I. Interestingly,
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immunoreactive lipocortin I was seen in the vascular endothelial cells of all other 
organs studied by this group. The presence of lipocortin I immunoreactivity in 
capillaries as well as larger blood vessels suggests that the protein may be 
associated with the endothelium and in support of this several studies have 
demonstrated the occurrence of lipocortin I in cultured endothelial cells (Hullin et 
al. 1989, Fujimoto etal. 1990, Patte etal. 1991, Raynal etal. 1992).
In normal CNS tissues very heavily stained cells were occasionally observed 
located within the lumen of blood vessels. Due to the intensity of staining, which 
tended to mask internal structure, many of these cells were difficult to identify 
although they are most likely to be polymorphonuclear leukocytes or monocytes 
since these circulatory blood cells have been shown to contain high levels of 
lipocortin I (Goulding et al. 1990, Comera et al. 1990). Furthermore, other 
workers have also found intravascular neutrophils and mononuclear cells to be 
amongst the most intensely stained cells present both in CNS and other tissues 
(Johnson et al. 1989ab, Fava et al. 1989).
In diseased CNS tissues lipocortin I immunostaining was markedly 
increased compared to the levels found in normal control samples. In CNS tissues 
from patients with MS, a slight elevation in lipocortin I immunoreactivity was 
observed in apparently uninvolved white matter remote from plaque areas, and a 
further substantial increase in immunostaining was found in actively demyelinating 
plaque tissue, confirming the results of previous Western blotting experiments.
The increased staining in apparently normal MS white matter was due to the 
presence of scattered lipocortin I-positive astrocytes. In active plaques strong 
staining for lipocortin I was observed in the cell bodies and processes of large 
numbers of reactive astrocytes. In chronic plaques a dense network of 
immunostained astrocyte fibres was seen (data not shown). The accumulation of 
numerous reactive and hypertrophic astrocytes in the vicinity of active MS plaques
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is, a characteristic pathological feature of the disease. Moreover, in the centre of 
clhronic plaques, fibrous processes from these cells form dense gliotic scars (Adams 
1976, Weller 1985). In addition, scattered reactive astrocytes are frequently found 
throughout the parenchyma at some distance from the lesions (Allen & McKeown 
1979, Newcombe et al 1986).
The apparent absence of lipocortin I in quiescent glial cells in normal 
human CNS tissue and the detection of significant amounts of the protein in 
activated astrocytes in tissues from patients with MS suggests that expression of 
lipocortin I in astrocytes may be related to the level of cellular activation. Findings 
in the present study are in accordance with the work of Johnson and colleagues 
who also observed that lipocortin I was not expressed by histologically normal 
astrocytes in human CNS tissue, but found intense lipocortin I immunoreactivity in 
reactive astrocytes surrounding areas of infarction in cases of head trauma and 
intracerebral haemorrhage, and in scattered reactive astrocytes in patients with 
Alzheimer's disease (Johnson et al 1989b). Furthermore, they have observed 
strong staining for lipocortin I in neoplastic cells of astrocytomas (Johnson et al 
1989a) and high levels of lipocortin I have also been detected in the Cg glioma cell 
line (Huang et al 1986).
Interestingly, in studies by Johnson et al (1989ab) lipocortin I 
immunoreactivity was also observed in macrophages infiltrating CNS lesions. In 
contrast, in the present study although such cells were seen immunostained for 
lipocortin I within the walls of blood vessels, lipocortin I-positive macrophages 
were not found in the parenchyma, although staining of adjacent sections with the 
macrophage marker EBM 11 confirmed the presence of significant numbers of 
these cells within the tissue. Macrophages in the CNS of patients with MS may be 
derived either from blood monocytes or resident microglia (Adams et al 1989), 
both of which are detected by EBM 11. Circulating monocytes are well
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documented as being a rich source of lipocortin I (Comera et al 1989,1990, 
Goulding et al 1990, Browning et al 1990) and the protein has recently been 
detected in cultured rat microglia (Gebicke-Haerter et al 1991). The reason why 
macrophages present in the CNS in MS did not stain positive for lipocortin I is not 
known. The results observed appear to suggest that in MS, blood monocytes 
migrating into the CNS tissue cease to express lipocortin I and/or that activated 
microglia do not express the protein in situ in the CNS.
Investigation of the distribution of immunoreactive lipocortin I in cervical 
spinal cords from EAE-inoculated rats revealed that, prior to the onset of 
symptoms, the distribution and degree of staining was similar to that observed in 
normal animals. Using Western blotting a slight increase in lipocortin I 
immunoreactivity was detected in CNS tissues from pre-diseased rats and 
measurement of serum corticosterone suggested that circulating glucocorticoids 
were also slightly elevated. A small rise in corticosteroids during the induction 
phase of EAE has previously been observed by other workers (Mackenzie et al
1989) and probably results from an acute reaction to the inoculum (Besedovsky et 
al 1975, Schauenstein et al 1987).
The emergence of clinical symptoms in rats immunised for EAE was 
accompanied by a marked increase in lipocortin I immunostaining which reached a 
maximum at the height of disease and then decreased following recovery, 
substantiating previous findings using Western blotting. Changes in the lipocortin I 
content of CNS tissues seemed to be proportional to the severity of symptoms and 
the number of lesions and also appeared to reflect serum corticosterone levels 
which were found to rise dramatically following the development of symptoms and 
then fell markedly after recovery. This pattern of adrenocortical response during 
the course of EAE has been reported in previous studies (Levine et al 1980. 
Mackenzie et al 1989, MacPhee et al 1989).
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In CNS tissues taken from CFA inoculated controls on day 15 post­
inoculation the intensity and distribution of lipocortin I immuno staining appeared 
to be no different to that observed in normal rats and in pre-diseased EAE- 
inoculated animals, although a slight elevation in levels of immunoreactive 
lipocortin I had been detected by Western blotting. Assessment of serum 
corticosterone suggested that endogenous steroid levels might be slightly increased 
in these animals, a finding which has been reported in other studies (Mackenzie et 
al 1989).
The source of changes in immunoreactive lipocortin I detected by Western 
blotting in CNS tissues from CFA controls and EAE-inoculated rats during the 
induction phase is not clear since on immunostained sections the degree and 
distribution of staining appeared to be the same as that found in normal animals. It 
is possible that smaller changes in lipocortin I immunoreactivity were not 
detectable using immunohistochemistry. An alternative explanation is that these 
slight increases were due to alterations in circulating levels of lipocortin. Goulding 
et al (1990) have demonstrated induction of lipocortin I in blood cells following in 
vivo treatment with corticosteroids. Endogenous steroids appeared to be slightly 
raised in both CFA and pre-diseased rats and it is possible that this may have 
caused induction of lipocortin in systemic leukocytes. Since animals used in this 
study were exsanguinated but not perfused, an elevation in circulatory lipocortins 
may have been detected as an apparent increase in the CNS tissue by Western 
blotting. Such changes would not easily be observed on immunostained tissue 
sections.
The increased immunostaining in CNS tissues from EAE-diseased animals 
was found to be due to widespread staining of the lesions, but in contrast to 
findings in MS, extensive staining of infiltrating macrophages and lymphocytes was 
observed and astrocytes did not appear to stain positive for lipocortin I. In
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addition, some very heavily stained cells were also seen in the vicinity of the lesions 
which appeared to be similar to some of those observed within the lumen of blood 
vessels in normal animals. These cells are probably blood derived 
monocytes/macrophages as the circulating cells known to contain the highest 
amounts of lipocortin I are monocytes and neutrophils (Comera et al 1989,1990, 
Goulding et al 1990), but polymorphonuclear leukocytes are rarely found invading 
the CNS in acute EAE in the Lewis rat (Paterson 1976, Shaw & Alvord 1984).
Although there have been no previous studies on lipocortins in the CNS in 
EAE, the association of lipocortin I with inflammatory cells is well established.
The protein was originally isolated from macrophages (Flower 1988) and lower 
levels of lipocortin I protein and mRNA have been found in lymphocytes (Pepinsky 
etal. 1988, Bronnegard et al. 1988, Goulding et al. 1990). Furthermore in other 
immunohistochemical studies, lipocortin I immunoreactivity has been detected in 
resident tissue macrophages in various rat organs (Fava et al 1989) and also in 
macrophages infiltrating lesions in human CNS tissue (Johnson et al 1989ab).
In both MS and EAE increased immunostaining in CNS tissues was found 
to be localised mainly in lesioned areas. However, in MS lipocortin I 
immunoreactivity was located in reactive astrocytes but in EAE, positive staining 
was detected in infiltrating lymphocytes and macrophages. The reason for these 
differences in the distribution of lipocortin I, particularly the apparent absence of 
the protein in inflammatory cells invading the tissue parenchyma in MS, is not clear 
but may be due to differences between the pathology of the human condition and 
animal model. Leibowitz (1983) has suggested that much of the divergence 
between the two diseases is due to differences in disease duration and it is possible 
that this may explain differences seen in the expression of lipocortin I. In human 
CNS tissue lipocortin I immunoreactivity appeared to be present in reactive but not 
quiescent astrocytes, implying that expression of the protein in astroglia is
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dependent upon the degree of cellular activation. A recent study by Reeves et al. 
(1992) suggests that the same is true of lipocortin II. Post-mortem studies on 
acute MS have shown that astrocytes do not become activated until about six 
weeks after commencement of an acute relapse (Adams et al. 1989). The duration 
of clinical disease in MS patients in the present study ranged from nine months to 
49 years and it is unlikely that many, if any, of the plaques were less than six weeks 
old. Thus the plaque tissue studied would be expected to contain a considerable 
number of activated astrocytes.
In contrast to the situation in MS, Lewis rats were inoculated for an acute 
form of EAE. In this model visible lesions do not start to appear in the CNS until 
about day nine or ten post-inoculation, therefore when animals were sampled at the 
height of disease on day 14, lesions in the CNS were approximately 4-5 days old.
It is possible that due to the short duration of disease there was insufficient time for 
astrocytes to become activated to express lipocortin I. In support of this 
suggestion, other studies have reported that reactive astrocytes are not present in 
acute EAE in the rat (Shaw & Alvord 1984). However some workers have 
detected increased immunostaining for GFAP (Smith et al. 1983, Cammer et al.
1990) suggesting that some activation of astrocytes does occur. Interestingly 
Gebicke-Haerter et al. (1991) observed that although lipocortin I was barely 
detectable in normal rat brain, cultured rat astrocytes rapidly accumulate high 
levels of the protein. Thus it may be that lipocortin I was not detected in 
astrocytes in acute EAE because the cells had not reached the required level of 
activation. It would therefore be very interesting to examine the distribution of the 
protein in a chronic relapsing model of EAE, where extensive astrogliosis and 
gliotic scar formation similar to that found in MS plaques, develop as the disease 
progresses (Smith & Eng 1987, Raine 1984).
203
It is difficult to rule out completely that some of the immunostaining 
observed in CNS tissue sections is not due to detection of lipocortin III. Cross­
reactivity of lipocortin antibodies with other members of the lipocortin family is 
common because the core structures of these proteins are so highly homologous. 
Lipocortins I and III share 49% sequence identity and the 842 antiserum is known 
to have a high titre of antibodies that recognise rat lipocortin III (Pepinsky et al 
1988). It should be noted however that in rat CNS tissue all staining (except that 
of neuronal nuclei) was inhibited by pre-adsorption of the antiserum with rh 
lipocortin I. Furthermore, Comera et al (1989) have reported that lipocortin III is 
absent from peripheral blood lymphocytes and monocytes, although to my 
knowledge there have been no studies which have investigated the presence of 
lipocortin III in astrocytes or endothelial cells.
As mentioned previously it was not possible to examine the distribution of 
lipocortins II, IV and V, however several other workers have recently investigated 
the immunolocalisation of lipocortins II and V in CNS and other tissues and it is 
interesting to note that the distribution of these proteins appears to be similar to 
that observed for lipocortin I. Like lipocortin I, lipocortin II also appears to be 
expressed by astroglial cells under certain circumstances. In a study on p36 
(lipocortin II) in rat cerebellum Burgoyne et al (1989) found the protein restricted 
to the cell processes of a sub-class of astrocytes. Furthermore, Reeves et al 
(1992) found annexin II undetectable in normal adult human brain but observed 
high levels of expression in tumour tissue of glioblastoma multiforme and highly 
anaplastic astrocytomas, although not in astrocytomas of lower pathological grade. 
They also detected annexin II in glial scar tissue and in cell lines established from 
highly malignant glial tumours and suggest that expression of the protein may be 
dependent upon the degree of cellular activation. In addition, lipocortin II-like
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protein has also been found in endothelial cells and macrophages in various rodent 
tissues (Gould et al. 1984).
A recent study on the distribution of lipocortin V in the rat, revealed high 
levels of the protein in the cell bodies and processes of both astrocytes and 
oligodendrocytes in the cerebellum and optic nerve. In addition lipocortin V was 
seen in capillary endothelial cells in many organs (Giambanco et al. 1991). 
Lipocortin V has also been detected in human peripheral blood lymphocytes and 
monocytes (Comera et al. 1989) and in rat peritoneal macrophages (Pepinsky et al. 
1988). Furthermore, Patte etal. (1991) have reported the presence of 
immunoreactive proteins corresponding to lipocortins II and V in cultured human 
endothelial cells.
In the present study immunoreactive lipocortin I was detected in endothelial 
cells in normal CNS tissue and additionally in lymphocytes, macrophages and 
astrocytes in inflammatory CNS disease. Studies by other workers indicate that 
lipocortins II and V may also be present in these cell-types. The precise function 
of the various members of the lipocortin family has not been determined, but the 
occurrence of these proteins in endothelial cells, astroglia, macrophages and 
lymphocytes in MS and EAE suggests a physiological role for lipocortins in the 
functioning of these cells and by inference in the pathological processes in which 
they are involved.
Lymphocytes and macrophages are key effector cells of the immune 
response and appear to play a fundamental role in the pathology of MS and EAE. 
Many studies have shown that cytokines, enzymes, eicosanoids and other 
mediators released by these cells can initiate and perpetuate inflammatory and 
immune responses (Nathan etal. 1982, Geczy 1984, Davis 1985). Macrophages 
also appear to be responsible for demyelination (Wisniewski 1977, Prineas & 
Connell 1978) which may be mediated via the action of PLA2  (Woelk et al.
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1974,1976, Trotter & Smith 1984). In addition, these cells are probably the major 
source of the increased levels of PLA2 -derived eicosanoid inflammatory mediators 
found in the CNS in MS and EAE (Humes et al 1977, Rosnowska et al 1981, 
Bolton etal 1984ab).
Mononuclear cells obviously play a pivotal role in inflammatory CNS disease 
and potentially the lipocortin they contain could influence many of the factors 
outlined above. Both lymphocytes and macrophages have glucocorticoid receptors 
(Lippman & Barr 1977, Werb et al 1978) and many aspects of their function are 
suppressed by steroids (Fauci 1979). Recently it has been shown that lipocortins 
can duplicate many of the anti-inflammatory (Flower 1988) and 
immunomodulatory (Hirata 1989) effects of corticosteroids. In particular, rh 
lipocortin I has been demonstrated to inhibit migration of leukocytes into 
inflammatory lesions (Errasfa & Russo-Marie 1989), and to block the generation of 
superoxide (Maridonneau-Parini et al 1989) and prostaglandins by macrophages 
(Cirino & Flower 1987b). Interestingly, Goulding and Guyre (1992) have recently 
discovered specific binding sites for lipocortin I on the surface of monocytes which 
they claim are receptors via which lipocortin I may influence the inflammatory 
actions of these cells.
Astrocytes perform several important functions in the CNS, they provide 
structural and metabolic support for neurones and appear to be involved in 
maintaining the integrity of the BBB. In addition, these cells play a key role in 
repair following damage to the CNS tissue and there is also evidence that astroglia 
have immune functions in the CNS. IL-1 and other cytokines have been shown to 
be mitogenic for astrocytes both in vitro and in vivo (Giulian & Lachman 1985, 
G iuliani al 1988, Selmaj etal 1990). Thus products from inflammatory cells 
may stimulate astrocyte proliferation and contribute to the reactive gliosis that is a 
prominent feature of MS plaques. Furthermore, astrocytes can be induced to
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express Class IIMHC antigenic determinants on their surface and expression of 
these antigens by astroglia has been detected in the CNS in MS and EAE (Traugott 
et al 1985, Hickey etal 1985, Lee et al 1990). In vitro studies have 
demonstrated that astrocytes can present MBP to encephalitogenic T cells 
(Fontana et al 1984), suggesting that these cells may function as antigen 
presenting cells in vivo and thereby up regulate the T lymphocyte response. There 
is also evidence that astrocytes may modulate immune reactivity in the CNS by 
releasing cytokines and other mediators, as cultured astrocytes have been found to 
produce IL-1 (Fontana et al 1982), IL-3 and IL-6 (Frei & Fontana 1989), IFNs 
(Borgeson etal 1989), tumour necrosis factor-a (Chung & Benveniste 1990),
PGs (Fontana et al 1982, Keller et al 1985) and complement components (Levi- 
Strauss & Mallat 1987). Moreover, astroglia appear to release factors that can 
suppress T cell proliferation and/or function and thus these cells may also mediate 
immunosuppression in the CNS (Borgeson et al 1989, Matsumoto et al 1993).
Steroids have been shown to inhibit astrocyte growth (Kniss & Burry 1985, 
Grasso 1976, Armelin & Armelin 1983) and to influence other aspects of astroglial 
function in vitro (De Vellis et al 1986). Furthermore, these compounds are 
known to have suppressive effects on the release of many of the immune and 
inflammatory mediators described above, and have been demonstrated to block 
production of cytokines (Nishida et al 1989) and eicosanoids (Gebicke-Haerter et 
al 1991, Brenner et al 1992) by astrocytes in culture. Presumably some of these 
steroid effects on astrocytes may be mediated by lipocortins.
It is also interesting to note that lipocortins may be involved in the regulation 
of astrocyte proliferation. One of the mediators proposed to induce astrogliosis is 
epidermal growth factor (EGF). EGF is mitogenic for astrocytes in vitro (Leutz & 
Schachner 1981, Simpson etal 1982), furthermore EGF receptors are found on 
astrocytes on the CNS (Simpson et al 1982) and enhanced expression of the gene
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encoding the EGF receptor/kinase has been observed in astrocytic neoplasms 
(Libermann et al 1984). p35 (lipocortin I) is known to be the major physiologic 
substrate for the EGF receptor/kinase (Fava & Cohen 1984, Pepinsky & Sinclair 
1986, Huang et al 1986), and may therefore be important in the signal 
transduction pathway of the EGF receptor, and thus in the regulation of astrocyte 
proliferation, astrogliosis and tissue repair. This mechanism may offer an 
alternative explanation for the increased expression of lipocortin I in reactive 
astrocytes in MS.
The presence of lipocortin I in CNS endothelial cells is particularly interesting 
since these cells constitute a major structural component of the BBB. Increased 
BBB permeability and CNS oedema are well defined features of MS and EAE 
which may be responsible for inhibiting neuronal conduction and thus causing the 
physical symptoms of these diseases (Sears etal 1978, Paterson 1982, Simmons et 
al 1982). The anti-oedematous properties of corticosteroids are well known and 
they are widely used for the clinical treatment of brain oedema (Reulen et al 
1972). Studies using computed tomography and magnetic resonance imaging 
suggest that corticosteroid therapy can reduce BBB abnormalities and oedema in 
MS (Sears etal 1978, Troiano etal 1984,1987, Kesselring etal 1989). 
Furthermore, Long and Holaday (1985) have demonstrated that CNS vascular 
permeability is increased in Adx rats and that this effect can be reversed by steroid 
replacement therapy, providing strong evidence that the integrity of the BBB is 
under the control of endogenous steroid hormones.
The location of lipocortin I in cells actively involved in the regulation of BBB 
function may indicate a role for this protein in control of BBB permeability, in MS 
and EAE, possibly through the influence of endogenous corticosteroids. Support 
for this suggestion is provided by the studies of Cirino et al (1989) which have 
demonstrated that local administration of rh lipocortin I can mimic the prevention
208
of peripheral oedema by steroids in the rat. Furthermore, in a model of cerebral 
ischaemia Relton et al. (1991) showed that central injection of an N-terminal 
fragment of lipocortin I caused a marked inhibition of cerebral oedema, whereas 
administration of a neutralising antibody increased fluid accumulation, suggesting 
that lipocortin I may be an endogenous inhibitor of oedema in the CNS.
In summary, in the present study increased lipocortin I immunoreactivity was 
detected in CNS tissues from MS patients and EAE-diseased rats and was found to 
be associated with reactive astrocytes, and infiltrating lymphocytes and 
macrophages, respectively. In the case of EAE, an apparent relationship between 
the lipocortin I content of the CNS and serum corticosterone levels was observed, 
however this does not necessarily indicate steroid induction of the protein, since 
these findings could equally be due to an influx of lipocortin rich cells from the 
blood. Likewise, increased expression of the protein in reactive astroglia in MS 
may be elicited by glucocorticoids or may result from a glucocorticoid independent 
mechanism. In examining the role of lipocortins in steroid action, the next 
approach was to determine the effect of steroids on lipocortin levels in the CNS. It 
would be very interesting to study the influence of steroid therapy on lipocortin 
levels in MS brain tissue. Unfortunately such a study would be very difficult to 
perform because although corticosteroids are frequently used to treat acute attacks 
of relapsing MS, it is very uncommon for patients to be receiving steroids at the 
time of death. Hence post-mortem CNS tissue from steroid treated MS patients is 
not readily available. The animal model EAE however, is amenable to 
manipulation of steroid levels and thus was used to investigate the influence of 
exogenous and endogenous steroids on lipocortins in inflammatory CNS disease.
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4.4 INFLUENCE OF EXOGENOUS AND ENDOGENOUS STEROIDS ON 
LIPOCORTIN LEVELS IN THE CNS DURING EAE
Studies so far had suggested that the increased levels of immunoreactive 
lipocortin I detected in the CNS of EAE-diseased animals might be induced by the 
rise in endogenous corticosteroids which is associated with spontaneous recovery 
from the disease. Therefore experiments were performed to investigate whether 
the amount of lipocortin I in CNS tissues can be influenced by artificial 
manipulation of serum corticosteroid levels during EAE.
In the first set of experiments animals were dosed with corticosteroids to 
determine if it was possible, by raising steroid levels, to cause a further induction of 
the protein. EAE-inoculated rats were treated therapeutically at the height of 
disease rather than prophylactically, because although prophylactic dosing has been 
shown to be very effective in controlling disease expression, CNS lesions do not 
develop (Rosenthale etal 1969, Levine & Strebel 1969, Greig et al 1970) and 
thus this would not provide a suitable model for studying the effect of steroids on 
lipocortins in the CNS. In addition, a fairly short treatment schedule of two or 
three doses over a 24 hour period was used because one well known action of 
steroids is to reduce leukocyte accumulation at inflammatory sites, and a decrease 
in the number of lipocortin-containing cells within the CNS tissue might mask any 
induction of the protein.
Initially corticosterone was studied because this is the main circulatory 
glucocorticoid hormone in the rat and therefore it is this compound which is 
thought to be responsible for self-cure and possibly the increase in CNS lipocortin 
levels. When animals were dosed at the height of disease with either 10 or 50 
mg/kg corticosterone, no effect on lipocortins I, II or V was detected. However, 
RIA of serum corticosterone, which would measure both natural and injected 
hormone, revealed that at the higher dose, serum corticosterone concentrations
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were significantly elevated. This indicated that substantial amounts of the drug 
were passing into the circulation and therefore probably into the CNS, since studies 
have shown the that steroids pass easily from the blood into the brain due to their 
high lipid solubility (Pardridge & Mietus 1979). Furthermore in EAE, breakdown 
of the BBB and oedema frequently occur in the vicinity of the lesions (Oldendorf & 
Towner 1974, Traugott et al. 1982, Daniel et al 1981) and this increase in 
vascular permeability may also permit passage of blood borne substances into the 
CNS tissue.
It was considered possible that induction of lipocortin I had not been 
observed in these experiments due to dosing animals at the height of disease. 
During this phase circulatory steroids and CNS lipocortin levels are already 
elevated and it may be that further induction of lipocortin could not be achieved 
because the cells were already maximally stimulated. In view of this, in another 
experiment animals were treated with corticosterone immediately after complete 
recovery from neurological symptoms. At this stage some inflammatory cells are 
still present in the CNS, but serum corticosterone levels have returned to near 
basal. Thus cells might be sub-maximally stimulated and susceptible to further 
induction of lipocortin by administration of exogenous steroids. However, when 
animals were dosed in the recovery phase with 10 mg/kg corticosterone no change 
in CNS lipocortins was detected. Although it should be noted that circulating 
corticosterone concentrations were not found to be statistically different in drug 
and vehicle treated groups, making it unlikely that cells in the CNS were exposed 
to significantly increased steroid levels.
When animals were dosed at the height of disease with corticosterone 
although there appeared to be a small clinical effect at the lowest dose studied, this 
was not borne out in a subsequent experiment using a higher dose and a greater 
number of animals. In experiments designed to investigate whether the effects of
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steroids may be mediated via induction of lipocortins, it would be preferable to 
induce an obvious clinical effect and then determine if lipocortin levels rise 
concomitantly. The doses of corticosterone used in the present study were 
calculated from a knowledge of the dose of dexamethasone shown to be effective 
in suppressing EAE (Bolton & Flower 1989), and the reported relative anti­
inflammatory potencies of corticosterone and dexamethasone in the rat 
carrageenan paw oedema model (Flower & Dale 1989). It is possible that with a 
higher dose or a longer treatment schedule an effect on symptoms may have been 
achieved. However, corticosterone is known to have very weak anti-inflammatory 
properties (Flower & Dale 1989). Furthermore, Komarek & Dietrich (1971) found 
that 30 mg/kg corticosterone was ineffective in inhibiting EAE and that the 
compound had an LD50  of 35 mg/kg in the rat.
Since it appeared that it might prove difficult to induce a therapeutic effect 
in EAE using corticosterone, the influence of the synthetic steroid dexamethasone 
was investigated. Dexamethasone has potent anti-inflammatory properties and 
several studies have demonstrated that this compound is able to inhibit, suppress 
and treat EAE (Levine & Strebel 1969, Komarek & Dietrich 1971, Levine & 
Sowinski 1980, Bolton & Flower 1989). Doses used in the present study have 
been shown to be effective in the rat model by Bolton and Flower (1989), although 
animals were treated over a longer period of time than in the present study.
Despite the reported efficacy of dexamethasone, when rats were dosed at the 
height of disease three times with 0.5 or 1 mg/kg no effect on symptoms was 
observed. This is probably due to the short duration of treatment. Levine and 
Sowinski (1980) observed that when rats were treated therapeutically with 
dexamethasone, recovery was accelerated slightly when three doses were given but 
not when one or two doses were injected, however, these workers used 5 mg/kg 
and the drug was administered over a three day period.
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Although treatment of EAE-inoculated animals with dexamethasone had no 
effect on the symptoms of the disease, measurement of serum corticosterone 
showed that levels of the natural hormone were below the limit of detection in all 
dexamethasone treated animals except one. Control of circulating corticosteroids 
is regulated by a complex series of events. Secretion of glucocorticoids from the 
adrenal cortex is stimulated by ACTH released from the anterior pituitary, which in 
turn is regulated by corticotrophin-releasing factor (CRF) derived from the 
hypothalamus. Glucocorticoids exert a negative feedback on their own release by 
inhibiting secretion of both ACTH and CRF. The finding that serum corticosterone 
was significantly suppressed in dexamethasone treated animals, indicates that the 
drug is participating in negative feedback at the level of the pituitary and/or 
hypothalamus and strongly suggests that the compound was entering the CNS.
The one dexamethasone treated rat in which very high serum corticosterone levels 
were detected appeared to be close to death when sampled and it is possible that in 
a moribund state, serum corticosterone escapes homeostatic control. Despite 
evidence that dexamethasone was entering the CNS, no effect on immunoreactive 
lipocortins I, II or V was detected.
The results of experiments with corticosterone and dexamethasone suggest 
that lipocortin levels in the CNS during EAE cannot be increased by dosing with 
additional steroids although it cannot be ruled out that a higher dose or in 
particular, a longer dosing schedule would have revealed an effect. Furthermore, 
since it has been hypothesised that steroid actions in EAE may be mediated 
through induction of lipocortins it would have been preferable to induce a clear 
clinical response to determine whether increased lipocortin levels are a prerequisite 
for such an effect. However, if steroid effects are mediated by induction of 
lipocortin, it might be expected that increases in the amount of protein would occur 
prior to improvement of symptoms. Moreover, it should be noted that in studies
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where induction of lipocortin by steroids has been detected in vivo this has usually 
been observed within a few hours of treatment (Blackwell et al 1980, Wallner et 
al. 1986, Smilli setal. 1989b, Goulding et al 1990, Solito etal 1990, Peers etal 
1993).
In a subsequent study an alternative approach to investigating the effects of 
steroids on CNS lipocortin levels was pursued. Rather than endeavouring to raise 
steroid levels, an attempt was made to block the effect of endogenous steroids by 
dosing animals with the glucocorticoid antagonist RU 38486. RU 38486 
(mifepristone), is a potent competitive progesterone and glucocorticoid receptor 
antagonist (Philibert etal 1981, Chrousos etal 1984), which has anti­
glucocorticoid activity both in vitro and in vivo (Chobert et al 1983, Gagne et al
1985). This compound has been shown to antagonise the immunosuppressive 
effects of glucocorticoids in a number of in vitro tests (Emilie et al 1984) and to 
reverse the anti-inflammatory actions of dexamethasone in several experimental 
models of inflammation in the rat including pleurisy (Peers et al 1988, Lelievre et 
al 1988), adjuvant arthritis, paw oedema and peritonitis (Hirschelmann et al 
1988ab).
EAE-inoculated rats were dosed twice daily with 2 0  mg/kg RU 38486 on 
days 10-14 post-inoculation inclusive. Thus dosing was started just prior to the 
disease-associated rise in serum corticosterone and therefore the clinical and 
biochemical effects of this should have been blocked. Clinical scores of RU 38486 
and vehicle treated EAE-inoculated animals were not statistically different, 
however this was probably due to the small sample sizes. Whereas vehicle treated 
animals appeared to be following the typical course of disease, all RU 38486 dosed 
rats were completely paralysed and appeared to be terminally ill at the time of 
sampling. The moribund condition of RU 38486 dosed animals suggests that the
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drug was effectively antagonising the rise in corticosterone which appears to 
mediate self-cure.
Serum corticosterone levels in RU 38486 and vehicle dosed groups were 
not significantly different but there was a trend towards higher levels in rats treated 
with the antagonist, which again was probably not significant due to the low 
sample numbers. Other workers have observed that RU 38486 administration 
elevates circulating ACTH and cortisol in non-human primates and man due to 
blocking glucocorticoid negative feedback (Healy et al 1983, Gaillard et al 1984), 
and results suggest that this may have occurred to some extent in the present study.
If lipocortin I levels in the CNS are modulated by endogenous 
glucocorticoids, then it would be expected that a lower amount of the protein 
would be detected in RU 38486 dosed than vehicle treated groups. However, 
administration of the glucocorticoid did not appear to significantly influence 
lipocortin levels in the cervical spinal cord of either normal or EAE-inoculated 
animals. Although no effect on lipocortin was observed, it is not known if the drug 
was efficiently blocking glucocorticoid receptors in the CNS. However, studies 
have shown that when injected intravenously, radiolabelled RU 38486 accumulates 
in cell nuclei in steroid sensitive areas of the brain, suggesting that the compound 
readily penetrates the BBB (Coutard & Duval 1985). In addition, in a more 
extensive study in EAE using the same dosing regimen, Bolton and Flower (1989) 
found that RU 38486 significantly enhanced neurologic symptoms and reduced 
survival rate. Moreover they showed that the drug was able to reverse 
dexamethasone-induced suppression of the disease. Furthermore in the present 
study, the apparent effects of RU 38486 on clinical signs and serum corticosterone 
suggest that the compound was having a pharmacological effect and probably was 
causing some blockade of glucocorticoid receptors in the CNS.
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Since there appeared to be no difference in the lipocortin content of cords 
from RU 38486 and vehicle treated animals this suggests that lipocortin levels in 
the CNS are not modulated by endogenous glucocorticoids. Moreover, since the 
amount of lipocortin I-like protein was elevated to the same extent in EAE- 
inoculated animals whether they were treated with the glucocorticoid antagonist or 
vehicle this suggests that endogenous corticosteroids are not responsible for 
mediating the increase in immunoreactive lipocortin I observed during EAE. 
However, because it was not possible to be sure that glucocorticoid receptors in 
the CNS were blocked in RU 38486 treated animals, the effect of adrenalectomy 
was investigated.
The adrenal cortex is the sole source of circulating corticosteroid 
hormones, thus Adx results in removal of all glucocorticoids from the blood. 
Assessment of serum corticosterone by RIA confirmed the success of 
adrenalectomy as values were below the limit of detection in most animals both at 
inoculation and at the time of sampling. When Adx rats were inoculated for EAE, 
they were found to be more susceptible to the disease than normal animals, 
succumbing several days early to a severe, rapidly progressive form of the disease. 
The increased susceptibility of Adx rats to EAE is well documented by other 
workers (Levine et al. 1962b, MacPhee et al 1989), who report that death rapidly 
ensues unless animals are supplemented with glucocorticoids, indicating the critical 
importance of adrenal steroids in the mechanism of self-cure. Interestingly, at 
inoculation a small number of animals had low levels of circulating corticosterone, 
which was presumably due to incomplete removal of adrenal tissue. These animals 
did not succumb early to EAE, but instead went on to develop the disease at the 
same rate as non-operated controls. Thus it appears that this low level of 
corticosterone was able to delay onset until the normal time, again confirming the 
protective effect of endogenous corticosteroids.
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In contrast, sham-operated rats appeared to be relatively resistant to the 
disease. In a preliminary experiment, sham-operated animals were found to 
develop a delayed, milder type of EAE than that which is normally observed in the 
Lewis rat. It is possible that this effect was also due to adrenal steroids. Various 
forms of stress have been shown to inhibit the development of EAE (Levine et al 
1962a, Bukilica et al. 1991). Although at least one week was allowed between 
surgery and inoculation, it may be that the physical trauma of the sham operation 
had a suppressive influence on the induction of the disease, possibly due to 
stimulating release of glucocorticoids. Measurement of serum corticosterone 
however appeared to yield conflicting results, on the one hand, at inoculation, 
levels in sham-operated animals were not significantly higher than in non-operated 
animals (although there may have been a marginal difference). On the other, levels 
in sham-operated animals decreased slightly (significantly in the third experiment), 
from inoculation to the day of sampling. This may indicate that circulating 
corticosterone was elevated above normal at inoculation, however, the different 
sampling techniques used at each time point should also be considered. At 
inoculation rats were anaesthetised with halothane and 1 ml of blood taken slowly 
by cardiac puncture. At the end of the experiments 2 ml of blood was collected 
relatively quickly, again by cardiac puncture, but from animals which were 
rendered unconscious by CO2  inhalation. Various types of anaesthesia are known 
to stimulate release of corticosteroids to a greater or lesser extent (Hedner & 
Rerup 1960, Cook etal 1973, S.H. Peers and R.J. Flower, personal 
communication) and it is possible that the apparent decrease in circulating 
corticosteroids in sham-operated animals between the time of inoculation and the 
time of sampling may be an artefact resulting from the influence of anaesthesia 
and/or the time taken to collect the sample.
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Assessment of lipocortins in cervical spinal cord samples taken from Adx, 
sham-operated and non-operated rats, revealed no difference in the levels of 
immunoreactive lipocortins II and V, but marked differences in lipocortin I 
immunoreactivity. In both experiments the amount of lipocortin I-like protein was 
considerably elevated in Adx rats compared to sham-operated and non-operated 
controls. In addition, in one experiment levels of immunoreactive lipocortin I in 
cords from sham-operated animals appeared to be lower than in non-operated rats, 
although in the other experiment this difference was only marginal.
The detection of lower levels of lipocortin I-like protein in CNS tissues 
from sham-operated animals is perhaps not surprising. In previous experiments it 
was observed that the amount of immunoreactive lipocortin I in the CNS during 
EAE appears to be closely related to both the stage of disease and the number of 
lesions. Sham-operated rats were sampled on day 10 PI, these animals appeared to 
be relatively resistant to the induction of EAE, but even in the normal course of 
events, only a few small, early lesions would be present in the CNS at this stage.
In contrast, both Adx and non-operated rats were sampled at the height of disease 
and would therefore have developed extensive lesions in the CNS. Thus 
differences between sham-operated and other groups are probably a reflection of 
the number of infiltrating lipocortin-containing cells in the CNS.
The higher levels of lipocortin I immunoreactivity observed in CNS tissues 
from Adx rats inoculated for EAE were completely unexpected. These animals 
had no (or virtually no) circulating corticosteroids both at the time of inoculation 
and at the end of the experiment. If the elevation in immunoreactive lipocortin I 
seen in the CNS of EAE inoculated rats is due to induction by endogenous 
glucocorticoids, then Adx rats would be expected to exhibit lower levels of the 
protein than non-operated controls. Interestingly, elevated levels of lipocortins 
have been detected in Adx animals by other workers. In an early study, Flower
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(1984) found increased macrocortin in peritoneal lavage cells from Adx rats than in 
sham-operated controls, which was attributed to a diminished rate of secretion of 
the protein secondary to the lack of endogenous steroids. In addition, in another 
study on the effect of Adx on lipocortins in peritoneal leukocytes Peers et al 
(1993) also reported encountering instances where the amount of lipocortin I 
present in cells from Adx rats was high and suggested that the trauma of surgery or 
a sub-clinical infection following the operation might activate cells to synthesise 
more lipocortin I through a non-glucocorticoid control mechanism.
Whilst it is possible that in the present study increased levels of lipocortin I- 
like protein may be due to accumulation of the protein caused by lack of secretion, 
or that surgical trauma and associated release of humoural factors may have 
activated cells to produce lipocortins, there are other possible explanations for the 
results observed. Adx rats are known to exhibit an exaggerated inflammatory 
response to irritants compared to sham-operated animals. Fluid exudation, 
leukocyte infiltration and release of eicosanoids in response to carrageenin have 
been demonstrated to be greatly enhanced in the absence of endogenous steroids 
(Parente & Flower 1985b, Flower et al 1986). Furthermore, endogenous 
corticosteroids also appear to be important for maintaining the patency of the BBB 
(Long & Holaday 1985). Since Adx rats were found to develop a more severe 
form of EAE, it may be envisaged that this was due to lack of endogenous steroids 
resulting in an enhanced inflammatory response in the CNS and that this was 
accompanied by passage of larger numbers of cells across the BBB. Thus the 
increased levels of lipocortin I in the CNS of EAE-diseased rats may simply be due 
to an increased number of infiltrating cells.
An alternative explanation arises from the effects that steroids are known to 
have on the distribution of circulating leukocytes, between the blood, lymphoid 
organs and other tissues. Administration of glucocorticoids causes
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lymphocytopenia, monocytopenia and neutrophilia (Fauci 1979). Presumably 
removal of endogenous corticosteroids may also result in some redistribution of 
these cell types. Since circulating leukocytes have been shown to contain 
significant amounts of lipocortin I (Comera et al 1989,1990, Goulding et al 1990) 
it is conceivable that adrenalectomy may cause a change in the levels of lipocortin I 
in the blood by altering the number or relative proportions of leukocytes and that 
this might be detected as an apparent increase in the CNS tissue.
In summary, if steroids do exert their anti-inflammatory effects in EAE via 
induction of lipocortins in the CNS, then it would be expected that steroid 
treatment of EAE-diseased animals might cause a further increase in lipocortins 
and that treatment with RU 38486 or adrenalectomy would cause a decrease in the 
amount of lipocortins detected in CNS tissues from these animals. No change in 
lipocortins was detected in the CNS of EAE-diseased rats following treatment with 
corticosterone or dexamethasone, suggesting that lipocortins cannot be 
upregulated by exogenous glucocorticoids. It is unfortunate that in these studies 
no effect on symptoms was observed because this would have confirmed whether 
enhanced expression of lipocortin was a pre-requisite for clinical effect. However 
measurement of serum corticosterone suggested that with respect to corticosterone 
the drug was passing into the circulation, and in the case of dexamethasone, that it 
was also probably entering the CNS, since suppression of the HPA axis was 
observed. In a study using the glucocorticoid antagonist RU 38486 no significant 
alteration in lipocortin levels was found, suggesting that endogenous 
glucocorticoids do not modulate lipocortins in the CNS in either normal or EAE- 
diseased animals. However it was not proven that glucocorticoid receptors in the 
CNS were blocked. The results of the Adx experiment are particularly interesting 
since a clear clinical effect was observed and there can be no doubt that steroid 
levels were significantly altered. Since lipocortin levels were not down regulated in
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Adx animals compared to controls this provides strong evidence that the amount of 
lipocortin in the CNS is not modulated by glucocorticoids. Furthermore, that the 
increase in lipocortin I in the CNS of EAE-diseased rats although occurring at the 
same time as, is not caused by, changes in serum corticosterone.
The steroid inducibility of lipocortins is a highly controversial subject (see 
introduction section: 1.3.3.2). The large number of studies which have 
investigated this problem have frequently produced conflicting results. There have 
been few reports on the effects of steroids on lipocortins in the CNS, but those 
which exist are not at variance with results observed in the present study. Using 
Western blotting, Smith et al. (1989b) detected no effect of Adx or dexamethasone 
treatment on the levels of lipocortins I and V either in steroid sensitive components 
of the HPA axis (adenohypophysis, hypothalamus and hippocampus) or in control 
areas (striatum and cortex) in the rat. Furthermore in a subsequent study by 
ELISA they observed no influence of the steroid on lipocortin I in specific brain 
nuclei (Smith et al. 1990c). Using immunohistochemistry to localise 
immunoreactive lipocortin I in the rat CNS, Strijbos and co-workers (1991) found 
that 2  hr peripheral administration of dexamethasone had no effect on the 
distribution of the protein in any areas or cell-types in the brain, but noted that Adx 
reduced neuronal staining in the hippocampus although no effect on any other brain 
region was detected.
Since in immunohistochemistry experiments it was found that lipocortin I 
immunoreactivity in the CNS of EAE-diseased rats is located predominantly in 
infiltrating lymphocytes and macrophages, studies on these cell-types are also 
relevant. Several workers have observed induction of lipocortins I (Wallner et al.
1986), I and II (Smillie et al. 1989b, Peers et al. 1993), and I, II and V (Solito et 
al. 1990), in rat peritoneal leukocytes following in vivo treatment with 
glucocorticoids. Furthermore it has been demonstrated that dosing animals with
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RU 38486 reduces lipocortins I and II (Smillie et al. 1989b) or reverses steroid 
induction of lipocortins I and II in these cells (Peers et al. 1993). Induction of 
lipocortin I in human peripheral blood mononuclear cells following administration 
of glucocorticoids has also been reported (Goulding et al. 1990). However there 
have been a significant number of studies where the authors have been unable to 
find induction of lipocortins by glucocorticoids in macrophages and lymphocytes in 
vitro (Northup et al. 1988, Bronnegard et al. 1988) and in vivo (Wong et al.
1991). Thus although there are no studies which are directly applicable, there are 
reports which both support and contradict results observed in the present study.
It should be noted that although no change was detected in the absolute 
amount of immunoreactive lipocortins I, II and V in CNS tissues following 
manipulation of serum corticosteroid levels, it cannot be ruled out that the 
treatments studied may have had an effect which was not detectable by the 
methods used. Western blotting is not sensitive to small changes in protein levels 
and probably would not pick up small variations in lipocortin, or a large alteration 
occurring in a small number of cells, although obviously these may be 
physiologically important. It would therefore be interesting to investigate whether 
such changes might be detected using immunohistochemistry to visualise 
lipocortins in different cell-types. Furthermore, it has recently been suggested that 
steroids may alter the subcellular localisation of lipocortins and that steroid 
treatment may cause increased expression of lipocortin on the cell surface where it 
may be biologically active (Smillie et al. 1989b, Goulding et al. 1990, Browning et 
al. 1990, Peers et al. 1993). Again this would not be detectable using Western 




Anti-inflammatory steroids are frequently used to treat acute relapse of MS 
because of their ability to hasten recovery from debilitating symptoms. These 
compounds are also effective in suppressing the animal counterpart, EAE. 
Furthermore, it appears that endogenous corticosteroids are responsible for 
mediating spontaneous recovery from EAE in the rat and there is some evidence 
that circulatory steroids may influence disease activity in MS. The mechanism 
though which steroids exert their effects in MS and EAE is unknown but steroids 
possess anti-inflammatory, anti-oedematous and immunomodulatory properties 
which potentially may all play a role in their actions in these diseases. Recently it 
has been proposed that the anti-inflammatory effects of corticosteroids may be 
mediated in part by the induction of "second messenger" proteins termed 
lipocortins. The present study has investigated whether the potential exists for 
lipocortins to play a role in the mechanism of action of steroids in MS and EAE.
The first aim of this project was to investigate the occurrence of lipocortins 
in the CNS of patients with MS and rats during EAE. Initial experiments indicated 
that CSF was not suitable for the study of lipocortins in these diseases. However, 
investigation of lipocortins in CNS tissue samples by Western blotting revealed the 
presence of immunoreactive lipocortins I, II, IV and V in normal human CNS 
tissues and lipocortins I, II and V in rat CNS samples. Furthermore, increased 
levels of all lipocortins were detected in diseased CNS tissues from MS patients 
and an elevated amount of immunoreactive lipocortin I in the CNS of rats with 
EAE. These observations indicate that the potential exists for lipocortins to be 
involved in the modulation of MS and EAE.
The second aim was to shed light on the functions of lipocortins in the CNS 
by studying the cellular localisation of these proteins. Using immunohistochemical
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techniques, lipocortin I immunoreactivity was observed to be located primarily in 
the walls of blood vessels in normal human and rat CNS tissues. The increased 
levels of lipocortin I-like protein detected in the CNS in MS and EAE by Western 
blotting, were found to be due to expression of the protein by reactive astrocytes, 
and widespread immunostaining of infiltrating lymphocytes and macrophages, 
respectively. All the cell-types in which immunoreactive lipocortin I was detected 
are known to be of central importance in the pathology of these diseases. 
Lymphocytes and macrophages are key effector cells of the immune response and 
phagocytic cells are also believed to mediate demyelination. Endothelial cells are a 
major component of the BBB which under normal circumstances maintains 
exclusion of circulating immune elements but in MS and EAE becomes permeable 
allowing passage of immunocompetent cells and humoral mediators into the CNS. 
Astrocytes too, form part of the BBB and also appear to modulate immune 
reactivity within the CNS and to mediate tissue repair following damage. Thus the 
observation of often high levels of expression of lipocortin I immunoreactivity 
within these cells suggests that the protein may play a role in the functioning of 
cells which are central to the pathology of MS and EAE. In these experiments, 
corticosterone levels in the serum of EAE-inoculated rats was also determined and 
it was found that increases in immunoreactive lipocortin I in the CNS coincided 
with changes in circulatory corticosterone, suggesting that endogenous 
corticosteroids may be causing induction of lipocortin I in the CNS during EAE.
The third aim of the present study was to explore the involvement of 
lipocortins in the mechanism of steroid action by investigating whether 
manipulation of corticosteroids in EAE-inoculated animals would induce a change 
in CNS lipocortin levels. Thus, circulating glucocorticoids were raised by 
administration of corticosterone or dexamethasone, antagonised by treatment with 
RU 38486, or abolished by Adx prior to inoculation. However corticosterone and
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dexamethasone were found to have no effect on lipocortin levels in the cervical 
spinal cord and RU 38486 and Adx did not prevent the accumulation of lipocortin 
I-like protein observed during the course of the disease. These results suggest that 
steroids do not modulate the absolute amount of lipocortins in CNS tissue, and 
furthermore, that the increase in immunoreactive lipocortin I found in the cervical 
spinal cord of EAE-diseased rats is not due to induction of the protein by 
endogenous steroids. However it is not proven that steroids had no effect on 
lipocortins as it cannot be ruled out that steroids caused a more subtle alteration in 
lipocortins which could not be detected using the techniques in this study. 
Moreover, neither do these findings prove that steroid effects are not mediated by 
lipocortins.
What is the function of lipocortins in the CNS in MS and EAE? The 
lipocortin theory states that lipocortins are steroid-inducible proteins which inhibit 
the activity of PLA2 , thus preventing generation of active arachidonic acid 
metabolites and thereby mediating the anti-inflammatory effects of steroids. Whilst 
it is possible that lipocortins may play such a role in MS and EAE, many other 
functions have been postulated for various members of the annexin family (see 
introduction section: 1.3.3) and the function of any one of these proteins has yet to 
be determined. Recently some very interesting work has emerged which is 
particularly relevant to the present study, demonstrating that lipocortin I has 
biological activity in the CNS. Intravenously administered rh lipocortin I has been 
shown to mimic the anti-pyretic effect of dexamethasone by preventing the febrile 
response to poly I:C in the rabbit (Davidson et al 1991). Furthermore, in studies 
in the rat Carey et al. (1990) have demonstrated that not only does central injection 
of a recombinant fragment (N-terminal 1-188) of lipocortin I reproduce the effect 
of dexamethasone in inhibiting cytokine-induced fever and thermogenesis, but also 
that the suppressive action of the steroid on the pyrogenic response can be
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reversed by administration of a neutralising antibody to the peptide, findings which 
suggest that lipocortin I may be a physiological mediator of the anti-pyretic actions 
of corticosteroids. Evidence has also accumulated that endogenous lipocortin I 
may be an inhibitor of oedema and protect against neuronal damage in the CNS. In 
a rodent model of cerebral ischaemia induced by occlusion of the middle cerebral 
artery, Relton etal (1991) have observed increased expression of immunoreactive 
lipocortin I around infarcted areas. In addition, these workers found that central 
injection of the 1-188 N-terminal fragment of lipocortin I reduced infarct size and 
the extent of oedema, whereas administration of neutralising antibody significantly 
potentiated ischaemic damage and oedema. Lipocortin I fragment 1-188 has also 
been shown to attenuate lesions in the rat CNS caused by NMD A receptor agonists 
and again in this model the neutralising antibody was found to increase neuronal 
damage (Black et al 1992). Taken together these studies strongly suggest a 
physiological role for lipocortins in the central actions of glucocorticoids on 
pyrogenesis and as an endogenous inhibitor of tissue damage in the brain.
Understanding the role played by lipocortins in the action of steroids in MS 
and other inflammatory diseases is of importance as it may lead to the development 
of new therapies which are free of the side effects which so frequently limit the use 
of these potent compounds. Findings in the present study suggest that steroids do 
not modulate the absolute amounts of lipocortins I, II and V in the CNS in EAE, 
which must raise a question mark over whether lipocortins do mediate the 
beneficial effects of glucocorticoids in inflammatory CNS disease. However, the 
presence of these proteins in cell-types central to the pathology of MS and EAE 
may indicate a role for lipocortins in these diseases. Further work is required to 
determine whether steroid effects are mediated by a more subtle modulation of 
lipocortins and to elucidate the function of these fascinating but elusive proteins.
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Summary
The calcium and phospholipid-binding proteins lipocortins 1, 2 and 5 have been detected, by electro­
transfer and immunoblotting techniques, in central nervous system (CNS) tissues of control Lewis rats and 
animals with experimental allergic encephalomyelitis (EAE). The cerebellum and spinal cord content of 
lipocortins 2 and 5 remained unchanged throughout the development of EAE but the amounts of the 
steroid-inducible protein lipocortin 1 increased in samples from pre-diseased and adjuvant-treated rats and 
were further enhanced in tissues from clinically sick and convalescent animals. The significance of these 
findings is discussed in conjunction with the ongoing changes in pathology which occur during the 
progression of EAE.
Introduction
Experimental allergic encephalomyelitis (EAE) 
has been extensively studied and widely used as an 
animal model of the human disabling disease mul­
tiple sclerosis (MS) (Paterson, 1976; Raine, 1984). 
Depending upon the species used and the method 
of induction, EAE can be characterised clinically 
by either acute paralytic signs or chronic relaps-
A d d ress for corresp on d en ce: C. B o lton , D ep a rtm en t o f  
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ing-remitting episodes of limb dysfunction (Las- 
mann, 1983). One feature common to models of 
the disease is the infiltration of the central nervous 
system (CNS) by inflammatory-type cells consist­
ing mainly of lymphocytes and macrophages. 
Many studies have shown that factors derived 
from cells of the lymphocyte-macrophage series 
can initiate and perpetuate the inflammatory re­
sponse (Humes et al., 1977; N athan et al., 1982; 
Geczy, 1984; Davies, 1985). In EAE, the brains 
and spinal cords of diseased animals have been 
shown to contain high levels of eicosanoids and 
lysosomal enzymes both of which may contribute 
to the increase in vascular permeability, oedema
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and demyelination observed during the course of 
the disease (Smith et al., 1974; Smith, 1979; Bol­
ton et al., 1984a, b).
One important inflammatory cell product im­
plicated in myelin breakdown and a pre-requisite 
for mediator production is the enzyme phos­
pholipase A 2 (PLA 2) (Woelk and Kanig, 1974; 
Fu et al., 1980; Trotter and Smith, 1986). Over the 
past decade much evidence has accumulated to 
show that the effects of PLA 2 may be controlled 
by the synthesis and release of glucocorticoid-in- 
ducible proteins. One such protein commanding 
particular attention is lipocortin 1, for which the 
structure has been elucidated, sequenced and 
cloned (Flower and Blackwell, 1979; Blackwell et 
al., 1980, 1982; Pepinsky et al., 1986; Wallner et 
al., 1986). Early reports on the distribution of 
lipocortin-like proteins revealed the brain and 
macrophage as prominent sources (Flower, 1988) 
and recent studies have shown an increased pres­
ence of lipocortin 1 in diseased human CNS tis­
sues to be associated with invading and resident 
macrophages (Johnson et al., 1989a, b). In ad­
dition, in vivo treatment with dexamethasone has 
been shown to raise basal levels of lipocortin 1 in 
rat brain by several fold and induce the synthesis 
and release of the protein from peritoneal and 
alveolar macrophages (Blackwell et al., 1982; 
Flower, 1984). Thus, it is evident that the potential 
exists, within the target tissues of EAE-diseased 
animals, for the control of PLA 2-mediated in­
flammation via the limiting actions of lipocortin 1, 
the levels of which may be influenced by exoge­
nous or endogenous steroids. In this study CNS 
tissues from control rats and animals in various 
stages of EAE have been assessed for the presence 
of lipocortin 1 and the structurally related lipo­
cortins 2 and 5. Possible sources of the lipocortins 
are considered and the relevance of the findings in 
relation to steroid function is discussed.
Materials and methods
Animals
Male Lewis rats (Bantin and Kingman, Hull, 
U.K.) weighing 200-250 g were used. The animals, 
housed six per cage, were maintained on Labsure 
CRM  rat diet and water ad libitum.
Induction of EAE
Two weeks were allowed for the rats to ada 
to their new environment before inoculation with 
encephalitogen. Each treatment group contained 
six animals which were injected in each hind 
footpad with 0.1 ml of an emulsion consisting 0f 
equal parts of guinea pig spinal cord, sterile phos­
phate-buffered saline (PBS) and Freund’s ..icom- 
plete adjuvant (FIA) containing 10 g 
Mycobacterium tuberculosis H 37Ra (Difco, currey 
U.K.). An equal volume of PBS was substituted 
for spinal tissue in control rats receiving Freund’s 
complete adjuvant (FCA) (equivalent to FIA plus 
mycobacteria).
Clinical evaluation of EAE
Animals were examined for clinical si ns of 
disease beginning 5 days post-inoculation (p.i.) 
and continuing for the duration of the experiment. 
Three phases in the development of EAE were 
chosen to determine the lipocortin content oi CNS 
tissues. Phase 1: 6 -7  days p.i., and coinciding with 
the presence, in target tissues, of neuroreaeiive T 
cells (Traugott et al., 1981, 1982). Phase 2 at the 
height of disease, 13-15 days p.i., and char­
acterised by complete hind limb paralysis, Dhase 
3: immediately after the total loss of neurological 
signs of EAE, 18-20 days p.i. The CNS tissues of 
rats receiving CFA alone were removed 14 days 
p.i. corresponding with the time of maximum dis­
ease intensity in EAE-inoculated animals.
Preparation of CNS tissues for immun electro­
phoretic and histological techniques
Rats were asphyxiated in carbon dioxide, ex­
sanguinated and the cerebellum and first 3 cm of 
spinal cord dissected, washed in ice-cold PBS to 
remove any excess blood and carefully blotted 
dry. CNS tissues were longitudinally bisected and 
the left side of each sample was stored in 10% 
formal saline for subsequent histolog '• Pr0" 
cessing (see below) while the remaining half was 
frozen at — 20 ° C until required.
Individual thawed tissues were cut up in 0.5 ml 
of chilled medium, pH 7.6, containing 10 m 
A -(2-hydroxyethyl)-piperazine-A  '- 2 -eitianesu 
phonic acid, sodium salt (Hepes) (Sigma), 5 m 
ethylenediaminetetraacetic acid (disodr n s a l t  j 
hydrate) (EDTA) (Sigma), 200 pM phenyl methyl-
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sulph° nyl fluor^^e (PMSF) (Sigma) and 100 mM 
0dium chloride (Sigma). In order to visualise 
lipocortin in CNS tissues, an homogenate of each 
sample was ma< e^ by equal and repeated aspira­
tion, at 4° C through a 19 and 21 gauge disposable 
needle, followed by three cycles of freeze-thawing. 
Supernatants were prepared by centrifugation of 
disrupted tissues at 30,000 X g for 30 min at 4° C. 
The protein content of each sample was de­
termined by the method of Bradford (1976), ad­
justed to 2 m g/m l and aliquots were mixed, and 
transferred to a boiling water bath for 5 min, after 
first adding an equal volume of buffer containing 
0.1 M Tris (hydroxymethyl)aminomethane/( N, 7V- 
bis[2-hydroxyethyl]glycine) (Tris/Bicine) (Sigma), 
2% sodium dodecyl sulphate (SDS) (BDH), 5% 
2 -mercaptoethanol (Fisons), 10% sucrose (BDH) 
and 0.05% bromophenol blue (BDH). Cooled sam­
ples were stored at - 2 0 ° C  until required for 
polyacrylamide gel electrophoresis (PAGE).
PAGE and electroblotting of CNS samples
PAGE was performed essentially as described 
by Laemmli (1970). Briefly, equal volumes from 
individual samples were pooled and 20 jul aliquots, 
containing 20 jag of protein, from each treatment 
were applied to SDS/polyacrylamide gels and 
constituent proteins were separated by electro­
phoresis using a ‘Mighty Small IF vertical slab gel
A
unit (Hoefer Scientific Instruments, U.S.A.). Gels 
were either stained with 0.2% PAGE blue 83 
(BDH) to visualise individual bands or subjected 
to electroblotting, using a Transphor electrophore­
sis unit (Hoefer Scientific Instruments, U.S.A.) to 
facilitate the transfer of proteins onto nitrocellu­
lose sheets.
Immunoblotting of CNS proteins with antibodies 
against lipocortins 1, 2 and 5
Following transfer, any unoccupied protein 
binding sites on the nitrocellulose membranes were 
blocked by agitation in PBS containing 3% milk 
protein plus 0.1% Tween 20. CNS proteins were 
then probed overnight with polyclonal rabbit anti­
sera directed against either human recombinant 
lipocortin 1 (code no. 842), native human lipo­
cortin 2 (code no. 774) or native rat lipocortin 5 
(code no. 890) (generously supplied by Dr. J.L. 
Browning, Biogen Research Corporation), diluted 
1 in 5000 with PBS/0.1 % Tween 20. Cross-reactiv­
ity data for the lipocortins are as stated by Pepin­
sky et al. (1988). Each lipocortin was detected by 
incubating respective blots with a 1 in 1000 dilu­
tion of goat anti-rabbit IgG conjugated to 
horseradish peroxidase (Sigma) followed by colour 
development in a solution containing 0.05% di- 
aminobenzidine hydrochloride (DAB) (Sigma) and
0.02% hydrogen peroxide (BDH).
B
1 1 6 . 0
5 8 . 0 -
3 6 . 5
2 6 . 6
.  - ,
" , • 3
.
. 1 ..............
1Lane no.  1 2  3 4 5 6
pig. 1. S D S -P A G E  o f  p o o led  sp in al cord  ( A )  an d  cereb e llu m  ( B ) su p ern atan ts from  norm al L ew is rats (la n e  2), co n tro ls  rece iv in g  
FCA (lane 3) and a n im als im m u n ised  w ith  adju van t p lu s gu in ea  p ig  sp in a l cord  b efo re  th e  o n se t  o f  E A E  (la n e  4), at the tim e o f  
paralysis (la n e  5) and  during recovery from  d isea se  (la n e  6). M olecu lar  w eigh t m arkers (la n e  1) are exp ressed  in  k D a .
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A B
L i p o c o r t i n  1
Lane no.  1 2 3 4 5 6 7  8 1 2 3 4 5 6 7  8
8 4  0
5 8 . 0
3 6 . 5
Lane no.  1 2 3 4 5 6 7  1 2 3 4 5 6 7
L i p o c o r t i n  2
Lipocortin 5
lgjj| if §J
8 4 . 0
5 8 . 0
3 6 . 5
2 6 . 6
Lane no.  1 2 3 4 5 6 7  1 2 3  4 5 6 7
F ig . 2. W estern  b lot an alysis illu stratin g  resu lts from  the se con d  o f  tw o  separate id en tica l exp erim en ts u sin g  p o o le d  su p e r n a ta n t  
from  sp inal cord s ( A ) and  cerebellu m s ( B )  o f  norm al, con tro l an d  E A E -sen sitised  rats p rob ed  w ith  an tib o d ies aga in st lip ocortin s 1 
an d  5. L ipocortin  1: lan es 1 and 8, m olecu lar  w eigh t m arkers (k D a ); la n e  2, n orm als; la n e  3, F C A -treated ; la n e  4, pre-d iseased; lane  
5, clin ica lly  d iseased; lan e 6, recovered; lan e 7 , recom b in an t h um an  lip o co rtin  1 (25 n g /im m u n o b lo t ) . L ip ocortin s 2 and  5: lanes 1 
an d  7, m olecu lar w eight m arkers (k D a); lan e 2, norm als; lan e 3, F C A -treated ; la n e  4 , pre-d iseased; la n e  5, c lin ica lly  d iseased ; lane 6 ,
recovered .
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Estimation of inflammatory infiltrates in CNS tis­
sues
Longitudinal-horizontal sections, at one stan­
dard depth, were taken from the spinal cords and 
cerebellums of control and EAE-inoculated 
animals. After staining with haematoxylin/eosin 
the number of perivascular infiltrates in each sec­
tion was determined by light microscopy.
Results
SDS-PAGE of pooled CNS supernatants from nor­
mal, control and EAE-inoculated rats
Fig. 1A and B shows that SDS-PAGE sep- 
irates pooled spinal cord and cerebellum super­
natants into constituent proteins enabling their 
ransfer onto nitrocellulose membranes for subse­
quent immunoblotting with relevant antibodies. 
Visual examination of the stained protein bands 
did not reveal any constituent differences between 
I treatments.
I Detection of lipocortins 1, 2 and 5 following electro­
transfer and immunoblotting of CNS proteins
Preliminary experiments revealed no single 
sample within any of the groups contained exces­
sively high levels of lipocortin compared to others 
in the same treatment (data not shown). Initial 
studies also showed slight variation in the inten­
sity of DAB-induced colour change when im- 
munoblots for each lipocortin were processed 
simultaneously. Therefore, pooled samples were 
used to eliminate any variation between groups 
thus enabling the true increase in lipocortin levels 
to be recorded.
Fig. 2 shows the presence of lipocortins 1, 2 
and 5 in pooled supernatants prepared from the 
upper spinal cord segments (A) and cerebellums 
f (B) of normal Lewis rats (lane 2 in each im- 
munoblot). Verification of the identity of lipo- 
: cortin 1 in samples was provided by co-migration 
I of the protein to an identical molecular weight as 
I that recorded for recombinant human lipocortin 1 
I (approximately 38 kDa, lane 7). Although no 
I standard lipocortin 2 or 5 was available for ab­
solute authentication of these proteins in samples 
the principal bands observed following incubation 
I with anti-lipocortin 2 and 5 antibodies had similar
T A B L E  1
T H E  O C C U R R E N C E  O F  P E R IV A S C U L A R  IN F IL T R A T E S  
IN  C N S  T IS S U E S  D U R I N G  T H E  C O U R S E  O F  A C U T E  
E A E
T reatm ent N u m b er o f  lesion s in se ction s cut 
at o n e standard d e p th /t is s u e  ( ±  S D )
Sp inal cord C erebellum
N orm als N D N D
F C A -treated 0 0
Pre-d iseased 0 0
C lin ica lly  d iseased 54 ± 1 3 2 ± 2
C lin ica lly  recovered 29 ± 1 0 4 ± 3
molecular weights (37 kDA and 35 kDa respec­
tively) to those reported by Pepinsky et al. (1988).
CNS tissues from animals receiving FCA ap­
peared to contain more lipocortin 1 compared to 
normals but the amounts of lipocortin 2 and 5 in 
controls did not vary (lanes 3). Indeed, no appre­
ciable differences occurrred in the lipocortin 2 or 
5 content of CNS samples from any of the treat­
ments analysed. Samples derived from spinal cords 
and cerebellums of rats immunised 6-7  days pre­
viously with adjuvant plus antigen showed a com­
parable degree of staining for lipocortin 1 (lanes 
4) to that seen in tissues from animals inoculated 
with FCA alone. Also the intensity of staining in 
cerebellum supernatants from rats with paralytic 
EAE (lane 5) was .equivalent to that observed in 
pre-diseased animals. The development of hind 
limb paralysis was characterised not only by the 
appearance of cellular lesions in the spinal cords 
of affected animals (Table 1) but also by an obvi­
ous increase in the quantity of lipocortin 1 present 
(lane 5). Recovery from clinical EAE coincided 
with a reduction in the number of inflammatory 
infiltrates in spinal tissue together with a notice­
able diminution of lipocortin 1 band intensity 
(lane 6). A slight increase in cerebellum lesion 
numbers was observed in convalescent rats and 
the tissue content of lipocortin 1 appeared aug­
mented (lane 6i compared to other treatments.
All immunoblots showed additional distinct 
bands, of unknown identity between 62 and 70 
kDa, the pattern of distribution remaining un­
changed throughout the course of EAE. It is possi­
ble that these higher molecular weight bands are 
multimers of lipocortin 1 and similar to those
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described by Ando et al. (1989) and Pepinsky et 
al. (1989). In addition, low molecular weight 
breakdown products of the lipocortins were 
minimal and, in the case of those present after 
probing with anti-lipocortin 1 antibody (ap­
proximately 33 kDa), appeared proportional to 
the intensity of the parent band.
Discussion
Results presented in this study describe the 
presence of lipocortins 1, 2 and 5 in the CNS 
tissues of normal, control and EAE-inoculated 
Lewis rats. The work also reveals, for the first 
time, that defined areas of the CNS removed from 
animals receiving CFA alone or together with 
guinea pig spinal cord contain increased quantities 
of the glucocorticoid-inducible protein lipocortin
1. Furthermore, the greatest amounts of lipocortin 
1 were detected in tissues infiltrated by inflamma­
tory cells and removed from clinically diseased or 
convalescent rats.
The lipocortins are a family of calcium and 
phospholipid-binding proteins which are capable 
of inhibiting the actions of PLA 2 in vitro and 
producing a systemic anti-inflammatory effect. 
Recent data has established the lipocortins as 
members of a wider group of proteins, collectively 
termed chromobindins, which share both func­
tional and sequence homology and act as sub­
strates for protein tyrosine kinase (Flollenberg et 
al., 1988). Although no information exists on the 
regulation of endogenous PLA2 activity by the 
lipocortins it may be that down-regulation of the 
actions of phospholipase by these proteins could 
assist in limiting the course of inflammation in 
vivo.
Characterisation of the proteins has revealed 
that lipocortins 1, 2 and 5 are structurally related 
and have approximate masses of 38 kDA, 38 kDa 
and 35 kDa respectively (Pepinsky et al., 1988) 
which compare to the molecular weights of the 
proteins detected in the current investigation. 
Knowledge of the functional properties of lipo­
cortins 1, 2 and 5 is limited to their in vitro 
biochemical activity and prominence as intrinsic 
cellular proteins (Comera et al., 1989). Interest­
ingly the levels of lipocortins 2 and 5 did not
change in CNS tissues with the progression of 
EAE suggesting that the proteins are not dramati­
cally affected by immunologically directed in­
flammatory cell invasion of target areas. In con­
trast, information on lipocortin 1 is more exter 
sive, encompassing its distribution, in vitro and in 
vivo activities and the relationship between the 
protein and steroid actions. In vitro, lipocortin 1 
has been shown to inhibit eicosanoid and lyso- 
platelet activating factor release and in vivo u, 
suppress models of pleurisy and paw oedema 
(Blackwell et al., 1982; Parente et al., 1984; Parente 
and Flower, 1985; Miele et al., 1988; Errasfa and 
Russo-Marie, 1989). Studies by Cirino and col­
leagues using human recombinant lipocortin 1 
have shown prevention of eicosanoid release from 
lung and arteriole tissue and, when administered 
locally, inhibition of irritant-induced paw swelling 
(Cirino and Flower, 1987; Cirino et al., 19C7,
1989).
To date the unequivocal demonstration of lino- 
cortin induction by steroids in every test system 
used remains elusive but many studies have shown 
increased levels of the protein in tissues, cells and 
lavage fluid following in vitro or in vivo treatment 
with the glucocorticoids (Hirata et al., 1^30; 
Flower, 1984; Errasfa et al., 1985; Lundgren e: al., 
1988; Goulding et al., 1989; Piltch et al., 1°89; 
Smith et al., 1989). The current study has shown 
an intensified presence of lipocortin 1 in cerebel­
lums and spinal cords from inoculated animals 
but without the involvement of exogenous steroids. 
Control tissue from rats receiving adjuvant aione, 
for 2 weeks, contained more lipocortin 1 than 
normal samples and similar amounts to tho: le-
tected in pre-diseased animals (Fig. 2.4 a H  B, 
lanes 2, 3 and 4). In order to offer an explanation 
for the changes in lipocortin 1 levels observed in 
these inoculated rats the effects of in vivo ex­
posure to antigen(s) and the clinical status of the 
animals at the time of sampling should be c o n s i d ­
ered. Work by Besedovsky et al. (1975) and 
Schauenstein et al. (1987) demonstrated that hir­
ing the first week following inoculation wit11 an 
antigen a significant rise in circulating gluco­
corticoids can be detected. Also, a recent and 
particularly relevant study by Mackenzie et al. 
(1989) showed that serum corticosterone in Lewis 
rats was elevated 3 -7  days after inoculation lor
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EAE. In addition, these workers found that 
animals immunised with FCA developed signifi­
cantly raised glucocorticoid levels approximately 2 
weeks p.i. It should be noted that the injection of 
FCA into Lewis and other strains of rats is known 
to cause experimental arthritis (Pearson, 1956; van 
Eden et al., 1985) with resulting stress due to 
chronic inflammation, physiological dysfunction 
and pain (De Castro Coster et al., 1981; Colpaert 
et al., 1982). Increased circulating levels of gluco­
corticoids either as a result of antigenic stimula­
tion or stress-induced changes may act similarly to 
exogenous steroids and facilitate the induction of 
lipocortin 1 synthesis. Consequently, such a re­
sponse, perhaps together with additional factors 
such as circulating cytokines, may account for the 
augmentation of lipocortin 1 in cerebellum and 
spinal cords from animals receiving adjuvant in 
the presence or absence of encephalitogen.
The development of stress as a consequence of 
EAE and the concomitant release of immunosup­
pressive quantities of corticosterone was thought 
to occur during the development of the disease 
and to be responsible for the characteristic loss of 
neurological signs (Levine et al., 1962; Levine and 
Strebel, 1969). Subsequent studies by MacPhee et 
al. (1989) and MacKenzie et al. (1989) have con­
firmed a significant increase in circulating corti­
costerone during the course of EAE and work by 
the authors (Bolton and Flower, 1989) using the 
anti-glucocorticoid RU38486 to antagonise the 
beneficial effects of endogenous steroids has pro­
vided additional information on their ability to 
‘self cure’ in rat models of EAE. The stress-in­
duced release of glucocorticoids into the systemic 
circulation of EAE-diseased rats may have similar 
effects to those generated in adjuvant-sensitised 
animals and thus cause an induction of lipocortin 
1 in the CNS and other tissues. The potential for 
additional amounts of lipocortin 1 to be present in 
cerebellum and spinal cords of sick and convales­
cent rats could be provided by a rich source of the 
protein in the form of invasive macrophages known 
to be present in perivascular lesions such as those 
quantitated in the present study. Therefore, it is 
possible that inflammatory cell-derived lipocortin 
1 in combination with an indirect induction of the 
protein, via endogenous steroids, accounts for the 
increased intensity of staining seen when examin­
ing CNS samples from animals during and after 
clinical signs of EAE (Fig. 2,4 and B, lanes 5 and 
6).
To summarise, evidence has been provided to 
show the existence of three forms of lipocortin in 
the CNS tissues from control rats and animals 
with the acute form of EAE. Although the amount 
of lipocortins 2 and 5 present in samples did not 
change with the development of disease, the quan­
tity of the steroid-inducible protein lipocortin 1 
increased in inoculated rats and was further en­
hanced in tissues removed from clinically diseased 
or recovered animals. Studies are in progress to 
identify the source of CNS lipocortins and de­
termine the effects of endogenous and exogenous 
steroids on the induction of lipocortin 1. It is 
hoped that a clearer understanding of the mecha­
nisms by which steroids exert their effects in EAE 
will be achieved together with an improvement in 
our knowledge of steroid action and therapy in 
human demyelinating diseases such as MS.
Acknowledgements
We are grateful to the Multiple Sclerosis Society 
of G reat Britain and N orthern Ireland for finan­
cial support and thank Mrs. Lesley Moore for her 
excellent technical assistance and Mrs. Helen 
Lynch for preparation of the manuscript.
References
A n d o , Y ., Im am ura, S., O w ad a, M .K ., K ak u n aga , T. and  
K a n n ag i, R . (1 9 8 9 ) C ro ss-lin k in g  o f  lip o co rtin  1 and en ­
h a n cem en t o f  its  C a 2+ se n s itiv ity  b y  tissu e  trans­
g lu ta m in a se . B ioch em . B io p h y s. R es. C o m m u n . 163, 9 4 4 -  
951 .
B e sed o v sk y , H ., Sorkin , E ., K eller , M . a n d  M uller, J. (19 7 5 )  
C h a n g es in  b lo o d  h o rm o n e  lev e ls  d u rin g  the  im m u n e re­
sp o n se . Proc. S oc . E xp. B io l. M ed . 150 , 4 6 6 -4 7 0 .
B la ck w e ll, G .J ., C a m u c c io , R ., D i R o sa , M ., F low er, R.J., 
P arente, L. and P ersico , P. (1 9 8 0 ) M acrocortin : a p o ly ­
p e p tid e  ca u sin g  th e  a n ti-p h o sp h o lip a se  e ffe c ts  o f  g lu co ­
co r tico id s. N a tu re  287, 1 4 7 -1 4 9 .
B la ck w e ll, G .J ., C a m u c c io , R ., D i R o sa , M ., F low er, R .J.,. 
L an gh am , C .S .J ., P arente, L ., P ersico , P., R u ssell-S m ith , 
N .C . a n d  S to n e , D . (1 9 8 2 ) G lu c o c o r t ic o id s  in d u ce the for­
m a tio n  a n d  release o f  a n ti- in fla m m a to ry  an d  an ti-p h os- 
p h o lip a se  p ro te in s in to  the  p er ito n ea l ca v ity  o f  the rat. Br. 
J. P harm aco l. 76 , 1 8 5 -1 9 4 .
180
B o lto n , C. an d  F low er, R .J. (1 9 8 9 ) T h e e ffe c ts  o f  the an ti-g lu ­
co co rtico id  R U 3 8 4 8 6  o n  stero id -m ed ia ted  su p p ression  o f  
exp erim en ta l allergic en cep h a lo m y e lit is  (E A E ) in  the L ew is  
rat. L ife  Sci. 45 , 9 7 -1 0 4 .
B o lto n , C ., G o rd o n , D . and T urk, J.L. (1 9 8 4 a ) A  lon g itu d in a l 
stu d y  o f  the p rostag lan d in  co n ten t o f  cen tra l n ervou s sy s­
tem  tissu es from  gu in ea  p ig s w ith  a cu te  exp erim en ta l a l­
lerg ic en cep h a lo m y elitis  (E A E ). Int. J. Im m u nop h arm . 6, 
1 5 5 -1 6 1 .
B o lto n , C ., G o rd o n , D . an d  T urk, J.L. (1 9 8 4 b ) P rostag lan d in  
and  th rom b oxan e levels in  centra l n ervou s system  tissu es  
from  rats d uring the in d u c tio n  and d ev e lo p m en t o f  exp eri­
m en ta l a llerg ic  en cep h a lo m y elitis  (E A E ). Im m u nop h ar-  
m a co lo g y  7, 1 0 1 -1 0 7 .
B radford , M .M . (1976) A  rap id  and se n s itiv e  m eth o d  for the  
q u an tita tio n  o f  m icrogram  q u a n tities  o f  p ro te in  u tiliz in g  
the p rin cip le  o f  p ro te in -d y e  b in d in g . A n a l. B ioch em . 72, 
2 4 8 -2 5 4 .
C ir in o , G . an d  F low er, R.J. (1 9 8 7 ) H u m a n  reco m b in a n t lip o ­
cortin  1 in h ib its  p rosta cy c lin  p ro d u ctio n  b y  hum an u m b ili­
ca l artery in  vitro. P rostag lan d in s 34 , 5 9 - 6 2 .
C ir in o , G ., F low er, R .J., B row nin g , J .L ., S incla ir, L .K . and  
P ep insky , R .B . (1 9 8 7 ) R eco m b in a n t h u m a n  lip o co rtin  1 
in h ib its  th rom b oxan e re lease  from  g u in ea  p ig  iso la ted  per­
fu sed  lung. N a tu re  328, 2 7 0 -2 7 2 .
C ir in o , G ., P eers, S .H ., F low er, R .J., B row nin g , J.L. an d  P ep in ­
sky, R .B . (1 9 8 9 ) H u m an  recom b in an t lip o co rtin  1 h as acute  
lo ca l a n ti-in flam m atory  prop erties in  the rat paw  ed em a  
test. Proc. N a tl. A cad . Sci. U .S .A . 86 , 3 4 2 8 -3 4 3 2 .
C o lp aert, F .C ., M eert, T ., D e  V iltie , P. an d  S ch m itt, P. (1 9 8 2 )  
F urther ev id en ce  va lid a tin g  adjuvant arthritis as an  exp eri­
m en ta l m o d e l o f  ch ron ic  p a in  in  the rat. L ife  Sci. 31, 6 7 - 7 5 .
C om era , C ., R oth hu t, B ., C avad ore, J .C ., V ilgrain , I., C och et,
C ., C ham baz, E. and R u sso -M arie , R . (1 9 8 9 ) F urther char­
acterisa tion  o f  four lip o co r tin s from  h u m an  peripheral 
b lo o d  m o n on u clear  cells. J. C ell. B ioch em . 40 , 3 6 1 -3 7 0 .
D a v ies , P. (1 9 8 5 ) M acrop h ages as e ffe c to r  ce lls . F ed . Proc. 44, 
2 9 2 5 -2 9 2 6 .
D e  C astro  C osta , M ., D e  Sutter, P ., G y b e ls , J. and  van  H ees , J. 
(1 9 8 1 ) A d ju van t-in d u ced  arthritis in  rats: a p o ss ib le  an im al 
m od el o f  ch ron ic  p a in . P ain  10, 1 7 3 -1 8 5 .
E rrasfa, M . an d  R u sso -M arie , F . (1 9 8 9 ) A  p u rified  lip o co rtin  
shares the an ti-in fla m m a to ry  e ffe ct o f  g lu co co rtico stero id s  
in  v iv o  in  m ice. Br. J. P harm acol. 97 , 1 0 5 1 -1 0 5 8 .
E rrasfa, M ., R oth hu t, B ., F rad in , A ., B iu llard on , C ., Junien , 
J.L ., Bure, J. and  R u sso -M arie , F . (1 9 8 5 )  T h e  p resen ce  o f  
lip o co rtin  in  h u m an  em b ry o n ic  sk in  fib ro b la sts  and  its  
regu lation  b y  an ti-in fla m m a to ry  stero id s . B ioch im . B io- 
p h ys. A cta  847, 2 4 7 -2 5 4 .
F lo w er , R.J. (1 9 8 4 ) M a crocortin  and th e  a n ti-p h o sp h o lip a se  
p rotein s. In: G . W eissm a n n  (E d .), A d v a n c e s  in  In flam m a­
tio n  R esearch , R aven  Press, N e w  Y ork , pp . 1 - 3 3 .
F lo w er , R.J. (1 9 8 8 ) L ip ocortin  an d  the m ech a n ism  o f  a c tio n  o f  
th e  g lu cocortico id s. Br. J. P harm acol. 94 , 9 8 7 -1 0 1 5 .
F lo w er , R.J. an d  B lack w ell, G .J . (1 9 7 9 ) A n ti-in fla m m a to ry  
stero id s in d u c e  b io sy n th esis  o f  a p h o sp h o lip a se  A 2 in h ib i­
tor w hich  preven ts p rosta g la n d in  g en era tio n . N a tu re  278, 
4 5 6 -4 5 9 .
F u , S .C ., M ozzi, R ., K rakow ka, S., H ig g in s, R .J. an d  H orrocks,
L .A . (1 9 8 0 ) P la sm a lo g en a se  and  p h o sp h o lip a se  A b A 2 and  
Lj a c tiv itie s  in  w h ite  m atter  in  ca n in e  d istem p er v iru s-asso­
c ia ted  d em y e lin a tin g  en cep h a lo m y e lit is . A cta  N eu ro p a th o l  
49 , 1 3 -1 8 .
G eczy , C .L . (1 9 8 4 ) T h e  role o f  ly m p h o k in es in  d elayed -typ e  
h yp ersen sitiv ity  reaction s. Springer S em in . Im m u n op ath o l  
7, 3 2 1 -3 4 6 .
G o u ld in g , N .J ., G o d o lp h in , J .L ., S am p so n , M .B ., M ad d ison  
P.J. an d  F lo w er , R.J. (1 9 8 9 ) H y d ro co r tiso n e  in d u ces lip o ­
cortin  1 p ro d u ctio n  b y  periphera l b lo o d  m o n o n u clea r  cells  
in  v iv o  in  m an. T rans. B ioch em . Soc. ( in  press).
H irata , F ., S ch iffm a n , D ., V en k atasu b ram an ian , K ., S alom on ,
D . an d  A x e lro d , J .A . (1 9 8 0 ) P h o sp h o lip a se  A 2 inh ib itory  
p ro te in  in  rabb it n eu tro p h ils  in d u ced  b y  g lu cocortico id s. 
Proc. N a tl. A ca d . Sci. U .S .A . 77 , 2 5 3 3 -2 5 3 6 .
H o llen b erg , M .D ., V a len tin e -B rau n , K .A . an d  N o rth u p , J.K.
(1 9 8 8 ) P rote in  tyrosin e  k in a se  substrates: R o se tta  S ton es or 
sim p ly  structural e lem en ts?  T ren ds P harm acol. Sci. 9, 6 3 -  
66 .
H u m es, J .L ., B on n ey , R .J., P elus, L., D ah lgren , M .E ., Sadow  
sk i, S .J., K u eh l, F .A . and D a v ie s , P. (1 9 7 7 ) M acrophages  
sy n th esise  an d  release p ro sta g la n d in s in  resp on se  to  in ­
f la m m a to ry  stim uli. N a tu re  269 , 1 4 9 -1 5 1 .
J o h n so n , M .D ., K am so-P ratt, J .M ., W h etse ll, W .O . an d  P ep in ­
sky, B. (1 9 8 9 a ) L ip ocortin -1  im m u n o rea ctiv ity  in  the nor­
m al h u m a n  cen tra l n ervou s sy stem  an d  le s io n s  w ith  astro- 
cy to sis . A m . J. C lin . P ath ol. 92 , 4 2 4 -4 2 9 .
J o h n so n , M .D ., K am so-P ratt, J., P ep in sk y , R .B . an d  W hetsell, 
W .O . (1 9 8 9 b ) L ip ocortin -1  im m u n o rea ctiv ity  in  centra l and 
p erip h era l n erv o u s system  g lia l tum ours. H u m . P athol. 20, 
7 7 2 -7 7 6 .
L a em m li, U .K . (1 9 7 0 ) C leavage o f  structural p ro te in s during  
the a ssem b ly  o f  the head  o f  b a cter io p h a g e  T4. N a tu re  227, 
6 8 0 -6 8 5 .
L assm an n , H . (1 9 8 3 ) C h ron ic  re lap sin g  exp er im en ta l allerH c  
en cep h a lo m y e lit is:  its v a lu e  as an  ex p er im en ta l m od e l for 
m u ltip le  sc lerosis . J. N eu ro l. 229 , 2 0 7 -2 2 0 .
L ev in e , S. an d  S trebel, R . (1 9 6 9 ) A llerg ic  en cep h a lom yeli 
in h ib it io n  o f  ce llu lar  p a ss iv e  transfer b y  e x o g en o u s and 
e n d o g e n o u s stero id s. E xp er ien tia  25 , 1 8 9 -1 9 1 .
L ev in e, S., S trebel, R ., W enk , E.J. an d  H arm an , P.J. (19^2; 
S u p press io n  o f  exp er im en ta l a llerg ic  en cep h a lo m y elitis  
stress. Proc. S oc. E xp . B iol. M ed . 109 , 2 9 4 -2 9 8 .
L u n d gren , J .D ., H irata , F ., M aron , Z ., L ogu n , C ., S teel, , 
K alin er , M . an d  Sh elh am er, J. (1 9 8 8 ) D ex a m eth a so n e  
h ib its  resp iratory  g ly co co n ju g a te  secretio n  from  fe lin e  air­
w a y s in  v itro  b y  the in d u c tio n  o f  lip o co r tin  (lip om od u lu i)  
sy n th esis . A m . R ev . R esp ir . D is . 37 , 3 5 3 -3 5 7 .
M a ck en zie , F .J ., L eonard , J.P . an d  C uzner, M .L . (1 9 8 °)  
C h a n g es in  ly m p h o cy te  ^ -ad ren erg ic  receptor  d en sity  and 
n ora d ren a lin e  co n ten t o f  the sp leen  are early  in d ica tors o f  
im m u n e reactiv ity  in  a cu te  exp er im en ta l a llerg ic encep  
lo m y e lit is  in  the L ew is rat. J. N eu ro im m u n o l. 23 , 9 3 -1 0 0
M a cP h ee , I .A .M ., A n to n i, F .A . an d  M a so n , D .W . (1989) 
S p o n ta n eo u s recovery  o f  rats from  exp er im en ta l allergic  
en cep h a lo m y e lit is  is  d ep en d en t o n  reg u la tio n  o f  the i" 
m u n e sy stem  b y  en d o g e n o u s adren al corticostero id s . J 
E xp. M ed . 169 , 4 3 1 -4 4 5 .
M ie le , L ., C o rd e lia -M ie le , E ., F a cch ia n o , A . and  M u k h eijee,
181
A .B . (1988) N o v e l anti-in flam m atory  p ep tid es from  the 
region o f  h ighest sim ilarity  b etw een  u teroglob in  and lip o ­
cortin  1. N atu re  335, 7 2 6 -7 3 0 .
N ath an , C .F ., M urray, H .W . and C ohn , Z .A . (1982) T he m ac­
rophage as an e ffector  cell. N e w  Engl. J. M ed . 303, 
6 2 2 -6 2 6 .
Parente, L. and  F low er, R.J. (1985) H yd rocortison e and m ac- 
rocortin  in h ib it the zym osan -ind u ced  release o f  ly so -P A F  
from  rat p eritoneal leucocytes. L ife Sci. 36, 1 2 2 5 -1 2 3 1 .
Parente, L., D i R osa, M ., F low er, R .J., G hiara, P., M eli, R ., 
Persico, P., Salm on , J.A. and W ood , J .N . (1984) R ela tio n ­
sh ips betw een  the an ti-p h osp h olip ase  and a n ti-in flam m a­
tory e ffects o f  g lu cocortico id -in d u ced  proteins. Eur. J. 
Pharm acol. 99, 2 3 3 -2 3 9 .
Paterson, P .Y . (1976) E xperim ental au to im m un e (a llergic) en ­
cep h alom yelitis: in d uction , p a th ogen esis and  suppression . 
In: P .A . M iescher and J.K . M ueller-E berhard  (E ds.), 
T extb ook  o f  Im m u nop ath ology , G rune and Stratton , N ew  
Y ork, pp. 1 7 9 -2 1 3 .
Pearson, C .M . (1956) D evelop m en t o f  arthritis, periarthritis 
and periostitis in rats given adjuvants. Proc. Soc. Exp. B iol. 
M ed. 91, 9 5 -1 0 1 .
Pepinsky, R .B ., Sinclair, L .K ., Brow ning, J.L ., M attaliano, 
R .J., Sm art, J.E., C how , E .P ., F a lb el, T ., R ib o lin i, A ., 
G arw in , J. and W allner, B.P . (1986) P urification  and partial 
sequ en ce analysis o f  a 3 7 K D a  protein  that in h ib its p h o s­
p h olipase  A  2 activ ity  from  rat periton ea l exudates. J. Biol. 
C hem . 261, 4 2 3 9 -4 2 4 6 .
Pepinsky, R .B ., T izard, R ., M atta lian o , R.J., S inclair, L .K ., 
M iller, G .T ., B row ning, J.L., P ingchang C how , E., B u m e, 
C., H uang, S .K ., Pratt, D ., W achter, L., H ession , C ., Frey,
A .Z . and W allner, B.P. (1988) F ive  d istin ct ca lciu m  and  
p h osp h o lip id  b in d in g  proteins share h o m o lo g y  w ith  lip o ­
cortin  1. J. B iol. C hem . 263, 1 0 7 9 9 -1 0 8 1 1 .
P epinsky, R .B ., S inclair, L .K ., C how , E.P. and O ’B rine-G reco,
B. (1989) A  d im eric form  o f  lipocortin -1  in hum an p lacenta . 
B iochem . J. 263, 9 7 -1 0 3 .
P iltch , A ., Sun, L., F ava , R .A . and H ayash i, J. (1989) L ipo- 
cortin -in d ep en d en t effect o f  d exam eth ason e on  p h o sp h o li­
p ase activ ity  in a thym ic ep ithelia l cell line. B iochem . J. 
261, 3 9 5 -4 0 0 .
R aine, C .S. (1984) A n a lysis o f  au to im m un e d em yelination : its 
im pact u p on  m ultip le  sclerosis. Lab. Invest. 50, 6 0 8 -6 1 3 .
Sch au en stein , K ., F assler, R ., D ietrich , H ., Schw arz, S., K rom er, 
G . and W ick , G . (1 9 8 7 ) D istu rb ed  im m u n e-en d o c r in e  co m ­
m un ica tion  in a u to im m u n e d isease. Lack o f  corticosteron e  
resp onse to  im m u n e signals in ob ese  strain  ch ick en s w ith  
sp on ta n eo u s au to im m u n e thyroid itis. J. Im m unol. 139, 
1 8 3 0 -1 8 3 3 .
Sm ith , M .E . (1979) N eu tra l protease activ ity  in  lym p h ocytes o f  
L ew is rats w ith  acu te experim ental allergic en cep h a lom yeli­
tis. N eu roch em . R es. 23, 6 8 9 -7 0 2 .
Sm ith , M .E ., Sed gew ick , L .M . and T agg, J.S. (1974) P roteo lytic  
en zym es and exp erim en ta l d em yelin a tion  in the rat and  
m onkey . J. N eu ro ch em . 23, 9 6 5 -9 7 1 .
Sm ith , S .F ., G o u ld in g , N .J ., T etley , T .D ., G o d o lp h in , J.L., 
G uz, A . and  F low er, R.J. (1989) A  p ossib le  a n ti-in flam m a­
tory m ech an ism  for g lu cocortico id s in  the hum an lung. 
C lin. Sci. 76, 20P .
T raugott, U ., S hevach , E., C hiba, J., S ton e, S .H . and R aine, 
C.S. (1981) A u to im m u n e en cep h alom yelitis: sim u ltan eou s  
id en tifica tion  o f  T - and  B -cells in target organ. Scien ce  214, 
1 2 5 1 -1 2 5 2 .
T raugott, U ., S hevach , E., C hiba, J., S ton e, S .H . and  R aine,
C .S. (1982) A cu te  exp erim en ta l a u to im m u n e en cep h a lom y­
elitis: T- and  B -cell d istr ib u tion  w ith in  the target organ. 
C ell. Im m u nol. 70, 3 4 5 -3 5 6 .
Trotter, J. and  Sm ith , M .E . (1986) T h e role o f  p h o sp h o lip ases  
from  in flam m atory  m acrophages in  d em yelina tion . N e u r o ­
chem . R es. 11, 3 4 9 -3 6 1 .
van  E den , W ., H o lo sh itz , J., N ev o , Z ., F renkel, A ., K lajm an , A . 
and C ohen , I.R . (1985) A rthritis in d uced  b y  a T -lym ph o-  
cy te  c lo n e  that resp on d s to  M ycobacteriu m  tuberculosis  and  
to  cartilage p roteog lycan s. Proc. N a tl. A cad . Sci. U .S .A . 82, 
5 1 1 7 -5 1 2 0 .
W allner, B .P., M atta lia n o , R.J., H ession , C ., C ate, R .L ., T izard, 
R ., S inclair, L .K ., F oeller, C ., P ingchang C how , E., B row n­
ing, J.L., R am achandran, K .L . and P ep insky, R .B . (1986)  
C lon in g  and  exp ression  o f hum an lip ocortin , a p h o sp h o li­
p ase  A  2 in h ib itor  w ith  p oten tia l an ti-in flam m atory  activ ity . 
N a tu re  320, 7 7 -8 1 .
W oelk , H . and K an ig , K . (1974) P h osp h o lip id  m etab o lism  in  
exp erim en ta l allergic en cep h alom yelitis: activ ity  o f  brain  
p h o sp h o lip a se  A , tow ards sp ec ifica lly  lab elled  g lycerop h os-  
p h o lip id s. J. N eu ro ch em . 23, 7 4 5 -7 5 0 .
Jou rn al o f  N euro im m unology, 39 (1 9 9 2 ) 9 1 -1 0 0
©  1992 E lsev ier  S c ien ce  P ub lishers B .V . A ll rights reserved  0 1 6 5 -5 7 2 8 /9 2 /$ 0 5 .0 0
91
JN I 02202
Lipocortins (annexins) 1, 2, 4 and 5 are increased in the central 
nervous system in m ultiple sclerosis
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Summary
W estern blotting and densitom etry have been used to investigate the lipocortin content of post-m ortem  
central nervous system (CNS) tissue samples from m ultiple sclerosis (MS) patients and norm al controls. 
Lipocortins 1, 2, 4 and 5 were all detected in normal control grey and white m atter. In white m atter 
samples from MS patients these lipocortins were found to be significantly increased, a fu rther elevation 
in lipocortin content was observed in MS plaque tissue. The implications of these findings with respect to 
the role of these proteins in inflammatory CNS disease and a possible mechanism of steroid action in the 
therapy of MS are discussed.
Introduction
MS is a chronic inflammatory and demyelinat- 
ing disease of the CNS which may be immunolog- 
ically m ediated. The disease is characterized by 
the presence in the CNS of dissem inated de- 
m yelinating lesions with perivascular infiltrates 
composed of m acrophages, lymphocytes and 
plasm a cells which may am algam ate to form 
plaques (Prineas and W right, 1978). Studies have 
dem onstrated the presence of oedem a, in tra the­
cal synthesis of IgG, abnorm alities in T-cell sub-
C o rre sp o n d en ce  to: C. B o lton , S ch oo l o f  Pharm acy and Phar­
m acology , U n iversity  o f  B ath , C laverton  D o w n , B ath B A 2  
7 A Y , U K .
set ratios, and enhanced expression of M HC anti­
gens and cytokines in the CNS of MS patients 
(W aksman, 1989). In addition, increased levels of 
pro-inflam m atory enzymes such as phospholipase 
A 2 (P L A 2) (Woelk and Peiler-Ichikawa, 1974; 
T ro tter and Smith, 1986) and P L A 2-derived 
ecosanoid m ediators (Rosnowska et al., 1981; 
Bolton et al., 1984) have been observed in MS 
plaques and cerebrospinal fluid. Such findings 
are indicative of ongoing inflammatory and im­
m une responses and may suggest dysregulation of 
these mechanisms.
Anti-inflam m atory steroids have been shown 
to be beneficial in the treatm ent of early acute 
relapse of MS. Several studies have dem onstrated 
that steroid therapy reduces the severity and du­
ration of disease exacerbation (Goas et al., 1983;
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Compston et al., 1987). Although steroids reduce 
CNS oedema and modify various immunological 
abnormalities present in MS (Troiano et al., 1987) 
their precise mode of action is unknown. Con­
ceivably their anti-inflammatory, anti-oedem atous 
and immunomodulatory actions may all play a 
role in suppression of the disease.
It was proposed independently by several 
groups that the anti-inflammatory actions of the 
glucocorticoids are effected via the induction of 
m ediator proteins which inhibit the activity of 
PL A 2 and were eventually named lipocortins (Di 
Rosa et al., 1984). At present six lipocortins have 
been identified (Pepinsky et al., 1988) and they 
are now recognised to be members of a larger 
family of structurally homologous, calcium- and 
phospholipid-binding proteins, term ed the annex- 
ins (Crumpton and Dedm an, 1990). With respect 
to their proposed function as glucocorticoid sec­
ond messengers the most widely studied of these 
proteins is lipocortin 1. Many studies have 
dem onstrated induction of lipocortin 1 following 
in vitro or in vivo treatm ent with glucocorticoids 
(Smillie et al., 1989; Goulding et al., 1990; Brown­
ing et al., 1990; Ambrose and Hunninghake, 1990; 
Solito et al., 1990), although it has not been 
demonstrable in all systems studied (N orthup et 
ah, 1988; Bronnegard et ah, 1988) and the steroid 
inducibility of lipocortins 2 and 5 has yet to be 
established (Parente et ah, 1990; Solito et ah, 
1990).
Inhibition of P L A 2 by lipocortins was observed 
in many early studies (Flower, 1988) and although 
the mechanism has become controversial (David­
son et ah, 1987), lipocortins have been dem on­
strated to have anti-inflam matory actions both in 
vitro and in vivo. In vitro lipocortin 1 has been 
shown to inhibit release of ecosanoids from 
leukocytes, guinea-pig perfused lung and human 
umbilical artery preparations (Parente et ah, 1984; 
Cirino et ah, 1987; Cirino and Flower, 1987) and 
to reduce superoxide generation by activated 
phagocytes (Stevens et ah, 1988; M aridonneau- 
Parini et ah, 1989). In vivo lipocortin 1 suppresses 
some animal models of inflammation, including 
carrageenin-induced pleurisy and carrageenin- 
and PL A 2-induced paw oedem a (Blackwell et ah, 
1982; Cirino et ah, 1989). Lipocortin 1 also ap­
pears to have powerful effects in the CNS, such
as inhibition of experimentally induced fever 
(Carey et ah, 1990; Davidson et ah, 1991) and 
prevention of ischaemic (Relton et ah, 1991) and 
chemically induced (Black et ah, 1991) neuronai 
damage. Recently recom binant human lipocortin 
2 has also been shown to possess anti-phospholi- 
pase and anti-inflammatory activity (Parente et 
ah, 1990).
There is much evidence to suggest that 
lipocortins have the ability to regulate powerful 
and potentially damaging inflammatory mecha­
nisms. Thus these proteins may be endogenous 
regulatory molecules, and in inflammatory dis­
ease states such as MS steroid therapy may re­
duce inflammation by stim ulating lipocortin pro 
duction and thus down regulating P L A 2 activitv 
In this study we have investigated the distribution 
of lipocortins 1, 2, 4 and 5 in post-m ortem  CNS 
tissues from MS patients and control cases in an 
attem pt to elucidate the potential role played uy 




Coded samples of post-m ortem  brain anJ 
spinal cord from six control cases without neu 
logical disease and seven cases of MS were ob­
tained from the M ultiple Sclerosis Society Tissue 
Bank at the Institute of Neurology, London. Clin­
ical diagnosis of MS was confirmed by routine 
histological staining with haematoxylin, eosin and 
oil red O. The average age of the MS p a tie n t 
was 50 years (range, 33-74 years) and the du 
tion of clinical disease 18 years (range 9 month' 
49 years). The mean interval between death and 
freezing was 41 h (range 27-82 h). Control cases 
had an average age of 38 years (range 20- dO 
years) and a mean death to freezing interval of /0  
h (range 9-33 h). Medical records indicated thai 
none of the patients had received steroid tre.. 
m ent within two years of death.
Small blocks of tissue were dissected from the 
MS cases to provide samples of: grey matter, 
plaque without white m atter, macroscopically 
norm al-appearing white m atter adjacent to 
plaques and apparently uninvolved white mattei
rem ote from plaque areas. Four of the plaques 
exhibited perivenular inflam m ation, hypercellu- 
larity and m acrophages containing oil red O-posi- 
tive degenerating myelin and these were consid­
ered to be actively dem yelinating lesions. Two 
hypocellular oil red O-negative dem yelinated 
plaques were classified as chronic plaques. No 
positive oil red O staining or myelin loss was 
detected  microscopically in the MS white m atter 
samples. Control samples of white and grey m at­
ter were obtained by dissection from correspond­
ing areas of brain and spinal cord of normal 
controls. In all, 35 sam ples of 100 mg each were 
stored at — 70°C until use.
Preparation o f  tissues fo r  sodium dodecyl sul- 
phate-polyacrylamide gel electrophoresis (SDS- 
PAG E)
Each tissue sample was added to 0.5 ml of 
chilled hom ogenisation medium  comprising 10 
mM Hepes ( iV-(2-hydroxyethyl) piperazine-./V'-2- 
e thanesulphonic acid, sodium salt, Sigma), 5 mM 
E D T A  (ethylenediam ine tetraacetic  acid, di­
sodium salt, dihydrate, Sigma), 100 mM sodium 
chloride (Sigma) and 200 p.M  phenylmethyl- 
sulphonyl fluoride (Sigma) pH 7.6. Samples were 
chopped using scissors and then hom ogenised on 
ice by repeated  passage through 19 and 21 gauge 
needles. The hom ogenates were then f re e z e /  
thaw ed twice and centrifuged at 15 000 X g for 30 
min at 4°C. Supernatants were collected, assayed 
for total protein by the m ethod of Bradford (1976) 
and diluted to 2 m g /m l protein with hom ogenisa­
tion medium. The diluted supernatan ts were then 
mixed in the ratio 1 :1  with a sample buffer 
comprising 0.1 M T ris /B ic in e  (Tris(hydroxy- 
m ethyl)am inoethane/7V , /V-bis[2-hydroxyethyl]gly- 
cine, Sigma), 2% sodium dodecyl sulphate (BDH), 
5%  2-m ercaptoethanol (Fisons), 10% sucrose 
(B D H ) and 0.05% brom ophenol blue (BDH), 
heated  in a boiling w ater bath for 5 min and 
stored at -  20°C prior to SD S-PAG E.
Detection o f  lipocortins by SD S-PAG E and im ­
munoblotting
C onstituent proteins were separated  by SDS- 
PA G E  essentially as described by Laemmli (1970) 
using a ‘Mighty Small II’ vertical slab gel unit 
(H oefer Scientific Instrum ents, USA). Prepared 
supernatan ts containing 5, 10 or 20 p g  protein
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were run on 10% acrylam ide/0 .26%  bisacryl- 
am ide (BD H ) resolving gels with 7.5% acryl- 
am id e /0 .2 %  bisacrylamide stacking gels, for ap­
proxim ately 1 h at 35 m A /g e l. Separated  pro­
teins were electrophoretically transferred  to 0.45- 
fim  nitrocellulose m em branes (Schleicher & 
Schuell, G erm any) by the m ethod of Towbin et 
al. (1979) using a T ransphor electrophoresis unit 
(H oefer Scientific Instrum ents, USA) at 80 V for 
1 h.
Lipocortins were visualised using a modified 
version of the m ethods of De Bias and Cherwin- 
ski (1983) and Frazer and W isdom (1985). Follow­
ing protein transfer the nitrocellulose m em branes 
were incubated for 1 h with 3% milk powder in 
phosphate-buffered saline (PBS) containing 0.1% 
Tw een 20 (PBS-Tween) to block rem aining pro­
tein binding sites. The m em branes were then 
probed overnight in PBS-Tween with a 1:5000 
dilution of rabbit antisera raised against one of 
the following: recom binant hum an lipocortin 1 
(code no. 842), native hum an lipocortin 2 (code 
no. 774), native bovine lipocortin 4 (code no. 179) 
or native rat lipocortin 5 (code no. 890). All 
antisera were generously supplied by Dr. J.L. 
Browning, Biogen Research C orporation, USA. 
Cross-reactivity data  for these antibodies are 
stated  in Pepinsky et al. (1988). A fter washing 
twice for 15 min in PBS-Tween the m em branes 
were incubated for 1 h with goat anti-rabbit IgG 
(Sigma) diluted 1 :500 in PBS-Tween, then 
washed again and incubated for 1 h with a 
1 :10000  dilution of rabbit peroxidase-anti-per­
oxidase complex (Sigma). Following two further 
washing steps first in PBS-Tween and then in 
PBS, the blots were incubated for 10 min with a 
solution containing 0.05% 3,3'-diam inobenzidine 
tetrahydrochloride (Sigma), 0.01% ammonium 
nickel sulphate (Fisons) and 0.01% cobalt chlo­
ride (Sigma) in PBS. The m em branes were then 
transferred  to an identical solution containing in 
addition 0.01% H 20 2, incubated until the colour 
was fully developed and then w ashed in distilled 
w ater. All incubations were perform ed at room 
tem perature.
Densitometry o f  immunoblots
In order to provide a sem i-quantitative assess­
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Fig. 1. W estern  b lo ts o f  M S and control p ost-m ortem  C N S  tissu es p robed  for lip ocortin s 1, 2, 4 and  5. S u p ern atan ts from  C'NS 
h o m o g en a tes w ere  lo a d ed  at a to ta l protein  co n cen tra tion  per lan e of: 5 fxg for lip ocortin s 1 and  5, 10 /xg  for lip ocortin  4 and 20 ' 
for lipocortin  2. R eco m b in a n t hum an lipocortin  1 standard  w as a p p lied  at 25 ng per lane. M W M , S igm a p resta in ed  m olecu lar mass
m arkers.
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m easured using a Joyce-Loebl Chromoscan 3. 
Results were expressed as integral values and 
following log transform ation to stabilize the vari­
ance, were analysed by One Way Analysis of 
V ariance. For com parison of white m atter sub- 
types three orthogonal contrasts were fitted: con­
trol versus all MS white m atter sub-types, rem ote 
MS white m atter versus plaque and adjacent white 
m atter, and adjacent white m atter versus plaque.
Results
Representative W estern blots of MS and con­
trol CNS tissues are shown in Fig. 1. In total 35 
samples were assayed, with 5 -7  samples per 
group. For clarity only three samples from each 
group are shown, although all 35 were quantified 
by densitometry. From  Fig. 1 it can be seen that 
lipocortins 1, 2, 4 and 5 are present in both the 
grey and the white m atter of normal control 
subjects. The m olecular masses of imm unoreac- 
tive proteins were estim ated from a calibration 
curve constructed using Sigma prestained m olec­
ular mass m arkers. On blots probed for lipocortin 
1 three distinct bands of 37, 35 and 33 kDa were 
consistently detected  in alm ost all samples. The 
m olecular mass of the 37 kDa band is concordant 
with that reported  for lipocortin 1 (Pepinsky et
al., 1988) and further confirm ation of the identity 
of this band was provided by its co-m igration with 
recom binant hum an lipocortin 1 standard. In ad­
dition to the presence in CNS samples of 35- and 
33-kDa bands, a small am ount of immunoreactive 
33-kDa protein was also observed to be contam i­
nating the lipocortin 1 standard . These lower 
m olecular mass species have been observed by 
other workers and appear to be degradation 
products of lipocortin 1 (H uang et al., 1987; Smith 
et al., 1990a; Ambrose and H unninghake, 1990). 
Following sem iquantitation of the blots by 
densito-m etry, a prelim inary Two Way Analysis 
of Variance including these bands as a second 
factor showed there was no difference between 
any of the groups in the proportion of protein in 
each band (data not shown). Furtherm ore plots 
of protein level against death  to freezing time for 
each group showed no indication of a relation­
ship between protein concentration and death to 
freezing interval (data not shown).
Several bands betw een 30 and 37 kDa were 
observed on blots probed for lipocortin 2 and 
there was some cross-reactivity of this antibody 
with lipocortin 1, although the major band had a 
m olecular mass of 35 kDa. The identity of this 
band as lipocortin 2 was later substantiated using 
a m ore specific antibody, code no. Ab 1, gener­
ously supplied by Dr. L. Parente, Sclavo, Italy
T A B L E  1
D E N S IT O M E T E R  V A L U E S  F O R  W E S T E R N  B L O T S  O F  M S A N D  C O N T R O L  C N S  T IS S U E S  P R O B E D  F O R  
L IP O C O R T IN S  1, 2, 4  A N D  5
T h e  d en sity  o f  im m u n ob lo t b an d s w as a ssessed  using a J o y ce-L o eb l C h rom oscan  3. R esu lts  are ex p ressed  as m ean  integral ±  S D . 
F or sta tistica l analysis the data  w ere  log  tran sform ed  to  stab ilize  the varian ce and an alysed  by O n e W ay A n a ly sis  o f  V arian ce. 
T h re e  orth o g o n a l con trasts w ere  fitted  for com p arison  o f  w h ite  m atter su b -typ es
T issu e n L ipocortin
1 2 4 5
W h ite  m atter C ontrol 7 865 +  247 981 ±  635 109 + 57 915 ±  272
M S -rem o te  from  p laq u e 6 2 5 5 1  ±  1 3 8 7 ) 1 822  ± 1 1 1 1  ) 468  +  399  ) 1243  +  1 8 4 )
M S -adjacen t to  p laq u e 5 2 5 8 5  +  1 111 > * * *  2 771 + O n * * * f a 4 8 6 +  168 c ' * * 1 356  ±  428 > *
M S -p laq u e 6 2 8 4 2 +  1 3 0 8  j 3 086  + 438 ) /  689 +  548  ) 1 530  ±  703 )
G rey m atter C ontrol 5 8 3 0 +  276 435 + 318 78 + 23 662 +  318
M S 6 841 ±  353 612  + 378 132 + 44  b 7 0 7 +  188
* P  <  0.05; * *  P  <  0 .02; * * *  P  <  0.001 for all M S w h ite  m atter su b -typ es versu s con tro l. 
a P  <  0 .02  M S w h ite  m atter  rem o te  from  p laq ue versu s p laq ue and adjacent w h ite  m atter. 
b P  <  0 .05  M S grey m atter v ersu s con tro l grey m atter. 
n , n um ber o f  sam p les p er grou p  (ex cep t c , w h ere  n =  4).
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(data not shown). For lipocortins 4 and 5 the 
main bands were 40 and 30 kDa, respectively. 
Unfortunately standards for lipocortins 2, 4 and 5 
were not available; however, the principle bands 
observed after incubation with the relevant anti­
bodies had very similar molecular masses to those 
reported by Pepinsky et al. (1988). On all blots 
bands of between 50 and 70 kDa were observed; 
these could be m ultim ers of lipocortin (Ando et 
al., 1989; Pepinsky et al., 1989) or alternatively 
may be due to cross-reactivity of the antisera with 
a related protein, for example the 68-kDa 
lipocortin (Pepinsky et al., 1988).
An overall comparison of all MS white m atter 
sub-types with control white m atter shows that 
lipocortins 1, 2, 4 and 5 are significantly increased 
in MS tissue ( P < 0.001, P < 0.001, P < 0.01, P < 
0.05 respectively, Table 1). In addition to the 
increased amount of lipocortin observed in ap­
parently normal MS white m atter com pared to 
controls, each lipocortin was further elevated in 
the white m atter adjacent to a plaque and also in 
plaque tissue. Thus within the MS CNS, the 
tissue content of each lipocortin was: plaque > 
white m atter adjacent to plaque > white m atter 
rem ote from plaque. This pattern  was observed 
for all four lipocortins although it reached statis­
tical significance only for lipocortin 2. W ithin the 
plaque group there appeared to be no relation­
ship between plaque subtype (i.e. active or 
chronic) and lipocortin content, although it should 
be noted that the sample numbers are small. 
Comparison of control and MS grey m atter 
showed that there is a slight increase in all 
lipocortins in MS grey m atter com pared to con­
trols, but this was only significant at P < 0.05 for 
lipocortin 4.
Discussion
In this study we have dem onstrated that 
lipocortins 1, 2, 4 and 5 are present in both grey 
and white m atter of normal control subjects. We 
have also shown that the levels of these lipocortins 
are consistently raised in white m atter from MS 
patients and appear to be further increased in 
plaque tissue and adjacent white m atter.
The detection of lipocortin 1 in human CNS 
tissue has been reported previously by Johnson et 
al. (1989a), although to our knowledge ours is the 
first study to dem onstrate the occurrence of 
lipocortins 2, 4 and 5. Using immunohistochem- 
istry, Johnson and coworkers have shown that in 
the normal human CNS lipocortin 1 imm unoreac­
tivity is localized primarily in ependymal cells and 
sub-ependymal astrocytes. Additionally, in stud­
ies on brain tissue from patients with various 
CNS diseases they have also observed staining fo r  
lipocortin 1 in reactive astrocytes and infiltrating 
m acrophages (Johnson et al., 1989a,b). In prelim­
inary immunohistochemical studies on MS plaque 
tissue we have found lipocortin 1 staining in 
astrocyte cell bodies and processes in both active 
and chronic plaques. In acute plaques lipocortin 
1 immunoreactivity was also observed in mono 
cy te s / m acrophages in the inflammatory infiltrat 
surrounding blood vessel walls (unpublished ob­
servations and Newcombe et al., 1991).
It has been proposed that lipocortins act as 
‘second m essengers’ of the anti-inflammatory ei- 
fects of the glucocorticoids. A lthough none of the 
patients in this study had recently received steroio 
therapy, all are presum ed to have possessed a 
intact and functional hypothalamic-pituitarv- 
adrenal axis. It has been suggested by Munck and 
co-workers (Munck et al., 1984) that one of the 
main physiological functions of the circulating 
glucocorticoids is to regulate inflammatory and 
immune mechanisms. They propose that normal 
basal steroid levels have a constant modulator;, 
effect on these systems and that when s t r e s s  
causes steroid levels to rise they serve to switch 
off inflammatory and immune mechanisms to 
prevent overshoot. Since lipocortins appear to be 
steroid-inducible molecules which possess anti-in 
flam m atory and im m unom odulatory  effect 
(Flower, 1988; H irata, 1989) it is conceivable that 
regulation of the immune system and inflamma 
tory responses by endogenous glucocorticoids may 
be m ediated via the lipocortins. Thus the pres­
ence of lipocortins in normal control CNS tissue 
may represent the basal level required for im­
mune and inflammatory regulation. In support of 
this, recent work by Carey et al. (1990) and Rel- 
ton et al. (1991) provides evidence for a physio­
logical role for lipocortin 1 in the central actions
of the glucocorticoids and suggests that lipocortins 
may be endogenous regulators of damage in the 
brain.
Recently we have dem onstrated the presence 
of lipocortins 1, 2 and 5 in the CNS of Lewis rats 
and shown that following the induction of an 
experimental counterpart of MS, namely experi­
m ental allergic encephalomyelitis, the levels of 
lipocortin 1 increase with the progression of clini­
cal symptoms and then decrease during the re­
covery phase of the disease (Bolton et al., 1990). 
The amount of lipocortin in the CNS appears to 
correlate very closely with serum corticosterone 
levels (unpublished observation) which also rise 
during the disease and are thought to be respon­
sible for the spontaneous recovery observed in 
this model (Levine et al., 1962; Bolton and Flower, 
1989; Mackenzie et al., 1989; M acPhee et al.,
1989). There is some evidence to suggest that 
stress may play a role in some MS exacerbations 
(Franklin et al., 1988; G rant et al., 1989) and that 
serum cortisol levels in MS are chronically or 
sporadically high (R eder et al., 1987). Thus the 
increased amount of lipocortin in MS tissue may 
be due to induction by endogenous steroids, pos­
sibly in combination with circulating or localized 
growth factors or cytokines (Browning et al.,
1990). In support of the hypothesis that lipocortin 
1 is glucocorticoid-regulated in man, Smith et al. 
(1990b) have recently dem onstrated a correlation 
between the concentration of lipocortin 1 in 
bronchoalveolar lavage fluid (BALF) and serum 
cortisol levels.
If lipocortins do act as endogenous regulators 
of inflam m ation, the increased am ount of 
lipocortin in the CNS of MS patients may repre­
sent an unsuccessful attem pt to overcome the 
chronic inflammation present in this disease. 
Failure to control the inflammatory process may 
be due to inactivation of lipocortin. High concen­
trations of auto-antibodies to lipocortin 1 have 
been observed in the serum of patients with 
rheum atoid arthritis on high dose glucocorticoid 
therapy and it has been suggested that these 
antibodies may reduce the effectiveness of 
lipocortin (Goulding et al., 1989). In addition, 
studies on lipocortin 1 in BALF (Smith et al., 
1990a) have shown that a greater proportion of 
lipocortin 1 is in a degraded form in patients with
inflammatory lung disease and the authors sug­
gest that enzymatic breakdown may cause inacti­
vation of the protein, leading to uncontrolled 
inflammation. It should be noted, however, that 
we find no difference between MS and controls 
in the proportion of native lipocortin and lower 
m olecular mass forms, which would suggest no 
difference in breakdown.
It is possible that in MS, for whatever reason, 
lipocortin levels are insufficient to suppress in­
flammation and the efficacy of steroid treatm ent 
may be due to induction of lipocortins which then 
rise to a level sufficient to alleviate symptoms of 
the disease. Several studies have dem onstrated 
that therapeutic doses of glucocorticoids can 
cause induction of lipocortin 1 in hum an tissues. 
Goulding et al. (1990) have observed increased 
levels of lipocortin 1 in hum an blood monocytes 
and neutrophils following systemic adm inistration 
of hydrocortisone and corticosteroid treatm ent 
has also been shown to increase lipocortin 1 in 
BALF from normal individuals and patients with 
inflammatory lung disease (Smith et al., 1989; 
Ambrose and Hunninghake, 1990).
In this study we have shown that lipocortins 1, 
2, 4 and 5 are present in normal hum an CNS 
tissues and are increased in tissue samples from 
MS patients, particularly in plaque areas. The 
next step in understanding the function of these 
proteins in MS will be to further characterise the 
cell types with which the lipocortin is associated. 
It is hoped that such studies will lead to a better 
understanding of the role played by lipocortins in 
the physiological and pharmacological regulation 
of inflammatory CNS disease.
Acknowledgements
We are grateful to the M ultiple Sclerosis Soci­
ety of G reat Britain and N orthern Ireland for 
financial support. Professor R.J. Flower is sup­
ported by an endowment from Lilly. We also wish 
to thank Dr. P. Christie for help with the statisti­
cal analyses and Dr. J. Browning of Biogen Re­
search Corporation for the generous gifts of 




A m b ro se , M .P . and H u n n in gh ak e, G .W . (1 9 9 0 ) C ortico ­
stero id s  in crease  lipocortin  1 in B A L  fluid  from  norm al 
in d iv id u als and p atien ts w ith  lung d isea se . J. A p p l. P hys­
io l. 68, 1 6 6 8 -1 6 7 1 .
A n d o , Y ., Im am ura, S., O w ada, M .K ., K akunaga, T. and  
K an n agi. R . (1 9 8 9 ) C ross-link ing o f  lip ocortin  1 and e n ­
h a n cem en t o f  its C a2+ sensitiv ity  by t issu e  tran sg lu tam i­
n ase . B io ch em . B iophys. R es. C om m u n . 163, 9 4 4 -9 5 1 .
B lack , M .D ., R e lto n , J.K., C arey, F ., C rossm an , A .R . and  
R o th w ell, N .J. (1991) L ipocortin-1 in h ib its N M D A -in -  
d u ced  n eu ron al d am age. Br. J. P harm acol. 104 (Su p p l.), 
C 34.
B lack w ell, G .J., C arnuccio , R ., D i R osa , M ., F low er, R .J., 
L an gh am , C .S .J., P aren te, L., P ersico , P ., R u ssel-S m ith , 
N .C . and S to n e , D . (1982) G lu co co r tico id s  in d uce the  
form ation  and re lea se  o f  an ti-in flam m atory  and anti-p h os-  
p h o lip a se  p ro te in s in to  the p er ito n ea l cavity o f  th e  rat. Br. 
J. P harm acol. 76, 1 8 5 -1 9 4 .
B o lto n , C. and F low er, R.J. (1989) T h e  e ffe c ts  o f  the anti-g lu- 
co co rtico id  R U  38486  on  stero id -m e d ia ted  su p p ression  o f  
ex p er im en ta l a llerg ic  en cep h a lo m y elitis  in the  L ew is rat. 
L ife Sci. 45, 9 7 -1 0 4 .
B o lto n , C ., T urner, A .M . and Turk, J.L. (1 9 8 4 ) P rostaglandin  
lev e ls  in cerebrosp in a l fluid from  m u ltip le  sc lerosis p a ­
tien ts  in rem m ission  and relap se . J. N eu ro im m u n o l. 6, 
1 5 1 -1 5 9 .
B o lto n , C ., E ld erfie ld , A .-J. and F low er, R .J. (1990) T h e  
d e te c t io n  o f  lip ocortin s 1, 2 and 5 in cen tra l nervous  
system  tissu es from  L ew is rats w ith  a cu te  exp erim en ta l 
a llerg ic  en cep h a lo m y elitis . J. N eu ro im m u n o l. 29, 1 7 3 -1 8 1 .
B ronn egard , M ., A n d ersson , O ., E dw all, D ., L und, J., 
N o rsted t, G . and C a rlsted t-D u k e , J. (1 9 8 8 ) H um an cal- 
p actin  II (lip ocortin  I) m essen g er  r ib o n u cle ic  acid is not 
in d u ced  by g lu cocortico id s. M ol. E n d ocrin o l. 88, 7 2 3 -7 3 9 .
B row nin g , J.L ., W ard, M .P ., W alln er , B .P . and P epinsky, R .B . 
(1 9 9 0 ) S tu d ies on the structural p ro p erties  o f  lipocortin-1  
and  the regu la tion  o f  its syn th esis by stero id s. In: M. M elli 
and  L. P arente (E d s.), C ytok ines and L ip ocortin s in In ­
flam m ation  and D iffer en tia tio n . W iley-L iss , N ew  Y ork, 
N Y , pp. 2 7 -4 5 .
B radford , M .M . (1976) A  rapid and sen sitiv e  m eth o d  for the  
q u an tita tion  o f  m icrogram  q u a n tities  o f  p ro te in  utiliz ing  
th e  p rin cip le  o f  p r o te in -d y e  b inding . A n a l. B ioch em . 72, 
2 4 8 -2 5 4 .
C arey, F ., F order, R ., E d ge, M .D ., G r e e n e , A .R ., H oran, 
M .A ., Strijbos, P .J.L .M . and R o th w ell, N .J. (1990)  
L ip ocortin  1 fragm ent m od ifies  p yrogen ic  action s o f  cy­
to k in es  in rats. A m . J. Physiol. 259, R 2 6 6 -R 2 6 9 .
C irino, G . and F low er, R.J. (1 9 8 7 ) H u m an  recom b in an t  
lip ocortin  1 inh ib its prostacyclin  p rod u ction  by hum an  
u m b ilica l artery in vitro. P rostag lan d in s 34, 5 9 -6 2 .
C irino, G ., F low er, R .J., B row ning, J.L ., S incla ir. L.K. and  
P ep in sk y , R .B . (1987) R ecom b in an t hum an  lipocortin  1 
in h ib its throm boxane re lea se  from  g u in ea  p ig  iso la ted  
p erfu sed  lung. N atu re 328, 2 7 0 -2 7 2 .
C irino, G ., P eers, S .H ., F low er, R .J., B row ning, J.L . and  
P epinsky R .B . (1989) H um an recom b in an t lip ocortin  1 has 
acu te  loca l an ti-in flam m atory  p rop erties in the rat paw  
o e d e m a  test. P roc. N atl. A cad . Sci. U S A  86, 3 4 2 8 -3 4 3 2 .
C om p ston , D .A .S ., M illigan , N .M . and H u g h es, P.J. (1987) A  
d o u b le  b lin d  con tro lled  trial o f  h igh d o se  m ethylpred  
n iso lo n e  in p a tien ts w ith m ultip le  sc lerosis . J. N eu rol 
N eu rosu rg . Psychiatr. 50, 5 1 7 -5 2 2 .
C rum pton , M .J. and D ed m a n , J .R . (1990) P rotein  term inology  
tangle . N atu re  345, 212.
D av id son , F .F ., D en n is , E .A ., P ow ell, M . and G len n ey , J.R. 
(1 9 8 7 ) In h ib ition  o f  p h osp h o lip a se  A 2 by lip ocortin s and  
ca lp a ctin s —  an e ffe c t o f  b inding to su b strate p h o sp h o ­
lip ids. J. B io l. C h em . 262, 1 6 9 8 -1 7 0 5 .
D av id so n , J., F low er, R .J., M ilton , A .S ., P eers, S .H . and 
R o to n d o , D . (1991) A n tip yretic  action s o f  hum an recom b i­
nant lip ocortin -1 . Br. J. Pharm acol. 102, 7 - 9 .
D e  B ias, A .L . and C herw inski, H .M . (1 9 8 3 ) D e te c t io n  o f  
a n tig e n s on  n itro ce llu lo se  pap er im m u n ob lo ts w ith  m ono­
c lon a l an tib o d ies . A n a l. B ioch em . 133, 2 1 4 -2 1 9 .
D i R osa , M ., F low er, R .J., H irata , F ., P aren te , L. and R usso  
M arie, F. (1 9 8 4 ) N om en cla tu re  a n n o u n cem en t. A n ti-p h os-  
p h o lip a se  p rote in s. P rostag lan d in s 28, 4 4 1 -4 4 2 .
F low er, R .J. (1 9 8 8 ) L ip ocortin  and the m ech an ism  o f  action  
the g lu co co rtico id s. Br. J. P harm acol. 79, 9 8 7 -1 0 1 5 .
Franklin , G .M ., N e lso n , L .M ., H ea to n , R .K ., Burks, J.S. and 
T h o m p so n , D .S . (1988) Stress and its re la tion sh ip  to a cu u  
exacerb a tio n  in m ultip le  sc lerosis . N eu rlo g y  38 (Su p p l. D  
254.
Frazer, H .E . and W isd om , G .B . (1985) D e te c t io n  o f  auto-anti- 
g en s by im m u n ob lo ttin g  using a p erox id ase-an ti-p e: 
o x id a se  com p lex . J. Im m unol. M eth od . 80, 2 2 1 -2 2 5 .
G rant, I., B row n, G .W ., H arris, T ., M cD o n a ld , W .I., P atter­
son , T . and T rim ble, M .R . (1989) Severly  threaten in g  
e v en ts and m arked  life d ifficu lties  p reced in g  o n se t o r 
exacerb ation  o f  m ultip le  sc lerosis . J. N eu ro l. N eurosurg. 
P sychiatr. 52 , 8 - 1 3 .
G oas, J .Y ., M arion , J.L. and M issoum , A . (1983) H igh  d os. 
in traven ous m eth y lp red n iso lo n e  in acu te  exacerb ation s o f  
m u ltip le  sc lerosis . J. N eu ro l. N eu rosu rg . Psychiatr. 46, 99.
G o u ld in g , N .J ., P odgorsk i, M .R ., H all, N .D ., F low er, R .j., 
B row nin g , J.L ., P ep insky, R .B . and M ad d ison , P.J. (1 9 8 m  
A u to a n tib o d ie s  to  recom b in an t lipocortin-1  in rheum atoid  
arthritis and system ic  lupus ery th em atosus. A n n . R heum . 
D is. 48 , 8 4 3 -8 5 0 .
G ou ld in g , N .J ., G od o lp h in , J.L., Sharland, P .R ., P eers, S.H . 
S am p son , M ., M ad d ison , P.J. and F low er, R.J. (1990) 
A n ti-in flam m atory  lip ocortin  1 p rod u ction  by peripheral 
b lood  leu co cy tes  in resp on se  to h yd rocortison e. L ancet 
335, 1 4 1 6 -1 4 1 8 .
H irata , F. (1 9 8 9 ) T h e  ro le o f  lip ocortin s in ce llu lar function  as 
a se co n d  m essen g er  o f  g lu cocortico id s. In: R .P . Sch leim er, 
N .H . C lam an and A . O ronsky (E d s.), A n ti-in flam m atory  
S tero id  A ctio n . B asic  and C lin ical A sp e c ts , A ca d em ic  
P ress, L on d o n , pp. 6 7 -9 5 .
H u an g, K .-S ., M cG ray, P., M atta lian o , R .J., B u rn e, C ., C how ,
E .P ., S incla ir , L.K. and P epinsky, R .B . (1987) P urification  
and ch aracteriza tion  o f  p ro teo ly tic  fragm ents o f  lipocortin -
99
1 that inhibit p h o sp h o lip a se  A t. J. B iol. C h em . 262, 7 6 3 9 -  
7645.
J oh n son , M .D ., K am so-Pratt, J .M ., W h etse ll, W .O . and  
P ep insky, R .B . (1989a) L ipocortin-1  im m u n oreactiv ity  in 
th e  norm al hum an cen tra l nervous system  and le s io n s  w ith  
astrocytosis . A m . J. C lin. P ath ol. 92, 4 2 4 -4 2 9 .
Joh n so n , M .D ., K am so-P ratt, J., P ep insky, R .B . and W h etse ll, 
W .O . (19 8 9 b ) L ipocortin-1 im m u n oreactiv ity  in cen tra l 
and p erip h era l nervous system  g lia l tum ours. H um an  
P ath o l. 20, 7 7 2 -7 7 6 .
L aem m li, U .K . (19 7 0 ) C lea v a g e  o f  structural p ro te in s during  
th e  assem b ly  o f  the head  o f  b acter io p h a g e  T4. N atu re  227, 
6 8 0 -6 8 5 .
L ev in e, S., S treb el, R ., W enk , E.J. and H arm an , P.J. (19 6 2 )  
S u p p ress ion  o f  ex p erim en ta l a llerg ic  en cep h a lo m y e lit is  by 
stress. Proc. Soc. Exp. B iol. M ed . 109, 2 9 4 -2 9 8 .
M a ck en zie , F .J., L eonard , J.P. and C u zn er, M .L . (19 8 9 )  
C h a n g es in lym phocyte /3-adrenergic rece p to r  d en sity  and  
n orad ren a lin e  co n ten t o f  th e  sp lee n  are early in d ica tors o f  
im m u n e reactivity in acu te  ex p erim en ta l a llerg ic  e n ­
cep h a lo m y e lit is  in th e  L ew is rat. J. N eu ro im m u n o l. 23, 
9 3 -1 0 0 .
M a cP h ee , I .A .M ., A n to n i, F .A . and M ason , D .W . (19 8 9 )  
S p o n ta n eo u s recovery o f  rats from  exp er im en ta l a llerg ic  
en cep h a lo m y e lit is  is d ep en d en t on  regu la tion  o f  th e  im ­
m un e system  by e n d o g e n o u s  ad ren al co r tico stero id s . J. 
Exp. M ed . 169, 4 3 1 -4 4 5 .
M arid on n eau -P arin i, J., E rrasfa, M. and R u sso -M a rie , F.
(1 9 8 9 ) Inh ib ition  o f  0 2 gen era tio n  by d ex a m eth a so n e  is 
m im ick ed  by lip ocortin  1 in a lveo lar m acro p h a g es. J. C lin. 
Invest. 83 , 1 9 3 6 -1 9 4 0 .
M unck, A ., G uyre, P .M . and H olb rook , N .J. (1 9 8 4 ) P h y sio lo g i­
cal fu n ctio n s o f  the g lu co co rtico id s in stress and their  
rela tion  to p h arm aco log ica l action s. E n d ocr. R ev . 5, 2 5 -4 4 .
N ew co m b e , J., Brar, A ., Li, H . and C u zn er, M .L . (19 9 1 )  
E xp ression  o f  the 14E a n tigen  in g lia l c e lls  in hum an  
norm al and p a th o lo g ic  cen tra l nervous system  tissu es . In: 
G lia l-N eu ro n a l In teraction s, A n n . N .Y . A cad . Sci. 633, 
5 5 6 -5 8 8 .
N orth u p , J .K ., V a len tin e -B ra u n , K .A ., Joh n so n , L.K ., S ev er­
son , D .L . and  H o llen b erg , M .D . (19 8 8 ) E va lu ation  o f  the  
an ti-in flam m atory  and p h o sp h o lip a se-in h ib ito ry  activ ity  o f  
ca lp actin  I I / l ip o c o r t in  I. J. C lin . Invest. 82 , 1 3 4 7 -1 3 5 2 .
P aren te , L„ D i R osa , M ., F low er R .J., G h iara , P., M eli, R ., 
P ersico , P., S a lm on , J .A . and W ood , J .N . (19 8 4 ) R e la t io n ­
sh ip s b e tw een  the a n ti-p h o sp h o lip a se  and a n ti-in fla m m a ­
tory e ffe c ts  o f  g lu co co rtico id -in d u ced  p rote in s. Eur. J. 
P harm acol. 99 , 2 3 3 -2 3 9 .
P aren te , L ., B ech eru cc i, C ., P eretti, M ., S o lito , E ., M u grid ge, 
K .G ., G a le o tti, C .L ., R a u g ei, G ., M elli, M. and S an so , M.
(19 9 0 ) A re th e  lip ocortin s the se co n d  m essen g ers  o f  the  
an ti-in flam m atory  a ction s o f  the g lu co co rtico id s?  In: M. 
M elli and L. P aren te (E d s.), C ytok in es and L ip ocortin s in 
In flam m ation  and D iffer en tia tio n , W iley-L iss , N ew  Y ork , 
N Y , pp. 5 5 -6 8 .
P ep insky, R .B ., T izard, R ., M atta lian o , R .J., S incla ir, L .K ., 
M iller, G .T ., B row ning, J.L ., C how , E .P ., B u rn e, C ., H u an g,
K .-S., Pratt, D ., W ach ter , L., H essio n , C ., Frey, A .Z . and  
W allner, B .P . (1 9 8 8 ) F ive d istin ct ca lciu m  and- p h o sp h o ­
lip id  b in d in g  p ro te in s sh are h om ology  w ith  lip ocortin  1. J. 
B iol. C h em . 263, 1 0 7 9 9 -1 0 8 1 1 .
P ep insky, R .B ., S in cla ir , L .K ., C how , E .P . and O 'B rin e-G reco ,
B. (19 8 9 ) A  d im eric form  o f  lipocortin-1  in hum an p la ­
cen ta . B io ch em . J. 263, 9 7 -1 0 3 .
P rineas, J. and  W right, R .G . (1978) M acrop h ages , lym p h o­
cytes and p lasm a c e lls  in the p erivascu lar com p artm en t in 
chron ic m ultip le  sc lerosis . Lab. Invest. 38 , 4 0 9 -4 2 1 .
R ed er , A .T ., L ow y, M .T ., M etlzer , H .Y . and A n te l, J.P . (1 9 8 7 )  
D ex a m e th a so n e  su p p ressio n  test ab n orm alities in m ultip le  
sclerosis: R e la tio n  to  A C T H  therapy. N eu ro lo g y  37, 8 4 9 -  
853.
R e lto n , J.K ., S trijbos, P .J .L .M ., O ’S h au ghn essy , C .T ., C arey,
F., F order, R .A ., T ild ers, F .J.H . and R oth w ell, N .J . (19 9 1 )  
L ipocortin -1  is an e n d o g e n o u s  inh ib itor o f  isch em ic  d a m ­
age in th e  rat brain . J. Exp. M ed . 174, 3 0 5 -3 1 0 .
R osnow sk a , M ., C en d row sk i, W ., S ob ocin sk a , Z . and W iec-  
zork iew icz, A . (1 9 8 1 ) P rostag lan d in s E 2 and F 2a in the  
cereb rosp in a l fluid  in p a tien ts  w ith  m ultip le  sc lero sis . A cta  
M ed. Pol. 22 , 9 7 -1 0 3 .
S m illie , F ., P eers, S .H ., E ld erfie ld , A .J ., B o lto n , C. and F low er, 
R.J. (1 9 8 9 ) D iffer en tia l regu la tion  by g lu co co rtico id s o f  
in tracellu lar lip ocortin  I, II and V  in rat m ixed p er ito n ea l 
leu k ocytes. Br. J. P harm acol. 97, 425P .
Sm ith , S .F ., G o u ld in g , N .J ., T e tley , T .D ., G o d o lp h in , J.L ., 
G u z, A . and F low er, R .J. (1989) A  p o ss ib le  an ti-in fla m m a ­
tory m ech an ism  for g lu co co rtico id s in the h um an lung. 
C lin. Sci. 76 (S u p p l. 21), 20P.
Sm ith , S .F ., T e tle y , T .D ., G u z, A . and F low er. R .J. (19 9 0 a )  
D e te c t io n  o f  lip ocortin  1 in h um an lung lavage fluid: 
L ip ocortin  d eg ra d a tio n  as a p o ss ib le  p ro teo ly tic  m ech a ­
nism  in th e  con tro l o f  in flam m atory m ed ia tors and in fla m ­
m ation . E n viron . H ea lth  P ersp ect. 85, 1 3 5 -1 4 4 .
Sm ith , S .F ., G o u ld in g , N .J ., G o d o lp h in , J.L ., T e tley , T .D ., 
R ob erts, C .M ., G u z, A . and F low er, R.J. (19 9 0 b ) A n  assay  
for th e  a ssessm en t o f  lip ocortin  1 lev e ls  in h um an lung  
lavage flu id . J. Im m u nol. M eth o d s 131, 1 1 9 -1 2 5 .
S o lito , E ., R a u g e i, G ., M elli, M. and P aren te , L. (1 9 9 0 ) E ffect  
o f  d ex a m eth a so n e  and p horbol m yristate a c e ta te  on  
lip ocortin  1, 2 and 5 m R N A  and p rote in  syn th esis . In: B. 
S a m u elsso n , P .W . R a m w ell, R. P a o le tti, G. F o lc o  and E. 
G ram strom  (E d s.), A d v a n ces  in P rostag lan d in , T h ro m b o x ­
ane and L eu k o tr ien e  R esea rch , V o l 20, R aven  P ress, N e w  
Y ork, N Y , pp. 2 9 1 -2 9 4 .
S teven s, T .R .J ., D rasd o , A .L ., P eers, S .H ., H all, N .D . and  
F low er, R .J. (1 9 8 8 ) S tim u lu s-sp ec ific  inh ib ition  o f  hum an  
n eu troph il H 20 2 p rod u ction  by hum an recom b in an t  
lip ocortin  1. Br. J. P harm acol. 93 , 139P.
T ow bin , H ., S ta e h e lin , T . and G ord on , J. (1 9 7 9 ) E le c ­
trop h oretic  tran sfer o f  p ro te in s from  p o lyacry lam id e g e ls  
to  n itr o ce llu lo se  sh e e ts . P roceed u re  and so m e  a p p lica ­
tions. Proc. N atl. A ca d . Sci. U S A  79, 4 3 5 0 -4 3 5 4 .
T ro ia n o , R ., C ook , S .D . and  D ow lin g , P.C . (1 9 8 7 ) S tero id  
therapy in m u ltip le  sc lero sis . A rch . N eu ro l. 44 , 8 0 3 -8 0 7 .
100
T rotter, J. and Sm ith, M .E . (1986) T h e role o f  p h osp h o lip ases  
from  inflam m atory m acrop h ages in d em yelin a tion . N e u ­
rochem . R es. 11, 3 4 9 -3 6 1 .
W aksm an, B .H . (1989) M ultip le  sc lerosis . Curr. O pin. Im ­
m unol. 1, 3 3 -7 3 .
W oelk , H . and P eiler-lch ik aw a, K. (19 7 4 ) O n the activity of  
p h osp h o lip a se  A 2, com pared  with l-A lk -l-en y l-2 -a cy l-  and 
l-a lk y l-2 -acy l-g lycerop h osph atid es in m ultip le sc lerosis. J 
N eu ro l. 207, 3 1 9 -3 2 6 .
Journal o f  the Neurological Sciences, 119 (1993) 146-153  
© 1993 Elsevier Science Publishers B.V. All rights reserved 0022-51 0 X /9 3 /$ 0 6 .0 0
jNS 04123
Lipocortin 1 (annexin 1) immunoreactivity in the cervical spinal cord 
of Lewis rats with acute experimental allergic encephalomyelitis
A-J. E lderfie ld  a, C. B olton a and  R .J. F low er b
“ School o f  Pharmacy and Pharmacology, Uniuersity o f  Bath, Bath, U K  and b Departm ent o f  Biochemical Pharmacology,
St. B artholom ew’s H ospital Medical College, London, UK
(R eceived 21 D ecem ber, 1992)
(R evised, received 28 April, 1993)
(A ccepted 18 May, 1993)
K ey w ords:  L ip o co rtin ; A n n ex in ; E x p er im en ta l a llerg ic  en c e p h a lo m y e lit is ;  C o r tic o ste r o n e ; B lo o d  v esse l;  E n d o th e lia l cell; 
L ym phocyte; M a cro p h a g e
S u m m a ry
S p o n ta n e o u s  reco v ery  from  a cu te  e x p e r im e n ta l a llerg ic  e n c e p h a lo m y e lit is  ( E A E )  by th e  L ew is rat is p rob ab ly  m e d ia te d  by 
e n d o g e n o u s  c o r t ic o ste r o id s . It h as b e e n  p r o p o se d  th a t th e  a n ti- in fla m m a to ry  a c tio n s  o f  th e  g lu c o c o r t ic o id s  m ay b e  e f fe c te d  via  
the in d u c tio n  o f  m e d ia to r  p ro te in s  term ed  lip o c o r t in s  an d  rece n tly  w e  h av e  d e m o n str a te d  in crea sed  le v e ls  o f  lip o co r tin  1 in the  
c en tra l n erv o u s sy stem  (C N S ) o f  E A E -d is e a se d  ra ts (B o lto n  C ., A -J . E ld e r f ie ld  an d  R .J . F lo w er  (1 9 9 0 ), J. N e u r o im m u n o l. 29: 
1 7 3 -1 8 1 ) . In  th is  stu d y , u tiliz in g  a n tisera  ra ised  a g a in st reco m b in a n t h u m a n  lip o co r tin  1, im m u n o h isto ch em istr y  an d  ligh t 
m icro sco p y  have b e e n  u sed  to  d e te r m in e  th e  d istr ib u tio n  o f  th e  p ro te in  in th e  cerv ica l sp in a l cord  o f  L ew is rats d u r in g  E A E . In 
norm al a n im a ls lip o co r tin  1 im m u n o rea ctiv ity  w as lo c a liz e d  p red o m in a n tly  in th e  w a lls  o f  larger  b lo o d  v e s se ls  an d  to  a le sser  
e x te n t ca p illa r ie s . T h e  sa m e sta in in g  p a ttern  w a s fo u n d  in a d ju v a n t-in o cu la ted  co n tro ls . In se c tio n s  from  E A E -in o c u la te d  
a n im a ls th e re  w a s n o  ch a n g e  d u rin g  th e  in d u c tio n  p h a se , but w ith  th e  o n se t  o f  c lin ica l sy m p to m s an d  th e  a p p e a r a n c e  o f  
in fla m m a to ry  in filtra te s  in th e  C N S , a m ark ed  in c r e a se  in lip o co r tin  1 im m u n o sta in in g  w as o b ser v ed . T h is  a d d itio n a l s ta in in g  w as  
d u e  to  w id e sp r e a d  im m u n o rea ctiv ity  o f  th e  le s io n s , w as m axim al at th e  h e ig h t o f  d ise a s e  an d  d e c r e a se d  fo llo w in g  reco v ery  and  
le s io n  reg re ss io n . W ith in  th e  le s io n s  th e  vast m ajority  o f  in filtra tin g  ly m p h o cy tes  an d  m a cro p h a g es  w ere  p o s it iv e  for lip o co r tin  1, 
in c lu d in g  so m e  very h eav ily  sta in ed  m a c r o p h a g e -lik e  c e lls . M e a su r e m e n t o f  c o r t ic o ste r o n e  in th e  sera  o f  th e se  a n im a ls sh o w e d  
th a t c h a n g e s  in lip o co r tin  1 im m u n o sta in in g  in th e  C N S  d u rin g  E A E  c lo se ly  p a ra lle l seru m  c o r t ic o s te r o n e  lev e ls .
Introduction
Acute exacerbations of multiple sclerosis (MS), an 
inflammatory and demyelinating disease of the CNS, 
are often treated with anti-inflammatory steroids 
(Troiano et al. 1987). Experimentally these compounds 
are also very effective in suppressing EAE, an animal 
model of MS (Rosenthale et al. 1969; Levine and 
Sowinski 1980; Bolton and Flower 1989). Furthermore 
there is considerable evidence that the spontaneous 
recovery which is characteristic of acute EAE in the 
Lewis rat is mediated by endogenous steroids released 
from the adrenal cortex. Several studies have demon­
strated that serum corticosterone levels rise dramati­
cally prior to the onset of remission (Levine et al. 1980;
Correspondence to: Dr. C. Bolton, School o f Pharmacy and Phar­
macology, University o f Bath, Claverton Down, Bath BA2 7AY, UK. 
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Mackenzie et al. 1989; MacPhee et al. 1989). If this 
glucocorticoid surge is prevented by adrenalectomy 
(Levine et al. 1962; MacPhee et al. 1989) or antago­
nized with the anti-glucocorticoid RU38486 (Bolton 
and Flower 1989) disease severity is increased and 
recovery delayed or abolished, effects which can be 
reversed by administration of exogenous steroids.
The mechanism of steroid action in MS and EAE 
has not been established. However, it has been pro­
posed by several groups that the anti-inflammatory 
effects of the glucocorticoids are in part mediated by 
the induction of effector proteins termed lipocortins 
which may act by inhibiting the activity of phospholi­
pase A 2 (PLA2) and thus the generation of pro-in­
flammatory arachidonic acid metabolites (for review 
see Flower 1988). Lipocortins have recently been found 
to be members of the annexin family of calcium and 
phospholipid binding proteins (Crumpton and Dedman
1990). The most widely studied of these proteins, 
lipocortin 1, has been sequenced and the human gene
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cloned (Wallner et al. 1986). Several studies have 
demonstrated that the recombinant protein has anti-in­
flammatory properties in vivo (Miele et al. 1988; Cirino 
et al. 1989; Errasfa and Russo-Marie 1989). Recently, 
lipocortin 1 has been found to have biological activity 
in the CNS: when administered intravenously it can 
prevent febrile reactions in the rabbit (Davidson et al.
1991) and intracerebroventricular injection of lipocortin 
1 inhibits cytokine induced fever in the rat (Carey et al. 
1999). There is also emerging evidence that endoge­
nous lipocortin 1 protects against neuronal damage in 
the brain. In a model of cerebral ischaemia, Relton 
and co-workers (1991) have observed increased expres­
sion of lipocortin 1 around infarcted areas, central 
injection of an N-terminal fragment of lipocortin 1 was 
found to reduce infarct size, conversely administration 
of a neutralizing antibody increased the extent of is- 
cheamic injury and oedema. In addition lipocortin 1 
| fragment has also been shown to inhibit other types of 
neuronal damage, such as that mediated via the NMDA 
receptor (Black et al. 1991).
Previous studies by our group have demonstrated 
increased levels of lipocortins 1, 2, 4 and 5 in the CNS 
of MS patients (Elderfield et al. 1992) and elevated 
amounts of lipocortin 1 in the cerebellum and spinal 
cord of EAE-diseased rats (Bolton et al. 1990). In this 
study we have used immunohistochemistry to investi­
gate the cellular distribution of lipocortin 1 in the 
cervical spinal cord of Lewis rats throughout the course 
of EAE. Identification of the cell types with which 
lipocortin 1 is associated in the target tissues of EAE, 
may provide further insight into the role of this protein 
in the regulation of inflammatory CNS disease.
! Materials and methodsInduction o f EAE
Male Lewis rats were obtained from Bantin and 
Kingman (Hull, UK) and allowed at least one week to 
adapt to their new environment prior to the start of an 
experiment. Animals were housed 4—6 per cage with 
free access to CRM rat diet and water. For the induc­
tion of EAE, rats weighing 200-250 g were inoculated 
in each hind foot pad with 0.1 ml of an emulsion
I
I | comprising guinea-pig spinal cord, incomplete Freund s 
adjuvant (Difco) and sterile phosphate buffered saline 
I (PBS) in the ratio 1 :1 :1  plus 10 m g/m l killed My­
cobacterium tuberculosis (H 37 RA, Difco). Normal con-
I  t r o l  a n im a ls  w e r e  n o t  in o c u la t e d  a n d  c o m p le t e  F r e u " d ^  
a d ju v a n t  (CFA) c o n t r o ls  r e c e iv e d  a n  e m u ls io n  in  w h ic h
I I  t h e  g u in e a - p ig  s p in a l  c o r d  w a s  s u b s t i t u t e d  w i t h  s t e r i l e  
PBS. E A E - i m m u n i z e d  a n im a ls  w e r e  w e ig h e d  a n d  e x ­
a m i n e d  d a i l y  f o r  c l in ic a l  s ig n s  o f  d is e a s e .  N o r m a l  a n d
I CFA controls were subjected to the same handling 
I procedure.
Serum and CNS tissue samples
In two separate experiments CNS tissue and serum 
samples were taken from groups of EAE-inoculated 
animals at various stages of the disease. Samples were 
collected during the pre-clinical phase, on days 4 and 7 
post-inoculation (PI); during the disease phase, on the 
first day of exhibiting either weight loss, flaccid tail, 
hind limb weakness or paralysis; and during the recov­
ery phase, on the first day of complete absence of 
clinical symptoms but only from animals which had 
previously shown definite clinical signs, i.e. complete or 
partial paralysis. CFA controls were sampled 15 days 
PI, corresponding with peak disease activity in EAE-in­
oculated animals. To limit fluctuations in circulating 
glucocorticoids due to circadian variation, all samples 
were taken in the morning when serum corticosterone 
levels are at their lowest (De Boer and Van der Gugten
1987). . .
For the collection of samples animals were initially 
rendered unconscious by carbon dioxide inhalation and 
2 ml of blood was extracted by cardiac puncture. The 
rats were then asphyxiated with carbon dioxide, exsan­
guinated and the first 3 cm of spinal cord dissected out.
Immunohistochemistry
Cervical spinal cords were bisected down the mid­
line and one half was fixed for 90 min in Carnoy’s fluid 
(Fava et al. 1989), dehydrated in three changes of 
absolute alcohol and cleared in cedar wood oil (Fisons) 
prior to embedding in paraffin. Longitudinal horizontal 
sections, 6 gm  thick, were cut at one standard depth 
and mounted onto 3-aminopropyltriethoxysilane (Sig­
ma) coated slides. In each experiment immunohisto­
chemistry was performed on CNS tissue samples from 
three representative animals in each group.
For immunohistochemistry the slides were de-paraf- 
finized in xylene and taken through graded alcohols to 
water. Sections were then blocked for 30 min with 10% 
goat serum (Sigma) and probed overnight at 4°C with a 
1:250 dilution of rabbit polyclonal antisera raised 
against recombinant human lipocortin 1 (code No. 
842). Cross-reactivity data for this antibody have been 
reported by Pepinsky et al. (1988). After washing three 
times for 5 min slides were incubated for 30 min with 
goat anti-rabbit IgG (Sigma) diluted 1:50, then washed 
again and incubated for a further 30 min with a 1:1000 
dilution of rabbit peroxidase-anti-peroxidase complex 
(Sigma). Following three more washes the sections 
were incubated with 0.05% 3-3 -diaminobenzidine te- 
trahydrochloride (Aldrich) plus 0.03% hydrogen perox­
ide (BDH) until fully stained, when the reaction was 
terminated by rinsing in distilled water. All incubations 
and washing steps were performed at room tempera­
ture in PBS unless otherwise stated.
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Control sections from normal and EAE-diseased 
animals were incubated either with PBS in place of all 
antibody reagents to test for endogenous peroxidase, 
or with PBS or non-immune rabbit serum instead of 
842 to determine specificity of staining. To further 
assess the specificity of immunostaining, in some exper­
iments lipocortin 1 antisera was diluted to 1:250 in
PBS and aliquots incubated with a range of concentra­
tions of recombinant human lipocortin 1 (0.1-100 /xg/ 
ml), firstly for 1 h at 37°C and then overnight at 4°C. 
This pre-adsorbed antisera was then used on sections 
from normal and EAE animals in place of 842, after 
which they were processed as described above.
All sections were lightly counterstained with Tolui-
Fig. 1. Lipocortin 1 immunoreactivity in the cervical spinal cord o f normal Lewis rats. Sections a -d  were incubated with lipocortin 1 antisera, (a) 
Low power view (xlO O ) showing localization o f lipocortin 1 immunoreactivity in the walls o f moderately stained blood vessels, plus very faint 
non-specific staining of neuronal nuclei. (b,c) Higher power fields o f lipocortin 1 positive blood vessels (X 400) and capillaries (x600) 
respectively, (d) Three typical examples o f the very heavily stained cells which were occasionally observed within the lumen of blood vessels 
(x 6 0 0 ) . (e) Control section incubated with lipocortin 1 antisera pre-adsorbed with 100 ju.g/m l lipocortin 1 ( X 100).
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dine Blue, dehydrated, cleared in xylene and mounted 
in DPX (BDH) prior to observation by light mi­
croscopy.
Corticosterone radioimmunoassay
Following cardiac puncture the blood was allowed 
to clot and serum samples were collected, clarified by 
centrifugation and stored at — 20°C prior to assay. 
Serum corticosterone was measured in samples from 
all animals using an ICN RSL'^I-Corticosterone Ra­
dioimmunoassay Kit (IDS, Tyne and Wear, UK) ac­
cording to the manufacturer’s instructions. Results were 
analysed using one-way ANOVA and the significance 
of differences between group means determined using 




In cervical spinal cord sections from normal animals 
lipocortin 1 immunoreactivity was localized predomi­
nantly in the walls of larger blood vessels (Fig. 1A and 
B). However, staining was uneven and many blood 
vessels appeared unstained or only weakly positive. 
Some capillaries were also very faintly stained (Fig. 
1C), although again most were below the visual limit of 
detection. Occasionally very heavily stained cells were 
observed located within the lumen of blood vessels and 
capillaries, as shown in Fig. ID. No specific staining 
was associated with either neurones, astrocytes or 
oligodendrocytes. Control sections where lipocortin 1 
antiserum was omitted or replaced with non-immune
Fig. 2. Lipocortin 1 immunoreactivity in the cervical spinal cord o f Lewis rats with EAE. All sections are from rats displaying symptoms of  
com plete paralysis, a - c  were incubated with lipocortin 1 antisera, (a) Low power view (XlOO) showing extensive immunostaining o f several 
inflammatory lesions, (b) A  typical perivascular lesion where the vast majority o f infiltrating cells appear to be positive for lipocortin 1 ( X 400). 
(c) High power view (X 6 0 0 ) o f inflammatory cells adjacent to a small blood vessel illustrating lipocortin 1 immunostaining o f a macrophage 
(M), a lymphocyte (L) and a very densely stained macrophage-like cell (* ) . (d) Control section incubated with antisera pre-adsorbed with 100 
/ ig /m l  lipocortin 1, several lesions can be seen lightly counterstained with toluidine blue, all immunostaining for lipocortin 1 was com pletely
abolished (x 100).
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rabbit serum were completely negative. However, when 
sections were incubated with antisera, which had been 
pre-adsorbed with 100 m g/m l lipocortin 1, all vascular 
and intravascular staining was inhibited, although faint 
non-specific staining of neuronal nuclei was observed 
(Fig. IE).
In the cervical spinal cord of EAE-inoculated ani­
mals, prior to the onset of clinical symptoms, the 
intensity and distribution of lipocortin 1 immunoreac­
tivity followed the same pattern as that found in nor­
mal rats (not shown). However, in clinically sick ani­
mals the appearance of inflammatory lesions was asso­
ciated with a marked increase in lipocortin 1 immunos­
taining (Fig. 2A). The extent of this staining appeared 
to be proportional to the number of lesions and the 
severity of disease: cords from rats exhibiting weight 
loss or flaccid tail, had only a few small lipocortin 
stained lesions, whereas progression of symptoms to 
hind limb weakness and paralysis was characterized by 
widespread staining of numerous infiltrates. Generally, 
fewer lipocortin-stained lesions were present in sec­
tions taken from animals which had recently recovered.
Staining of the lesions was quite variable: whilst a 
few were totally unstained, in many more all infiltrat­
ing cells appeared to be positive for lipocortin 1. In 
general, however, lipocortin 1 immunoreactivity was 
present in the vast majority of cells constituting the 
inflammatory infiltrates. A typical lesion surrounding a 
blood vessel is shown in Fig. 2B. Most of the cells were 
moderately stained and were morphologically typical of 
lymphocytes and macrophages (Fig. 2C). In addition, 
some very heavily stained cells, which were slightly 
larger and irregularly shaped, were also observed in 
association with the cellular infiltrates and often some 
distance into the surrounding tissue (Fig. 2C). These 
cells appeared to be similar to those occasionally seen 
within the blood vessels of normal animals (Fig. ID) 
and their size and morphology suggests that these are 
also macrophage-type cells.
Throughout the course of EAE there appeared to 
be no difference in the type or proportion of cells 
positive for lipocortin 1, nor in the staining intensity of 
each cell-type. Furthermore staining of blood vessels 
did not change during the disease and neurones, oligo- 
dendroglia and astrocytes remained unstained. Sec­
tions from CFA controls were identical in intensity and 
pattern of immunoreactivity to those from normal and 
pre-diseased animals (not shown). On sections from 
EAE-diseased rats staining of lesions was completely 
inhibited when lipocortin 1 antisera was omitted or 
pre-adsorbed with 100 m g/m l recombinant lipocortin 
1 (Fig. 2D).
Serum corticosterone
Corticosterone levels in the sera of rats in the exper­
imental groups from which spinal cord samples were
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Fig. 3. Corticosterone levels in serum from normal and CFA-inoc- 
ulated controls and from EA E -inoculated Lewis rats at various 
stages o f the disease. Normal rats (Norm). CFA controls (CFA) w re 
sam pled 15 days PI. EA E-inoculated rats were sampled on day 4 or 7 
PI or on the first day of exhibiting weight loss (WL), hind limb 
weakness (HLW ), paralysis (Para) or recovery (R ec). Results re 
expressed as m e a n ± S D  and are pooled  from two separate experi­
ments, the number o f animals in each group is shown in parenthesis. 
Results were analysed using A N O V A  and the significance o f ditAr- 
ences between group means determ ined using the Newman-Keuls 
procedure: * =  P  <  0.01 when com pared to normal controls.
taken, are shown in Fig. 3. Baseline serum corticos­
terone in normal animals was 39 + 51 ng/m l (mean ± 
SD, n — 9). In pre-diseased EAE-inoculated animals, 
corticosterone was slightly elevated at day 4 PI but had 
returned to baseline by day 7. However, clinically sick 
rats had serum corticosterone levels which were signifi­
cantly higher than in normal controls and which pro­
gressively increased with the severity of sympton >, 
peaking at the paralysis stage at 276 + 186 ng/m l 
(n = 7, Z3 < 0.01). Following recovery, levels were re­
duced and although slightly elevated in comparison 
they were not statistically different to normal animals. 
The serum corticosterone concentration of CFA-inoc- 
ulated rats was 138 ± 36 ng /m l (n = 4) and although 
this appeared to be higher than that of normal contrc is 
and somewhat lower than the value obtained for corr - 
sponding EAE-inoculated rats neither difference 
reached statistical significance.
Discussion
In the cervical spinal cord of normal animals w e  
found lipocortin 1 immunoreactivity localized in t' e 
walls of blood vessels and capillaries and recently w e  
have observed a very similar distribution in human 
CNS tissue (Newcombe, Elderfield, Bolton and F lo w e r ,  
unpublished observation). Although Fava et al. (1989) 
were unable to detect lipocortin 1 in rat spinal cord, in  
studies on rat brain Strijbos and co-workers (19° 
similarly observed patchy lipocortin 1 immunoreactivit' 
in CNS blood vessels. In addition these workers found
■brain tanycytes, ependymal cells and certain varicose 
nerve fibres and neuronal cell bodies were also positive 
for lipocortin 1. Interestingly immunoreactive lipocortin 
1 was seen in the vascular tissue of all other organs 
studied by this group. The presence of lipocortin 1 
immunoreactivity in capillaries as well as larger blood 
vessels suggests that the protein may be associated with 
the endothelium and in support of this several studies 
have demonstrated the occurrence of lipocortin 1 in
I
 cultured endothelial cells (Hullin et al. 1989; Fujimoto 
et al. 1990; Patte et al. 1991).
The emergence of clinical symptoms in EAE-inoc­
ulated rats was accompanied by a marked increase in 
lipocortin 1 immunostaining of the cervical spinal tis­
sue, which was maximal at the height of disease and 
decreased following recovery, substantiating our previ­
ous findings using Western blotting (Bolton et al. 1990). 
Changes in the lipocortin content of the CNS occurred 
at the same time and followed the same pattern as 
serum corticosterone levels which rose dramatically 
with the development of symptoms. This surge in circu­
lating glucocorticoids immediately prior to the onset of 
recovery is well documented (Levine et al. 1980; 
Mackenzie et al. 1989; MacPhee et al. 1989). Further­
more, the slight elevations in serum corticosterone 
apparent in EAE-inoculated rats during the induction 
phase and in CFA-immunized animals on day 15 PI 
have also been observed by other workers (Mackenzie 
et al. 1989) and probably reflect respectively, an acute 
reaction to the inoculum and the development of stress 
due to the induction of adjuvant arthritis (Bolton et al.
1990).
The increased amount of lipocortin 1 in the spinal 
cord of EAE-diseased animals resulted from wide­
spread immunostaining of the inflammatory lesions 
which contained many lymphocytes and macrophages 
positive for lipocortin 1. In addition, some very heavily 
stained macrophage-like cells were observed in the 
vicinity of the infiltrates and the presence of similar 
cells within the lumen of blood vessels in normal 
animals suggests that these are blood derived. In sup­
port of these findings, an immunohistochemical study 
by Fava et al. (1989) also showed immunoreactive 
lipocortin 1 in intravascular and resident tissue macro­
phages in various rat organs and Johnson and co­
workers (1989a,b) have found lipocortin 1 immunoreac­
tivity in mononuclear cells infiltrating inflammatory 
CNS lesions in man. The association of lipocortin 1 
with inflammatory cells is well established, the protein 
was originally isolated from rat peritoneal lavage fluid 
and macrophages are well documented as being a rich 
source of lipocortins (Flower 1988). Lower levels of 
lipocortin 1 and lipocortin 1 mRNA have also been 
detected in lymphocytes (Pepinsky et al. 1988; 
Bronnegard et al. 1988; Goulding et al. 1990a). Induc­
tion by steroids of lipocortin 1 in mononuclear cells has
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been demonstrated both in primary cultures (Browning 
et al. 1990; Goulding et al. 1990a) and in vivo in the rat 
and in humans (Solito et al. 1990; Goulding et al. 
1990a), although other workers have found no induc­
tion (Bronnegard et al. 1988). In addition, Vishwanath 
et al. (1992) have recently shown that adrenalectomy 
causes a down-regulation of lipocortin 1 mRNA in rat 
tissues and that this can be prevented by administra­
tion of exogenous glucocorticoid, findings which lend 
weight to the concept that the gene for lipocortin 1 is 
under tonic steroid control. With respect to the present 
study it should be noted that although we have ob­
served an apparent relationship between the lipocortin 
1 content of the CNS and serum corticosterone levels 
this does not necessarily indicate steroid induction of 
the protein since our results could equally be due to an 
influx of lipocortin rich cells from the blood. Clarifica­
tion of this point awaits further pharmacological stud­
ies at present underway in our laboratory.
EAE is principally a T-cell-mediated disease charac­
terized histologically by the presence, primarily in the 
brain stem and spinal cord, of perivascular infiltrates 
composed mainly of lymphocytes, macrophages and 
plasma cells. Macrophages invading the CNS express 
MHC Class II antigens (Polman et al. 1986), appear to 
function in antigen presentation and also seem to be 
involved in demyelination (Lamper and Kies 1967), 
possibly via the action of PLA2 (Trotter and Smith 
1984). Increased levels of PLA2-derived eicosanoid 
mediators have been found in the CNS of rats with 
EAE (Bolton et al. 1984). Mononuclear cells obviously 
play a pivotal role in EAE and several studies suggest 
that the lipocortin 1 they contain may influence many 
of the factors outlined above. Of particular relevance is 
the ability of the protein to suppress some in vivo 
models of inflammation (Miele et al. 1988; Cirino et al. 
1989; Errasfa and Russo-Marie 1989). In addition, 
lipocortin 1 has been shown to prevent eicosanoid 
release from isolated tissues and leukocytes (Cirino 
and Flower 1987a,b; Cirino et al. 1987) which may be 
achieved by limiting the activity of PLA2 although the 
mechanism of PLA2 inhibition is controversial (David­
son et al. 1987). Early studies by Hirata and co-workers 
demonstrated that lipocortins possess immunomodula­
tory actions (Hirata 1989) and recently specific binding 
sites for lipocortin 1 have been discovered on the 
surface of monocytes (Goulding et al. 1990b). Clearly, 
there are many potential sites of action for lipocortin 1 
in EAE.
The presence of lipocortin 1 in CNS endothelial 
cells may be of particular importance since increased 
blood brain barrier (BBB) permeability and CNS 
oedema are well defined features of EAE which are 
thought by many to be responsible for the physical 
symptoms of the disease (Levine et al. 1966; Simmons 
et al. 1982). The anti-oedematous properties of steroids
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are well known and studies using computed tomogra­
phy and magnetic resonance imaging suggest that corti­
costeroid therapy can reduce BBB abnormalities and 
oedema in the CNS of MS patients (Troiano et al. 
1987; Kesselring et al. 1989). The location of lipocortin 
1 in cells actively involved in the regulation of BBB 
function may indicate a role for this protein in the 
control of BBB permeability in EAE. Support for this 
suggestion is provided by the studies of Cirino et al. 
(1989) which have shown that local administration of 
recombinant human lipocortin 1 can mimic the preven­
tion of peripheral oedema by steroids in the rat and 
Relton et al. (1991) who have recently provided evi­
dence that lipocortin 1 may be an endogenous inhibitor 
of oedema in the brain.
The mechanism of steroid-induced recovery from 
EAE has not yet been established. One possible sce­
nario which arises from the results presented in this 
paper is that by modulating the amount or activity of 
lipocortin 1, steroids may indirectly affect the function 
of endothelial cells, lymphocytes and macrophages and 
in this way influence the largely unknown chain of 
events leading to regression of oedema, migration of 
cells from the tissue and ultimately clinical recovery. It 
is hoped that elucidation of the role of lipocortins in 
steroid mediated self-cure, will provide further insight 
into the mechanism of steroid action in EAE and thus 
lead to improved therapies for MS and other steroid 
responsive diseases.
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